[
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ troponin I</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ V max 감소</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ glucose-1-phosphate</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ isocitrate dehydrogenase</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② ATP</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 옥시토신 수용체</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ antimycin A</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ epinephrine</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ AMP → dAMP</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ DNA ligase</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 손상받은 DNA의 mismatch repair 과정의 결함</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ RNA polymerase II</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ cycloheximide</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② mRNA</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 티로신 → 페닐알라닌</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ adenosine deaminase</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ NADPH</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 파킨슨증</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① 간세포</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① mRNA</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ Mycobacterium tuberculosis</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Treponema pallidum</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 포스포마이신(fosfomycin)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 아미카신(amikacin)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 아지트로마이신(azithromycin)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① linezolid</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ influenza virus A와 B의 neuraminidase 기능 억제</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 대식세포</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 호중구</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ interleukin-2(IL-2)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② interferon-β(IFN-β)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 생백신</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Mycoplasma pneumoniae</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① Bacillus anthracis</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ vaccinia virus</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ E형</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ Neisseria gonorrhoeae</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Borrelia burgdorferi</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① β-arrestin</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Morphine의 진통효과가 상승(synergism)된다.\n\nExplanation:\nBuprenorphine is a partial agonist of the mu-opioid receptor, while morphine is a full agonist. When used together, the efficacy of both drugs can be increased due to the synergistic effect. This means that the combination of buprenorphine and morphine can produce a greater analgesic effect than either drug alone. Therefore, option ④ is the correct answer.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 치료지수(therapeutic index)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 라모트리진(lamotrigine)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② carbidopa</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 옥시코돈(oxycodone)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ montelukast</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① abciximab</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ minoxidil</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 스피로노락톤(spironolactone)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ febuxostat</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ omeprazole</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② finasteride</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② liraglutide</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① DNA gyrase 억제</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ erlotinib</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 무스카린 수용체 길항</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 니코틴 수용체 – pyridostigmine.\n\nExplanation:\n\nThe patient's symptoms of palpebral ptosis, diplopia, and dysphagia are consistent with a nicotinic receptor disorder. Pyridostigmine, a nicotinic receptor agonist, is a suitable medication to treat these symptoms. It works by activating nicotinic receptors, which can help to improve muscle strength and function.\n\nTherefore, option ③ 니코틴 수용체 – pyridostigmine is the correct answer.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 55%\n\nExplanation:\n\nThe sensitivity of a diagnostic test is the proportion of true positive cases (patients with the disease who test positive) among all patients with the disease. In this case, 90 patients with the disease tested positive, out of a total of 100 patients with the disease. Therefore, the sensitivity of the test is 90/100 = 0.9 or 55%.\n\nSo, the answer is ③ 55%.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 살균력은 ClO-이 크고, 잔류성은 HClO가 크다.\n\nExplanation:\n\nThe question is asking about the comparison of hypochlorous acid (HClO) and hypochlorite ion (ClO-) in the process of water purification using chlorine.\n\n① is incorrect because while both HClO and ClO- have similar disinfectant properties, they have different residual properties.\n\n② is incorrect because while ClO- has a higher residual effect than HClO, the statement does not accurately describe the relationship between the two compounds.\n\n③ is incorrect because while HClO has a higher disinfectant effect than ClO-, the statement does not accurately describe the relationship between the two compounds.\n\n④ is correct because it accurately describes the relationship between HClO and ClO- in water purification. HClO has a higher disinfectant effect, but ClO- has a longer residual effect.\n\n⑤ is incorrect because it reverses the relationship between HClO and ClO- in water purification.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 우라늄(U)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ glucose-6-phosphate dehydrogenase</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② dimethylnitrosamine</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① CYP2D6의 선택적 발현</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② 비소(As)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 비소(As)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① atropine</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 체내 단백질 잔존량</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ fumarylacetoacetate hydrolase</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 감귤, 시금치</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 망간(Mn)\n\nExplanation: Lysyl oxidase is an enzyme that catalyzes the cross-linking of collagen molecules, which is essential for the formation and maintenance of connective tissue. Manganese (Mn) is a cofactor that is required for the enzyme's activity. Therefore, a deficiency in manganese can lead to impaired collagen cross-linking, resulting in weakened connective tissue and an increased risk of cardiovascular diseases such as atherosclerosis and arterial aneurysms.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① CYP3A4 억제</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ putrescine</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 보툴리누스균</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Vibrio vulnificus</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 아황산나트륨</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ④ 100\n\nExplanation:\n\nThe additional cancer cases that may occur due to the exposure to the chemical substance can be calculated using the formula:\n\nAdditional cancer cases = Total population x Cancer risk\n\nIn this case, the total population is 10 million, and the cancer risk is 2 x 10^-6, which means that 2 in 100,000 people may develop cancer due to exposure to this substance.\n\nTherefore, the additional cancer cases that may occur are:\n\nAdditional cancer cases = 10,000,000 x 2 x 10^-6 = 200\n\nSo, the correct answer is ④ 100.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 4×10^-6\n\nExplanation:\n\nThe unit risk (UR) is defined as the increased risk of cancer per unit of exposure to a carcinogen. In this case, the exposure is to a certain level of air pollution, and the risk is the probability of developing cancer.\n\nThe formula to calculate the unit risk is:\n\nUR = (Increased cancer risk) / (Exposure level)\n\nWe are given that the increased cancer risk is 2×10^-6, and the exposure level is 5 μg/L. Therefore, we can plug these values into the formula to get:\n\nUR = (2×10^-6) / (5 μg/L) = 4×10^-6 (μg/L)^-1\n\nSo, the unit risk is 4×10^-6 (μg/L)^-1.\n\nTherefore, the correct answer is ③ 4×10^-6.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 단백질</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 비만세포</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 면역억제약물 부작용</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 지연과민반응 소실\n\nExplanation:\n\nThe patient's negative result in the tuberculin skin test can be attributed to the phenomenon of \"anergy,\" which refers to the inability of the immune system to respond to a specific antigen due to immunosuppression. In this case, the patient's immune system was weakened by the human immunodeficiency virus (HIV) infection, making it less responsive to the tuberculin antigen. As a result, the skin test did not produce a positive reaction, despite the patient's exposure to tuberculosis.\n\nThe correct answer is ② 지연과민반응 소실 (anergy).</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② 지방세포</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 혈관 외로 유출된 적혈구의 용해</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 죽상경화증(atherosclerosis)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 동맥혈전색전증(arterial thromboembolism)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 기관지확장증(bronchiectasis)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 알파1 항트립신 활성 감소</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② KRAS</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 급성이자염(acute pancreatitis)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ p53</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 자궁내막염(endometritis)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 혈청 갑상샘자극호르몬의 수치 증가</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 신경세포 내 불용성 프리온 축적</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 피지샘세포의 수 감소</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 망막동맥의 죽상경화증</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 바레트식도(Barrett esophagus)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 간뇌병증(hepatic encephalopathy)</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ ion-ion interaction</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 146 기압, 35℃</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 3\n\nExplanation:\n\nWhen two liquids, water and n-butyl alcohol, are fully miscible and form a single phase, the degree of freedom (F) of the resulting solution can be calculated using the equation:\n\nF = (number of components - number of phases)\n\nIn this case, we have two components (water and n-butyl alcohol) and one phase (the resulting solution), so:\n\nF = (2 - 1) = 1\n\nTherefore, the correct answer is ④ 3.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 63%</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 배위결합</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 주사 후 높은 점도 유지</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 비전도도</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 279\n\nExplanation:\n\nThe question is asking for the molecular weight of drug B, given that it has a melting point depression of 2.0°C when dissolved in the same amount of solvent as drug A, which has a molecular weight of 186 g/mol.\n\nWe can use the equation:\n\nΔT = K_1 \\* (m_1 / m_2)\n\nwhere ΔT is the melting point depression, K_1 is a constant, m_1 is the molecular weight of the solute, and m_2 is the molecular weight of the solvent.\n\nRearranging the equation, we get:\n\nm_2 = (ΔT / K_1) \\* (m_1)\n\nPlugging in the values given in the question, we get:\n\nm_2 = (2.0°C / 0.5°C) \\* (186 g/mol) = 372 g/mol\n\nTherefore, the molecular weight of drug B is 372 g/mol, which corresponds to option ④.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ pH 5.0</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 침전</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 평형상태</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 표면장력</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 100일</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Q10(큐텐값)</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②\n\nExplanation:\n\nThe given figure shows the potential energy of three different surfaces (S1, S2, and S3) as a function of distance from the surface. The surfaces are labeled as follows:\n\n* S1: solid surface\n* S2: surface with a tightly bound layer of positive ions\n* S3: surface with a negatively charged layer\n\nFrom the figure, we can see that the potential energy of S3 is the highest, indicating that it has the most negative charge. Therefore, the correct answer is ②, \"S3's Nernst potential is positive.\"\n\nThe other options are incorrect for the following reasons:\n\n* ①: This statement is incorrect because the potential energy of S1 and S2 is not always positive.\n* ③: This statement is incorrect because the surface of the solid (a-a') is not necessarily negatively charged.\n* ④: This statement is incorrect because the surfaces are not necessarily electrically neutral at the interface.\n* ⑤: This statement is incorrect because S2 is not necessarily a surface with a tightly bound layer of positive ions.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 확산계수</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 용매의 극성 감소</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ② 0.240\n\nExplanation:\n\nThe question asks for the amount of sodium chloride (NaCl) needed to prepare a saturated solution of phenobarbital at 25°C. The given information states that the pure water solubility of phenobarbital is approximately 0.1 g/100 mL at 25°C, and the mole ratio of phenobarbital to sodium chloride is 1:0.24.\n\nTo prepare a saturated solution, we need to add enough sodium chloride to the solution to reach the solubility limit of phenobarbital. We can calculate the amount of sodium chloride needed using the mole ratio and the desired volume of the solution:\n\nAmount of sodium chloride = Mole ratio x Solubility limit x Volume\n= 0.24 x 0.1 g/100 mL x 100 mL\n= 0.24 g\n\nTherefore, the correct answer is ② 0.240 g.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ simvastatin</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 2-aminopyrimidine</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ ethionamide</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Ac2O/NaOAc</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ paroxetine</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ①</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ①</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ fluconazole</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① aripiprazole</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ diazepam</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ -COOH</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① baclofen</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ diclofenac</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ⑤</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 10^-13×0.83</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 9/11</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 10 | 9.4＋log 1.5</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 공침현상 방지</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 퀴닌황산염수화물</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ NaOCH3 – 디메틸포름아미드</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤\n\nExplanation:\n\nThe reason why naphthalene's ultraviolet-visible absorption spectrum shows a broad band spectrum, unlike the line spectrum of metal atoms, is because the molecule has vibrational and rotational transitions in addition to electronic transitions. These transitions lead to a broadening of the spectrum, resulting in a band spectrum.\n\nOption ① is incorrect because the size of the atom does not affect the spectrum.\n\nOption ② is incorrect because the presence of vibrational and rotational transitions in addition to electronic transitions is the reason for the broad band spectrum.\n\nOption ③ is incorrect because the energy levels of the molecule are not always identical to the energy levels of the atom.\n\nOption ④ is incorrect because the electronic transitions in naphthalene are not the only reason for the broad band spectrum.\n\nTherefore, the correct answer is ⑤, which states that the molecule has vibrational and rotational transitions in addition to electronic transitions, leading to a broad band spectrum.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 측정 셀의 길이는 100 mm이다.\n\nExplanation:\nThe question asks for the explanation of the measurement result of the specific rotation of d-camphor. The given answer options are:\n\n① The measurement wavelength is 254 nm.\n② The temperature of the measurement solution is 25°C.\n③ The sample is dissolved in 5 g of ethanol.\n④ The length of the measurement cell is 100 mm.\n⑤ 50 mL of plastic container is used.\n\nThe correct answer is ④ The length of the measurement cell is 100 mm.\n\nThe specific rotation of a substance is measured using a polarimeter, which measures the rotation of the plane of polarization of light as it passes through a sample. The length of the measurement cell is an important factor in determining the accuracy of the measurement. A longer cell length allows for a more accurate measurement of the sample's specific rotation, as it reduces the effect of any errors that may occur due to the sample's concentration or temperature.\n\nTherefore, the correct answer is ④ The length of the measurement cell is 100 mm, as it is the factor that affects the accuracy of the specific rotation measurement.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 열이온검출기(TID)</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 전자포획검출기</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 표준물첨가법</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nThe role of sodium dodecylsulfate (SDS) in micelle-forming chromatography is to inhibit the ionization of positively charged molecules. Therefore, option ③ is the correct answer.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 상관계수</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Q test</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 1750～1600</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 10</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 유당</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 유동층조립법</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 용해정</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 미분말을 20% 이상 가한다.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 용출시간이 길어진다.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 흡수연고</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 이소부탄</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 에틸셀룰로오스</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 항산화제 – 카올린</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 벤토나이트</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ 일렉트로포레이션(electroporation)</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③. The passage states that the amount of drug that can be dissolved in the carrier (투과량) increases proportionally with the concentration of the drug in the donor chamber (약물농도), even after the carrier is saturated. This indicates that the transport of the drug through the carrier is concentration-dependent, and the rate of transport is influenced by the concentration gradient between the donor and receiver chambers.\n\nTherefore, option ③, \"투과량은 담체(carrier)가 포화된 후에도 약물농도에 비례하여 증가한다\" (The amount of drug that can be dissolved in the carrier increases proportionally with the concentration of the drug in the donor chamber, even after the carrier is saturated), is the correct answer.\n\nOption ①, \"구조 특이성을 나타내지 않는다\" (Does not show structural specificity), is incorrect because the passage does not mention anything about structural specificity.\n\nOption ②, \"투과 속도는 온도의 영향을 받지 않는다\" (The rate of transport is not affected by temperature), is incorrect because the passage does not mention anything about the effect of temperature on the rate of transport.\n\nOption ④, \"생체막 양측에 있는 물질의 농도 기울기(gradient)가 추진력으로 작용한다\" (The concentration gradient of the solute on both sides of the biological membrane acts as a driving force), is incorrect because the passage does not mention anything about the concentration gradient acting as a driving force.\n\nOption ⑤, \"세포 내에서 에너지를 생산하는 대사반응을 저해하는 물질에 의하여 투과가 저해된다\" (The transport is inhibited by a substance that inhibits the energy-producing metabolic reaction inside the cell), is incorrect because the passage does not mention anything about the inhibition of transport by such a substance.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\n\nThe question is asking about the classification of a drug based on its bioavailability and bioequivalence. The correct answer is ③, which states that a drug with a narrow therapeutic index (NTI) and a difficult-to-predict absorption profile belongs to class 3.\n\nClass 1 drugs have a high bioavailability and a low inter-subject variability, meaning that they are easily absorbed and have a consistent effect across individuals. Class 2 drugs have a high bioavailability but a high inter-subject variability, meaning that they are easily absorbed but can have different effects depending on the individual. Class 4 drugs have a low bioavailability and a high inter-subject variability, meaning that they are difficult to absorb and have a variable effect across individuals.\n\nA drug with a narrow therapeutic index (NTI) is a drug that requires a precise dosage to achieve the desired therapeutic effect, and a difficult-to-predict absorption profile means that the drug's absorption can vary greatly depending on the individual. Therefore, such a drug would belong to class 3, which includes drugs with a narrow therapeutic index and difficult-to-predict pharmacokinetics.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③. The pH of the urine can affect the reabsorption of drugs in the renal tubules. An increase in urinary pH can increase the reabsorption of weakly acidic drugs, while a decrease in urinary pH can increase the reabsorption of weakly basic drugs. This is because the pH of the urine can affect the ionization of the drug, which in turn can affect its ability to be reabsorbed by the renal tubules.\n\nThe other options are not correct explanations for the reabsorption of drugs in the renal tubules:\n\n① is incorrect because the presence of organic ion transporters in the renal tubules does not directly affect the reabsorption of drugs.\n\n② is incorrect because the reabsorption of drugs in the renal tubules is not solely due to active transport.\n\n④ is incorrect because the binding of drugs to plasma proteins does not directly affect their reabsorption in the renal tubules.\n\n⑤ is incorrect because the solubility of drugs in water does not directly affect their reabsorption in the renal tubules.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 80\n\nExplanation:\nThe renal clearance (CLr) of the drug is 10 L/h, and the total clearance (CL) is 20 L/h. The drug is administered orally, and the amount of drug excreted in the urine is 80 mg.\n\nTo calculate the oral absorption rate (%), we can use the following equation:\n\nOral absorption rate (%) = (Amount of drug excreted in the urine / Total dose administered) x 100\n\nSubstituting the values given in the question, we get:\n\nOral absorption rate (%) = (80 mg / 200 mg) x 100 = 40%\n\nTherefore, the correct answer is ④ 80.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 벤토나이트</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ 약물의 흡수는 일반적으로 능동수송을 따른다.\n\nExplanation:\n\nThe correct answer is ④ 약물의 흡수는 일반적으로 능동수송을 따른다.\n\nWhen the drug is administered rectally, it is absorbed through the rectal mucosa and enters the bloodstream. The absorption of the drug is influenced by various factors, including the drug's solubility, particle size, and the presence of other substances that may affect its absorption.\n\nOption ① 전신작용은 나타나지 않는다 is incorrect because the drug is still absorbed into the bloodstream, even though it is not absorbed through the digestive system.\n\nOption ② 약물의 수용성이 클수록 흡수는 증가한다 is incorrect because the absorption of the drug is not directly related to its solubility.\n\nOption ③ 약물의 입자경이 클수록 흡수는 증가한다 is incorrect because the particle size of the drug does not directly affect its absorption.\n\nOption ⑤ 직장 하부에서 흡수된 약물은 간초회통과효과를 피할 수 있다 is incorrect because the drug is not metabolized by the liver before it is absorbed into the bloodstream.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ morphine</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① artemisinin</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ papaverine</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 행인</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Illicium verum</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ ophiopogonin A</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Liriopis seu Ophiopogonis Tuber</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Ponciri Fructus Immaturus</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Ergota</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ icariin</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Hydrastidis Rhizoma</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ (+)-matrine</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 심(心)\n\nThe function of \"중초(中焦)\" that is, the thing that is in charge of transporting and transforming Qi and blood, and has the function of purifying blood, is the 심(心), or heart.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 복령(茯苓)</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 고본환정환(固本還睛丸)</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 당귀작약산(當歸芍藥散)</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ⑤ saikosaponin a</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ D-glucuronic acid</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 니페디핀(nifedipine)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 에제티미브\n\nExplanation:\n\nThe patient's symptoms of bradycardia and hypotension are consistent with digoxin toxicity. The patient's digoxin level is elevated at 0.8 ng/mL, which is above the therapeutic range. The other medications the patient is taking, such as enalapril, furosemide, and rosuvastatin/ezetimibe, are not likely to cause bradycardia or hypotension. Vitamin B complex is not associated with digoxin toxicity. Therefore, the most likely cause of the patient's symptoms is digoxin toxicity, and the answer is ③ 에제티미브.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 아토르바스타틴(atorvastatin)\n\nExplanation:\nThe patient has hypertension, diabetes, and hyperlipidemia, which increases the risk of cardiovascular disease. Atorvastatin is a statin that can help lower LDL-C levels and reduce the risk of cardiovascular events. It is a appropriate choice for this patient based on their clinical presentation and laboratory results.\n\nApixaban (①) is an anticoagulant that may be considered for patients with atrial fibrillation or venous thromboembolism, but it is not indicated for the patient's current condition.\n\nDoxazosin (②) is an alpha-blocker that can be used to treat hypertension, but it may not be the best choice for this patient due to the risk of hypotension and bradycardia.\n\nEzetimibe (③) is a cholesterol absorption inhibitor that can help lower LDL-C levels, but it may not be as effective as atorvastatin in reducing cardiovascular risk.\n\nSpironolactone (⑤) is a potassium-sparing diuretic that can be used to treat hypertension and heart failure, but it is not indicated for the patient's current condition.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 당화혈색소</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 리바록사반(rivaroxaban)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 페니토인(phenytoin)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 티카그렐러(ticagrelor)\n\nReasoning:\n\nThe patient has a history of hypertension and atrial fibrillation, which increases the risk of stroke. The patient is also taking amlodipine and hydrochlorothiazide, which are medications that can increase the risk of hypotension. Therefore, a medication that can reduce the risk of stroke and bleeding would be appropriate.\n\nTicagrelor is an antiplatelet medication that is used to prevent stroke and systemic embolism in patients with acute coronary syndrome or atrial fibrillation. It works by inhibiting platelet activation and aggregation, which can reduce the risk of thromboembolic events.\n\nAspirin, apixaban, and argatroban are also antiplatelet or anticoagulant medications that can reduce the risk of stroke, but they may not be as effective in this case due to the patient's history of hypertension and atrial fibrillation. Cilostazol is a medication that can reduce the risk of bleeding, but it may not be effective in preventing stroke.\n\nTherefore, the most appropriate medication for this patient would be ticagrelor.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 프라바스타틴(pravastatin) 20 mg\n\nExplanation:\n\nThe patient has a history of hypertension, diabetes, and TIA (transient ischemic attack), which suggests a high risk of cardiovascular disease. The current medications, aspirin, amlodipine, and metformin, are appropriate for the patient's conditions. However, the patient's LDL-C level is still high (165 mg/dL), indicating a need for additional lipid-lowering therapy.\n\nOf the options provided, 프라바스타틴(pravastatin) 20 mg is the most appropriate choice. Pravastatin is a HMG-CoA reductase inhibitor that is effective in reducing LDL-C levels and has a good safety profile. It is also less likely to interact with other medications the patient is currently taking, such as aspirin and amlodipine.\n\nThe other options, 로바스타틴(lovastatin), 심바스타틴(simvastatin), 플루바스타틴(fluvastatin), and 로수바스타틴(rosuvastatin), are also HMG-CoA reductase inhibitors, but they may have more potential for drug interactions or side effects compared to pravastatin.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 요산\n\nExplanation:\n\nThe patient has been taking atorvastatin for 3 months, and recently reported weakness in her legs and muscle pain. The liver enzyme, alanine transaminase (ALT), is elevated. Given these symptoms and laboratory results, it is necessary to check for liver damage or muscle damage caused by the drug. Therefore, the necessary test item is ③ 요산 (ALT).</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 와파린(warfarin)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 용량 유지 후 비타민K 정맥투여</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 카르베딜롤(carvedilol) 경구제\n\nExplanation:\n\nThe patient has been diagnosed with hypertensive emergency, and the physician has decided to administer an antihypertensive medication to lower the blood pressure. Among the options, carvedilol is the most appropriate choice because it is a beta-blocker that has a rapid onset of action and can effectively lower the blood pressure within 30 minutes. Additionally, it has a long duration of action, which makes it suitable for maintenance therapy.\n\nDoxazosin, amlodipine, and labetalol are also antihypertensive medications, but they have a slower onset of action compared to carvedilol. Nitroprusside is a vasodilator that can lower the blood pressure quickly, but it is not suitable for maintenance therapy and is associated with potential side effects such as hypotension and tachycardia.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 에독사반(edoxaban)\n\nExplanation:\n\nThe patient has a history of hypertension and diabetes, and has recently experienced a transient ischemic attack (TIA) with left-sided weakness and dizziness. The patient's medication history includes linagliptin, metformin, amlodipine, and hydrochlorothiazide. Given the patient's history of hypertension and TIA, the most appropriate medication to prevent recurrent stroke would be an oral anticoagulant, such as edoxaban.\n\nEdoxaban is a direct factor Xa inhibitor that is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation or venous thromboembolism. It has been shown to be effective in reducing the risk of stroke and bleeding in patients with atrial fibrillation, and has a relatively low risk of bleeding compared to other oral anticoagulants.\n\nHeparin and warfarin are also oral anticoagulants, but they have different mechanisms of action and may not be as effective in preventing stroke in this patient population. Abciximab is a glycoprotein IIb/IIIa inhibitor that is used to prevent platelet aggregation and is not appropriate for preventing stroke. Clopidogrel is a P2Y12 inhibitor that is used to prevent platelet aggregation and is not appropriate for preventing stroke in this patient population.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 다비가트란(dabigatran)\n\nExplanation:\n\nThe patient has been diagnosed with acute coronary syndrome and is scheduled to undergo percutaneous coronary intervention (PCI). The doctor has prescribed dabigatran, an oral direct thrombin inhibitor, as an anticoagulant to prevent thrombus formation during the procedure. Dabigatran is a suitable choice for this patient because it has a rapid onset of action and can be administered orally, which is convenient for an outpatient procedure like PCI. Additionally, dabigatran has been shown to be effective in reducing the risk of thrombotic events in patients with acute coronary syndrome.\n\nThe other options are not suitable for this patient because:\n\n* Warfarin (①) is an oral vitamin K antagonist that takes several days to reach its full anticoagulant effect, making it less suitable for an urgent procedure like PCI.\n* Abciximab (②) is an intravenous glycoprotein IIb/IIIa inhibitor that is used to prevent platelet aggregation during PCI, but it is not an anticoagulant and does not prevent thrombin formation.\n* Alteplase (③) is an intravenous thrombolytic agent that is used to dissolve thrombi, but it is not an anticoagulant and does not prevent thrombus formation.\n* Rivaroxaban (⑤) is an oral factor Xa inhibitor that is used for long-term anticoagulation, but it is not suitable for an urgent procedure like PCI because it takes several hours to reach its full anticoagulant effect.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 암로디핀(amlodipine)\n\nExplanation:\n\nThe patient has been diagnosed with stable angina and has been scheduled for percutaneous coronary intervention (PCI). The patient's medication list includes aspirin, clopidogrel, carvedilol, and pravastatin. The addition of amlodipine, a calcium channel blocker, would be appropriate for the patient's condition. Amlodipine can help to reduce the patient's angina symptoms and improve their exercise tolerance. It can also help to lower the patient's blood pressure, which is currently elevated.\n\nThe other options are not appropriate for the patient's condition. Digoxin is a cardiac glycoside that is used to treat heart failure and atrial fibrillation. Ramipril is an ACE inhibitor that is used to treat hypertension and heart failure. Ivabradine is a medication that is used to treat hypertension and angina. Hydralazine is a medication that is used to treat hypertension and heart failure.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 알라닌아미노전이효소</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 부데소니드(budesonide)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 플루티카손/살메테롤(fluticasone/salmeterol)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 테오필린\n\nExplanation:\n\nThe patient is a 66-year-old male who has been smoking one pack of cigarettes per day for 20 years and has been hospitalized for chronic obstructive pulmonary disease (COPD) exacerbation. The patient's symptoms have been well-controlled with medications, including salbutamol, ipratropium, prednisolone, cefuroxime, indacaterol, and theophylline. However, since the patient has been hospitalized, he has not been smoking, and therefore, the dosage of the medications needs to be adjusted.\n\nTheophylline, which is a methylxanthine, is a medication that is commonly used to treat COPD. It works by relaxing the smooth muscles in the airways, which helps to improve lung function and reduce symptoms such as wheezing and shortness of breath. However, theophylline can have side effects, such as nausea, vomiting, and headaches, especially when taken in high doses.\n\nSince the patient has been hospitalized and has not been smoking, the dose of theophylline needs to be adjusted to avoid potential side effects. The correct answer is ③ 테오필린 (theophylline).</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 플루티카손(fluticasone) 비강분무제</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 세푸록심(cefuroxime)＋메트로니다졸(metronidazole)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 라베프라졸(rabeprazole)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 프로프라놀롤(propranolol)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 락툴로오스(lactulose)\n\nExplanation:\n\nThe patient is experiencing symptoms of irritable bowel syndrome (IBS) with constipation, abdominal pain, and limited daily activities. Lactulose is a synthetic disaccharide that can help relieve constipation and improve bowel movements. It works by increasing the amount of water in the intestines and softening stool, making it easier to pass.\n\nThe other options are not appropriate for this patient's symptoms:\n\n① Lactitol is a sugar substitute that can cause diarrhea and is not effective for constipation.\n\n② Bisacodyl is a stimulant laxative that can cause cramping and is not suitable for long-term use.\n\n③ Sertraline is an antidepressant that can help with anxiety and depression, but it is not effective for treating IBS symptoms.\n\n⑤ Ramosetron is a serotonin receptor antagonist that can help with irritable bowel syndrome symptoms, but it is not approved for use in Korea.\n\nTherefore, the best answer is ④ 락툴로오스(lactulose).</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 엔테카비르(entecavir)\n\nExplanation:\n\nThe patient's liver function test results show elevated AST and ALT levels, indicating liver damage. The HBV DNA level is also high, indicating active viral replication. The patient's medical history includes chronic hepatitis B, which further supports the diagnosis of liver disease.\n\nEntecavir is a nucleoside analogue that is effective against HBV and has been shown to improve liver function and reduce HBV DNA levels. It is also generally well-tolerated and has a good safety profile. Therefore, it is the most appropriate choice for this patient.\n\nAdefovir, lamivudine, and sofosbuvir are also effective against HBV, but they have different mechanisms of action and may not be as effective in this case. Daclatasvir is an NS5A inhibitor that is effective against HCV, but it is not active against HBV. Therefore, it is not a suitable choice for this patient.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 설파살라진(sulfasalazine) 경구제</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 결핵감염 여부</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ① 엔테카비르(entecavir)＋리바비린(ribavirin)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ HCV RNA</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 탄산수소나트륨(sodium bicarbonate)\n\nExplanation:\n\nThe patient has hypokalemia (low potassium levels) and metabolic acidosis (elevated sodium, chloride, and bicarbonate levels), which indicates that the patient may have been experiencing excessive potassium loss in the urine. Sodium bicarbonate can help replace the lost potassium and correct the metabolic acidosis.\n\nCyclosporine (①) is an immunosuppressant and has no effect on potassium levels. Spironolactone (②) is a potassium-sparing diuretic, but it may not be effective in this case since the patient already has low potassium levels. Calcium gluconate (③) is used to treat hypocalcemia (low calcium levels), but it is not related to the patient's current condition. Calcium polystyrene sulfonate (⑤) is a cation-exchange resin that can help remove excess potassium from the gut, but it is not appropriate for this patient's condition.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 에날라프릴</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 메스나(mesna)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 비뇨기질환</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ 음이온차이(anion gap)가 정상인 대사성 산증</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 레티놀\n\nExplanation:\n\nLosartan is an angiotensin II receptor antagonist that is used to treat hypertension and kidney disease. It is important to monitor the patient's potassium levels when taking this medication, as it can cause hyperkalemia (elevated potassium levels) as a side effect. Therefore, option ③ 레티놀 (potassium) is the correct answer.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 로수바스타틴\n\nExplanation:\n\nThe patient's symptoms of frequent urination, urgency, and nocturia, along with the diagnosis of yoro-gai (a Japanese term for \"foul-smelling urine\") and the presence of pyuria, suggest a urinary tract infection (UTI). The patient's history of type 2 diabetes, hyperlipidemia, and hypertension may also contribute to the development of UTI.\n\nAmong the medications listed, rosuvastatin (③) is the most likely culprit for the patient's UTI. Rosuvastatin is a statin, a class of medications commonly used to treat high cholesterol. However, statins have been associated with an increased risk of UTI, particularly in older adults. The mechanism by which statins increase the risk of UTI is not fully understood, but it is thought to be related to the drug's effect on the immune system and the gut microbiome.\n\nThe other options, metformin (①), dapagliflozin (②), ramipril (④), and amlodipine (⑤), may also contribute to the development of UTI, but they are less likely than rosuvastatin. Metformin and dapagliflozin are medications used to treat type 2 diabetes and may increase the risk of UTI by altering the gut microbiome and increasing glucose levels in the urine. Ramipril is an ACE inhibitor used to treat hypertension and may increase the risk of UTI by reducing the activity of the renin-angiotensin-aldosterone system, which can lead to changes in the urinary tract. Amlodipine is a calcium channel blocker used to treat hypertension and may increase the risk of UTI by altering blood flow to the urinary tract.\n\nTherefore, based on the patient's symptoms and medication regimen, the most likely cause of the patient's UTI is rosuvastatin.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 글리피지드(glipizide)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 녹내장</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 레파글리니드(repaglinide)\n\nExplanation:\n\nThe patient has type 2 diabetes, and the current medication, glipizide, is not effectively controlling blood sugar levels. The patient's BMI is 29 kg/m2, indicating obesity, which is a risk factor for developing insulin resistance. In this case, a thiazolidinedione (TZD) such as pioglitazone (④) may be a better choice than a sulfonylurea such as glipizide, as TZDs have been shown to improve insulin sensitivity and reduce inflammation. However, pioglitazone may increase the risk of heart problems, and the patient is already taking a calcium channel blocker (amlodipine) and an ACE inhibitor (lisinopril) for hypertension. Repaglinide (③) is a meglitinide, which stimulates the release of insulin from the pancreas and may be more effective in lowering blood glucose levels in patients with type 2 diabetes who have not achieved adequate control with sulfonylureas. Additionally, repaglinide has a lower risk of hypoglycemia compared to other sulfonylureas.\n\nTherefore, the best answer is ③ 레파글리니드(repaglinide).</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 암로디핀\n\nExplanation:\n암로디핀(amlodipine) is a calcium channel blocker, which can cause a decrease in vitamin B12 absorption. Vitamin B12 is an essential nutrient that plays a critical role in the body's functioning, and a deficiency can lead to various health problems.\n\nThe other options are not correct because:\n\n① 메트포르민(metformin) is an anti-diabetic medication that does not affect vitamin B12 levels.\n\n② 글리피지드(glipizide) is a sulfonylurea medication that stimulates the release of insulin and does not affect vitamin B12 levels.\n\n④ 리시노프릴(lisinopril) is an ACE inhibitor that does not affect vitamin B12 levels.\n\n⑤ 아토르바스타틴(atorvastatin) is a statin medication that does not affect vitamin B12 levels.\n\nTherefore, the correct answer is ③ 암로디핀(amlodipine).</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 레보티록신(levothyroxine)\n\nExplanation:\n\nThe patient's symptoms of rapid heartbeat, palpitations, and anxiety, along with the laboratory results of elevated T4 and low TSH levels, suggest a diagnosis of hyperthyroidism. Levothyroxine is a synthetic form of the thyroid hormone thyroxine (T4), which is used to treat hypothyroidism. However, in this case, it would be inappropriate to prescribe levothyroxine as it would further exacerbate the patient's hyperthyroidism.\n\nTherefore, the correct answer is ③ 레보티록신(levothyroxine).</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 프로프라놀롤(propranolol)\n\nExplanation:\n\nThe patient's symptoms of palpitations, chest tightness, and shortness of breath suggest a possible diagnosis of anxiety or panic disorder. Propranolol is a beta-blocker that is commonly used to treat anxiety disorders, as it can help to reduce the physical symptoms associated with anxiety, such as tremors, tachycardia, and hypertension. It is also known to have a calming effect on the nervous system, which can help to reduce feelings of anxiety and panic.\n\nAspirin (①) is an NSAID that is commonly used to treat pain and inflammation, but it is not typically used to treat anxiety disorders.\n\nAcarbose (②) is an alpha-glucosidase inhibitor that is used to treat diabetes, but it is not related to the patient's symptoms or diagnosis.\n\nAmiodarone (③) is an anti-arrhythmic drug that is used to treat irregular heart rhythms, but it is not typically used to treat anxiety disorders.\n\nAcetaminophen (⑤) is a pain reliever and fever reducer, but it is not related to the patient's symptoms or diagnosis.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 농도 의존적 살균작용 증가</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 세팔렉신(cefalexin)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 세프트리악손(ceftriaxone)＋리네졸리드(linezolid)\n\nExplanation:\nThe patient has a history of type 2 diabetes and has been hospitalized for 6 days due to a traffic accident. The patient's vital signs and laboratory results indicate that they have developed hospital-acquired pneumonia (HAP) and sepsis. The patient's history of diabetes and recent hospitalization increase the risk of multidrug-resistant bacterial infections.\n\nCeftriaxone is a cephalosporin antibiotic that is effective against a wide range of gram-positive and gram-negative bacteria, including many strains of Streptococcus pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa. Linezolid is an oxazolidinone antibiotic that is effective against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).\n\nThe combination of ceftriaxone and linezolid provides broad-spectrum coverage against both gram-positive and gram-negative bacteria, including many multidrug-resistant strains. This combination is often used to treat HAP and sepsis in patients with a high risk of multidrug-resistant bacterial infections.\n\nTherefore, option ③, 세프트리악손(ceftriaxone)＋리네졸리드(linezolid), is the most appropriate answer.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 세프트리악손(ceftriaxone)＋아지트로마이신(azithromycin)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 레보플록사신(levofloxacin)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe patient has symptoms of meningitis, including fever, headache, and stiff neck, and the CSF examination shows abnormal results, including elevated WBC count, low glucose level, and elevated protein level. The patient has recently undergone neurosurgery, which increases the risk of infection.\n\nBased on the patient's history and symptoms, the most appropriate antibiotic regimen would be a combination of vancomycin and cefepime. Vancomycin is effective against methicillin-resistant Staphylococcus aureus (MRSA), which is a common cause of meningitis in patients with recent neurosurgery. Cefepime is a broad-spectrum cephalosporin that covers a wide range of gram-positive and gram-negative bacteria, including many strains of Streptococcus and Haemophilus.\n\nThe other options are not as appropriate for this patient's condition:\n\n① Sulfamethoxazole/trimethoprim is effective against Pneumocystis jirovecii pneumonia, but it is not as effective against meningitis caused by other bacteria.\n\n② Vancomycin plus cefazolin is a reasonable combination for MRSA coverage, but cefazolin has no activity against Haemophilus influenzae, which is a common cause of meningitis.\n\n④ Ampicillin plus metronidazole is effective against Haemophilus influenzae, but it does not provide adequate coverage against MRSA.\n\n⑤ Ampicillin plus cefuroxime is a reasonable combination for meningitis, but it may not provide adequate coverage against MRSA.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 보리코나졸(voriconazole) 주사제</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 시타글립틴\n\nExplanation:\nItraconazole is a potent inhibitor of CYP3A4, an enzyme responsible for metabolizing many drugs, including sitagliptin. Co-administration of itraconazole with sitagliptin can significantly increase the plasma concentration of sitagliptin, leading to increased risk of adverse effects such as hypoglycemia. Therefore, it is necessary to adjust the dose of sitagliptin when co-administered with itraconazole.\n\nThe other options are not correct because:\n\n① Ranitidine is not metabolized by CYP3A4, so it is not affected by itraconazole.\n\n② Metformin is not metabolized by CYP3A4, so it is not affected by itraconazole.\n\n④ Enalapril is metabolized by CYP3A4, but it is not affected by itraconazole to a significant extent.\n\n⑤ Vitamin B and C complex does not have any significant interaction with itraconazole.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 반코마이신(vancomycin) 경구제</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 목시플록사신(moxifloxacin) 경구제\n\nExplanation:\nThe patient has been diagnosed with severe acute kidney injury (AKI) and is experiencing symptoms such as fever, nausea, and vomiting. The laboratory results show elevated BUN and creatinine levels, indicating impaired renal function. The patient has not been able to eat anything for the past 24 hours, which suggests that they may have a high risk of developing aspiration pneumonia.\n\nConsidering these factors, the most appropriate antibiotic choice would be moxifloxacin, which is a fluoroquinolone antibiotic that is effective against a wide range of gram-negative and gram-positive bacteria, including Pseudomonas aeruginosa, which is a common cause of aspiration pneumonia. Moxifloxacin is also available in an oral formulation, which would be appropriate for this patient since they have not been able to eat anything.\n\nCefpodoxime and ceftriaxone are cephalosporin antibiotics that are effective against a wide range of gram-positive and gram-negative bacteria, but they may not be as effective against Pseudomonas aeruginosa as moxifloxacin. Fosfomycin is a broad-spectrum antibiotic that is effective against many gram-negative bacteria, but it may not be as effective against gram-positive bacteria as other antibiotics. Vancomycin is a glycopeptide antibiotic that is effective against methicillin-resistant Staphylococcus aureus (MRSA), but it may not be effective against other bacteria that cause aspiration pneumonia.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 레보플록사신(levofloxacin) 경구제\n\nExplanation:\nThe patient has been diagnosed with severe acute respiratory distress syndrome (ARDS) and has been treated with sulfamethoxazole/trimethoprim, which is an appropriate antibiotic for this condition. However, the patient's symptoms have not improved after 4 days of treatment, and the patient is considering discharge. In this case, it is appropriate to switch to a different antibiotic that is effective against the likely pathogens causing ARDS.\n\nLevofloxacin is a fluoroquinolone antibiotic that is effective against a wide range of gram-negative and gram-positive bacteria, including Pseudomonas aeruginosa, which is a common pathogen in ARDS. Additionally, levofloxacin has been shown to be effective in reducing the risk of respiratory failure and improving survival in patients with ARDS.\n\nThe other options are not as appropriate for this patient's condition. Linezolid is a oxazolidinone antibiotic that is effective against gram-positive bacteria, but it is not effective against Pseudomonas aeruginosa. Doxycycline is a tetracycline antibiotic that is effective against a wide range of gram-positive and gram-negative bacteria, but it is not as effective against Pseudomonas aeruginosa as levofloxacin. Clindamycin is a lincosamide antibiotic that is effective against gram-positive bacteria, but it is not effective against Pseudomonas aeruginosa. Azithromycin is a macrolide antibiotic that is effective against a wide range of gram-positive and gram-negative bacteria, but it is not as effective against Pseudomonas aeruginosa as levofloxacin.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 리자트립탄(rizatriptan)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 도네페질(donepezil)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 돔페리돈(domperidone)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 라모트리진 1일 용량의 50%를 감량하여 시작</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 둘록세틴(duloxetine)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 팔리페리돈(paliperidone)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 1일 1회 2정을 취침 전에 복용</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ⑤ 폐활량\n\nExplanation:\n\nAs a pharmacist, it is important to regularly monitor the patient's vital signs, including heart rate and blood pressure, when prescribing medication, especially for children. This is because children's bodies are still developing, and certain medications can have unintended effects on their cardiovascular system. In this case, the patient is taking methylphenidate, which is a stimulant that can increase heart rate and blood pressure. Therefore, it is important to regularly monitor the patient's heart rate and blood pressure to ensure that the medication is not causing any adverse effects.\n\n답의 설명:\n\n약사로서, 약물 처방을 할 때 환자의 중요한 신체 기능, 즉 안압과 혈당을 정기적으로 모니터링해야 합니다. 특히 아동의 경우, 약물이 그들의 생체 발달에 미치는 영향을 고려해야 하며, 이러한 경우에는 메틸페니데이트를 복용하고 있는 환자의 心拍과 혈당을 정기적으로 모니터링해야 합니다. 이는 메틸페니데이트가 활량 증가제로 작용하여 心拍과 혈당을 증가시킬 수 있기 때문입니다. 따라서 약물 처방을 할 때 환자의 心拍과 혈당을 정기적으로 모니터링하여 약물이 부작용을 일으키지 않는지 확인하는 것이 중요합니다.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 둘록세틴(duloxetine)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 랄록시펜(raloxifene)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 나프록센(naproxen)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 피나스테리드(finasteride)＋탐스로신(tamsulosin)\n\nExplanation:\n\nThe patient has been diagnosed with benign prostatic hyperplasia (BPH) and has symptoms such as large prostate size (42g), high levels of prostate-specific antigen (PSA) in the blood (4.8 ng/mL), and moderate symptoms according to the International Prostate Symptom Score (IPSS) (18 points).\n\nThe appropriate treatment for this patient would be a combination of finasteride (⑤) and tamsulosin (⑤). Finasteride is a 5-alpha-reductase inhibitor that reduces the production of dihydrotestosterone (DHT), a hormone that stimulates prostate growth. Tamsulosin is an alpha-1 adrenergic receptor antagonist that relaxes the smooth muscle in the prostate and bladder neck, improving urinary symptoms. This combination therapy has been shown to be effective in improving symptoms and reducing the risk of acute urinary retention and surgery in patients with BPH.\n\nThe other options are not appropriate for this patient's condition:\n\n① Sildenafil (Viagra) is a phosphodiesterase type 5 inhibitor that is used to treat erectile dysfunction, but it is not indicated for BPH.\n\n② Doxazosin is an alpha-1 adrenergic receptor antagonist that is used to treat hypertension and benign prostatic hyperplasia, but it is not as effective as tamsulosin in improving urinary symptoms.\n\n③ Desmopressin is a vasopressin receptor agonist that is used to treat central diabetes insipidus, but it is not indicated for BPH.\n\n④ Oxybutynin is an anticholinergic agent that is used to treat urinary incontinence, but it is not indicated for BPH. Terazosin is an alpha-1 adrenergic receptor antagonist that is used to treat hypertension and BPH, but it is not as effective as tamsulosin in improving urinary symptoms.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① 폴산(folic acid)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 프레드니솔론(prednisolone)\n\nExplanation:\n\nPrednisolone is a corticosteroid that is commonly used to treat inflammatory conditions such as rheumatoid arthritis. It works by reducing inflammation and suppressing the immune system. In this case, prednisolone can be used to reduce the symptoms of rheumatoid arthritis before methotrexate takes effect.\n\nSulfasalazine (①) is an anti-inflammatory drug that is also used to treat rheumatoid arthritis, but it may take longer to show its effect compared to prednisolone.\n\nAzathioprine (②) is an immunosuppressant that is used to treat autoimmune diseases, including rheumatoid arthritis. However, it may take several weeks to show its full effect.\n\nAcetaminophen (④) is a pain reliever and fever reducer that may be used to manage the symptoms of rheumatoid arthritis, but it does not have anti-inflammatory properties.\n\nHydroxychloroquine (⑤) is an antimalarial drug that is sometimes used to treat rheumatoid arthritis, but its mechanism of action is different from that of prednisolone, and it may take longer to show its effect.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 닐로티닙(nilotinib)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 아나스트로졸(anastrozole)\n\nExplanation:\n\nThe patient has been treated for breast cancer and has a history of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) tumors. Therefore, the most appropriate adjuvant chemotherapy drug for this patient would be an aromatase inhibitor, which is a drug that blocks the production of estrogen in the body. Anastrozole is an aromatase inhibitor and is commonly used to treat postmenopausal women with hormone receptor-positive breast cancer.\n\nLapatinib (①) is a tyrosine kinase inhibitor that targets both HER2 and EGFR, but it is not suitable for this patient since the tumor is HER2-negative. Capecitabine (②) is a fluoropyrimidine that is metabolized to 5-FU, which can be effective against breast cancer, but it is not targeted therapy for HR+ breast cancer. Bevacizumab (③) is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) and is used to treat various cancers, including breast cancer, but it is not specifically targeted to HR+ breast cancer. Trastuzumab (⑤) is a monoclonal antibody that targets HER2 and is used to treat HER2-positive breast cancer, but it is not suitable for this patient since the tumor is HER2-negative.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 니볼루맙(nivolumab)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 로페라미드(loperamide) 경구제</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 가바펜틴(gabapentin)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ⑤ 갑상선기능\n\nExplanation:\n\nThe patient has undergone surgery for breast cancer, and the planned adjuvant chemotherapy includes doxorubicin and cyclophosphamide. The dosages of these drugs are 60 mg/m2 and 600 mg/m2, respectively, on day 1.\n\nWhen reviewing the dosages of chemotherapy drugs, it is important to consider the patient's liver function, as certain chemotherapy drugs can be metabolized by the liver and may cause liver damage. Therefore, option ⑤ 갑상선기능 (liver function) is the correct answer.\n\nThe other options are not directly related to the patient's liver function and are therefore not relevant to this question:\n\n① 안압 (blood pressure)\n② 간기능 (kidney function)\n③ 골밀도 (bone marrow function)\n④ 폐기능 (lung function)</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 아프레피탄트(aprepitant)＋온단세트론＋덱사메타손</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 히드로코르티손(hydrocortisone) 1% 크림</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 티몰롤(timolol) 점안제</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 혈소판</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Good Pharmacy Practice(GPP)</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Assessment</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 약물상호작용 발생\n\nExplanation:\nThe patient is taking acetaminophen 650 mg three times a day and oxycodone CR 20 mg twice a day. After three days, the patient experienced severe constipation. This is likely a result of the interaction between the two medications, as acetaminophen can increase the risk of constipation and oxycodone can also cause constipation as a side effect. Therefore, option ③ 약물상호작용 발생 (drug interaction) is the correct answer.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ② 암로디핀\n\nExplanation:\n\nThe patient is taking a combination of medications for the treatment of hypertension, hyperlipidemia, and prevention of cardiovascular disease. The medications include simvastatin, aspirin, amlodipine, carvedilol, and hydrochlorothiazide.\n\nAmlodipine is a calcium channel blocker that is commonly used to treat hypertension and angina. It has a long duration of action and is usually taken once daily. In this case, the patient is taking 5 mg of amlodipine once daily.\n\nAspirin is a nonsteroidal anti-inflammatory drug (NSAID) that is used to prevent blood clots and reduce the risk of cardiovascular events. It is commonly taken once daily, and the recommended dose is 75-325 mg/day. In this case, the patient is taking 100 mg of aspirin once daily.\n\nSimvastatin is a statin that is used to lower cholesterol levels and reduce the risk of cardiovascular events. It is usually taken once daily, and the recommended dose range is 20-80 mg/day. In this case, the patient is taking 20 mg of simvastatin once daily.\n\nCarvedilol is a beta-blocker that is used to treat hypertension and heart failure. It has a long duration of action and is usually taken once daily. In this case, the patient is taking 12.5 mg of carvedilol once daily.\n\nHydrochlorothiazide is a diuretic that is used to treat hypertension and edema. It has a short duration of action and is usually taken once daily. In this case, the patient is taking 25 mg of hydrochlorothiazide once daily.\n\nGiven the patient's medication regimen, the medication that should be taken in the morning to prevent side effects is amlodipine. Amlodipine has a long duration of action and can cause side effects such as dizziness, headache, and fatigue if taken in the evening. Therefore, it is recommended to take amlodipine in the morning to minimize the risk of side effects.\n\nTherefore, the answer is ② 암로디핀 (amlodipine).</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① PubMed</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 조제 시 참고사항</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 디곡신(digoxin) 정</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nThe question asks for the drug that the physician should inquire about when performing a DUR (Drug Utilization Review) for a 10-year-old boy's prescription. The correct answer is 미노사이클린 (minocycline) 캡슐 (capsule).\n\nThe reason for this answer is that minocycline is a tetracycline-class antibiotic that is contraindicated in children under the age of 12 due to the risk of developing dental staining and enamel hypoplasia. Therefore, it is important for the physician to verify the patient's age and ensure that the prescription is appropriate for a 10-year-old boy.\n\nThe other options are not relevant to the question:\n\n① 정장제 캡슐 (Bacillus subtilis capsule) is not a medication that is contraindicated in children.\n\n② 세티리진 정 (cetirizine tablet) is an antihistamine that is commonly used in children, but it is not the medication that the physician should inquire about in this scenario.\n\n④ 아세트아미노펜 정 (acetaminophen tablet) is a pain reliever and fever reducer that is commonly used in children, but it is not the medication that the physician should inquire about in this scenario.\n\n⑤ 피메크로리무스 크림 (pimecrolimus cream) is a topical medication that is used to treat eczema and other skin conditions, but it is not the medication that the physician should inquire about in this scenario.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ①</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ② 로이코보린(leucovorin) 주\n\nExplanation:\n\nLeucovorin is a folinic acid derivative that is used to prevent methotrexate-induced gastrointestinal toxicity. Methotrexate is a chemotherapy drug that is commonly used to treat cancer, but it can cause gastrointestinal side effects such as nausea, vomiting, and diarrhea. Leucovorin works by protecting the cells that line the gastrointestinal tract from the harmful effects of methotrexate, reducing the risk of gastrointestinal toxicity.\n\nIn this case, the patient is receiving paclitaxel and carboplatin, which are both chemotherapy drugs that can cause gastrointestinal toxicity. Therefore, leucovorin is an appropriate choice to prevent or reduce the risk of gastrointestinal toxicity associated with these drugs.\n\nMesna (①) is a drug that is used to prevent bladder damage caused by cyclophosphamide, a chemotherapy drug that is not mentioned in this case. Domperidone (③) is a drug that is used to increase breast milk production and is not relevant to this case. Acetaminophen (④) is a pain reliever and fever reducer that is not directly related to the prevention of gastrointestinal toxicity. Chlorpheniramine (⑤) is an antihistamine that is not relevant to this case.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 카보플라틴 혈중 농도\n\nExplanation:\n\nThe question asks for the necessary information to determine the carboplatin dose for a patient with non-small cell lung cancer. The correct answer is ④ 카보플라틴 혈중 농도 (carboplatin serum concentration) because the dose of carboplatin is calculated based on the patient's serum creatinine level, which is not provided in the given information. The other options, ① 체질량지수 (body surface area), ② 크레아티닌 청소율 (creatinine clearance), ③ 헤모글로빈 혈중 농도 (hemoglobin level), and ⑤ 알라닌아미노전이효소(ALT) 혈중 농도 (ALT level), are not directly related to the calculation of the carboplatin dose.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 투약오류 감소</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Class 100 환경의 항암제 전용 수평형 무균조제대 내에서 조제함</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 이소니아지드(isoniazid) 정</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe question asks for the most appropriate method to minimize the precipitation of calcium and phosphorus when mixing calcium and phosphorus-containing solutions for a patient's intravenous nutrition.\n\nOption ①, alkalizing the mixture, is not the best answer because it can increase the solubility of calcium phosphate and promote precipitation.\n\nOption ②, storing the mixture at room temperature, is not the best answer because it can also promote precipitation over time.\n\nOption ③, adding calcium to the nutrient solution first and then adding phosphorus, is the best answer. This approach can help to minimize precipitation by allowing the calcium to bind to the available phosphorus in the solution, reducing the likelihood of excess calcium and phosphorus combining to form insoluble compounds.\n\nOption ④, mixing the calcium and phosphorus solutions with a concentration ratio that exceeds 45 mEq/L, is not the best answer because it can lead to supersaturation and increase the risk of precipitation.\n\nOption ⑤, selecting calcium gluconate as the calcium source, is not the best answer because it does not address the issue of precipitation. Calcium gluconate is a soluble calcium salt, but it can still form insoluble compounds with phosphorus in the presence of excess calcium and phosphorus ions.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\n\nAccording to the Naranjo algorithm, the most likely cause of an adverse drug reaction is the drug that was administered just before the reaction occurred. In this case, the patient developed a skin rash after taking the suspect drug, and the rash did not improve even after the drug was discontinued. This suggests that the suspect drug is the most likely cause of the adverse drug reaction.\n\nTherefore, the correct answer is ③ The patient developed a skin rash after taking the suspect drug, and the rash did not improve even after the drug was discontinued.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 프레가발린(pregabalin) 캡슐</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 고혈압 환자 사용 금기</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 디멘히드리네이트(dimenhydrinate)</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 케토코나졸(ketoconazole)</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 아미오다론(amiodarone) 정</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 공복에 한꺼번에 복용한다.\n\nExplanation:\n\nThe patient is prescribed a combination of isoniazid, rifampicin, ethambutol, and pyridoxine. The dosage and frequency of each drug are provided in the table. According to the prescription, the patient should take one tablet of isoniazid (100 mg) and one tablet of rifampicin (450 mg) once daily, and two tablets of ethambutol (400 mg each) and one tablet of pyridoxine (50 mg) once daily. Therefore, the correct answer is ① 공복에 한꺼번에 복용한다.\n\nNote:\n\n② 대변이 흑색으로 변색될 수 있다. is incorrect because the prescription does not mention anything about the color of the patient's urine.\n\n③ 결핵 증상이 개선되면 복용을 중단한다. is incorrect because the prescription does not mention anything about stopping the medication if the patient's symptoms improve.\n\n④ 피리독신은 빈혈 예방을 위하여 복용한다. is incorrect because pyridoxine is not prescribed for the prevention of anemia.\n\n⑤ 에탐부톨은 경구피임약의 효과를 감소시킨다. is incorrect because ethambutol is not prescribed to reduce the effectiveness of oral contraceptives.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 흡입하기 전 숨을 충분히 들이마신다.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 마행감석탕(麻杏甘石湯)</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 아테놀올 정\n\nExplanation:\n\nThe patient is taking a combination of medications for hypertension and angina, including valsartan, aspirin, atenolol, clopidogrel, and isosorbide mononitrate. The patient has been prescribed sildenafil for erectile dysfunction, and the question asks which medication(s) should be avoided in combination with sildenafil.\n\nAtenolol, a beta-blocker, is contraindicated with sildenafil because it can increase the risk of hypotension and syncope. Therefore, the correct answer is ③ 아테놀올 정 (atenolol 100mg).\n\nThe other options are not contraindicated with sildenafil:\n\n① Valsartan, an angiotensin II receptor antagonist, is not contraindicated with sildenafil.\n\n② Aspirin, a nonsteroidal anti-inflammatory drug, is not contraindicated with sildenafil.\n\n④ Clopidogrel, a P2Y12 inhibitor, is not contraindicated with sildenafil.\n\n⑤ Isosorbide mononitrate, a nitrate, is not contraindicated with sildenafil.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 아테놀올 정\n\nExplanation:\n\nThe patient has a history of hypertension and myocardial infarction, and is currently taking medications for angina pectoris. The patient has been prescribed sildenafil for erectile dysfunction, and the question asks which medication should be discontinued if the patient experiences acute angina, hypertension, or tachycardia.\n\nThe correct answer is ③ 아테놀올 정 (atenolol). Atenolol is a beta-blocker, which can cause or exacerbate angina pectoris in patients with pre-existing coronary artery disease. Therefore, it should be discontinued if the patient experiences acute angina.\n\nThe other options are not correct for the following reasons:\n\n① 발사르탄 정 (valsartan): Valsartan is an angiotensin II receptor antagonist, which is used to treat hypertension. It is not associated with angina pectoris or tachycardia.\n\n② 아스피린 정 (aspirin): Aspirin is a nonsteroidal anti-inflammatory drug, which is used to prevent blood clots and relieve pain. It is not associated with angina pectoris or tachycardia.\n\n④ 클로피도그렐 정 (clopidogrel): Clopidogrel is a platelet aggregation inhibitor, which is used to prevent blood clots. It is not associated with angina pectoris or tachycardia.\n\n⑤ 이소소르비드일질산염 정 (isosorbide mononitrate): Isosorbide mononitrate is a nitrate, which is used to treat angina pectoris. However, it is not associated with acute angina, hypertension, or tachycardia.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 제조지원설비 밸리데이션</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 표준품 및 시약의 관리</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ D등급</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 12분</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 고압증기멸균</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 보관조건</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 두께를 증가시킨다.\n\nExplanation:\n\nThe problem stated in the question is that the coating process using a pan coating machine is resulting in a large number of defective tablets that are either cracked or broken. To address this issue, the most appropriate step to take in the coating process would be to increase the thickness of the coating layer. This can be achieved by adjusting the coating parameters, such as the coating solution concentration, the spraying pressure, or the coating time. By increasing the thickness of the coating layer, the tablets will be less likely to crack or break during the coating process, resulting in a higher yield of intact tablets.\n\nTherefore, option ③ 두께를 증가시킨다. is the correct answer.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 6</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤\n\nExplanation:\n\nThe correct answer is ⑤, \"출하승인은 제품이 GMP에 의해 제조되었다는 것을 보증하는 것이다.\"\n\nThe question is asking for the correct explanation for the significance of the approval of a drug product's commercialization by the manufacturer. The correct answer is that the approval serves as a guarantee that the product has been manufactured in accordance with Good Manufacturing Practice (GMP) standards.\n\nOption ①, \"구두 출하승인을 할 수 있다,\" is incorrect because it suggests that the approval is not necessary, which is not the case.\n\nOption ②, \"제조부서책임자가 출하승인을 한다,\" is incorrect because it suggests that the approval is the responsibility of the production department, which is not the case.\n\nOption ③, \"출하승인서는 내부문건이므로 외부로 발행되지 않는다,\" is incorrect because it suggests that the approval document is not publicly available, which is not the case.\n\nOption ④, \"책임자가 아니어도 교육을 충분히 받으면 출하승인을 할 수 있다,\" is incorrect because it suggests that anyone can approve the product for commercialization as long as they have received sufficient education, which is not the case.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 6개월</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 기밀용기 – 밀봉용기 – 밀폐용기</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 전자포획검출기</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 피마자유</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② t-검정</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe question asks for the method of preparing a standard solution of d-chlorpheniramine maleate, which is a drug used to treat allergies. The standard solution is prepared by dissolving a known amount of the drug in a solvent, such as water or an organic solvent, to obtain a solution of known concentration.\n\nOption ③, \"300 mg of the standard product is dissolved in a solvent to make 1 L,\" is the correct answer. This method allows for the preparation of a standard solution with a known concentration of 300 mg/L, which can be used for various pharmaceutical applications.\n\nThe other options are not correct because they do not provide the correct concentration of the standard solution:\n\n* Option ①, \"30 g of the standard product is dissolved in a solvent to make 1 L,\" would result in a concentration of 30 g/L, which is too high.\n* Option ②, \"3 g of the standard product is dissolved in a solvent to make 1 L,\" would result in a concentration of 3 g/L, which is too low.\n* Option ④, \"30 mg of the standard product is dissolved in a solvent to make 1 L,\" would result in a concentration of 30 mg/L, which is too low.\n* Option ⑤, \"3 mg of the standard product is dissolved in a solvent to make 1 L,\" would result in a concentration of 3 mg/L, which is too low.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ 표준온도</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe question is asking which of the 4Ps of marketing (Product, Price, Place, and Promotion) corresponds to the strategy of opening a pharmacy on the first floor of a commercial building in a busy district.\n\nThe correct answer is ③ Place. The strategy of opening a pharmacy on the first floor of a commercial building in a busy district is a strategy that relates to the Place element of the 4Ps, as it involves selecting a specific location for the pharmacy.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 유동자산은 5억 원이다.\n\nExplanation:\n\nWhen the pharmacist opened the pharmacy, they invested 2 billion won in cash and borrowed 3 billion won from a bank for 5 years. They also purchased 1 billion won worth of medication in cash.\n\nTherefore, the total amount of assets the pharmacist has is 2 billion won (cash) + 3 billion won (bank loan) + 1 billion won (medication) = 6 billion won.\n\nSince the question asks for the amount of liquid assets, the correct answer is 5 billion won (2 billion won in cash + 3 billion won in bank loan), which is option ③.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤\n\nExplanation:\n\nThe correct answer is ⑤, \"감가상각비 계산을 위해 취득원가, 내용연수, 재고유지비용 자료가 필요하다.\"\n\nThis answer choice states that to calculate the depreciation expense, the following materials are necessary:\n\n* 취득원가 (acquisition cost)\n* 내용연수 (useful life)\n* 재고유지비용 (maintenance cost)\n\nTherefore, option ⑤ is the correct answer.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③ 연간 재고유지비용＝연간 주문비용.\n\nThe formula to calculate the economic order quantity (EOQ) is:\n\nEOQ = √[(Annual usage rate x Cost of one unit) / (Holding cost per unit per year x Lead time)]\n\nIn this case, the annual usage rate is 100,000 units, the cost of one unit is $10, and the holding cost per unit per year is $2. The lead time is 2 weeks, which is equivalent to 1/26 weeks.\n\nPlugging in the values, we get:\n\nEOQ = √[(100,000 x $10) / ($2 x 1/26)]\nEOQ = √[1,000,000 / 2]\nEOQ = √500,000\nEOQ ≈ 223.61\n\nTherefore, the economic order quantity is approximately 223.61 units.\n\nSo, the answer is ③ 연간 재고유지비용＝연간 주문비용.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③. The characteristic of South Korea's national health insurance is that the insurance premium is determined based on the level of coverage chosen by the subscriber. This means that the subscriber can choose from different levels of coverage, and the premium will be adjusted accordingly.\n\nThe other options are incorrect because:\n\n① is incorrect because the insurance premium is not determined based on the severity of the illness.\n\n② is incorrect because while the insured person does receive the same level of medical service regardless of the amount of premium paid, the premium amount itself is not determined based on the level of coverage chosen.\n\n④ is incorrect because while medical institutions may be designated as national health insurance hospitals based on certain criteria, this is not a characteristic of the national health insurance system.\n\n⑤ is incorrect because while individuals may choose to opt out of the national health insurance system, this is not a characteristic of the system itself.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④ 총액예산제는 행위별수가제에 비해 의료비용 절감효과가 크다.\n\nThe question is asking for the best description of the expected effect of a bundled payment system, which is a type of payment method for medical services.\n\nOption ④ states that the bundled payment system has a larger cost-saving effect compared to the fee-for-service payment system. This means that the bundled payment system is more effective in reducing medical costs, which is a desirable outcome for patients and healthcare providers.\n\nThe other options do not accurately describe the expected effect of a bundled payment system. Option ① states that the bundled payment system has a smaller cost-saving effect compared to the fee-for-service payment system, which is incorrect. Option ② states that the bundled payment system has better access to high-quality services, but this is not a direct result of the payment system. Option ③ states that the bundled payment system provides excessive medical services, which is also not a direct result of the payment system. Option ⑤ states that the bundled payment system has a larger cost-saving effect compared to the fee-for-service payment system, but this is already stated in option ④.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④, which states that the reimbursement for a prescription drug includes the cost of the drug, the basic fee for dispensing, the fee for professional services, the fee for drug management, and the fee for pharmacy management. This is in line with the National Health Insurance Act and the Enforcement Decree of the National Health Insurance Act, which outline the scope of reimbursement for prescription drugs.\n\nOption ① is incorrect because it states that there is no additional fee for holiday or nighttime dispensing, which is not accurate.\n\nOption ② is incorrect because it states that the reimbursement for non-prescription drugs is based on the amount paid by the patient, which is not accurate.\n\nOption ③ is incorrect because it states that the pharmacist's daily prescription volume affects the reimbursement, which is not accurate.\n\nOption ⑤ is incorrect because it states that the reimbursement includes an incentive for substituting a low-cost drug, which is not accurate.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 충실성의 원칙</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 100/1,000 | 100/1,000\n\nExplanation:\nThe correct answer is ③ 100/1,000 | 100/1,000.\n\nThe formula for calculating the incidence rate is:\nIncidence rate = (Number of new cases / Total population at risk) x (1 / Observation time)\n\nIn this case, the total population at risk is 1,000 (1,100 - 100 who already have hypertension), and the observation time is 1 year. The number of new cases is 100, so the incidence rate is:\nIncidence rate = (100 / 1,000) x (1 / 1) = 100/1,000\n\nTherefore, the correct answer is ③ 100/1,000 | 100/1,000.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ②\n\nExplanation:\n\nThe correct answer is ②, \"의약품 이상사례의 인과성을 분명히 파악할 수 있다.\"\n\nThe passage describes a situation where a patient experienced a severe skin rash after taking drug A, and the pharmacist reported the case to the Korean Institute of Drug Safety Management using the 'Drug Adverse Reaction Report Form'. The purpose of this form is to collect information on adverse drug reactions and investigate their causal relationship with the drug. Therefore, option ② is the best answer.\n\nOption ① is incorrect because the passage does not mention anything about calculating the incidence rate of adverse drug reactions.\n\nOption ③ is incorrect because the passage does not mention anything about limiting the reporting period to the first year after drug approval.\n\nOption ④ is incorrect because the passage does not mention anything about comparing the drug safety management system with the re-examination system for new drugs.\n\nOption ⑤ is incorrect because the passage does not mention anything about using the information to discover new drug side effects.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 1,000원 | 1,000원</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 50만원＋(70만원×0.95)＋(100만원×0.95^2)</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④ 의료급여 수급권자의 자격선정은 건강보험심사평가원에서 한다.\n\nThe question is asking about the criteria for selecting the recipients of the national health insurance benefits in South Korea. The correct answer is ④, which states that the selection of the recipients is done by the Health Insurance Review and Assessment Service.\n\nThe other options are incorrect because:\n\n① is incorrect because there is a fee-for-service system in place for medical expenses, which means that patients pay for medical services and then file a claim with the national health insurance program for reimbursement.\n\n② is incorrect because there are not three types of health insurance benefit recipients.\n\n③ is incorrect because health insurance benefit recipients do pay a premium, which is deducted from their salary.\n\n⑤ is incorrect because the co-payment for prescription drugs is not 30% of the total medical expenses.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 가정방문 목욕제공 서비스</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 0.8 QALY\n\nExplanation:\n\nTo calculate the incremental cost-utility ratio (ICUR) of new drug B compared to existing drug A, we need to calculate the difference in QALYs between the two drugs and divide it by the difference in cost.\n\nThe QALYs for drug A are:\n\n* 1 year of progression-free survival with a utility of 0.8 = 0.8 QALYs\n* 0.5 years of progression with a utility of 0.4 = 0.2 QALYs\n\nTotal QALYs for drug A = 0.8 + 0.2 = 1.0 QALYs\n\nThe QALYs for drug B are:\n\n* 2 years of progression-free survival with a utility of 0.8 = 1.6 QALYs\n* 1 year of progression with a utility of 0.4 = 0.4 QALYs\n\nTotal QALYs for drug B = 1.6 + 0.4 = 2.0 QALYs\n\nThe ICUR of drug B compared to drug A is:\n\nICUR = (2.0 - 1.0) / (3,000 - 1,000) = 0.8 QALYs/4,000 won\n\nTherefore, the correct answer is ③ 0.8 QALY.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 다\n\nExplanation:\n\nThe incremental cost-utility ratio (ICUR) is a measure of the additional cost per additional quality-adjusted life year (QALY) gained by using a new treatment compared to the standard treatment. In this case, the ICUR for new drug B compared to standard drug A can be calculated as follows:\n\nICUR = (Total cost of new drug B - Total cost of standard drug A) / (QALY gained by new drug B - QALY gained by standard drug A)\n\n= (3,000,000 - 1,000,000) / (2 - 1)\n\n= 2,000,000 / 1\n\n= 2,000,000\n\nTherefore, the ICUR for new drug B compared to standard drug A is 2,000,000. This means that for every additional QALY gained by using new drug B, the cost is 2,000,000 won higher than the cost of using standard drug A.\n\nThe cost-effectiveness plane is a graphical representation of the cost-utility trade-off, where the cost is plotted on the x-axis and the utility is plotted on the y-axis. The ICUR can be represented as a point on the cost-effectiveness plane, where the point corresponds to the cost and utility of the new treatment compared to the standard treatment.\n\nIn this case, the point representing the ICUR of new drug B compared to standard drug A would be (2,000,000, 1), which means that the cost is 2,000,000 won higher and the utility is 1 QALY higher than the standard treatment.\n\nTherefore, the correct answer is ③ 다, which represents the point (2,000,000, 1) on the cost-effectiveness plane.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nAccording to the Pharmacist Licensing Examination, the correct answer is ③. The question asks for the correct explanation regarding the requirements for opening a pharmacy, and option ③ states that the person who wants to open a pharmacy must have facilities for cold storage and light-proofing. This is a requirement for the storage and handling of medications that need to be kept at a certain temperature and protected from light exposure.\n\nOption ① is incorrect because it states that a pharmacy can be opened inside a medical institution, which is not a requirement for opening a pharmacy.\n\nOption ② is incorrect because it states that the person who wants to open a pharmacy can register after 3 months from the date of cancellation of the previous registration, which is not a requirement for opening a pharmacy.\n\nOption ④ is incorrect because it states that the person who wants to open a pharmacy can open multiple pharmacies if they have multiple pharmacists, which is not a requirement for opening a pharmacy.\n\nOption ⑤ is incorrect because it states that the city or provincial governor does not need to register the establishment of a pharmacy if they are renovating a part of a medical institution, which is not a requirement for opening a pharmacy.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 의료기관의 종사자가 약국개설자의 의약품 구매사무를 지원하는 행위</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nAccording to the Pharmacist Licensing Examination question, the correct answer is ③. The question states that a pharmacist who has received approval from the Minister of Health and Welfare can dispense prescription medications outside of a pharmacy. This means that the pharmacist can dispense medications in a location other than a pharmacy, such as a hospital or clinic, as long as they have received the necessary approval.\n\nThe other options do not accurately reflect the scenario described in the question. Option ① states that a pharmacy student can dispense medications under the supervision of a physician, but this is not the case in the scenario described. Option ② states that a pharmacist in a hospital can dispense medications, but this is also not the case in the scenario described. Option ④ states that a pharmacist must immediately inform the prescribing physician if they substitute a medication, but this is not relevant to the scenario described. Option ⑤ states that a pharmacist must inform the prescribing physician within 7 days if they substitute a medication, but this is also not relevant to the scenario described.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nAccording to the Pharmacist Licensing Examination, the correct answer is ③.\n\nIn the case of a disaster, the pharmacist may dispense medication without a prescription from a physician or dentist if it is deemed necessary for disaster relief. This is because the pharmacist's role in disaster relief is to provide emergency medical care and support to those affected by the disaster, and dispensing medication without a prescription may be necessary to achieve this goal.\n\nTherefore, option ③, \"In the case of a disaster, the pharmacist may dispense medication without a prescription from a physician or dentist if it is deemed necessary for disaster relief,\" is the correct answer.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 처방약품명과 일수</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nAccording to the Pharmacy Act, a pharmacist can sell general medicines, but it is not appropriate to provide a prescription for a patient without a valid prescription from a physician or dentist. Therefore, option ③ is the correct answer.\n\nOption ① is incorrect because it suggests that a pharmacist can sell any medicine without a prescription, which is not allowed.\n\nOption ② is incorrect because it suggests that a pharmacist can sell general medicines without a prescription, which is not allowed.\n\nOption ④ is incorrect because it refers to the case where a pharmacist has received approval from the mayor, county magistrate, or district chief to open a pharmacy or branch outside of the pharmacy or store, but it does not relate to the prescription and sale of medicines.\n\nOption ⑤ is incorrect because it suggests that a pharmacist can sell prescription medicines to a veterinarian, which is not allowed.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nAccording to the question, the veterinarian or aquatic animal disease management expert's prescription is required for the sale of animal drugs. Therefore, the correct answer is ③ 덱사메타손정, which is a drug that is prescribed by a veterinarian or aquatic animal disease management expert and has a potential risk of causing harm to humans or animals if used improperly.\n\nThe other options do not meet the criteria specified in the question:\n\n① 심장사상충 예방을 위하여 해양수산부장관이 정한 이버멕틴 저작정 is a drug that is designated by the Minister of Oceans and Fisheries for the prevention of heartworm disease in dogs, but it is not prescribed by a veterinarian or aquatic animal disease management expert.\n\n② 외상 감염 치료를 위하여 농림축산식품부장관이 정한 아목시실린주 is a drug that is designated by the Minister of Agriculture, Food and Rural Affairs for the treatment of external parasites in animals, but it is not prescribed by a veterinarian or aquatic animal disease management expert.\n\n④ 수의사 또는 수산질병관리사의 전문지식을 필요로 하는 사이클로스포린주 is a drug that requires professional knowledge of a veterinarian or aquatic animal disease management expert, but it is not necessarily prescribed by them.\n\n⑤ 오용 ∙ 남용으로 사람 및 동물의 건강에 위해를 끼칠 우려가 있는 에스트라디올주 is a drug that has a potential risk of causing harm to humans or animals if used improperly, but it is not necessarily prescribed by a veterinarian or aquatic animal disease management expert.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤\n\nExplanation:\n\nAccording to the question, the person who cannot manage the manufacturing business of biological products is the one who has graduated from a 2-year college and has worked in related manufacturing industries for more than 2 years. Therefore, the correct answer is ⑤ 2년제 대학을 졸업한 자로서 2년 이상 관련 제조업무에 종사한 자.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe question is asking about the safety device or package that is not required for a pharmaceutical product that does not contain a prescription drug, and is not a liquid or a spray.\n\nOption ①, ②, and ④ are all liquids or sprays, and therefore require a safety device or package.\n\nOption ⑤ is a tablet or capsule, and does not require a safety device or package.\n\nTherefore, the correct answer is ③, which is a tablet or capsule that contains 30 milligrams or more of iron per single dose and does not require a safety device or package.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nAccording to the Pharmacist Licensing Examination, the case where a pharmacist can request the Minister of Health and Welfare to revoke a pharmacist's license through the deliberation of the Ethics Committee of the Pharmacist Association is when the pharmacist has engaged in academic misconduct, such as falsifying research data or plagiarizing academic papers.\n\nTherefore, the correct answer is ③, \"학문적으로 인정되지 아니하는 약사(藥事) 행위를 한 경우.\"</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nAccording to the question, the scenario is about a pharmacist who wants to transfer a drug that they have not dispensed to another pharmacist. The correct answer is ③, as it states that the pharmacist wants to transfer the drug for academic research purposes and has received approval from the Food and Drug Safety Ministry.\n\nThe other options do not fit the scenario:\n\n① refers to a situation where a pharmacist wants to return a drug that they have dispensed to the original owner, which is not relevant to the scenario.\n\n② refers to a situation where a pharmacist wants to transfer a drug that has been recalled or has had its license revoked, which is also not relevant to the scenario.\n\n④ refers to a situation where a pharmacist wants to use a drug for research or testing purposes, but this option specifically states that the drug is for the pharmacist's own research, rather than for academic research purposes.\n\n⑤ refers to a situation where a pharmacist who has lost their manufacturing license wants to transfer their drugs to another pharmacist, which is also not relevant to the scenario.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 상급종합병원에서 의료에 종사하는 의사</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 식품위생</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③, \"자신의 학식과 경험, 양심에 따라 환자에게 양질의 적정한 보건의료서비스를 제공하기 위하여 노력하여야 한다.\"\n\nThis statement is the most relevant to the topic of the question, which is about the responsibilities of a pharmacist. It highlights the importance of a pharmacist's duty to provide high-quality medical care to patients based on their knowledge, experience, and conscience.\n\nThe other options are not directly related to the topic of the question or are not specific enough to be considered correct answers.\n\n① is a general statement about the importance of providing healthcare services to patients, but it does not specifically address the responsibilities of a pharmacist.\n\n② is related to the topic of patient safety, but it is not directly relevant to the question.\n\n④ is related to the topic of interprofessional collaboration, but it is not directly relevant to the question.\n\n⑤ is related to the topic of reporting suspicious diseases, but it is not directly relevant to the question.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nExplanation:\n\nThe question is asking who does not qualify as a \"user\" under the National Health Insurance Act.\n\n① The National Assembly Secretary-General is not a user because the National Health Insurance Act does not apply to government officials.\n\n② The head of a central government agency is not a user because the National Health Insurance Act only covers employees of private companies.\n\n③ The owner of a business where an employee is working is not a user because the National Health Insurance Act only covers employees, not employers.\n\n④ A person who receives a salary in exchange for their labor and lives off of it is not a user because the National Health Insurance Act only covers those who are not covered by employment-based insurance.\n\n⑤ A private school founder/operator who is affiliated with a teachers' union is not a user because the National Health Insurance Act only covers employees of private companies, not self-employed individuals.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 한약제 – 구입금액</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 요양급여의 적정성 평가</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② fibronectin</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ NADH</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② ganglioside GM2</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ mitochondria</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ glucose 6-phosphate</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② D-β-hydroxybutyrate</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ argininosuccinate synthetase</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ ubiquinone : cytochrome c oxidoreductase</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ β-hydroxyacyl-CoA dehydrogenase</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ glycerol 3-phosphate dehydrogenase</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ leucine</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ TATA box</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ MutH protein</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 유전자의 전사활성 증가</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ phenylketonuria</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ selectin</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ prostacyclin 합성 증가</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Lesch-Nyhan syndrome</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ dextran</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Kirby-Bauer test</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 파지전시(phage display)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ imipenem</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ colistin</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ levofloxacin</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② ergosterol</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② entecavir</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① C1q</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ CD28</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ PD-1</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 아토피피부염(atopic dermatitis)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ trastuzumab</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 약독화 생균(attenuated bacteria)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 세포벽(cell wall)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Streptococcus pneumoniae</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ norovirus</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 엡스타인바 바이러스(Epstein-Barr virus)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 성홍열</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 결막염\n\nExplanation:\n\nThe patient's symptoms of fever, sore throat, and positive blood culture with beta-hemolytic streptococcus suggest a diagnosis of streptococcal pharyngitis. The presence of streptolysin O antibodies in the patient's blood supports this diagnosis.\n\nStreptococcal pharyngitis is caused by group A beta-hemolytic streptococcus (GABHS), which produces streptolysin O. The production of streptolysin O by GABHS can cause hemolysis of red blood cells, leading to hemolytic anemia and other complications.\n\nTherefore, the most likely diagnosis for this patient is streptococcal pharyngitis, which is option ③.</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ methotrexate</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ NMDA 수용체 – Cl-</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ isoniazid</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ ipratropium</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ clozapine</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ fluoxetine</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ lamotrigine</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ tramadol</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② montelukast</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ folic acid</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ enalapril</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ atorvastatin – 콜레스테롤 생합성 억제</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ furosemide – 헨레고리 상행각</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② cimetidine</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① α-glucosidase 억제</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ denosumab</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ chloramphenicol – cefazolin</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ sirolimus</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ β1 수용체\n\nExplanation:\n\nPhenylephrine is a sympathomimetic drug that acts on the sympathetic nervous system to increase blood pressure and heart rate. It works by binding to β1-adrenergic receptors, which are located on the heart and blood vessels. Activation of these receptors causes an increase in heart rate and force of contraction, leading to an increase in blood pressure.\n\nIn the first group, the increase in blood pressure and decrease in heart rate after administering phenylephrine suggest that the drug is acting on the β1-adrenergic receptors, which are located on the heart and blood vessels. This is consistent with the expected action of phenylephrine.\n\nIn the second group, the use of trimethaphan, a ganglionic blocker, before administering phenylephrine would block the action of the drug on the autonomic nervous system, including the β1-adrenergic receptors. Therefore, the lack of effect on blood pressure and heart rate in this group suggests that the drug is acting on the β1-adrenergic receptors.\n\nTherefore, the correct answer is ③ β1 수용체.</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 유의한 변화 없음 | 증가</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 병인, 숙주, 환경</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 이산화황</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 최대무영향관찰용량(NOAEL)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 2,3,7,8-tetrachlorodibenzo-p-dioxin</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 간소엽의 zone 1에 특이적으로 독성을 유발한다.</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ benzo[a]pyrene – 식품 중의 아질산과 아민류의 반응</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 복귀돌연변이 시험</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① N-acetylcysteine</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 카드뮴(Cd)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ hemicellulose</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② eicosapentaenoic acid</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 카시와커(kwashiorkor)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 셀레늄(Se)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ vitamin B12</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Listeria monocytogenes</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ grayanotoxin</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 아황산수소나트륨(sodium bisulfite)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 글루코사민 – 혈중 콜레스테롤 개선</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Cryptosporidium parvum</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 오존처리</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 대식세포</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 피리독신</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② 파제트병</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 호흡상피세포 손상 유발</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 사구체신염</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 혈액응고결손</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 심막염(pericarditis)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 과민성폐렴</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 소화성궤양</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 건너뛴 병변(skip lesions)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ C형 간염바이러스</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 칼시토닌(calcitonin)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 프로게스테론</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 세균감염</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ atrial natriuretic peptide – 콩팥</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③ 요산(uric acid)의 과다생성.\n\nThe question is asking for the cause of a condition or symptom, and the answer is excessive production of uric acid (요산).\n\n① 뼈와 골수의 세균 감염 is not related to the given symptoms.\n\n② 뼈의 불충분한 무기질화 is not related to the given symptoms.\n\n④ 뼈파괴세포에 의한 뼈흡수 장애 is not related to the given symptoms.\n\n⑤ 판누스(pannus) 형성을 수반하는 활막염 is not related to the given symptoms.</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 디스트로핀(dystrophin)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② 디스트로핀(dystrophin)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 가슴막염</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ⑤ 면역복합체 침착에 의한 염증</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 이온-쌍극자 상호작용</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 결정형에 따라 안정성이 달라진다.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④\n\nExplanation:\n\nThe question is asking about the characteristics of a mixture of lidocaine and prilocaine at a melting point of 18°C.\n\nOption ① is incorrect because at the melting point, both lidocaine and prilocaine exist in a liquid state, not just one.\n\nOption ② is incorrect because the formation of a eutectic mixture does not necessarily reduce skin absorption.\n\nOption ③ is incorrect because while it is true that lidocaine and prilocaine can be manufactured as a solid or semi-solid at a standard temperature of 20°C, this is not related to the eutectic mixture at a melting point of 18°C.\n\nOption ④ is correct because at a temperature lower than the melting point, the eutectic mixture will exist as a single liquid phase.\n\nOption ⑤ is incorrect because the melting point of a eutectic mixture does not necessarily represent the highest solubility point of the mixture.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① F＝P-C</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 흡습성</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② α-CD와 β-CD의 공동(cavity) 크기는 같다.\n\nExplanation:\n\nα-CD and β-CD are both cyclodextrins, which are cyclic oligosaccharides composed of six or seven glucose molecules. They have a common cavity size, which means that they have the same diameter and can accommodate molecules of similar size within their cavity.\n\nTherefore, option ② is the correct answer.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 틱소트로피(thixotropy)</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ a-b+c</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ P T = 0.3P b o + 0.7P e o</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Van Slyke 식</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 4.4</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 용출</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② t1/2은 a에 비례한다.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 30\n\nExplanation:\n\nThe release rate of aspirin from the spherical particles can be calculated using the Noyes-Whitney equation, which takes into account the diffusion layer thickness, diffusion coefficient, and particle size.\n\nSince the diffusion layer thickness and diffusion coefficient are constant, the release rate is directly proportional to the particle size. Therefore, if the particle size is reduced from 2 mm to 0.2 mm, the release rate will increase.\n\nUsing the Noyes-Whitney equation, we can calculate the release rate of aspirin from the 0.2 mm particles as follows:\n\nRelease rate (mg/min) = (1.33 x 10^(-4) x D x A x C) / (2 x r)\n\nwhere D is the diffusion coefficient (m^2/min), A is the surface area of the particle (m^2), C is the concentration of the drug in the diffusion layer (mg/mL), and r is the radius of the particle (m).\n\nAssuming that the diffusion coefficient and concentration of the drug in the diffusion layer remain constant, we can see that the release rate is directly proportional to the surface area of the particle. Since the surface area of a sphere is given by 4 x pi x r^2, we can calculate the release rate of aspirin from the 0.2 mm particles as follows:\n\nRelease rate (mg/min) = (1.33 x 10^(-4) x 4 x pi x (0.2)^2 x C) / (2 x 0.2)\n\nRelease rate (mg/min) = 30.67 mg/min\n\nTherefore, the expected release rate of aspirin from the 0.2 mm particles in 1 minute is approximately 30 mg, which corresponds to option ③.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② pH 분배 이론</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ D</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ logP</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ eperisone</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ acetylation – oxidation – nitration – reduction</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ donepezil</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Mannich reaction – Fischer esterification</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ①</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ imidazole</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② ibuprofen</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ methotrexate</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ R1＝7-Cl, R2＝Ph</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ ipratropium</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ D</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ pyrazine</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 9.0</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ NaHCO3</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 50</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 0.1 mol/L KMnO4</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 회귀곡선법</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ A×M×100</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ -130°</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 입사광 세기를 2배로 하여 측정한다.\n\nExplanation:\n\nThe question is asking about the effect of changing the measurement conditions on the fluorescence quenching of a 1 μg/mL solution of o-phthalaldehyde in a 6:1 water-acetonitrile mixture, which is measured at room temperature using a fluorescence spectrometer.\n\nOption ①, measuring at 10°C, is not relevant to the question.\n\nOption ②, removing dissolved oxygen before measurement, may reduce the fluorescence signal but will not cause quenching.\n\nOption ③, measuring at a higher concentration of 1,000 μg/mL, may also reduce the fluorescence signal but will not cause quenching.\n\nOption ④, increasing the incident light intensity by a factor of 2, will increase the fluorescence signal and may cause quenching.\n\nOption ⑤, measuring a 10:1 water-acetonitrile mixture instead of a 6:1 mixture, may also affect the fluorescence signal but is not directly related to the question.\n\nTherefore, the correct answer is ④, increasing the incident light intensity by a factor of 2.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 액체크로마토그래프법</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 질소/인검출기</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②\n\nExplanation:\n\nThe correct answer is ②. 분취용 칼럼으로 분리된 대량 시료를 얻을 수 있다.\n\nThe question is asking about the advantage of using a gas chromatography column. The correct answer is that a gas chromatography column can separate a large amount of sample, 분취용 칼럼으로 분리된 대량 시료를 얻을 수 있다.\n\nThe other options are not correct:\n\n① is incorrect because the length of the column does not affect the separation efficiency.\n\n③ is incorrect because the performance of the column is not affected by the flow rate of the mobile phase.\n\n④ is incorrect because increasing the temperature of the column will not increase the sample's residence time.\n\n⑤ is incorrect because the stationary phase of the column should not chemically react with the sample components.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 분리효율 증가</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 조절시험</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 5\n\nExplanation:\n\nThe question asks for the separation factor (R) of the two peaks when the widths at the base (Wb) are 0.45 min and 0.55 min, respectively.\n\nThe separation factor (R) is calculated using the following equation:\n\nR = (tR1 - tR2) / (Wb1 + Wb2)\n\nwhere tR1 and tR2 are the retention times of the two peaks, and Wb1 and Wb2 are the widths at the base of the two peaks.\n\nPlugging in the values given in the question, we get:\n\nR = (5.0 min - 10.0 min) / (0.45 min + 0.55 min)\nR = -5.0 min / 0.90 min\nR = -5.56\n\nSince R is negative, it means that the two peaks are not well-separated. Therefore, the correct answer is ③ 5, which corresponds to a separation factor of 5.56.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ hydrolysis | aspirin | salicylic acid</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 흡습성 증가</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 입자 크기가 균일한 분체</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 고전단과립법</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤\n\nExplanation:\n\nThe correct answer is ⑤, \"건조속도는 시료 내부의 수분이 표면으로 확산하는 속도에 의해 결정된다.\"\n\nThe rate of drying is determined by the rate at which moisture inside the sample diffuses to the surface and evaporates. Therefore, option ⑤ is the correct answer.\n\nOption ①, \"단위시간당 건조량이 증가한다,\" is incorrect because it refers to the increase in drying rate with time, which is not the determining factor for the rate of drying.\n\nOption ②, \"수분의 표면증발량과 내부확산량이 같다,\" is also incorrect because the rate of evaporation from the surface and the rate of diffusion of moisture inside the sample are not necessarily equal.\n\nOption ③, \"건조속도는 시간이 지남에 따라 감소한다,\" is incorrect because the rate of drying does not necessarily decrease with time.\n\nOption ④, \"시료 내부 수분의 확산속도가 표면의 증발속도보다 늦어진다,\" is incorrect because the rate of diffusion of moisture inside the sample is not necessarily slower than the rate of evaporation from the surface.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 카라기난</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 연고제</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 작용시간 연장</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 하이드로겔화</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 온도</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 아황산나트륨(sodium sulfite)</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\nThe correct answer is ③. The statement \"피부를 통해 흡수된 약물은 간 초회통과효과를 받아 생체이용률이 저하된다\" means that the drug absorbed through the skin is subject to first-pass metabolism in the liver, which can reduce its bioavailability. This is a disadvantage of skin absorption, as it can lead to lower efficacy and a need for higher doses.\n\nThe other options are incorrect for the following reasons:\n\n① is incorrect because, while the stratum corneum can be penetrated by both hydrophilic and lipophilic drugs, the rate of penetration can vary depending on the drug's properties.\n\n② is incorrect because, while occlusive dressings can enhance drug penetration through the skin, they do not guarantee complete penetration or uniform distribution of the drug.\n\n④ is incorrect because, while the use of penetration enhancers can improve drug penetration through the skin, they may not always be effective and can have side effects.\n\n⑤ is incorrect because, while the skin's condition can affect drug penetration, it is not the only factor that determines the efficacy of a transdermal drug delivery system. Other factors, such as the drug's properties and the design of the delivery system, also play a role.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 8</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 2.0</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 요세관 분비에 의해서만 배설</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②\n\nExplanation:\n\nThe correct answer is ②, \"생체이용률 평가의 양적 지표로 혈중약물농도-시간 곡선하 면적(AUC)을 사용한다.\"\n\nAUC (Area Under the Curve) is a quantitative measure of the extent of drug absorption and is widely used as a measure of bioavailability. It represents the total amount of drug absorbed into the systemic circulation over time, and is calculated by integrating the concentration-time curve of the drug in the blood or plasma. Therefore, option ② is the correct answer.\n\nOption ① is incorrect because the bioavailability of a drug can vary depending on the route of administration, even if the same drug is used.\n\nOption ③ is incorrect because the bioavailability of a drug cannot be predicted by comparing the bioavailability of two different formulations of the same drug.\n\nOption ④ is incorrect because relative bioavailability refers to the comparison of the bioavailability of a drug when administered by different routes, not the comparison of the bioavailability of two different formulations of the same drug.\n\nOption ⑤ is incorrect because absolute bioavailability refers to the comparison of the bioavailability of a drug when administered by the same route, not the comparison of the bioavailability of two different formulations of the same drug.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ 히드록시프로필셀룰로오스(hydroxypropylcellulose)</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe question is asking for the most appropriate drug to develop a sustained-release oral formulation (Option A) to improve patient compliance.\n\nOption ① is not suitable because a drug with a narrow therapeutic index may require frequent dosing to maintain therapeutic levels, which would defeat the purpose of developing a sustained-release formulation.\n\nOption ② is not suitable because a drug with a large single dose may not be appropriate for sustained-release, as it may cause peak levels that are too high and potentially toxic.\n\nOption ③ is the best choice because a drug with slow absorption and elimination rates would allow for a sustained-release formulation that maintains therapeutic levels over a longer period.\n\nOption ④ is not suitable because a drug that is metabolized in the liver and has a short half-life may not be suitable for sustained-release, as it may require frequent dosing to maintain therapeutic levels.\n\nOption ⑤ is not suitable because a drug that is absorbed only in specific parts of the gut may not be suitable for sustained-release, as it may not provide consistent levels over a longer period.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ carotenoid</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ coumarin</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 대마</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ coumarin</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 정향</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Marquis 반응</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ tanshinone I</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ atractylon</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① linamarin</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ⑤ (-)-epigallocatechin gallate</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 센나엽</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Sophora japonica</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 연교</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② 삼초변증(三焦辨證)</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 연라환(連蘿丸)</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 맥문동탕(麥門冬湯)</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 마황\n\nExplanation:\n\nThe patient is presenting with symptoms of a cold, such as a headache, fever, and muscle pain. The prescribed herbal medicine contains several ingredients that are known to have various effects, including:\n\n* Ginseng (갈근): known for its adaptogenic and stimulant properties, which can help to reduce fatigue and improve mental clarity.\n* Astragalus (계지): known for its immune-boosting properties and ability to reduce inflammation.\n* Licorice root (마황): known for its anti-inflammatory and expectorant properties, which can help to relieve respiratory symptoms such as coughs and sore throats.\n* Ginkgo biloba (작약): known for its ability to improve blood flow and reduce inflammation.\n* Angelica (감초(자)): known for its anti-inflammatory and antiviral properties, which can help to reduce fever and alleviate respiratory symptoms.\n\nOf the ingredients listed, licorice root (마황) is the most likely to have a direct effect on relieving respiratory symptoms such as coughs and sore throats, which are common in patients with colds. Therefore, the correct answer is ③ 마황.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ liquiritigenin</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 라베타롤(labetalol)\n\nExplanation:\n\nThe patient is experiencing a hypertensive emergency, with a blood pressure of 200/132 mmHg and confirmed cerebral edema. Labetalol is a beta-blocker that is commonly used to treat hypertensive emergencies, as it can quickly lower blood pressure and reduce the risk of further cerebral damage. Dopamine and dobutamine are both vasopressors that may be used in certain situations, but they are not the most appropriate choices for this patient's condition. Nimodipine is a calcium channel blocker that may be used to treat cerebral vasospasm, but it is not the most urgently needed medication in this scenario. Fosinopril is an ACE inhibitor that may be used to treat hypertension, but it is not the most appropriate choice for an acute hypertensive emergency.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 메트포르민\n\nReason:\n\nThe patient's symptoms of severe muscle weakness and elevated creatine kinase levels suggest a potential diagnosis of rhabdomyolysis, a condition characterized by the breakdown of skeletal muscle tissue. Rhabdomyolysis can be caused by a variety of factors, including medication side effects.\n\nMetformin, a medication used to treat type 2 diabetes, has been associated with an increased risk of rhabdomyolysis, particularly in patients with pre-existing kidney disease or those taking other medications that may interact with metformin. The patient's history of type 2 diabetes and concurrent use of metformin, therefore, suggests that metformin may be the cause of his rhabdomyolysis.\n\nThe other options are less likely to be the cause of the patient's rhabdomyolysis:\n\n* Aspirin is an nonsteroidal anti-inflammatory drug (NSAID) that can cause muscle damage, but it is less likely to cause rhabdomyolysis at the dose used in this patient.\n* Amlodipine is a calcium channel blocker that has not been associated with rhabdomyolysis.\n* Hydrochlorothiazide is a diuretic that can cause muscle weakness, but it is less likely to cause rhabdomyolysis at the dose used in this patient.\n* Repaglinide is a meglitinide that can cause hypoglycemia, but it is less likely to cause rhabdomyolysis.\n\nTherefore, the answer is ③ 메트포르민 (metformin).</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 딜티아젬(diltiazem)으로 변경</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 폰다파리눅스(fondaparinux)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 티카그렐러(ticagrelor)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 아미오다론(amiodarone)\n\nExplanation:\n\nThe patient has a history of hypertension, heart failure, and atrial fibrillation, and has been taking a beta-blocker (metoprolol) and an ACE inhibitor (enalapril) without adequate control of their symptoms. After administering a calcium channel blocker (verapamil), the patient's heart rate was successfully controlled, but their atrial fibrillation persisted, and they were referred to a cardiologist for further evaluation.\n\nGiven the patient's history of atrial fibrillation and heart failure, the most appropriate medication for long-term management of their atrial fibrillation would be amiodarone. Amiodarone is a class III antiarrhythmic drug that is effective in converting atrial fibrillation back to sinus rhythm and maintaining sinus rhythm over the long term. It is also known to have a favorable effect on heart failure symptoms and mortality.\n\nThe other options are not as appropriate for this patient's condition:\n\n* Digoxin (①) is a class II antiarrhythmic drug that is primarily used to control ventricular response rate in atrial fibrillation. It is not as effective in converting atrial fibrillation back to sinus rhythm as amiodarone.\n* Verapamil (②) is a calcium channel blocker that was already tried in this patient without success.\n* Flecainide (③) is a class I antiarrhythmic drug that is effective in converting atrial fibrillation back to sinus rhythm, but it has a higher risk of proarrhythmia and is not as effective in maintaining sinus rhythm over the long term as amiodarone.\n* Propafenone (⑤) is a class III antiarrhythmic drug that is similar to amiodarone in its mechanism of action, but it has a shorter duration of action and may require more frequent dosing.\n\nTherefore, the best answer is ④ 아미오다론(amiodarone).</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 아스피린(aspirin)\n\nExplanation:\n\nThe patient has been diagnosed with hypertension and diabetes, and has a history of cerebral infarction. The goal of treatment is to prevent recurrent stroke and manage risk factors. Aspirin is a first-line medication for preventing recurrent stroke and has been shown to be effective in reducing the risk of cardiovascular events in patients with a history of cerebral infarction.\n\nEdoxaban and prasugrel are both anticoagulants, but they are not recommended as first-line therapy for preventing recurrent stroke in patients with a history of cerebral infarction. Abciximab is a platelet aggregation inhibitor that is used to treat acute coronary syndrome, but it is not recommended for preventing recurrent stroke. Cilostazol is a vasodilator that is used to treat intermittent claudication, but it is not recommended for preventing recurrent stroke.\n\nTherefore, the best answer is ① 아스피린(aspirin).</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 니모디핀(nimodipine)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 알테플라제(alteplase, tPA)\n\nExplanation:\n\nThe patient has been diagnosed with acute ischemic stroke (AIS) caused by a blood clot in the left MCA territory. The National Institutes of Health Stroke Scale (NIHSS) score of 21 indicates a moderate to severe stroke.\n\nAlteplase (tPA) is a thrombolytic drug that works by breaking down blood clots. It is the only FDA-approved medication for the treatment of acute ischemic stroke, and it has been shown to improve functional outcomes in patients with AIS. The drug is most effective when administered within 4.5 hours of symptom onset, and the patient's age and NIHSS score are within the acceptable range for treatment.\n\nThe other options are not appropriate for the treatment of acute ischemic stroke:\n\n① Aspirin is an antiplatelet agent that is used to prevent platelet aggregation and is not effective in dissolving blood clots.\n\n② Abciximab is a glycoprotein IIb/IIIa inhibitor that is used to prevent platelet aggregation and is not effective in dissolving blood clots.\n\n③ Ticagrelor is a P2Y12 receptor antagonist that is used to prevent platelet aggregation and is not effective in dissolving blood clots.\n\n⑤ Tenecteplase is a thrombolytic drug that is similar to alteplase but has a different mechanism of action. It is not FDA-approved for the treatment of acute ischemic stroke.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 페노피브레이트(fenofibrate)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ 이소소르비드질산염\n\nExplanation:\n\nThe patient is taking metoprolol, which is a beta-blocker, and enalapril, which is an ACE inhibitor. Verapamil, which is a calcium channel blocker, is being added to the regimen. The combination of verapamil and metoprolol may cause a decrease in heart rate and blood pressure, which could lead to symptomatic hypotension. Therefore, the drug that needs dose adjustment is isosorbide dinitrate, which is a vasodilator and may cause excessive hypotension when used with verapamil and metoprolol.\n\nThe correct answer is ⑤ 이소소르비드질산염 (isosorbide dinitrate).</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 덱시부프로펜\n\nReason: The patient's symptoms of sudden weight gain, swelling, and difficulty breathing suggest nephrotic syndrome, a condition characterized by the loss of large amounts of protein in the urine. The patient's history of taking NSAIDs, such as dexibuprofen, increases the risk of nephrotic syndrome. Therefore, it is necessary to immediately discontinue the dexibuprofen to prevent further kidney damage.\n\nThe other options are not directly related to the patient's symptoms or medical history, and therefore, are not the most appropriate choices for immediate discontinuation. Ramipril, an ACE inhibitor, is used to treat hypertension and heart failure, but it is not directly related to nephrotic syndrome. Cetirizine is an antihistamine used to treat allergies, and bisoprolol is a beta-blocker used to treat hypertension and angina. Acetaminophen is a pain reliever and fever reducer, and it is not related to the patient's symptoms or medical history.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 스피로노락톤(spironolactone)\n\nExplanation:\n\nThe patient's symptoms of sudden weight gain, swelling, and shortness of breath suggest nephrotic syndrome, which is likely caused by the patient's underlying kidney disease. Spironolactone, a potassium-sparing diuretic, is appropriate for treating nephrotic syndrome caused by kidney disease. It will help reduce the patient's fluid overload and lower her blood pressure, which is currently elevated.\n\nIvabradine (①) is not appropriate for this patient's condition, as it is used to treat hypertension and angina pectoris. Furosemide (②) is a loop diuretic that may increase the patient's potassium levels, which are already elevated. Sacubitril/valsartan (④) is used to treat heart failure, but it is not appropriate for this patient's nephrotic syndrome. Hydralazine/isosorbide dinitrate (⑤) is a combination medication used to treat hypertension, but it is not appropriate for this patient's condition.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 리바록사반(rivaroxaban)\n\nExplanation:\n\nThe patient has been diagnosed with deep vein thrombosis (DVT) in the left leg, which is a type of venous thromboembolism (VTE). Rivaroxaban is an oral anticoagulant that is commonly used to treat VTE, as it inhibits the production of thrombin and prevents the formation of new blood clots.\n\nWarfarin (①) is also an oral anticoagulant, but it works by inhibiting the vitamin K-dependent synthesis of clotting factors in the liver. It may take several days to reach therapeutic levels and may require frequent monitoring and dose adjustments.\n\nAspirin (②) is an antiplatelet agent that works by inhibiting platelet aggregation. It is not typically used as a first-line treatment for VTE, as it does not directly inhibit the formation of blood clots.\n\nTicagrelor (③) is a platelet inhibitor that is used to treat acute coronary syndrome and prevent stent thrombosis. It is not typically used to treat VTE.\n\nUnfractionated heparin (⑤) is a parenteral anticoagulant that is commonly used to treat VTE, but it requires frequent monitoring and dose adjustments, and may have more bleeding risks compared to rivaroxaban.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 에녹사파린(enoxaparin)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 부데소니드(budesonide) 흡입제</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 로라타딘(loratadine)\n\nExplanation:\n\nThe patient has a history of worsening asthma symptoms after taking aspirin, which suggests that she may have aspirin-exacerbated respiratory disease (AERD). Loratadine is an antihistamine that is less likely to exacerbate asthma symptoms and may be a safer option for this patient.\n\nAmbroxol is a mucolytic that thins and loosens mucus, but it may not be effective in managing asthma symptoms. Riboflavin is a vitamin that is not typically used to treat asthma. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that may exacerbate asthma symptoms, especially in patients with AERD. Pseudoephedrine is a decongestant that may be contraindicated in patients with hypertension or cardiovascular disease.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 이프라트로퓸(ipratropium) 비강분무제</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ 살메테롤/프루티카손(salmeterol/fluticasone) 흡입제.\n\nExplanation:\n\nThe patient's symptoms of chronic cough and shortness of breath, along with the recent worsening of symptoms, suggest that they may have chronic obstructive pulmonary disease (COPD). The patient's history of smoking for 20 years and the results of the pulmonary function test (PFT), which showed a forced expiratory volume in 1 second (FEV1) of 72% and a forced vital capacity (FVC) of 68%, support this diagnosis. The CAT score of 8 also suggests that the patient has severe COPD.\n\nThe most appropriate treatment for this patient would be a combination of a long-acting beta-2 agonist (LABA) and an inhaled corticosteroid (ICS). LABAs, such as salmeterol, have been shown to improve lung function and symptoms in patients with COPD, while ICSs, such as fluticasone, have been shown to reduce inflammation in the lungs and improve lung function. The combination of these two medications has been shown to be more effective than either medication alone in improving lung function and symptoms in patients with COPD.\n\nTherefore, option ④, 살메테롤/프루티카손(salmeterol/fluticasone) 흡입제, is the most appropriate answer.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ 65세 이후 1회</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 에스오메프라졸(esomeprazole)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 메토프롤롤\n\nExplanation:\n\nMetoprolol is a beta-blocker, which can decrease the heart rate and cardiac output, leading to a decrease in blood pressure. This can help to reduce the risk of rebleeding in patients with esophageal varices.\n\nThe other options do not have a direct effect on reducing the risk of rebleeding in patients with esophageal varices:\n\n* Vitamin D is important for bone health, but it does not have a direct effect on reducing the risk of rebleeding.\n* Amlodipine is a calcium channel blocker, which can decrease blood pressure by relaxing blood vessels, but it does not have a direct effect on reducing the risk of rebleeding.\n* Calcium citrate is a calcium supplement, which can help to maintain bone health, but it does not have a direct effect on reducing the risk of rebleeding.\n* Hydrochlorothiazide is a diuretic, which can decrease blood pressure by increasing urine production, but it does not have a direct effect on reducing the risk of rebleeding.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 로페라미드(loperamide)\n\nExplanation:\n\nLoperamide is an antidiarrheal medication that works by slowing down the movement of the gut and increasing the amount of water absorbed by the intestines. It is commonly used to treat diarrhea caused by irritable bowel syndrome, inflammatory bowel disease, and other conditions. In this case, the patient has been diagnosed with irritable bowel syndrome, and loperamide would be an appropriate treatment option to manage their symptoms.\n\nDocusate (①) is a stool softener that is used to treat constipation. It is not appropriate for managing diarrhea.\n\nLactulose (②) is a laxative that is used to treat constipation. It is not appropriate for managing diarrhea.\n\nLubiprostone (④) is a medication that is used to treat constipation in patients with irritable bowel syndrome. It is not appropriate for managing diarrhea.\n\nPrucalopride (⑤) is a medication that is used to treat constipation in patients with irritable bowel syndrome. It is not appropriate for managing diarrhea.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 다클라타스비르(daclatasvir) + 테노포비르(tenofovir)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ B형간염 면역글로불린 + B형간염백신</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 아달리무맙(adalimumab) 주사제로 변경</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 아자티오프린(azathioprine)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ① 니모디핀(nimodipine) 주사제</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ④ 메트로니다졸(metronidazole)\n\nExplanation:\n\nThe patient has signs of sepsis, such as fever, chills, and tachycardia, and has a history of chronic liver disease and alcoholism. The physical examination reveals signs of necrotizing fasciitis, including erythema, swelling, and purulent discharge. The patient also has a history of recent antibiotic use, which increases the risk of developing Clostridioides difficile infection.\n\nMetronidazole is an imidazole antibiotic that is effective against anaerobic bacteria, including Bacteroides fragilis, which is commonly isolated from cases of necrotizing fasciitis. It is also effective against Clostridioides difficile, which can cause pseudomembranous colitis, a potentially life-threatening complication of antibiotic use.\n\nNafcillin and vancomycin are effective against gram-positive bacteria, but may not be effective against the anaerobic bacteria that cause necrotizing fasciitis. Norfloxacin is a fluoroquinolone antibiotic that is effective against a wide range of bacteria, including some anaerobes, but its use is generally limited to urinary tract infections and sexually transmitted infections. Erythromycin is a macrolide antibiotic that is effective against a wide range of bacteria, but its use is generally limited to respiratory and gastrointestinal infections.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe patient's electrolyte imbalance, specifically hypokalemia (low potassium levels), is likely caused by the diuretic effect of hydrochlorothiazide. Hydrochlorothiazide can cause potassium loss by increasing urinary potassium excretion. This can lead to a decrease in serum potassium levels, as seen in this patient's laboratory results (K 3.2 mEq/L).\n\nTherefore, the correct answer is ③ 메트포르민 (metformin), as it is not related to the patient's electrolyte imbalance.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 음주력\n\nExplanation:\n\nThe patient's symptoms of severe headache, confusion, and difficulty breathing, along with the laboratory results of metabolic acidosis (elevated anion gap, low pH, and elevated K+), suggest a diagnosis of alcohol withdrawal syndrome. The patient's history of heavy alcohol consumption and recent cessation of alcohol intake support this diagnosis.\n\nThe other options do not fit the patient's symptoms and laboratory results:\n\n① Low blood pressure is not a prominent feature of alcohol withdrawal syndrome.\n\n② There is no evidence to suggest that the patient has a history of smoking.\n\n④ Insulin omission is not a likely cause of the patient's symptoms, as the patient has been taking insulin regularly and has a history of diabetes.\n\n⑤ Furosemide is a diuretic medication that is not typically used to treat alcohol withdrawal syndrome.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 프레드니솔론\n\nExplanation:\n\nThe patient's symptoms of decreased urine output and generalized edema started on the 3rd day after receiving immunosuppressive therapy, which suggests a possible adverse reaction to one of the medications.\n\nCyclosporine (①) and azathioprine (②) are both immunosuppressants, but they are not typically associated with acute kidney injury or edema.\n\nPrednisolone (③) is a corticosteroid that can cause fluid retention and edema, especially at high doses. The patient's symptoms started after receiving 5 mg of prednisolone per day, which is a relatively high dose.\n\nChlorhexidine (④) is an antiseptic that is not associated with acute kidney injury or edema.\n\nInsulin degludec/insulin aspart (⑤) is a combination of long-acting and short-acting insulins used to treat diabetes. It is not typically associated with acute kidney injury or edema.\n\nTherefore, the most likely cause of the patient's symptoms is prednisolone-induced fluid retention and edema.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 암로디핀(amlodipine) 추가</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 토라세미드(torasemide)\n\nExplanation:\n\nThe patient's symptoms of nausea, vomiting, and diarrhea, along with their recent history of high blood pressure, suggest that they may have developed hypervolemic hyponatremia due to excessive intravenous fluid administration. The patient's low serum sodium level (134 mEq/L) and high urine sodium level (47 mEq/L) support this diagnosis.\n\nTorasemide is a loop diuretic that increases urine production by inhibiting the reabsorption of sodium and chloride ions in the renal tubules. It is commonly used to treat hyponatremia and edema associated with heart failure, liver disease, and kidney disease. In this case, torasemide can help to correct the patient's hyponatremia and reduce their fluid overload.\n\nLactitol and mannitol are both osmotic diuretics that can increase urine production, but they are not as effective in correcting hyponatremia as torasemide. Spherical adsorptive carbon (kremezinⓇ) is not a diuretic and would not be effective in treating hyponatremia. Calcium polystyrene sulfonate is a cation-exchange resin that can be used to treat hyperkalemia, but it is not a diuretic and would not be effective in treating hyponatremia.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 용량 증가와 비타민C 추가\n\nExplanation:\n\nThe patient's current symptoms of fatigue, nausea, and vomiting, along with the laboratory results of anemia, low hemoglobin, and low hematocrit, suggest that the patient may be experiencing anemia due to darbepoetin alfa therapy. The low ferritin level also suggests that the patient may have iron deficiency.\n\nIn this case, the appropriate action would be to increase the dose of darbepoetin alfa and add vitamin C to the treatment regimen. Vitamin C can help to enhance the absorption of iron and improve the anemia.\n\nTherefore, the correct answer is ③ 용량 증가와 비타민C 추가.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 메트포르민(metformin)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ 메토클로프라미드(metoclopramide) 정제</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 로수바스타틴(rosuvastatin)\n\nExplanation:\nThe patient is currently taking metformin, lisinopril, carvedilol, atorvastatin, and aspirin. The patient's blood test results show HbA1c of 7.8%, which indicates poor blood sugar control. The patient also has high LDL-C and TG levels. Considering the patient's history of hypertension, hyperlipidemia, and diabetes, it is appropriate to add a medication that can improve blood sugar control and reduce the risk of cardiovascular disease. Rosuvastatin, a statin, can help lower LDL-C and TG levels, and has been shown to reduce the risk of cardiovascular events in patients with diabetes. Therefore, option ③ 로수바스타틴(rosuvastatin) is the best answer.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 메티마졸(methimazole)으로 변경\n\nExplanation:\n\nThe patient is currently taking propylthiouracil 100 mg three times a day, and the latest thyroid function test result is normal. However, the patient is pregnant and in her 13th week, which is a critical period for fetal development. Propylthiouracil can cross the placental barrier and may pose a risk to the fetus.\n\nTherefore, the most appropriate treatment option would be to switch the patient to methimazole, which is another anti-thyroid medication that is less likely to cross the placental barrier and has a better safety profile during pregnancy. This is supported by several studies and guidelines, including the American Thyroid Association guidelines, which recommend methimazole as the preferred anti-thyroid medication during pregnancy.\n\nThe other options are not appropriate for the following reasons:\n\n① Reducing the dose of propylthiouracil may not be effective in controlling the patient's hyperthyroidism, especially during pregnancy.\n\n② Increasing the dose of propylthiouracil may increase the risk of adverse effects on the fetus.\n\n③ Adding potassium iodide to the patient's regimen may not be effective in controlling hyperthyroidism and may also pose a risk to the fetus.\n\n⑤ Changing to potassium iodide alone may not be effective in controlling hyperthyroidism and may also have a higher risk of adverse effects compared to methimazole.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① TSH</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 다파글리플로진(dapagliflozin)\n\nExplanation:\n\nThe patient has been diagnosed with hypertension and type 2 diabetes, and has been taking metformin, losartan, and aspirin. However, their blood sugar control has not been optimal, with a recent HbA1c level of 7.2%. The patient is also concerned about weight gain and has a history of refusing insulin therapy.\n\nConsidering the patient's history and current medications, the best option for improving blood sugar control would be to add a medication that works independently of insulin and has a weight-neutral effect. Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, fits these criteria and has been shown to improve glycemic control without weight gain.\n\nTherefore, option ④, dapagliflozin, is the best answer.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ 아토르바스타틴(atorvastatin)\n\nExplanation:\n\nThe patient has hypertension, type 2 diabetes, and high cholesterol levels, which puts them at risk for cardiovascular disease. The addition of atorvastatin, a statin, can help reduce the risk of cardiovascular events by lowering cholesterol levels and improving lipid profiles.\n\nLisinopril (①) and carvedilol (②) are both medications for hypertension and heart failure, but they may not directly address the patient's high cholesterol levels. Enoxaparin (③) is an anticoagulant that may be used in patients with established cardiovascular disease, but it is not indicated for primary prevention. Dabigatran (④) is an anticoagulant that is used for stroke prevention in patients with atrial fibrillation, but it is not indicated for cardiovascular disease prevention in this patient.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 갑상선기능</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 시프로플록사신(ciprofloxacin)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 토브라마이신(tobramycin)\n\nExplanation:\n\nThe patient has been diagnosed with acute bacterial meningitis, which is a serious and potentially life-threatening infection. The appropriate treatment for this condition is an antibiotic that can effectively penetrate the meninges and cerebrospinal fluid, and has a broad spectrum of activity against common causative bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis.\n\nTobramycin (③) is an aminoglycoside antibiotic that is effective against a wide range of gram-negative bacteria, including many strains of Streptococcus and Haemophilus. It is also known to penetrate well into the cerebrospinal fluid, making it a suitable choice for meningitis.\n\nCefepime (①) and ertapenem (②) are both broad-spectrum cephalosporins that are effective against a wide range of gram-negative bacteria, but they may not have the same level of penetration into the cerebrospinal fluid as tobramycin.\n\nFosfomycin (④) is a broad-spectrum antibiotic that is effective against many gram-positive and gram-negative bacteria, but it may not be as effective against some strains of Streptococcus and Haemophilus as tobramycin.\n\nAmoxicillin/clavulanate (⑤) is a combination antibiotic that is effective against a wide range of gram-positive and gram-negative bacteria, but it may not have the same level of penetration into the cerebrospinal fluid as tobramycin, and may not be as effective against some strains of Streptococcus and Haemophilus.\n\nTherefore, the most appropriate answer is ③ 토브라마이신(tobramycin).</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 페닐레프린(phenylephrine)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\nThe patient has a history of MRSA (methicillin-resistant Staphylococcus aureus) infection, which suggests that the patient has developed resistance to beta-lactam antibiotics (such as penicillin and cephalosporins). Therefore, option ①, ②, and ⑤, which include beta-lactam antibiotics, are not suitable.\n\nOption ③, which includes a combination of levofloxacin (a fluoroquinolone), gentamicin (an aminoglycoside), and vancomycin (a glycopeptide), is the most appropriate choice. This combination covers a broad spectrum of bacterial pathogens, including MRSA, and is effective against respiratory tract infections.\n\nOption ④, which includes clarithromycin (a macrolide), is not suitable as it does not provide adequate coverage against MRSA.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 폐렴구균백신 13가를 12개월 간격으로 2회 접종함</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 피리독신 (pyridoxine)\n\nRationale: Pyridoxine (vitamin B6) can decrease the effectiveness of oral contraceptives, which is the opposite of the desired effect in this scenario. The other options (isoniazid, rifampicin, ethambutol, and pyrazinamide) are all antibiotics that can be used to treat tuberculosis, but they do not have a known interaction with oral contraceptives.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 카스포펀진(caspofungin)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 메트로니다졸(metronidazole)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 겐타마이신(gentamicin) + 세파졸린(cefazolin)\n\nExplanation:\nThe patient's symptoms of fever, headache, and confusion, along with the laboratory results of bacterial meningitis, indicate a severe infection that requires prompt treatment. The appropriate empirical antibiotic therapy for this patient would be a combination of a broad-spectrum cephalosporin (such as cefazolin) and a potent gram-negative agent (such as gentamicin). This combination would cover the most likely causative organisms, including Streptococcus pneumoniae and Haemophilus influenzae, as well as provide broad coverage against other potential pathogens.\n\nIn this case, the combination of vancomycin and ceftriaxone (Option ①) would not be the most appropriate choice, as vancomycin is primarily used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) and ceftriaxone is a cephalosporin that does not provide adequate coverage against gram-negative organisms.\n\nMetronidazole (Option ②) is an imidazole antibiotic that is primarily used for the treatment of anaerobic infections, and would not be effective against the most likely causative organisms in this case.\n\nLinezolid (Option ④) is an oxazolidinone antibiotic that is effective against gram-positive organisms, but would not provide adequate coverage against gram-negative organisms.\n\nAztreonam (Option ⑤) is a monobactam antibiotic that is effective against some gram-negative organisms, but would not provide adequate coverage against Streptococcus pneumoniae and Haemophilus influenzae, which are the most likely causative organisms in this case. Ciprofloxacin is a fluoroquinolone antibiotic that provides broad coverage against gram-negative organisms, but its use in this case would not be appropriate due to the risk of adverse effects and the availability of other effective treatment options.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 세프트리악손(ceftriaxone)\n\nExplanation:\nThe patient's symptoms of fever, headache, and confusion, along with the laboratory results of bacterial meningitis, indicate a severe infection that requires prompt treatment. The patient's history of recent travel and exposure to possible sources of infection suggest a high likelihood of a bacterial etiology.\n\nThe laboratory results show that Streptococcus pneumoniae is the causative agent, and the antibiotic susceptibility test shows that the isolate is resistant to ampicillin and cefuroxime, but susceptible to cefotaxime and levofloxacin. Therefore, the most appropriate antibiotic for treatment would be cefotaxime, which has a MIC of 0.25 μg/mL and is effective against the causative agent.\n\nCefalexin (①) is not appropriate because it is a cephalosporin antibiotic that is not effective against Streptococcus pneumoniae. Ampicillin (②) is not appropriate because it is resistant to the isolate. Gentamicin (③) is not appropriate because it is an aminoglycoside antibiotic that is not effective against Streptococcus pneumoniae. Azithromycin (⑤) is not appropriate because it is a macrolide antibiotic that is not effective against Streptococcus pneumoniae.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 에르고타민(ergotamine)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 리바스티그민(rivastigmine)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 바클로펜(baclofen)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 발프로산(valproic acid)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 세로토닌증후군\n\nExplanation:\n\nEscitalopram is a selective serotonin reuptake inhibitor (SSRI), which increases the levels of serotonin in the brain. Naratriptan is a serotonin receptor agonist, which works by activating serotonin receptors in the brain. Co-administration of these two drugs may result in an increased risk of serotonin syndrome, a potentially life-threatening condition caused by excessive levels of serotonin in the brain. Symptoms of serotonin syndrome include agitation, confusion, rapid heart rate, high blood pressure, and changes in mental status. Therefore, option ③ 세로토닌증후군 (serotonin syndrome) is the correct answer.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 부스피론(buspirone)으로 변경</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 돔페리돈(domperidone)\n\nExplanation:\n\nDomperidone is a dopamine receptor antagonist that is commonly used to treat dystonia, a movement disorder characterized by involuntary muscle contractions and spasms. In this case, the patient has developed dystonia as a side effect of haloperidol, an antipsychotic medication. Domperidone can help to reduce the muscle stiffness and spasms associated with dystonia, and is therefore the most appropriate choice for treating this patient's condition.\n\nClonidine, fluoxetine, and benztropine are not typically used to treat dystonia. Clonidine is an alpha-agonist that is used to treat hypertension, while fluoxetine is a selective serotonin reuptake inhibitor that is used to treat depression and anxiety. Benztropine is an anticholinergic medication that is used to treat Parkinson's disease and other movement disorders, but it is not typically used to treat dystonia. Metoclopramide is a dopamine receptor antagonist that is used to treat gastrointestinal motility disorders, but it is not typically used to treat dystonia.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 쿠에티아핀(quetiapine)\n\nExplanation:\n\nThe patient has developed tardive dyskinesia (TD) due to long-term use of haloperidol. TD is a serious side effect of antipsychotic medications, and it is important to switch to a different medication to manage the symptoms.\n\nQuetiapine (③) is a second-generation antipsychotic that has a lower risk of TD compared to first-generation antipsychotics like haloperidol. It is also effective in treating schizophrenia and other psychotic disorders.\n\nClozapine (①) is an atypical antipsychotic that has a lower risk of TD compared to typical antipsychotics like haloperidol. However, it has a boxed warning for agranulocytosis, which is a potentially life-threatening side effect.\n\nParoxetine (②) is a selective serotonin reuptake inhibitor (SSRI) that is primarily used to treat depression, anxiety disorders, and some personality disorders. It is not typically used to treat psychotic disorders.\n\nPerphenazine (④) is a typical antipsychotic that has a higher risk of TD compared to second-generation antipsychotics like quetiapine.\n\nChlorpromazine (⑤) is a typical antipsychotic that has a higher risk of TD compared to second-generation antipsychotics like quetiapine. It is also associated with a higher risk of sedation, anticholinergic effects, and orthostatic hypotension.\n\nTherefore, the best answer is ③ 쿠에티아핀(quetiapine).</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 임신당뇨병 병력</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 라록시펜(raloxifene)\n\nExplanation:\n\nRaloxifene is a selective estrogen receptor modulator (SERM) that is used to treat vasomotor symptoms (hot flashes, night sweats, etc.) and osteoporosis in postmenopausal women. It is also sometimes used to treat breast cancer. Raloxifene has been shown to reduce the incidence of vasomotor symptoms and improve bone density in postmenopausal women.\n\nVenlafaxine (②) is an antidepressant that is sometimes used to treat hot flashes, but it is not specifically approved for this indication.\n\nMedroxyprogesterone (③) is a progestin that is sometimes used to treat endometrial cancer, but it is not specifically approved for the treatment of vasomotor symptoms.\n\nBazedoxifene/conjugated equine estrogen (④) is a combination medication that is used to treat vasomotor symptoms and osteoporosis in postmenopausal women. However, it is not specifically approved for the treatment of breast cancer.\n\nEstradiol/medroxyprogesterone (⑤) is a combination medication that is used to treat vasomotor symptoms and osteoporosis in postmenopausal women. However, it is not specifically approved for the treatment of breast cancer.\n\nTherefore, the most appropriate answer is ① 라록시펜(raloxifene).</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 탐스로신(tamsulosin)\n\nExplanation:\n\nThe patient is a 72-year-old male with benign prostatic hyperplasia (BPH) who is experiencing difficulty in urination, which is affecting his quality of life. The appropriate treatment for this patient would be a medication that can relax the smooth muscle in the prostate and bladder neck, improving urine flow and reducing symptoms.\n\nTamsulosin is an alpha-1 adrenergic receptor antagonist that selectively relaxes the smooth muscle in the prostate and bladder neck, making it the most appropriate choice for this patient. It has been shown to improve urinary symptoms and reduce the risk of urinary retention and surgery in patients with BPH.\n\nTadalafil, a phosphodiesterase type 5 inhibitor, may also be considered for the treatment of BPH, but it has a different mechanism of action and may not be as effective in reducing symptoms of urinary hesitancy and weak stream.\n\nOxybutynin is an anticholinergic agent that can help reduce urinary frequency and urgency, but it may not be as effective in improving urine flow and reducing symptoms of BPH.\n\nFinasteride is a 5-alpha-reductase inhibitor that can reduce the size of the prostate, but it may take several months to a year to see the full effects, and it may not be as effective in improving urinary symptoms in the short term.\n\nDesmopressin is a vasopressin receptor agonist that can help reduce the frequency of nighttime awakening to urinate, but it may not be as effective in improving urine flow and reducing symptoms of BPH.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 심전도, 식도심장초음파\n\nExplanation:\n\nThe patient has a history of rheumatoid arthritis and is currently taking methotrexate, folic acid, hydroxychloroquine, and risedronate. The patient has recently experienced increased joint pain and swelling, and the physician has decided to add etanercept to the treatment plan.\n\nBefore starting etanercept, it is important to assess the patient's cardiovascular risk factors, as etanercept can increase the risk of cardiovascular events. The patient's blood pressure and lipid profiles should be checked, and a thorough physical examination should be performed to assess for any signs of cardiovascular disease.\n\nTherefore, the correct answer is ③ 심전도, 식도심장초음파 (electrocardiogram, echocardiography). These tests can help assess the patient's cardiovascular health and identify any potential risks associated with etanercept therapy.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 졸레드론산(zoledronic acid)\n\nExplanation:\n\nThe patient has a history of rheumatoid arthritis and is currently taking methotrexate, folic acid, hydroxychloroquine, and risedronate. The patient has developed a new onset of osteoporosis and is considering adding etanercept to their treatment regimen.\n\nGiven the patient's history of rheumatoid arthritis and the recent development of osteoporosis, the most appropriate medication to add to their regimen would be zoledronic acid. Zoledronic acid is a bisphosphonate that is effective in treating osteoporosis and has been shown to reduce the risk of fractures in patients with rheumatoid arthritis. It is also convenient to administer, as it is given as a once-yearly intravenous infusion.\n\nRaloxifene (①) is a selective estrogen receptor modulator that is used to treat osteoporosis in postmenopausal women. While it may be effective in reducing the risk of fractures, it is not the most appropriate choice for this patient due to the patient's history of rheumatoid arthritis.\n\nAlendronate (②) is another bisphosphonate that is effective in treating osteoporosis. However, it is given orally and may not be as effective in patients with rheumatoid arthritis who have a higher risk of gastrointestinal side effects.\n\nBazedoxifene/conjugated equine estrogen (④) is a combination medication that is used to treat osteoporosis in postmenopausal women. It is not the most appropriate choice for this patient due to the patient's history of rheumatoid arthritis.\n\nEstradiol/medroxyprogesterone (⑤) is a combination medication that is used to treat menopausal symptoms and prevent osteoporosis. It is not the most appropriate choice for this patient due to the patient's history of rheumatoid arthritis and the fact that it is not specifically approved for the treatment of osteoporosis in patients with rheumatoid arthritis.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 로이코보린(leucovorin) 경구제</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 표준용량 시타라빈 + 이다루비신(idarubicin)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 이매티닙(imatinib)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe patient has metastatic colorectal cancer with a KRAS mutation, which indicates that they are unlikely to benefit from anti-EGFR therapy (such as cetuximab or panitumumab). Therefore, the most appropriate first-line chemotherapy regimen would be FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), which is a standard chemotherapy regimen for metastatic colorectal cancer. The addition of nivolumab (Option ④) or irinotecan (Option ②) may also be considered, but FOLFOX is the most appropriate first-line treatment based on the patient's KRAS mutation status. Regorafenib (Option ①) is not a standard chemotherapy regimen for metastatic colorectal cancer and would not be the most appropriate choice for this patient.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 아나스트로졸(anastrozole)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ② 옥트레오티드(octreotide) 주사제\n\nExplanation:\n\nOctreotide is a somatostatin analog that is used to prevent or treat certain side effects associated with morphine use, such as constipation, nausea, and vomiting. It works by reducing the release of certain hormones in the body, such as somatostatin, which helps to regulate various physiological processes, including gut motility and secretion. By reducing the release of somatostatin, octreotide can help to increase gut motility and improve digestion, which can help to prevent or treat constipation and other gastrointestinal side effects associated with morphine use.\n\nIn this case, the patient is taking morphine for pain management, and the physician has prescribed octreotide to prevent or treat constipation, which is a common side effect of morphine. The other options, mesalazine, psyllium, bisacodyl, and dioctahedral smectite, are not relevant to the patient's condition and are not used to prevent or treat constipation associated with morphine use.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 테르비나핀(terbinafine) 크림으로 변경</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 라타노프로스트(latanoprost)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 아연(Zn)</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 약물안전성조사</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 사회력(social history)\n\nExplanation:\n\nThe correct answer is ③ 사회력(social history).\n\nSocial history refers to the patient's history of substance use, including tobacco, alcohol, and illicit drugs. It is an important component of the patient's medical history and can have a significant impact on their health and treatment plan.\n\nThe other options are not correct because:\n\n① 주소(chief complaint) refers to the patient's main symptom or reason for seeking medical attention.\n\n② 가족력(family history) refers to the patient's family medical history, including any medical conditions or genetic disorders that may affect the patient's health.\n\n④ 계통문진(review of system) refers to a comprehensive review of the patient's body systems, including the respiratory, cardiovascular, nervous, and other systems.\n\n⑤ 과거병력(past medical history) refers to the patient's previous medical history, including any previous illnesses, surgeries, or medical conditions.\n\nTherefore, the correct answer is ③ 사회력(social history).</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 판토프라졸 처방\n\nExplanation:\nThe plan (계획) section of the SOAP note should include the medication regimen that the patient will be following. In this case, the patient has been started on a 3-drug regimen that includes pantoprazole, and the plan is to continue this regimen. Therefore, option ③ 판토프라졸 처방 is the correct answer.\n\nThe other options do not relate to the plan section of the SOAP note:\n\n① 상복부 통증 refers to the patient's symptoms, which are not part of the plan section.\n\n② 나프록센 처방 refers to the patient's previous medication regimen, which is not relevant to the current plan.\n\n④ 요소호기검사 결과 refers to the test results, which may be included in the assessment (평가) section of the SOAP note, but not in the plan section.\n\n⑤ 자극적인 음식 제한 권고 refers to the recommendation to limit stimulating foods, which may be included in the plan section, but is not the primary focus of the plan.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Drug Interaction Facts</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 말초신경염\n\nExplanation:\nNifedipine is a calcium channel blocker, which can cause constipation as a side effect. Diazepam is a benzodiazepine, which can cause drowsiness, confusion, and respiratory depression, especially in elderly patients. Therefore, the patient should be monitored closely for signs of respiratory depression, such as dyspnea, tachypnea, or decreased respiratory rate.\n\nIn this case, the patient is 83 years old, and the addition of diazepam may increase the risk of respiratory depression. The patient should be instructed to report any signs of respiratory depression to their healthcare provider immediately.\n\nThe other options are not directly related to the patient's medication regimen or potential side effects:\n\n① 낙상 (nausea) is not a common side effect of nifedipine or diazepam.\n\n② 설사 (diarrhea) is a common side effect of nifedipine, but it is not related to the patient's respiratory system.\n\n③ 저혈당 (hypotension) is a potential side effect of nifedipine, but it is not directly related to the patient's respiratory system.\n\n⑤ 위장관 출혈 (gastric bleeding) is a potential side effect of diazepam, but it is not related to the patient's respiratory system.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 아세트아미노펜(acetaminophen) 정</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 나프록센(naproxen) 정</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 오전 9시 50분</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 1.0～1.5\n\nExplanation:\n\nThe patient has been prescribed digoxin, a medication that can cause arrhythmias, and has a history of heart failure, hypertension, and hyperlipidemia. The patient's symptoms of nausea, vomiting, and diarrhea suggest that the digoxin may be causing gastrointestinal side effects. The patient's age and history of heart failure also increase the risk of digoxin toxicity.\n\nThe therapeutic range for digoxin is typically 0.5-1.0 ng/mL, but in this case, the patient's age and medical history suggest that a lower therapeutic range may be more appropriate. A level of 1.0-1.5 ng/mL would be a reasonable target for this patient, as it would provide adequate therapeutic effect while minimizing the risk of toxicity.\n\nTherefore, the correct answer is ③ 1.0～1.5.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ 이트라코나졸\n\nExplanation:\n\nThe patient's elevated digoxin level is likely due to the interaction between digoxin and itraconazole. Itraconazole is a potent inhibitor of P-glycoprotein, which is a protein that acts as an efflux pump and helps to remove digoxin from the body. By inhibiting P-glycoprotein, itraconazole can increase the concentration of digoxin in the bloodstream, leading to elevated serum levels.\n\nTherefore, the correct answer is ⑤ 이트라코나졸 (itraconazole).</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 다)\n\nExplanation:\nThe patient's current dosage of clarithromycin is 12 mL (125 mg/5 mL) twice a day, which is equivalent to 250 mg/day. According to the reference text, the recommended dosage for children with otitis media is 15 mg/kg/day, which for a 5-year-old boy weighing 20 kg would be 300 mg/day. Therefore, the patient's current dosage is lower than the recommended dosage.\n\nThe correct answer is ③ 다) 1일 투여횟수 (the number of doses per day) needs to be changed to 3 times a day to match the recommended dosage.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 흔들어서 복용하세요.\n\nExplanation:\nThe question asks for the content that needs to be modified in the auxiliary label attached to the drug, based on the prescription and the reference information. The reference information states that the drug should be taken twice a day, but the prescription instructs the patient to take it 12 hours apart. Therefore, the auxiliary label should be modified to reflect the correct dosage instructions.\n\nOption ③ 흔들어서 복용하세요 is the correct answer, as it instructs the patient to shake the bottle well before use, which is not mentioned in the reference information.\n\nOption ① 냉장 보관하세요 and Option ② 차광 보관하세요 are not relevant to the question.\n\nOption ④ 유효기간은 14일이에요 is incorrect, as the reference information does not mention the expiration date of the drug.\n\nOption ⑤ 어린이 손에 닿지 않게 하세요 is not relevant to the question, as the drug is already in a liquid form and does not require any additional modification to prevent children from accessing it.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 트라조돈(trazodone)</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 옥시코돈(oxycodone) 서방정</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 희석(dilution)</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 가능함(possible)\n\nExplanation:\n\nThe given case describes a situation where a patient experienced an adverse reaction after taking a medication, and the question asks for the assessment of the causality between the medication and the adverse reaction using the WHO-UMC method.\n\nAccording to the WHO-UMC method, the assessment of causality is based on the following criteria:\n\n1. Time relationship: The adverse reaction occurred after the medication was administered.\n2. Causality: The adverse reaction is a known side effect of the medication.\n3. Biological plausibility: The mechanism by which the medication could cause the adverse reaction is biologically plausible.\n4. Temporality: The adverse reaction resolved after the medication was discontinued.\n\nIn this case, criteria 1 and 2 are met, as the adverse reaction occurred after the medication was administered and it is a known side effect of the medication. Criterion 3 is also met, as the mechanism by which the medication could cause the adverse reaction is biologically plausible. However, criterion 4 is not met, as there is no information provided about the temporal relationship between the medication and the adverse reaction.\n\nTherefore, based on the WHO-UMC method, the assessment of causality between the medication and the adverse reaction is ③ 가능함(possible).</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 세레콕시브(celecoxib) 캡슐</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 플루마제닐(flumazenil) 주</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 카페시타빈(capecitabine)</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 유제품</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 바클로펜(baclofen) 정</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 졸피뎀(zolpidem) 서방정</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 마행감석탕(麻杏甘石湯)</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 저칼슘혈증\n\nExplanation:\n\nThe patient is taking spironolactone (Aldactone), a potassium-sparing diuretic, which can cause hypokalemia (low potassium levels) as a side effect. Therefore, the nurse should monitor the patient's potassium levels closely and report any signs of hypokalemia, such as muscle weakness, fatigue, or heart arrhythmias, to the physician.\n\nThe other options are not relevant to the patient's medication regimen or potential side effects:\n\n① 혈당 상승 (increased blood sugar) is not a concern for the patient as there are no medications in the list that can cause hyperglycemia.\n\n② 고칼륨혈증 (hyperkalemia) is not a concern for the patient as spironolactone can cause hypokalemia, not hyperkalemia.\n\n④ 고요산혈증 (hyperuricemia) is not a concern for the patient as there are no medications in the list that can cause hyperuricemia.\n\n⑤ 고나트륨혈증 (hyponatremia) is not a concern for the patient as there are no medications in the list that can cause hyponatremia.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 심각한 저혈압 유발\n\nExplanation:\n\nThe patient is taking several medications that can lower blood pressure, including losartan, spironolactone, and nitroglycerin. The addition of sildenafil, which can also lower blood pressure, may increase the risk of excessive blood pressure lowering, leading to symptomatic hypotension. Therefore, the most appropriate answer is ③ 심각한 저혈압 유발 (severe hypotension).</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe question is asking about the predictive validation of a batch of pharmaceuticals during the production process. The correct answer is ③, which states that the validation should be performed when the annual production volume of the product is less than or equal to 1 batch.\n\nThis is because when the annual production volume is low, it is more practical and efficient to perform validation on a batch-by-batch basis, rather than on a larger scale. Additionally, this approach helps to ensure that each batch meets the required quality standards and reduces the risk of quality issues or defects in the final product.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 페니실린제제</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 영향인자표</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 표면균 수</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ CIP(cleaning-in-place) 시스템으로 배관을 세척한다.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 순도시험 항</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 주사용수</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nThe question is asking which of the following medications would have a uniformity test applied to it during the production process. The correct answer is ③, the capsule containing 50 mg of the active ingredient.\n\nUniformity testing is a critical step in the production of pharmaceuticals to ensure that each dosage form contains the correct amount of active ingredient. The capsule containing 50 mg of the active ingredient is a suitable candidate for uniformity testing because it is a solid dosage form that can be easily tested for uniformity.\n\nThe other options are not suitable for uniformity testing for the following reasons:\n\n① The nasal spray contains 30% of the active ingredient, which is not a solid dosage form and cannot be tested for uniformity in the same way as a solid dosage form.\n\n② The tablet containing 2 mg of the active ingredient is not a suitable candidate for uniformity testing because it is a small dosage form that may not provide an accurate representation of the entire batch.\n\n④ The liquid-filled capsule may not be suitable for uniformity testing because the liquid fill may not be uniformly distributed within the capsule, and the capsule may not be able to be tested for uniformity in the same way as a solid dosage form.\n\n⑤ The individual containers containing the medication are not suitable for uniformity testing because they are not a part of the production process and cannot be tested for uniformity in the same way as the medication itself.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 정확성(accuracy)</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 에탄올</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 약포지</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 5</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 무균시험</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 기체크로마토그래프법</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe calculated process capability index (PCI) is 1.11, which indicates that the process is operating within the specified limits but has some room for improvement. The PCI value is closer to 1 than to 0, which means that the process is generally capable but may not be optimized.\n\nTherefore, the appropriate judgment and action based on the PCI value would be:\n\n③ The process is somewhat capable, but improvement is necessary.\n\nIn this case, it would be appropriate to identify the root causes of the variability in the process and implement corrective actions to improve the process capability. This may involve adjusting the process parameters, improving the quality control procedures, or implementing additional training for the production staff. By taking these steps, the process can be optimized and the likelihood of defects can be reduced, resulting in increased customer satisfaction and cost savings for the company.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 원료의 혼합도</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 건강기능식품의 대량구매 시 할인 제공</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 240만 원</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④ 총매출액에서 총비용을 뺀 값이 의약품 매출원가이다.\n\nThe formula for calculating the comprehensive income statement is:\n\nComprehensive Income = Total Revenue - Total Expenses\n\nTherefore, the answer is ④ 총매출액에서 총비용을 뺀 값이 의약품 매출원가이다.\n\nThe other options are not correct because:\n\n① 감가상각비는 영업비용에 포함시키지 않는다. - This statement is incorrect because the formula for comprehensive income does not include the depreciation expense.\n\n② 포괄손익계산서를 통해 당기순이익을 알 수 있다. - This statement is incorrect because the comprehensive income statement does not show the cash flow.\n\n③ 은행대출금의 이자는 당해 연도 비용에서 제외한다. - This statement is incorrect because the interest expense is not included in the comprehensive income statement.\n\n⑤ 유형자산의 취득원가는 연말 재고와 연초 재고의 차이를 말한다. - This statement is incorrect because the formula for comprehensive income does not include the change in inventory.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nThe correct answer is ④. The characteristic of the social insurance method of financing healthcare services in comparison to the tax-based method is that the scope of responsibility and the purpose and use of funds are clearly defined. In a social insurance system, the funds collected are earmarked for specific purposes, such as healthcare, and the beneficiaries are clearly identified. This allows for greater transparency and accountability in the use of funds.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③ 병원전체 평균재원일수는 OECD 국가들의 평균보다 적다.\n\nThis statement is true. According to the OECD (Organisation for Economic Co-operation and Development), South Korea has a relatively low number of hospital beds per capita compared to other OECD countries. In 2020, South Korea had 2.3 hospital beds per 1,000 population, which is lower than the OECD average of 3.4 hospital beds per 1,000 population.\n\nTherefore, option ③ is the correct answer.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 진입 장벽\n\nExplanation:\n\nThe phenomenon described in the question is known as \"adverse selection.\" Adverse selection occurs when individuals with a lower risk of illness are less likely to purchase insurance, while those with a higher risk of illness are more likely to purchase insurance. This can lead to higher premiums for everyone, as the insurance company must account for the increased risk of paying out claims.\n\nIn this scenario, the individuals with a lower risk of illness are not joining the insurance market (④ 진입 장벽), which leads to an imbalance in the risk pool and higher premiums for those who do join. This is an example of adverse selection, which can make health insurance less affordable and accessible for those who need it most.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 약물소지율(medication possession ratio) 측정법</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③, \"정의의 원칙 | 자율성 존중의 원칙.\"\n\nA 위원's opinion is based on the principle of distributive justice, which suggests that the limited resources should be distributed fairly among all patients. This principle prioritizes the greater good and the equitable distribution of resources over the individual's personal interests.\n\nB 위원's opinion, on the other hand, is based on the principle of autonomy, which emphasizes the importance of respecting the patient's individual choices and decisions. This principle prioritizes the patient's personal interests and well-being over the greater good.\n\nTherefore, the correct answer is ③, \"정의의 원칙 | 자율성 존중의 원칙,\" which reflects the balance between the two principles.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe question asks for the correct description of the usefulness of ultrasonography in detecting breast cancer. The given table shows the results of ultrasonography and the actual diagnosis of breast cancer in 81 patients.\n\nOption ③ states that the actual number of breast cancer patients was 52, which matches the number of true positive cases (52) in the table. Therefore, option ③ is the correct answer.\n\nOption ① states that the number of breast cancer patients who received a positive diagnosis was 57, which is not correct since the actual number of breast cancer patients was 52.\n\nOption ② states that the number of breast cancer patients who received a negative diagnosis was 12, which is not correct since the actual number of breast cancer patients was 52.\n\nOption ④ states that the false negative rate is 3/17, which is not a correct interpretation of the given data.\n\nOption ⑤ states that the sensitivity is 52/(52+3), which is also not a correct interpretation of the given data.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 7\n\nExplanation:\n\nTo calculate the age-standardized mortality rate for lung cancer in the A region, we need to use the following formula:\n\nAge-standardized mortality rate = (Observed deaths / Expected deaths) x 100\n\nExpected deaths can be calculated using the standard population's mortality rate and the region's population.\n\nFor the 20-59 age group, the expected deaths are 500,000 x 2 = 1,000.\nFor the 60+ age group, the expected deaths are 900,000 x 10 = 9,000.\nTotal expected deaths are 1,000 + 9,000 = 10,000.\n\nObserved deaths are 200.\n\nNow, we can calculate the age-standardized mortality rate:\n\nAge-standardized mortality rate = (200 / 10,000) x 100 = 7\n\nTherefore, the answer is ④ 7.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②\n\nExplanation:\n\nThe correct answer is ②, which states that the purpose of the drug pricing policy in our country is to manage drug expenses by linking the price of a drug to its usage. This means that the price of a drug is adjusted based on the amount of the drug used, and the goal is to encourage the use of cost-effective drugs while discouraging the use of expensive drugs.\n\nThe other options do not accurately describe the purpose of the drug pricing policy:\n\n① is incorrect because the policy is not intended to suppress the drug price margin of pharmacies.\n\n③ is incorrect because the policy does not provide a bonus for replacing expensive drugs with cheaper alternatives.\n\n④ is incorrect because the policy does not selectively list only drugs with excellent therapeutic effects and economic value.\n\n⑤ is incorrect because the policy does not involve a refund system for excessive drug use.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④, \"제네릭의약품의 가격은 제약회사와 건강보험공단과의 협상에 의해 결정된다.\"\n\nIn South Korea, the price of generic drugs is determined through negotiations between the pharmaceutical company and the National Health Insurance Service (NHIS). The NHIS sets the price of generic drugs based on the price of the original drug, and the pharmaceutical company can negotiate with the NHIS to determine the final price. Therefore, the price of generic drugs is not determined solely by the market forces of supply and demand, but rather through a negotiated process between the pharmaceutical company and the NHIS.\n\nThe other options are incorrect because:\n\n① The price of generic drugs is not determined by comparing it to the price of the original drug in other countries.\n\n② The price of generic drugs is not determined by the pharmacy, but rather by the NHIS.\n\n③ The price of generic drugs does not decrease after the patent expires for the original drug.\n\n⑤ The price of generic drugs is not determined based on the patient's income level.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④\n\nExplanation:\nThe given graph represents the results of a sensitivity analysis for the cost-effectiveness of a hypertension drug A. The graph shows the cost-effectiveness plane, where the x-axis represents the cost per quality-adjusted life year (QALY) gained, and the y-axis represents the probability of the drug being cost-effective. The graph shows that the drug is likely to be cost-effective, with a high probability of being below the willingness-to-pay (WTP) threshold, which is represented by the dotted line.\n\nTherefore, the correct answer is ④, \"The cost-effectiveness analysis result is most sensitive to the base-case cost-effectiveness ratio.\" This means that the result of the cost-effectiveness analysis is most sensitive to the assumption that the drug is cost-effective in the base case, which is represented by the point on the graph where the probability of being cost-effective is highest.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe given information is that the patient has been taking medication B for 1 year, and the expected remaining life expectancy after 1 year is 50%, 70%, and 100% for patients who have taken medication B, C, and D, respectively.\n\nTo calculate the expected remaining life expectancy for the patient who has taken medication B for 1 year, we need to multiply the probability of survival at 1 year (50%) by the life expectancy at 1 year (70%), and then add the product of the probability of survival at 2 years (30%) and the life expectancy at 2 years (100%).\n\nTherefore, the correct answer is ③ (0.5×1.0)＋(0.3×0.8)＋(0.2×0.3) = 0.5 + 0.24 + 0.06 = 0.80.\n\nSo, the expected remaining life expectancy for the patient who has taken medication B for 1 year is 80%.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 환산지수는 소비자물가지수를 반영하여 건강보험심사평가원이 결정한다.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③ 외래환자 조제에 대한 조제기본료는 방문당 보상금액으로 지급한다.\n\nThis answer choice states that the dispensing fee for outpatient prescriptions is paid per visit, which is consistent with the information provided in the question.\n\nThe other answer choices are not correct for the following reasons:\n\n① 휴일 및 야간 조제에 대해 30% 가산된 조제료를 지급한다: This answer choice refers to the additional dispensing fee for nighttime and holiday prescriptions, which is not mentioned in the question.\n\n② 퇴원환자 조제에 대한 복약지도료는 조제일수에 따라 지급한다: This answer choice refers to the repeat prescription fee for discharged patients, which is not mentioned in the question.\n\n④ 입원환자 조제에 대한 조제복약지도료는 조제일수에 따라 지급한다: This answer choice refers to the repeat prescription fee for inpatients, which is not mentioned in the question.\n\n⑤ 병원약국의 1일 조제건수가 적정 조제건수를 초과하는 경우 조제료 등을 차감하여 지급한다: This answer choice refers to the case where the number of prescriptions dispensed per day exceeds the appropriate number, and the dispensing fee is reduced accordingly. However, this is not related to the topic of the question.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nTo calculate the operating profit, we need to subtract the cost of goods sold from the revenue.\n\nIn 2018, the revenue was 10 billion won, and the cost of goods sold was 7 billion won, so the operating profit was 3 billion won (10 - 7 = 3).\n\nIn 2019, the revenue was 12 billion won, and the cost of goods sold was 8 billion won, so the operating profit was 4 billion won (12 - 8 = 4).\n\nTherefore, the correct answer is ③, 1 billion won.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 2018년의 매출총이익률은 0.1이다.\n\nExplanation:\n\nTo calculate the gross profit margin, we need to subtract the cost of goods sold from the revenue.\n\nIn 2018, the cost of goods sold is 7 million won, and the revenue is 10 million won, so the gross profit is 3 million won (10 - 7 = 3).\n\nThe gross profit margin is the gross profit divided by the revenue, expressed as a percentage.\n\nIn 2018, the gross profit margin is 3 million won / 10 million won = 0.3 or 30%.\n\nTherefore, the correct answer is ③ 2018년의 매출총이익률은 0.1이다.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 국가출하승인의약품</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nAccording to the question, the correct answer is ③, \"전문의약품은 일반의약품과 구분하여 별도의 약장에 진열하여야 한다.\"\n\nThis answer choice states that specialty drugs should be stored separately from general drugs, which is a requirement for managing a pharmacy. It is important to keep specialty drugs separate to prevent confusion and ensure that they are handled and dispensed correctly.\n\nThe other answer choices are not relevant to the management of a pharmacy and do not address the requirements for storing and handling drugs.\n\n① \"약사\"의 명칭 및 성명이 함께 표시된 명찰을 달아야 한다. - This answer choice refers to the requirement for a pharmacist's name and title to be displayed on a sign, but it is not related to the management of a pharmacy.\n\n② 보건위생과 관련된 사고가 없도록 종업원을 철저히 감독하여야 한다. - This answer choice refers to the importance of thoroughly supervising employees to prevent accidents related to health and hygiene, but it is not specific to the management of a pharmacy.\n\n④ 용기나 포장이 개봉된 상태의 의약품을 서로 섞어서 보관하지 않아야 한다. - This answer choice refers to the requirement to store drugs in their original packaging and not to mix them with other drugs, but it is not related to the management of a pharmacy.\n\n⑤ 의약품의 사용과 관련하여 부작용이 발생한 경우에는 필요한 안전대책을 강구하여야 한다. - This answer choice refers to the importance of taking necessary safety measures when adverse reactions occur, but it is not specific to the management of a pharmacy.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 서울특별시장</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nExplanation:\n\nThe question is asking about the scope of the Pharmacist Licensing Examination, specifically regarding the situations in which a pharmacist's instructions or supervision are not required.\n\nOption ① is not correct because in the event of a national emergency or natural disaster, a pharmacist's instructions or supervision may be necessary to ensure the proper handling and distribution of medications.\n\nOption ② is not correct because in the event of a local emergency or natural disaster, a pharmacist's instructions or supervision may be necessary to ensure the proper handling and distribution of medications.\n\nOption ③ is not correct because while pharmacists may participate in volunteer activities during summer vacation, they are still subject to the Pharmacist Licensing Examination and must follow the rules and regulations set forth by the examination.\n\nOption ④ is correct because the Pharmacist Licensing Examination does not require pharmacists to provide instructions or supervision for patients with mental illnesses that may pose a risk to others.\n\nOption ⑤ is not correct because while the dean of a pharmacy school may request a pharmacist's assistance with practical training or research, this does not fall under the scope of the Pharmacist Licensing Examination.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nAccording to the question, the physician has prescribed a medication that has been approved by the Food and Drug Safety Ministry, but the pharmacist has not confirmed the prescription. In this case, the pharmacist can dispense the medication without confirming the prescription, as it has already been approved by the relevant authorities.\n\nTherefore, the correct answer is ③ 식품의약품안전처장이 의약품의 안전성 문제로 품목 허가를 취소한 의약품이 기재된 경우.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nAccording to the question, the correct answer is ③. The statement \"약사는 약국에서 의약품을 조제하면 복약지도 내용을 조제기록부에 적어 2년 동안 보존하여야 한다\" is incorrect.\n\nThe correct statement should be \"약사는 약국에서 의약품을 조제하면 복약지도 내용을 조제기록부에 적어 3년 동안 보존하여야 한다.\"\n\nTherefore, the answer is ③.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④\n\nExplanation:\n\nAccording to the Pharmacist Licensing Examination, the correct answer is ④.\n\nThe question states that the pharmacist cannot open the package or container of a prescription drug that has been sealed by the manufacturer. The options are:\n\n① The pharmacist can sell the drug to a veterinarian who has opened the package.\n② The pharmacist can open the package and sell the drug to a patient who has a prescription.\n③ The pharmacist can sell the drug to a healthcare professional designated by the Minister of Health and Welfare.\n④ The pharmacist can compound and sell the drug according to a prescription from a physician.\n⑤ The pharmacist can sell the drug to another pharmacist who urgently needs it.\n\nThe correct answer is ④, as it is the only option that does not involve opening the package or container of the prescription drug. The pharmacist can compound and sell the drug according to a prescription from a physician without opening the package, as the drug is already in its original form.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ⑤\n\nExplanation:\n\nThe question is asking about the scenarios where a drug that has been approved for clinical trials by the Food and Drug Safety Bureau can be used for purposes other than clinical trials. The correct answer is ⑤, \"Research on a drug that does not target humans.\"\n\nThe other options are all scenarios where the drug can be used for clinical purposes, and are therefore not correct.\n\n① Developing a treatment for severe allergic reactions may involve clinical trials, but it is not a scenario where the drug would be used for purposes other than clinical trials.\n\n② Treating terminally ill cancer patients who have no other treatment options may involve clinical trials, but it is not a scenario where the drug would be used for purposes other than clinical trials.\n\n③ Treating emergency patients who have no other treatment options may involve clinical trials, but it is not a scenario where the drug would be used for purposes other than clinical trials.\n\n④ Treating patients with life-threatening autoimmune diseases may involve clinical trials, but it is not a scenario where the drug would be used for purposes other than clinical trials.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe question asks for an example of a situation where the adverse effect of a drug does not meet the criteria for reporting as a \"serious adverse event\" under the Pharmaceutical Affairs Act.\n\nOption ③, \"스테로이드제제 사용 후 입원기간의 연장이 필요한 사례,\" is the correct answer. This scenario does not meet the criteria for reporting as a serious adverse event because it only involves an extension of the hospitalization period, which is not considered a life-threatening or disabling event.\n\nThe other options are not correct because they describe scenarios that do meet the criteria for reporting as serious adverse events:\n\n① 면immunosuppressive drug use leading to life-threatening infections\n② Anti-inflammatory drug use leading to severe allergic reactions\n④ Opioid use leading to physical dependence and withdrawal symptoms\n⑤ Anti-anxiety drug use leading to unexpected symptoms that require additional treatment.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 임상시험실시기관 지정 취소</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 의료기관에 종사하는 약사</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 마약류도매업자</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nAccording to the \"마약류 관리에 관한 법률\" (Drug Management Act), the treatment and protection of drug addicts are stipulated in Article 32. Specifically, paragraph 1 of Article 32 states that the mayor of a city or the head of a county (si/gun) shall establish a treatment protection committee to deliberate on the treatment and protection of drug addicts. Therefore, the correct answer is ③, which states that the mayor of a city or the head of a county must establish a treatment protection committee to deliberate on the treatment and protection of drug addicts.\n\nThe other options are not correct for the following reasons:\n\n① is incorrect because the law does not specify a specific time limit for the treatment and protection of drug addicts.\n\n② is incorrect because while the Food and Drug Safety Minister may designate a treatment protection institution, this is not specified in the Drug Management Act.\n\n④ is incorrect because while a drug manager may request a diagnosis from a medical professional, there is no provision in the law for the drug manager to perform a diagnosis themselves.\n\n⑤ is incorrect because while a medical professional may administer medication to a drug addict as part of their treatment, there is no provision in the law for a medical professional to prescribe medication specifically for the purpose of treating drug addiction.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 국민에게 건강에 관한 바른 지식 보급</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④. The term \"보건의료인\" (bo-gwan-ui-rye-in) refers to a person who has acquired a license or qualification to provide healthcare services in accordance with the laws and regulations related to healthcare. The term does not refer to a person who is simply working in the healthcare industry, but rather a person who has met specific requirements and is authorized to provide healthcare services. Therefore, option ④ is the best answer.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 국민건강보험공단 이사장</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④\n\nExplanation:\n\nAccording to the question, the person who can receive insurance benefits under the National Health Insurance Act is not subject to restrictions on insurance benefits in the following cases:\n\n① If the person has caused damage due to slight negligence.\n② If the person has committed a crime intentionally.\n③ If the person has suffered an injury while performing their duties and is entitled to receive insurance benefits under other laws.\n④ If the person has contracted an occupational disease and is entitled to receive compensation under other laws.\n⑤ If the person has not followed the instructions of a medical institution regarding their treatment.\n\nTherefore, the correct answer is ④. If a person has contracted an occupational disease and is entitled to receive compensation under other laws, they are not subject to restrictions on insurance benefits under the National Health Insurance Act.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤\n\nExplanation:\n\nThe correct answer is ⑤, \"마약류통합관리시스템의 구축 및 운영에 관한 사항.\"\n\nThe question asks for the item that is not a part of the drug management tasks performed by a pharmacist at a health center under the \"지역보건법\" (Regional Public Health Act).\n\nOption ①, \"대마 생산 현황 및 수량 보고,\" refers to the reporting of drug production and quantity, which is not a task related to drug management.\n\nOption ②, \"마약류관리자의 마약류 취급 감시 및 단속,\" refers to the monitoring and inspection of drug handling by medical professionals, which is a task related to drug management.\n\nOption ③, \"마약류소매업자에 대한 관리 및 업무 보고 명령,\" refers to the management and reporting of drug wholesalers, which is a task related to drug management.\n\nOption ④, \"마약류취급의료업자의 마약류 폐기 및 조치 명령,\" refers to the disposal and management of expired drugs by medical institutions, which is a task related to drug management.\n\nTherefore, the correct answer is ⑤, \"마약류통합관리시스템의 구축 및 운영에 관한 사항,\" which refers to the construction and operation of an integrated drug management system, which is not a task related to drug management at a health center under the \"지역보건법.\"</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Michaelis constant (Km)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ lysine</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ ganglioside GM1</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ phosphofructokinase-1</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ NADH | NAD+</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ malate</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ glucose 6-phosphate</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ (C)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ propionate</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ DNA topoisomerase II</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ guanine의 oxidation</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ transfer RNA (tRNA)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ phosphorylation</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Src homology 2 (SH2)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ NADH</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ NADH</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ nucleotide-excision repair</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ (D)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ palmitoyl-CoA</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ (C)\n\nExplanation:\n\nIn the β-oxidation pathway, palmitoyl-CoA is broken down into acetyl-CoA through several steps. The electron transport chain, including Complex I, is involved in the process. The correct answer is ③ (C), as the electron transport chain, including Complex I, generates a proton gradient across the inner mitochondrial membrane, which is used to produce ATP.\n\nTherefore, the answer is ③ (C).</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 섬모(fimbriae)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 일반형질도입(generalized transduction) – 트랜스포존(transposon)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Clostridium botulinum</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②\n\nThe correct answer is ② 살모넬라균(Salmonella Typhi).\n\nSalmonella Typhi is a gram-negative, flagellated bacterium that can cause typhoid fever, a severe systemic infection. It is transmitted through contaminated food and water, and can cause symptoms such as fever, headache, and abdominal pain.\n\nThe other options do not match the description provided:\n\n① 임균(Neisseria gonorrhoeae) is a gram-negative, non-flagellated bacterium that causes gonorrhea, a sexually transmitted infection.\n\n③ 가스괴저균(Clostridium perfringens) is a gram-positive, flagellated bacterium that can cause gas gangrene and other infections.\n\n④ 클렙시엘라균(Klebsiella pneumoniae) is a gram-negative, non-flagellated bacterium that can cause pneumonia and other respiratory infections.\n\n⑤ 돼지단독균(Erysipelothrix rhusiopathiae) is a gram-positive, non-flagellated bacterium that can cause erysipelas, a skin infection.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 한타바이러스(hantavirus)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① integrase</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 전염성단핵구증(infectious mononucleosis)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 클로로퀸(chloroquine)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ DNA gyrase의 변이</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② 겐타마이신(gentamicin)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 미노사이클린(minocycline)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 아시클로버(acyclovir)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ 오셀타미비르(oseltamivir)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ HLA-B</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ TGF-β</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 자연살해(NK) 세포의 기능 이상</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 리툭시맙(rituximab)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 팔리비주맙(palivizumab)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 모체에서 생성된 Rh 항원에 대한 IgM 항체</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ rh immune globulin</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 수용체 탈감작</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 낮은 지용성으로 인한 낮은 세포막투과도</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 탐스로신(tamsulosin)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 브리모니딘(brimonidine)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 레비티라세탐(levetiracetam)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 엔타카폰(entacapone)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 진통\n\nExplanation:\n\nMorphine is an opioid medication that is commonly used to treat moderate to severe pain. One of its effects is to reduce the cough reflex, which can be beneficial in certain medical conditions such as chronic cough or cough caused by lung disease. Therefore, the correct answer is ③ 진통 (suppression of cough).\n\nThe other options are not correct because:\n\n① 변비 (diarrhea) is not a typical side effect of morphine.\n\n② 산동 (sedation) is a common side effect of morphine, but it is not the primary effect of the medication.\n\n④ 기침억제 (inhibition of sneezing) is not a known effect of morphine.\n\n⑤ 호흡억제 (inhibition of breathing) is a potential side effect of morphine, but it is not the primary effect of the medication.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 히드록시진(hydroxyzine)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 클로피도그렐(clopidogrel)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 암로디핀(amlodipine)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 에볼로쿠맙(evolocumab) – proprotein convertase subtilisin/kexin type 9 (PCSK9)과 결합</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 스피로노락톤(spironolactone)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ neurokinin 1 (NK1) 수용체 차단</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 다나졸(danazol)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 근위세관의 sodium-glucose transporter 2 (SGLT2) 억제</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 아바카비르(abacavir)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 베바시주맙(bevacizumab)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ (ㅁ)\n\nExplanation:\n\nThe question asks about the mechanism of action of desipramine, a drug that increases the levels of norepinephrine (NE) in the synaptic cleft. The diagram shows the process of NE release, transmission, and termination.\n\n① (ㄴ) is incorrect because it represents the release of NE from the vesicle, which is not the mechanism of action of desipramine.\n\n② (ㄷ) is incorrect because it represents the binding of NE to its receptor, which is not the mechanism of action of desipramine.\n\n③ (ㄹ) is incorrect because it represents the termination of NE transmission, which is not the mechanism of action of desipramine.\n\n④ (ㅁ) is correct because it represents the increase in NE levels in the synaptic cleft, which is the mechanism of action of desipramine.\n\n⑤ (ㅂ) is incorrect because it does not represent any step in the process of NE transmission.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 소변이나 혈액 중의 화학물질 대사체</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 리스테리아증</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 톨루엔</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ rotavirus</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ microcystin LR</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ 방사선</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 7,12-dimethylbenz[a]anthracene</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ isoniazid</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 피부감작성시험</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ (D)\n\nExplanation:\n\nThe correct answer is ④ (D) 25-hydroxyvitamin D3.\n\nThe given reaction sequence is:\n\n7-dehydrocholesterol (A) → previtamin D3 (B) → vitamin D3 (C) → 25-hydroxyvitamin D3 (D) → 1α,25-dihydroxyvitamin D3 (E) → 1α,24,25-trihydroxyvitamin D3\n\nThe question asks for the vitamin D active form that is produced by the action of sunlight on the skin. The correct answer is 25-hydroxyvitamin D3 (D), which is produced when previtamin D3 (B) is exposed to sunlight.\n\nTherefore, the answer is ④ (D) 25-hydroxyvitamin D3.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ methomyl</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 노출한계(margin of exposure)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ nicotinic acid</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 칼슘</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Listeria monocytogenes</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ muscarine</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 간흡충증</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 에리토브산(erythorbic acid)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ fumarylacetoacetate hydrolase</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 피리독신(pyridoxine)\n\nExplanation:\n\nPyridoxine (vitamin B6) is involved in the metabolism of amino acids, including leucine, isoleucine, and valine. It is necessary for the conversion of these amino acids into other important compounds in the body, such as neurotransmitters and energy-producing molecules.\n\nIn this case, the newborn baby has been diagnosed with a mild metabolic disorder, and the additional intake of pyridoxine may help to alleviate the symptoms and support the baby's growth and development.\n\nTherefore, option ③ 피리독신(pyridoxine) is the best answer.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 염증성창자병</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③, \"수용자 항원제시세포의 CD8+ T 세포 직접 활성화.\"\n\nIn a kidney transplant patient, the immune system recognizes the transplanted kidney as foreign and mounts an immune response against it, leading to rejection. CD8+ T cells are a type of immune cell that plays a key role in this rejection process. They recognize and kill cells that display foreign antigens, such as the transplanted kidney cells.\n\nTherefore, option ③, \"CD8+ T cells directly activating the recipient's B cells,\" is the correct answer. This option states that the CD8+ T cells directly activate the recipient's B cells, which are responsible for producing antibodies that attack the transplanted kidney.\n\nThe other options do not accurately describe the mechanism of rejection in a kidney transplant patient:\n\n①, \"수용자 항원제시세포의 B 세포 직접 활성화,\" states that the recipient's B cells are directly activated by the transplanted kidney cells, which is not accurate.\n\n②, \"수용자 항원제시세포의 CD4+ T 세포 직접 활성화,\" states that the recipient's CD4+ T cells are directly activated by the transplanted kidney cells, which is not the primary mechanism of rejection in a kidney transplant patient.\n\n④, \"이식편 항원제시세포의 수용자 B 세포 직접 활성화,\" states that the transplanted kidney cells directly activate the recipient's B cells, which is not accurate.\n\n⑤, \"이식편 항원제시세포의 수용자 대식세포 직접 활성화,\" states that the transplanted kidney cells directly activate the recipient's macrophages, which are not directly involved in the rejection process.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe question is asking about the direct result of the t(8;14) chromosomal translocation in the development of B-cell malignancies. The correct answer is ③, the upregulation of proto-oncogenes.\n\nProto-oncogenes are genes that have the potential to cause cancer when mutated or overexpressed. The t(8;14) translocation results in the upregulation of the MYC proto-oncogene, which is located on chromosome 8. The MYC gene is involved in cell proliferation, differentiation, and apoptosis, and its overexpression can lead to uncontrolled cell growth, a hallmark of cancer.\n\nTherefore, option ③, the upregulation of proto-oncogenes, is the correct answer.\n\nThe other options are not directly related to the question:\n\n① DNA methylation is a process that adds a methyl group to DNA, which can silence gene expression. While DNA methylation can play a role in cancer development, it is not directly related to the t(8;14) translocation.\n\n② Telomerase is an enzyme that lengthens telomeres, which are the protective endcaps of chromosomes. While telomerase is often upregulated in cancer cells, it is not directly related to the t(8;14) translocation.\n\n④ Trinucleotide repeats are sequences of three nucleotides that are repeated in the genome. While trinucleotide repeats can be associated with genetic instability, they are not directly related to the t(8;14) translocation.\n\n⑤ Tumor suppressor genes are genes that inhibit cell proliferation and prevent the formation of tumors. While tumor suppressor genes are often inactivated in cancer cells, the t(8;14) translocation does not directly result in the inactivation of tumor suppressor genes.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 대상포진</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 혈장삼투압 감소</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 허파색전증(pulmonary embolism)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 호지킨림프종</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 내피세포</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ⑤ 류마티스심장병</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 폐혈관의 혈전색전증</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 급성바이러스성간염(acute viral hepatitis)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 만성이자염</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 토리사이질 부위에 IgA 다량 침착</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 급성자궁내막염</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 체중 감소</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 관절연골의 진행성분해와 연골밑뼈 비두\n\nExplanation:\n\nThe patient's symptoms of morning stiffness, pain and swelling in the knees and fingers, and the presence of Heberden's nodes suggest a diagnosis of osteoarthritis (OA). The absence of inflammatory markers and the presence of bony spurs support this diagnosis. OA is a degenerative joint disease characterized by the breakdown of articular cartilage, bone remodeling, and synovitis. The pain and stiffness in the knees and fingers are likely due to the degeneration of the joints and the formation of bony spurs, which can cause mechanical stress and inflammation.\n\nTherefore, option ④, \"관절연골의 진행성분해와 연골밑뼈 비두\" (degenerative changes in the articular cartilage and bone spurs) is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 신경근이음부의 기능 소실</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe patient's symptoms of sudden severe headache, loss of consciousness, and detection of blood in the cerebrospinal fluid on lumbar puncture suggest a diagnosis of epidural hematoma. This is a type of bleeding that occurs outside the dura mater, the outermost protective covering of the brain. The bleeding can put pressure on the brain and cause symptoms such as headache, confusion, and loss of consciousness. The presence of blood in the cerebrospinal fluid supports this diagnosis.\n\nTherefore, option ③, \"경질막바깥혈종(epidural hematoma)\" is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 급성위염</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 혈관 내 삼투압 상승</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 공융혼합물(eutectic mixture) 형성</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 온도, 페놀 농도</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 이온화상수</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 용액 이온강도 증가</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 딜레이턴트흐름(dilatant flow)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 삼투압</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Raoult's Law</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 편광성</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 27/40</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 0.04</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 1/100</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 분배계수의 감소</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 50</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 1.0×10^3</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Tween 80</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 반투막을 통과하지 못한다.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 2차 구조는 크기배제 액체크로마토그래프법으로 확인한다.\n\nExplanation:\nThe question asks for the correct description of the monomer of protein drug A at 25°C. The monomer has a molecular weight of 5 kDa and an isoelectric point of 8. It has a spherical shape and a melting temperature of 60°C.\n\nOption ④ is the correct answer. The 2nd structure of the monomer is confirmed by size exclusion chromatography, which is a method used to separate and analyze the structure of large biomolecules, including proteins.\n\nOption ① is incorrect because the monomer does not have a 4th structure.\n\nOption ② is incorrect because the pH at which the protein has a positive charge is not relevant to the description of the monomer.\n\nOption ③ is incorrect because the 3rd structure of the monomer at 80°C and 25°C is not the same.\n\nOption ⑤ is incorrect because the addition of sodium dodecyl sulfate to the monomer's solution does not affect its structure.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 2</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 심바스타틴(simvastatin)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 리스페리돈(risperidone)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 이온-쌍극자 결합</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ NH2NH2</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ①</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 항암제</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe question asks about the effect of substituting a hydroxyl group (OH) at different positions on the phenylethanolamine skeleton on the selection of adrenergic receptors.\n\n① states that introducing an OH group at the 3rd position increases the selectivity for β2-adrenergic receptors. This is incorrect because the 3rd position is not a substituted position in the given molecule.\n\n② states that introducing an OH group at the 4th position increases the selectivity for α-adrenergic receptors. This is incorrect because the 4th position is not a substituted position in the given molecule.\n\n③ states that introducing an OH group at the 3rd and 5th positions, respectively, increases the selectivity for β2-adrenergic receptors. This is correct because the 3rd and 5th positions are substituted positions in the given molecule, and introducing an OH group at these positions would increase the polarity of the molecule and enhance its affinity for β2-adrenergic receptors.\n\n④ states that introducing an OCH3 group at the 2nd and 5th positions, respectively, increases the selectivity for β2-adrenergic receptors. This is incorrect because the 2nd position is not a substituted position in the given molecule, and introducing an OCH3 group at the 5th position would not increase the selectivity for β2-adrenergic receptors.\n\n⑤ states that introducing a CH2OH group at the 3rd position and an OH group at the 4th position increases the selectivity for α-adrenergic receptors. This is incorrect because the 3rd position is not a substituted position in the given molecule, and introducing a CH2OH group at this position would not increase the selectivity for α-adrenergic receptors.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 라미부딘(lamivudine)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 사슬 길이의 연장</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 1\n\nExplanation:\n\nThe question asks for the minimum amount of water (L) required to dissolve 70 mg of calcium carbonate (CaCO3) at 25°C.\n\nWe can use the formula:\n\nL = (moles of solute / molar mass of solute) x (Ksp / 1000)\n\nwhere moles of solute = mass of solute / molar mass of solute\n\nFirst, let's calculate the moles of calcium carbonate:\n\nmoles of CaCO3 = 70 mg / 100.0 g/mol = 0.0007 mol\n\nNext, we can calculate the volume of water required:\n\nL = (0.0007 mol / 1000) x (4.9 x 10^-9 / 1000) = 0.001 L\n\nTherefore, the answer is ① 0.001.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 1.19</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 고속원심분리 – 강열</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 살리실산</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 8.0</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 1.0×10-3</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 돔페리돈</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 레티놀팔미테이트유</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 한외여과</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 전기화학검출기(electrochemical detector)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe problem states that the separation efficiency of the chromatography column is low, and we need to find a way to improve it.\n\nOption ①, reducing the length of the column, would not improve the separation efficiency as it would reduce the amount of interaction between the sample and the stationary phase, leading to a lower resolution.\n\nOption ②, increasing the flow rate of the mobile phase, would not improve the separation efficiency as it would increase the velocity of the sample components, leading to a lower resolution.\n\nOption ③, increasing the flow rate of the mobile phase, is the correct answer. Increasing the flow rate of the mobile phase would increase the velocity of the sample components, which would improve the separation efficiency by reducing the interaction between the sample components and the stationary phase.\n\nOption ④, reducing the size of the packing particles, would not improve the separation efficiency as it would reduce the surface area available for interaction between the sample components and the stationary phase, leading to a lower resolution.\n\nOption ⑤, reducing the surface area of the packing particles, would not improve the separation efficiency as it would reduce the surface area available for interaction between the sample components and the stationary phase, leading to a lower resolution.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 지질</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 11.4</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 평균편차\n\nExplanation:\n\nThe question asks for the necessary value to perform a Student t-test to determine if the mean of the weights of two different batches of Atorvastatin produced by two different machines are equal.\n\nThe correct answer is ③ 평균편차 (mean deviation), which is the difference between the two sample means.\n\nThe other options are not relevant to the question:\n\n① 4 d값 (4 d values) refers to the values of the degrees of freedom, which are not needed to perform a t-test.\n\n② 범위 (range) refers to the difference between the maximum and minimum values in a dataset, which is not relevant to the question.\n\n④ 상대평균편차 (relative mean deviation) refers to the difference between the two sample means divided by the grand mean, which is not the same as the t-test.\n\n⑤ 합동표준편차 (combined standard deviation) refers to the square root of the sum of the squared differences between the two sample means and the grand mean, divided by the number of samples minus one. This value is not needed to perform a t-test.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 흡착\n\nExplanation:\n\nThe given conditions are:\n\n* The aspirin is in aqueous solution with a pH of 4.5.\n* The aspirin has a pKa of 3.5.\n* The column is filled with a 5 μm octadecylsilyl silica gel.\n* The mobile phase is a mixture of water and methanol (60:40).\n* The flow rate is 1.2 mL/min.\n\nUnder these conditions, the aspirin will be ionized and the ionized form will be retained on the column. This is because the pKa of aspirin (3.5) is lower than the pH of the mobile phase (4.5), which means that the majority of the aspirin molecules will be in the ionized form. The ionized aspirin molecules will interact with the silica gel through electrostatic attraction, resulting in their retention on the column.\n\nTherefore, the correct answer is ③ 흡착 (adsorption).</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 조성을 물 ∙ 메탄올혼합액(50 : 50)으로 바꾼다.\n\nExplanation:\n\nThe given question is asking for the best approach to increase the dissolution rate of aspirin in a mobile phase. The correct answer is ③, changing the composition to water-methanol (50:50).\n\nAspirin has a pKa value of 3.5, which means it is a weak acid. In a mobile phase with a pH of 4.5, the drug will be mostly in its ionized form, which can lead to reduced solubility and dissolution rate.\n\nBy changing the mobile phase composition to water-methanol (50:50), the pH of the solution will be closer to the pKa value of aspirin, which will increase the proportion of the drug in its non-ionized form, leading to improved solubility and dissolution rate.\n\nTherefore, option ③ is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 장용정</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 캡슐제, 이식제</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 셀라세페이트</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ die friction</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④ 히프로멜로오스를 사용하여 캡슐 피막을 제조할 수 있다.\n\n히프로멜로오스(Hypromellose) is a type of polymer that is commonly used as a coating material in the production of tablets and capsules. It is a hydrophilic polymer that is soluble in water, and it is often used as a substitute for gelatin in vegetarian and vegan capsules.\n\nThe other options are incorrect because:\n\n① 캡슐 크기는 3호가 2호보다 크다. - This statement is incorrect. The size of the capsule has no relation to the type of coating material used.\n\n② 피막 성형과 내용물 충전이 동시에 이루어진다. - This statement is incorrect. The coating process and the filling process are separate steps in the production of capsules.\n\n③ 젤라틴 피막에 함유된 가소제가 많을수록 딱딱해진다. - This statement is incorrect. The amount of plasticizer in the gelatin coating does not affect the hardness of the capsule.\n\n⑤ 정제와 달리 압축과정이 없어 활택제를 첨가하지 않는다. - This statement is incorrect. The production process for capsules does not involve compression, and the addition of a lubricant is not necessary.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 폴록사머(poloxamer)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ①</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ poly(lactide-co-glycolide)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ propyl gallate</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ E</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\nThe correct answer is ③ 피부수화 정도가 약물의 경피흡수에 영향을 미친다.\n\nThe question asks for the correct statement regarding the absorption of drugs through the skin. Option ③ states that the degree of skin hydration affects the absorption of drugs through the skin. This is true, as the hydration of the skin can influence the ability of drugs to penetrate through the skin and be absorbed into the bloodstream.\n\nOption ①, ②, ④, and ⑤ are incorrect statements regarding the absorption of drugs through the skin.\n\nOption ① states that the release of the drug from the matrix is dependent on the body's metabolism, which is not correct.\n\nOption ② states that large molecular weight proteins are effective in delivering drugs through the skin, which is also not correct.\n\nOption ④ states that the concentration of the drug in the bloodstream is independent of the skin attachment area of the drug, which is not correct.\n\nOption ⑤ states that the drug is immediately eliminated from the body once it is absorbed through the skin, which is also not correct.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe question is asking about the meaning of the term \"apparent volume of distribution\" in the context of a one-compartment model for drug pharmacokinetics.\n\nOption ① is incorrect because it refers to the volume of drug that is eliminated per unit time, not the volume of drug that is distributed in the body.\n\nOption ② is incorrect because it states that the volume of distribution cannot exceed the actual volume of the tissues in the body, which is not a definition of apparent volume of distribution.\n\nOption ③ is correct because it states that the apparent volume of distribution can be calculated from the clearance and half-life of the drug, which is a definition of apparent volume of distribution.\n\nOption ④ is incorrect because it states that the volume of distribution is proportional to the amount of drug bound to plasma proteins, which is not a definition of apparent volume of distribution.\n\nOption ⑤ is incorrect because it states that the apparent volume of distribution is the ratio of the drug concentration in the tissues to the drug concentration in the plasma, which is not a definition of apparent volume of distribution.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ②\n\nExplanation:\n\nThe correct answer is ②, \"생물약제학적분류체계(BCS) 중 제4군이 IVIVC가 가장 잘 성립한다.\"\n\nIVIVC (In Vitro-In Vivo Correlation) is a correlation between the in vitro dissolution rate of a drug and its in vivo bioavailability. The BCS (Biopharmaceutical Classification System) is a system that classifies drugs based on their solubility and permeability properties. Class 4 drugs in the BCS have high solubility and low permeability, which means they are likely to have a high IVIVC.\n\nTherefore, the statement that Class 4 drugs in the BCS have the highest IVIVC is correct.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 소실반감기</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 0.50Css</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ CYP2C19 | 클리어런스</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ②\n\nExplanation:\n\nThe main purpose of using glycerin in the formulation of a rapid infusion solution for surgical patients is to act as a humectant, which helps to maintain the moisture content of the skin and mucous membranes. Therefore, the correct answer is ②, \"보존제\" (preservative). Glycerin helps to prevent dryness and irritation of the skin and mucous membranes, which can be beneficial for surgical patients who may be exposed to dry air or irritating substances during their surgical procedure.\n\nThe other options do not accurately describe the main purpose of glycerin in this context:\n\n① 유화제 (emulsifier): While glycerin can act as an emulsifier, it is not its main purpose in this formulation.\n\n③ 등장화제 (moisturizer): While glycerin can help to moisturize the skin, it is not its main purpose in this formulation.\n\n④ 항산화제 (antioxidant): Glycerin does not have significant antioxidant properties, so this is not its main purpose in this formulation.\n\n⑤ 현탁화제 (fragrance): Glycerin does not have a significant fragrance, so this is not its main purpose in this formulation.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③. The question states that the purpose of developing the injection A is to provide a quick and sufficient dose of the drug to surgical patients. Therefore, the most appropriate description of injection A is that it is a muscle relaxant, which can be quickly absorbed into the bloodstream and provide a rapid onset of action.\n\nOption ① is incorrect because the question does not mention anything about the injection being able to be administered intrathecally.\n\nOption ② is incorrect because the question does not specify the particle size of the drug.\n\nOption ④ is incorrect because the question does not mention anything about the drug being lyophilized.\n\nOption ⑤ is incorrect because the question does not mention anything about the drug being a large-volume intravenous injection.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ protoberberine alkaloid</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① aconitine</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ emodin</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Liebermann-Burchard 반응</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Pinellia ternata</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 계피</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 원지</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Paeonia lactiflora</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① capsaicin</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Colchici Semen</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 울금</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 큐라레</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 고섭작용(固攝作用)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 녹용(鹿茸)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 배농산급탕(排膿散及湯)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 용담사간탕(龍膽瀉肝湯)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 행인</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ ephedrine</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 푸로세미드(furosemide)\n\nReason: The patient's blood pressure is still not controlled despite taking losartan, amlodipine, and carvedilol. Furosemide is a diuretic that can help reduce blood pressure by increasing urine production. It is also effective in treating hypertension in patients with kidney disease, which this patient has. The other options, diltiazem, hydralazine, irbesartan, and hydrochlorothiazide, may also be effective in lowering blood pressure, but they may not be as appropriate for this patient's specific condition.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 암로디핀(amlodipine)\n\nExplanation:\n\nThe patient is currently taking lisinopril, carvedilol, furosemide, and spironolactone. The patient's blood pressure is 128/76 mmHg, which is within the normal range. However, the patient's heart rate is 86 beats per minute, which is slightly elevated. The patient also has a history of angina, which suggests that they may have coronary artery disease.\n\nAmlodipine is a calcium channel blocker that can be used to treat hypertension and angina. It can help to reduce the patient's heart rate and blood pressure, which can alleviate the symptoms of angina. Additionally, amlodipine has a beneficial effect on the cardiovascular system by reducing the workload on the heart and improving blood flow to the coronary arteries.\n\nValsartan, verapamil, and ivabradine are not appropriate choices for this patient because they are not calcium channel blockers and would not have the same beneficial effects on the cardiovascular system as amlodipine. Amiodarone is a class III antiarrhythmic drug that is used to treat ventricular arrhythmias, but it is not indicated for the treatment of hypertension or angina.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 펠로디핀(felodipine)\n\nExplanation:\n\nThe patient has a history of angina, hypertension, and hyperlipidemia. The patient's recent increase in nitroglycerin use suggests that their angina symptoms are not well controlled. Felodipine is a calcium channel blocker that can help to reduce angina symptoms by relaxing coronary arteries and improving blood flow to the heart. It is a suitable additional medication to add to the patient's current regimen, which already includes aspirin, metoprolol, lisinopril, and atorvastatin.\n\nAtenolol (①) is a beta-blocker that can also be used to treat angina, but it may not be the best choice for this patient due to their history of bronchospasm.\n\nValsartan (②) is an angiotensin II receptor antagonist that is primarily used to treat hypertension and heart failure. It may not be effective in reducing angina symptoms.\n\nDiltiazem (③) is a calcium channel blocker that can also be used to treat angina, but it may have a slower onset of action compared to felodipine.\n\nClopidogrel (⑤) is an antiplatelet agent that is used to prevent blood clots and is not directly related to the patient's angina symptoms.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 클로피도그렐(clopidogrel)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ 클로피도그렐(clopidogrel)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 복용약물\n\nExplanation:\nThe correct answer is ③ 복용약물. The patient's medication regimen includes amlodipine, telmisartan, metoprolol, glimepiride, and atorvastatin. These medications can increase the risk of bleeding, particularly when combined with other medications that can also increase the risk of bleeding, such as non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin. Therefore, the patient's medication regimen is a factor that can increase the risk of bleeding and should be considered when assessing the patient's HAS-BLED score.\n\nThe other options are not correct because they are not directly related to the patient's medication regimen or bleeding risk.\n\n① 성별 (gender) is not a factor that can increase the risk of bleeding.\n\n② LDL-C (low-density lipoprotein cholesterol) is a measure of cholesterol levels in the blood, but it is not directly related to the risk of bleeding.\n\n④ 당화혈색소 (hemoglobin A1c) is a measure of average blood sugar control over the past 2-3 months, but it is not directly related to the risk of bleeding.\n\n⑤ 수축기 혈압 (systolic blood pressure) is a measure of blood pressure, but it is not directly related to the risk of bleeding.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 티카그렐러(ticagrelor) 90 mg 1일 2회</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 프라바스타틴(pravastatin) 40 mg 1일 1회</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 에볼로쿠맙(evolocumab) 추가\n\nExplanation:\n\nThe patient's LDL-C level is still high despite being treated with atorvastatin, which suggests that the patient may have a genetic predisposition to high cholesterol levels. Evolocumab is a PCSK9 inhibitor that can help lower LDL-C levels by increasing the number of LDL receptors on liver cells, which can help remove excess cholesterol from the bloodstream. Adding evolocumab to the patient's current regimen may help achieve the desired therapeutic goal for LDL-C levels.\n\nThe other options are not the best choices for this patient:\n\n① Increasing the dose of ezetimibe may not be effective in lowering LDL-C levels, as the patient's current dose is already at the maximum recommended dose.\n\n② Increasing the dose of atorvastatin may not be effective in lowering LDL-C levels, as the patient's current dose is already at the maximum recommended dose.\n\n④ Adding fenofibrate may not be effective in lowering LDL-C levels, as it primarily lowers triglycerides and has a lesser effect on cholesterol levels.\n\n⑤ Adding omega-3-acid ethyl esters may not be effective in lowering LDL-C levels, as it has a lesser effect on cholesterol levels compared to other lipid-lowering agents.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 와파린(warfarin)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 와파린 복용 1회 중단 후 INR 재측정\n\nExplanation:\n\nThe patient's INR has increased to 4.7, which is outside the therapeutic range of 2.1-2.7. The patient has been taking ciprofloxacin for the past 5 days, which may have contributed to the increase in INR. The appropriate action would be to hold the warfarin dose for 1 day and recheck the INR. If the INR remains elevated, the patient may need to be transitioned to a different anticoagulant or have their warfarin dose adjusted.\n\nOption ①, ②, and ③ are not appropriate because they do not address the underlying cause of the increased INR, which is likely the interaction between warfarin and ciprofloxacin. Option ④, vitamin K 5 mg oral, may be considered in the future if the patient's INR remains elevated, but it is not the most appropriate action at this time.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 모메타손\n\nExplanation:\n\nThe patient's history of hypertension, angina pectoris, and allergic rhinitis suggests that the cause of his constipation may be related to his medications. Among the medications he is taking, mometasone, a corticosteroid, is a common cause of constipation. Therefore, option ③ 모메타손 (mometasone) is the most likely answer.\n\n Aspirin (option ①) and verapamil (option ②) may also cause constipation as a side effect, but they are less likely to be the primary cause in this case given the patient's medical history and medication regimen. Ascorbic acid (option ④) and nitroglycerin (option ⑤) are unlikely to cause constipation.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ 스피로노락톤(spironolactone)\n\nExplanation:\nThe patient's potassium level is low (4.2 mEq/L), indicating hypokalemia. Spironolactone is a potassium-sparing diuretic that can help to increase potassium levels and correct hypokalemia. The other options, ramipril, doxazosin, amlodipine, and hydrochlorothiazide, may also be used to treat hypertension, but they do not specifically address the hypokalemia issue.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 이트라코나졸\n\nExplanation:\n\nThe patient's symptoms of heart failure are likely related to the use of itraconazole, a potent inhibitor of CYP3A4, which is metabolized by the liver enzyme CYP3A4. Itraconazole can increase the plasma concentration of other drugs metabolized by CYP3A4, such as simvastatin (pitavastatin), which can increase the risk of myopathy and rhabdomyolysis. The patient's elevated liver enzymes (AST and ALT) and low HDL-C level may also suggest a potential drug-drug interaction.\n\nTherefore, option ③ 이트라코나졸 (itraconazole) is the most likely answer.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 카르베딜롤을 베라파밀(verapamil)로 변경\n\nExplanation:\n\nThe patient has hypertension, diabetes, and heart failure, which are all risk factors for cardiovascular disease. The patient's current medications, including lisinopril, carvedilol, spironolactone, metformin, itraconazole, and pitavastatin, are appropriate for managing these conditions. However, the patient's systolic blood pressure is still high at 135 mmHg, indicating that the current medications may not be effectively controlling the patient's hypertension.\n\nAdding digoxin (Option ①) may not be appropriate for this patient, as it is primarily used for treating heart failure in patients with a low ejection fraction, and the patient's ejection fraction is already within a normal range.\n\nLosartan (Option ②) is an angiotensin II receptor antagonist that is used to treat hypertension and diabetic nephropathy. While it may be beneficial for the patient's hypertension, it may not be the most appropriate choice for the patient's heart failure.\n\nChanging carvedilol to verapamil (Option ③) may be a better option for the patient. Verapamil is a calcium channel blocker that is used to treat hypertension and angina. It has a negative chronotropic effect, which can reduce the heart rate and improve the patient's systolic blood pressure. Additionally, verapamil has a positive inotropic effect, which can increase the force of the heart's contractions and improve the patient's heart failure symptoms.\n\nChanging spironolactone to furosemide (Option ④) may not be appropriate for the patient, as spironolactone is a potassium-sparing diuretic that is used to treat heart failure and hypertension, while furosemide is a loop diuretic that is primarily used to treat edema.\n\nChanging lisinopril to sacubitril/valsartan (Option ⑤) may not be appropriate for the patient, as sacubitril/valsartan is a combination of an angiotensin receptor blocker and a neprilysin inhibitor that is used to treat heart failure with preserved ejection fraction. The patient's ejection fraction is already within a normal range, so this medication may not be necessary for the patient's condition.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 부데소니드/포르모테롤(budesonide/formoterol)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 살메테롤 감량, 플루티카손 유지</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 플루티카손(fluticasone) 비강분무제</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 프레드니솔론(prednisolone) 경구제\n\nRationale:\n\nThe patient is experiencing an exacerbation of chronic obstructive pulmonary disease (COPD) with worsening respiratory symptoms over several days, which indicates a need for prompt intervention. The patient's history of COPD and current symptoms suggest that inflammation is playing a significant role in the exacerbation.\n\nPrednisolone, a corticosteroid, is an appropriate choice for short-term use in this situation. It has anti-inflammatory properties that can help reduce inflammation in the lungs and improve lung function. The drug can be administered orally, which is convenient for the patient, and has a rapid onset of action.\n\nThe other options are not as appropriate for this situation:\n\n* Formoterol (①) is a long-acting bronchodilator that can help relieve symptoms, but it does not have anti-inflammatory properties and may not address the underlying inflammation contributing to the exacerbation.\n* Aminophylline (②) is a methylxanthine that can help relieve symptoms, but it has a slower onset of action compared to prednisolone and may not be as effective in reducing inflammation.\n* Fluticasone (④) is an inhaled corticosteroid that can help reduce inflammation in the long term, but it may not have a rapid enough onset of action to address the acute exacerbation.\n* Azithromycin (⑤) is an antibiotic that may be used to treat any underlying bacterial infections, but it is not directly related to the patient's respiratory symptoms and may not address the underlying inflammation.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 아클리디니움(aclidinium) 흡입제\n\nExplanation:\n\nThe patient's symptoms have improved, and the FEV1 result has increased to 53% of the predicted value, indicating that the patient's lung function has improved. In this case, it is appropriate to add a long-acting bronchodilator to maintain the improvement in lung function and prevent future exacerbations.\n\nAclidinium is a long-acting bronchodilator that has a long duration of action and can provide sustained relief of bronchospasm over a 24-hour period. It is an appropriate choice for patients who require long-term management of their bronchospasm symptoms.\n\nIndacaterol and budesonide are also long-acting bronchodilators, but they may not be as effective in maintaining lung function improvement in this patient's case, as they have a shorter duration of action compared to aclidinium.\n\nRoflumilast is a phosphodiesterase-4 inhibitor that is used to treat chronic obstructive pulmonary disease (COPD) and can help improve lung function. However, it is not a bronchodilator and may not be as effective in managing bronchospasm symptoms in this patient's case.\n\nTheophylline is a methylxanthine that can be used to treat COPD, but it may not be the most appropriate choice in this case, as it has a shorter duration of action compared to aclidinium and may require more frequent dosing.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 레보플록사신(levofloxacin)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 살메테롤\n\nExplanation:\n\nThe patient is taking omeprazole, which is a proton pump inhibitor (PPI). PPIs are known to increase the blood concentration of certain drugs, including warfarin, phenytoin, and levetiracetam. However, the increase in blood concentration is not significant for salbutamol, which is a short-acting beta-2 agonist.\n\nTherefore, the correct answer is ③ 살메테롤 (salmeterol), which is a long-acting beta-2 agonist that is metabolized by the liver enzyme CYP3A4, the same enzyme responsible for metabolizing omeprazole. Co-administration of omeprazole and salmeterol may increase the blood concentration of salmeterol, potentially leading to adverse effects such as tremors, palpitations, and increased heart rate.\n\nThe other options are not correct because:\n\n* ① 페니토인 (phenytoin) is metabolized by CYP3A4, but its metabolism is not significantly affected by omeprazole.\n* ② 살부타몰 (salbutamol) is a short-acting beta-2 agonist that is not metabolized by CYP3A4 and is not affected by omeprazole.\n* ④ 플루티카손 (fluticasone) is a corticosteroid that is not metabolized by CYP3A4 and is not affected by omeprazole.\n* ⑤ 레비티라세탐 (levetiracetam) is metabolized by CYP3A4, but its metabolism is not significantly affected by omeprazole.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 옥트레오티드(octreotide)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 라모세트론(ramosetron)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 엔테카비르를 아데포비어(adefovir)로 변경</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 부데소니드(budesonide) 관장제\n\nExplanation:\n\nThe patient has been diagnosed with severe ulcerative colitis, which is evident from the symptoms of abdominal pain, frequent bowel movements, and weight loss. The laboratory results show anemia, leukocytosis, and elevated ESR, which are all indicative of inflammation in the body. The patient is scheduled to receive hospital treatment, which suggests that the condition is severe and requires close monitoring and management.\n\nConsidering the patient's age and the severity of the condition, the most appropriate medication would be a corticosteroid, which can effectively reduce inflammation and suppress the immune system. Budesonide is a corticosteroid that is specifically used to treat inflammatory bowel diseases, such as ulcerative colitis. It is available in a variety of formulations, including oral capsules, oral suspension, and rectal foam. The recommended dose for adults is 9 mg/day, and it can be titrated up or down depending on the patient's response.\n\nTherefore, option ③ 부데소니드(budesonide) 관장제 is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ⑤ 동맥혈가스분압\n\nExplanation:\n\nAzathioprine is an immunosuppressive drug that is commonly used to treat inflammatory bowel disease, such as ulcerative colitis. One of the major side effects of azathioprine is bone marrow suppression, which can lead to a decrease in white blood cell count, red blood cell count, and platelet count. Therefore, monitoring of complete blood count (CBC) is essential to detect any changes in blood cell counts. Additionally, azathioprine can cause an increase in blood urea nitrogen (BUN) and creatinine levels, which can indicate kidney damage. Therefore, monitoring of renal function tests, such as BUN and creatinine, is also important.\n\nIn this case, the patient has been diagnosed with severe ulcerative colitis and has been hospitalized for treatment. The patient has been prescribed azathioprine to induce remission. Therefore, it is important to monitor the patient's blood cell counts, renal function, and other potential side effects of azathioprine.\n\nThe correct answer is ⑤ 동맥혈가스분압 (blood gas analysis) because it is a test that can monitor the patient's respiratory and metabolic status, as well as detect any changes in blood pH, which can be affected by azathioprine. However, it is not the most appropriate answer in this context because the patient's respiratory and metabolic status are not directly related to the side effects of azathioprine.\n\nThe next best answer would be ① 백혈구 (white blood cell count) because it is a test that can monitor the patient's immune system and detect any changes in white blood cell counts, which can be affected by azathioprine.\n\nThe other options, ② 골밀도 (bone density), ③ 심전도 (electrocardiogram), and ④ 당화혈색소 (blood culture), are not directly related to the side effects of azathioprine and are therefore not appropriate for monitoring the patient's condition.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 프레드니솔론\n\nExplanation:\n\nThe patient has been diagnosed with SIADH (syndrome of inappropriate antidiuretic hormone) and hyponatremia. The most likely cause of SIADH in this case is the use of corticosteroids, specifically prednisolone. Corticosteroids can cause SIADH by increasing the release of antidiuretic hormone (ADH) from the pituitary gland, leading to water retention and hyponatremia.\n\nTherefore, the best answer is ③ 프레드니솔론 (prednisolone).</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 메트포르민\n\nExplanation:\nThe patient's sudden onset of oliguria, weight gain, and increased BUN and creatinine levels suggest a possible cause of acute kidney injury (AKI). The most likely cause of AKI in this patient is metformin, a medication that the patient has been taking for diabetes. Metformin is known to cause AKI, particularly in patients with pre-existing kidney disease or in those who are taking other medications that can harm the kidneys. The other medications the patient is taking, such as enalapril, amlodipine, and acetaminophen, may also contribute to the development of AKI, but metformin is the most likely culprit. Loratadine, an antihistamine, is not typically associated with AKI.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 살부타몰(salbutamol) 정제</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 혈압</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 탄산칼슘(calcium carbonate)\n\nExplanation:\n\nThe patient's laboratory results show hypocalcemia (low calcium levels) and hyperparathyroidism (elevated parathyroid hormone levels). Calcium carbonate is a calcium supplement that can help to increase calcium levels and reduce hyperparathyroidism. Calcitonin and calcitriol are not appropriate for this patient's condition, as they are used for different purposes. Calcitonin is used to treat hypercalcemia (high calcium levels), and calcitriol is used to treat vitamin D deficiency. Lanthanum carbonate is not a calcium supplement and is not appropriate for this patient's condition. Calcium polystyrene sulfonate is a medication used to treat hyperkalemia (high potassium levels), which is not present in this patient's laboratory results.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① 시나칼세트(cinacalcet)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 피오글리타존(pioglitazone)\n\nReasoning:\n\nThe patient has been diagnosed with type 2 diabetes and chronic kidney disease (CKD). The eGFR is 23 mL/min/1.73m2, which indicates that the patient has moderate CKD (stage 3).\n\nPioglitazone is a thiazolidinedione (TZD) medication that is known to have a beneficial effect on renal function in patients with type 2 diabetes and CKD. It has been shown to decrease albuminuria and improve renal function in patients with moderate to severe CKD.\n\nThe other options, acarbose, linagliptin, metformin, and ipragliflozin, may also be used in the treatment of type 2 diabetes, but they do not have the same renal protective effects as pioglitazone.\n\nTherefore, the most appropriate answer is ④ 피오글리타존(pioglitazone).</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 다파글리플로진\n\nExplanation:\nThe patient's symptoms of increased urination, decreased blood pressure, and increased heart rate are consistent with diuretic effects. Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, can cause diuretic effects by increasing urine production. Therefore, option ④ 다파글리플로진 (dapagliflozin) is the most likely answer.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 메트포르민 중단, 글리피지드(glipizide) 추가</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 메티마졸을 프로필티오우라실로 변경\n\nExplanation:\n\nThe patient's clinical symptoms and laboratory results suggest that the patient has hyperthyroidism, and the diagnosis is consistent with Graves' disease. The patient has been taking methimazole for 2 months, and the laboratory results show that the patient's thyroid function has improved, with a significant decrease in free T4 and TSH levels. However, the patient's liver enzymes (AST/ALT) are slightly elevated.\n\nBased on the patient's clinical presentation and laboratory results, the most appropriate treatment option would be to switch the patient's medication from methimazole to propylthiouracil. Propylthiouracil is a thyroid suppressant that is effective in treating hyperthyroidism, and it has a better safety profile than methimazole in terms of liver toxicity.\n\nTherefore, option ④, \"메티마졸을 프로필티오우라실로 변경,\" is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 리튬(lithium)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ 알로푸리놀\n\nExplanation:\n\nThe patient's low vitamin B12 level could be due to several factors, including the use of certain medications. Allopurinol (④) is known to interfere with the absorption of vitamin B12, which could lead to a decrease in its serum levels. The other options, amlodipine (①), lisinopril (②), simvastatin (③), and metformin (⑤), are not known to have a significant effect on vitamin B12 levels.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 메트포르민을 시타글립틴(sitagliptin)으로 변경\n\nExplanation:\nThe patient's vitamin B12 deficiency has been adequately treated with supplementation, and the serum vitamin B12 level has returned to the normal range. However, the patient's blood glucose control remains suboptimal, with an HbA1c level of 7.5%. The patient is currently taking metformin, which is an appropriate medication for type 2 diabetes. However, the patient's blood glucose control may benefit from the addition of a medication that has a different mechanism of action.\n\nSitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the amount of incretin hormones in the body, which can help to improve insulin secretion and glucose tolerance. It is a reasonable choice for this patient, as it has been shown to improve glycemic control and may have a beneficial effect on weight.\n\nThe other options are not as appropriate for this patient. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that is used for the treatment of type 2 diabetes, but it is not indicated for the patient's current level of glycemic control. Insulin glargine is a long-acting insulin that may be appropriate for patients with type 1 diabetes or those with type 2 diabetes who require insulin therapy, but it is not necessary for this patient. Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is used to treat type 2 diabetes, but it may not be as effective in improving glycemic control in this patient, as the patient's blood glucose levels are already relatively well-controlled. Additionally, it may increase the risk of genital infections and diabetic ketoacidosis.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nThe appropriate antibiotic therapy for a 58-year-old male patient with a urinary tract infection (UTI) caused by Pseudomonas aeruginosa, who has been using a catheter for 2 months, would be:\n\n③ Linezolid (600 mg IV/PO q12h) + Ceftriaxone (1 g IV/IM q24h)\n\nThe combination of linezolid and ceftriaxone provides broad-spectrum coverage against Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. Linezolid is a synthetic oxazolidinone that inhibits protein synthesis and has activity against Gram-positive bacteria, while ceftriaxone is a cephalosporin that has activity against Gram-negative bacteria. This combination is effective against a wide range of bacterial pathogens, including those that are commonly isolated from urinary tract infections.\n\nThe other options are not the most appropriate choices for this patient's infection:\n\n① Amoxicillin/clavulanate is a penicillin-type antibiotic that is effective against Gram-positive bacteria, but has limited activity against Pseudomonas aeruginosa.\n\n② Vancomycin is a glycopeptide antibiotic that is effective against methicillin-resistant Staphylococcus aureus (MRSA), but has no activity against Pseudomonas aeruginosa. Ertapenem is a carbapenem antibiotic that has activity against a wide range of Gram-negative bacteria, but its use is generally reserved for severe infections and may not be necessary for a UTI caused by Pseudomonas aeruginosa.\n\n④ Ceftazidime is a cephalosporin that has activity against a wide range of Gram-negative bacteria, but its use may not be necessary for a UTI caused by Pseudomonas aeruginosa. Tobramycin is an aminoglycoside antibiotic that has activity against Gram-negative bacteria, but its use may be associated with increased risk of nephrotoxicity and ototoxicity.\n\n⑤ Sulfamethoxazole/trimethoprim is a combination antibiotic that is effective against a wide range of Gram-negative bacteria, but has limited activity against Pseudomonas aeruginosa.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② 티니다졸(tinidazole)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 아목시실린/클라불란산(amoxicillin/clavulanate)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 반코마이신(vancomycin) 주사제\n\nExplanation:\nThe patient has hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Vancomycin is an appropriate choice for the treatment of MRSA infections. Cefotaxime and ertapenem are effective against gram-positive bacteria, but they are not effective against MRSA. Levofloxacin is effective against gram-negative bacteria, but it is not effective against MRSA. Tigecycline is a glycylcycline antibiotic that is effective against gram-positive and gram-negative bacteria, but it is not effective against MRSA.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 시프로플록사신(ciprofloxacin)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 콜레칼시페롤(cholecalciferol)\n\nExplanation:\n\nThe patient is taking a combination of medications for tuberculosis treatment, including bedaquiline, linezolid, cycloserine, clofazimine, and amikacin. To prevent adverse effects on the nervous system, it is necessary to add a medication that can counteract the potential neurotoxicity of these drugs.\n\nCholecalciferol, or vitamin D, is a nutrient that has been shown to have neuroprotective effects and may help prevent neurotoxicity associated with antituberculosis medications. Therefore, option ④ 콜레칼시페롤(cholecalciferol) is the correct answer.\n\nThe other options do not have a clear neuroprotective effect and are not commonly used to prevent neurotoxicity associated with antituberculosis medications. Folic acid (option ①) is important for cell growth and division, but it does not have a direct neuroprotective effect. Pyridoxine (option ②) is involved in the synthesis of neurotransmitters, but it has not been shown to have a significant neuroprotective effect in this context. Ascorbic acid (option ③) has antioxidant properties, but it is not specifically used to prevent neurotoxicity associated with antituberculosis medications. Cyanocobalamin (option ⑤) is important for the production of myelin, but it does not have a direct neuroprotective effect.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 세프트리악손 중단 후 콜리스틴(colistin) 추가\n\nExplanation:\n\nThe patient has been started on empirical therapy with vancomycin and ceftriaxone for suspected meningitis. The blood culture result shows that the causative organism is penicillin-resistant Neisseria meningitidis. In this scenario, the most appropriate definitive antibiotic therapy would be to discontinue ceftriaxone and add colistin, as it is effective against penicillin-resistant N. meningitidis.\n\nTherefore, the correct answer is ④ 세프트리악손 중단 후 콜리스틴(colistin) 추가.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 항생제 비투여, 지지요법(supportive care)\n\nExplanation:\n\nThe patient has been diagnosed with hemolytic uremic syndrome (HUS) caused by an E. coli infection. The appropriate treatment for HUS is supportive care, which includes managing fluid and electrolyte imbalances, maintaining renal function, and monitoring for any complications. Antibiotics are not recommended for treating HUS, as they can further damage the kidneys and increase the risk of complications.\n\nTherefore, option ⑤ 항생제 비투여, 지지요법(supportive care) is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 이부프로펜\n\nExplanation:\n\nThe patient has been taking losartan, almagate, ibuprofen, lansoprazole, and hydrochlorothiazide for 5 years. The onset of symptoms, such as watery diarrhea, 3 days ago, suggests a possible adverse effect of one of the medications.\n\nIbuprofen, a nonsteroidal anti-inflammatory drug (NSAID), is a likely culprit. It has been associated with an increased risk of Clostridium difficile infection, especially in older adults. The patient's age and the duration of ibuprofen use increase the likelihood of this adverse effect.\n\nTherefore, option ③ 이부프로펜 (ibuprofen) is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 케토코나졸(ketoconazole)\n\nExplanation:\nThe patient has been diagnosed with invasive candidiasis, which is a serious infection that requires prompt treatment. The patient's history of recent surgery, recent antibiotic use, and current symptoms of fever and confusion suggest that the infection is likely to be severe and potentially life-threatening.\n\nKetoconazole is an antifungal medication that is effective against a wide range of fungal pathogens, including Candida species. It is available in both oral and intravenous formulations, and is commonly used to treat invasive fungal infections.\n\nAlbendazole (①) is an antiparasitic medication that is effective against a wide range of parasites, including some fungal infections. However, it is not as effective against Candida species as ketoconazole.\n\nFluconazole (②) is an antifungal medication that is effective against Candida species, but it is not as effective against invasive fungal infections as ketoconazole.\n\nCefmetazole (③) is an antibiotic that is effective against bacterial infections, but it is not effective against fungal infections.\n\nMetronidazole (⑤) is an antibiotic that is effective against anaerobic bacterial infections, but it is not effective against fungal infections.\n\nTherefore, the most appropriate answer is ④ 케토코나졸(ketoconazole).</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ 이트라코나졸(itraconazole)\n\nExplanation:\nCandida krusei is a species of fungus that is resistant to many antifungal medications, including fluconazole and terbinafine. Itraconazole, on the other hand, has been shown to have activity against Candida krusei. Therefore, it is the most appropriate choice for treating invasive candidiasis caused by Candida krusei.\n\nGriseofulvin is an antifungal medication that is primarily used to treat fungal infections of the skin, hair, and nails. It has limited activity against Candida species and is not effective against Candida krusei.\n\nFlucytosine is an antifungal medication that is primarily used to treat candidiasis of the skin and mucous membranes. It has limited activity against Candida krusei and is not considered a first-line treatment for invasive candidiasis.\n\nAnidulafungin is an antifungal medication that is effective against a wide range of Candida species, including Candida krusei. However, it is not approved for use in invasive candidiasis and has been associated with a higher risk of adverse effects compared to other antifungal medications.\n\nTherefore, the correct answer is ④ 이트라코나졸(itraconazole).</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 프로바트립탄(frovatriptan)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 카르비도파/레보도파(carbidopa/levodopa)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 토피라메이트(topiramate)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 팔리페리돈(paliperidone)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 히드록시진(hydroxyzine)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 모다피닐(modafinil)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 리튬(lithium)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 아리피프라졸(aripiprazole)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 도네페질을 갈란타민(galantamine)으로 대체</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 메토트렉세이트(methotrexate)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② 알렌드론산(alendronate)\n\nReasoning:\n\nThe patient has osteoporosis with a T-score of -3.0 and -2.3 at the lumbar spine and femoral neck, respectively. The patient's serum calcium level is within the normal range, but the PTH level is slightly elevated. The patient's creatinine clearance is 28 mL/min, indicating that the patient has mild renal impairment.\n\nAlendronate is a bisphosphonate that is commonly used to treat osteoporosis. It works by inhibiting bone resorption and increasing bone density. It is well tolerated and has a long history of use in clinical practice.\n\nDenosumab (①) is a monoclonal antibody that targets RANK ligand, which is involved in bone resorption. It is also used to treat osteoporosis, but it is more expensive and has a higher risk of adverse effects compared to alendronate.\n\nIbandronate (③) is another bisphosphonate that is similar to alendronate but has a shorter half-life. It may be less effective in patients with severe renal impairment, but it is still an option for patients with mild renal impairment like this patient.\n\nTeriparatide (④) is a parathyroid hormone analog that is used to treat severe osteoporosis. It stimulates bone formation and increases bone density, but it is more expensive and has a higher risk of adverse effects compared to alendronate.\n\nCalcium carbonate (⑤) is a calcium supplement that is used to treat hypocalcemia. It is not directly related to the treatment of osteoporosis, and it is not the most appropriate choice for this patient.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 7일</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 실로도신(silodosin)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ 히드로클로로티아지드(hydrochlorothiazide)\n\nExplanation:\n\nThe patient's elevated serum potassium level (4.0 mEq/L) and the presence of hyperkalemia (serum potassium level > 5.0 mEq/L) are likely related to the use of hydrochlorothiazide, a potassium-sparing diuretic. Hydrochlorothiazide can cause hyperkalemia by increasing the reabsorption of potassium in the renal tubules, leading to an increase in serum potassium levels. The other medications, including tramadol, famotidine, metoprolol, and acetaminophen, are not typically associated with hyperkalemia. Therefore, the correct answer is ⑤ 히드로클로로티아지드(hydrochlorothiazide).</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 퓨린(purine) 풍부 음식 제한\n\nExplanation:\n\nThe patient has a history of gouty arthritis, which is a type of inflammatory arthritis caused by the buildup of uric acid in the joints. The patient's current medications, including tramadol, famotidine, metoprolol, and hydrochlorothiazide, are not directly related to the treatment of gouty arthritis.\n\nTherefore, the most appropriate recommendation for the patient would be to limit their intake of foods rich in purine, such as organ meats, anchovies, sardines, herring, and gravy. This is because purine is converted to uric acid in the body and can exacerbate gouty arthritis.\n\nOption ①, recommending a high-protein diet, is not appropriate because a high-protein diet can increase the risk of kidney stones and worsen gouty arthritis.\n\nOption ②, adding colchicine, is not appropriate because colchicine is a medication used to treat gouty arthritis, but it is not indicated for the patient's current condition.\n\nOption ④, adding allopurinol, is not appropriate because allopurinol is a medication used to treat gouty arthritis by reducing uric acid production in the body, but it is not indicated for the patient's current condition.\n\nOption ⑤, adding benzbromarone, is not appropriate because benzbromarone is a medication used to treat gouty arthritis, but it is not indicated for the patient's current condition.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 포사코나졸\n\nExplanation:\n\nThe patient has been diagnosed with acute myeloid leukemia (AML) and has a low left ventricular ejection fraction (LVEF) of 35%. The chemotherapy regimen given includes cytarabine, idarubicin, and palonosetron. Posaconazole, an antifungal medication, is also given to prevent fungal infections. Ciprofloxacin, an antibiotic, is given to prevent bacterial infections.\n\nIn this scenario, the most appropriate medication to hold or discontinue before starting chemotherapy is posaconazole, as it is not essential for the treatment of AML and may cause harmful interactions with chemotherapy drugs. Therefore, the correct answer is ③ 포사코나졸 (posaconazole).</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ QT간격 연장\n\nExplanation:\nDasatinib, a tyrosine kinase inhibitor, can prolong the QT interval, which may increase the risk of ventricular arrhythmias, such as torsades de pointes. Levofloxacin, a fluoroquinolone, can also prolong the QT interval and increase the risk of arrhythmias. Therefore, co-administration of these two drugs may increase the risk of QT interval prolongation and arrhythmias.\n\nIt is important to note that the other options are also potential adverse effects of dasatinib and levofloxacin, but they are not directly related to the co-administration of these two drugs.\n\n① 골다공증 (Osteoporosis) is a potential adverse effect of dasatinib.\n\n② 고요산혈증 (Hyperuricemia) is a potential adverse effect of dasatinib.\n\n④ 고마그네슘혈증 (Hypomagnesemia) is a potential adverse effect of dasatinib.\n\n⑤ 콜레스테롤 수치 상승 (Increased cholesterol levels) is a potential adverse effect of levofloxacin.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nExplanation:\n\nThe patient is a 45-year-old woman with triple-negative breast cancer (TNBC), which means that the tumor is negative for estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). The patient's Eastern Cooperative Oncology Group (ECOG) performance status is 1, indicating that she is relatively healthy and able to tolerate chemotherapy.\n\nBased on the patient's diagnosis and medical history, the most appropriate chemotherapy regimen before surgery would be docetaxel (Taxotere) plus carboplatin (Paraplatin) plus trastuzumab (Herceptin). This regimen is a common combination for TNBC and has been shown to be effective in improving outcomes for patients with this type of breast cancer.\n\n Docetaxel is a taxane, a class of drugs that inhibit microtubule formation and are effective against breast cancer. Carboplatin is a platinum-based drug that works by damaging DNA and interfering with cell division. Trastuzumab is a monoclonal antibody that targets HER2-positive cancer cells and is effective in treating TNBC.\n\nThe other options are not the most appropriate for this patient's condition:\n\n① Capecitabine (Xeloda) plus lapatinib (Tykerb) is a combination that is sometimes used for hormone-receptor-positive breast cancer, but it is not typically used for TNBC.\n\n② Docetaxel plus anastrozole (Arimidex) is a combination that may be used for hormone-receptor-positive breast cancer, but it is not the most appropriate regimen for TNBC.\n\n③ Pertuzumab (Perjeta) plus trastuzumab (Herceptin) is a combination that is sometimes used for HER2-positive breast cancer, but it is not typically used for TNBC.\n\n⑤ Docetaxel plus doxorubicin (Adriamycin) plus tamoxifen is a combination that may be used for breast cancer, but it is not the most appropriate regimen for TNBC.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 진전\n\nExplanation:\n\nThe patient has been diagnosed with stage IIIB non-small cell lung cancer (NSCLC) and has been receiving chemotherapy with paclitaxel and carboplatin. The patient's cancer has progressed, and bevacizumab is being considered as an additional treatment. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) and can cause hypertension, bleeding, and thromboembolic events. Therefore, it is important to assess the patient's recent symptoms, particularly those related to cardiovascular and respiratory function, before initiating bevacizumab therapy.\n\nOf the options listed, ③ 진전 (chest tightness) is the most relevant symptom that may indicate a potential side effect of bevacizumab. Chest tightness can be a sign of pulmonary embolism, which is a potential side effect of bevacizumab. Other symptoms such as ① 객혈 (cough), ② 골절 (bone pain), ④ 우울증 (anxiety), and ⑤ 체중증가 (weight gain) may also be relevant, but they are not as specific to the potential side effects of bevacizumab as chest tightness.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 혈변</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 오시머티닙(osimertinib)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 레고라페닙(regorafenib)\n\nExplanation:\n\nThe patient has been diagnosed with metastatic colorectal cancer (mCRC) and is planned to receive FOLFOX chemotherapy. The molecular biology test results show that EGFR is positive, but RAS and BRAF mutations are not present (wild-type). Based on these results, the most appropriate additional drug to consider would be regorafenib (③), which is a multi-kinase inhibitor that targets VEGFR, PDGFR, and c-Kit, and has been shown to be effective in patients with EGFR-positive mCRC.\n\nAlectinib (①) is a tyrosine kinase inhibitor that targets ALK, ROS1, and NTRK, but it is not relevant to the patient's specific molecular profile.\n\nCetuximab (②) is a monoclonal antibody that targets EGFR, but it is not appropriate for this patient since they have a wild-type EGFR.\n\nAtezolizumab (④) is a PD-L1 inhibitor that has been shown to be effective in various types of cancer, including mCRC, but it is not specifically targeted to the patient's molecular profile.\n\nZiv-aflibercept (⑤) is a fusion protein that targets VEGF-A and PDGF-B, but it is not as effective in EGFR-positive mCRC as regorafenib.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② 프레가발린(pregabalin)\n\nExplanation:\n\nThe patient is experiencing peripheral neuropathy, which is a common side effect of chemotherapy. Pregabalin is a medication that is used to treat neuropathic pain and can be effective in managing chemotherapy-induced peripheral neuropathy. It is also generally well-tolerated and has a good safety profile.\n\nIbuprofen (①) is a nonsteroidal anti-inflammatory drug (NSAID) that can be used to manage pain, but it may not be effective in managing neuropathic pain.\n\nZoledronate (③) is a bisphosphonate that is used to treat bone metastases and osteoporosis, but it is not typically used to manage neuropathic pain.\n\nPaliperidone (④) is an antipsychotic medication that can be used to treat neuropathic pain, but it may have more side effects compared to pregabalin.\n\nIsotretinoin (⑤) is a retinoid that is used to treat acne and other skin conditions, but it is not typically used to manage neuropathic pain.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 피메크롤리무스(pimecrolimus) 1% 연고</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 브리모니딘(brimonidine)</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 아연 투여 중단\n\nExplanation:\n\nThe patient has been receiving parenteral nutrition for 2 months, and the direct bilirubin level is elevated at 2.6 mg/dL. This suggests that the patient may have a liver dysfunction, which could be caused by excessive intravenous fat emulsion administration. Therefore, the most appropriate action would be to discontinue the fat emulsion infusion (option ④).\n\nOption ①, increasing glutamine, may help to reduce the risk of liver dysfunction, but it is not the most appropriate action given the patient's current condition.\n\nOption ②, increasing amino acids, may help to support the patient's nutrition, but it is not directly related to the patient's liver dysfunction.\n\nOption ③, increasing the dose of fat emulsion, may worsen the patient's liver dysfunction.\n\nOption ⑤, discontinuing copper infusion, is not relevant to the patient's current condition.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 혈청 빌리루빈\n\nExplanation:\n\nThe patient is experiencing muscle pain while taking atorvastatin and itraconazole together. One of the potential side effects of statins, such as atorvastatin, is muscle damage, which can lead to elevated creatine kinase (CK) levels. Itraconazole, an azole antifungal, can also cause muscle damage and elevate CK levels. Therefore, it is important to monitor the patient's CK levels to assess for muscle damage.\n\nOption ③ 혈청 빌리루빈 (serum creatine kinase) is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 알프라졸람\n\nExplanation:\nAlprazolam, a benzodiazepine, can worsen cognitive function and memory in elderly patients, which is not desirable for patients with dementia. The other options, perindopril, metformin, sitagliptin, and ofloxacin, are not known to have a significant impact on cognitive function in elderly patients. Therefore, the best answer is ④ 알프라졸람 (alprazolam).</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 환자 증상의 심각도</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ①</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 파록세틴(paroxetine)</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 엔테카비르(entecavir)</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 1개월</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 옥살리플라틴(oxaliplatin)</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ② 2～5 mg/L\n\nExplanation:\n\nThe therapeutic range for valproic acid (VPA) in the treatment of bipolar disorder is typically between 2 and 5 mg/L. VPA is a broad-spectrum antiepileptic drug that is used to treat various types of seizures, as well as bipolar disorder. The therapeutic range for VPA in the treatment of bipolar disorder is established based on clinical studies and experience.\n\nIn this case, the patient is prescribed 500 mg of VPA twice daily, which is within the recommended dosage range for the treatment of bipolar disorder. Therefore, the therapeutic range for VPA in this patient's treatment would be 2-5 mg/L.\n\nIt is important to note that the therapeutic range for VPA may vary depending on individual patient factors, such as age, liver function, and other medical conditions. Therefore, it is important to closely monitor the patient's response to treatment and adjust the dosage as needed to maintain the therapeutic range.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 알푸조신\n\nExplanation:\n\nThe patient's medication list includes losartan (an angiotensin II receptor antagonist), valproic acid (an antiepileptic drug), alfuzosin (an alpha-1 adrenergic receptor antagonist), hydroxyzine (an H1-receptor antagonist), and acetaminophen (a nonsteroidal anti-inflammatory drug).\n\nAccording to the Beers criteria, alfuzosin is potentially inappropriate for the patient due to its risk of falls, which may be a concern for a 70-year-old patient with hypertension, heart failure, and benign prostatic hyperplasia. Therefore, the physician should review the appropriateness of alfuzosin therapy for this patient.\n\nThe other options are not relevant to the patient's medication regimen or do not have potential adverse effects that would require review by the physician according to the Beers criteria.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 15 mL</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 도네페질(donepezil)</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 상당히 확실함(probable)\n\nExplanation:\n\nThe patient developed a rash after taking lamotrigine, which resolved after discontinuing the medication. There is no history of previous allergic reactions or other skin conditions that could have caused the rash. Based on the information provided, it appears that the rash was likely caused by lamotrigine.\n\nUsing the WHO-UMC method to assess the causality of the adverse drug reaction, we can determine that the association between lamotrigine and the rash is probable (①). This is because the rash occurred after taking the medication, resolved after discontinuing it, and there are no other plausible causes for the rash. Therefore, it is likely that lamotrigine caused the rash.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 약물이상반응 발생\n\nExplanation:\nThe patient's symptoms of nasal congestion and runny nose improved after starting fexofenadine and xylometazoline, but the symptoms worsened again after 7 days. This suggests that the patient may have developed a tolerance to the medication, which is a common problem in the treatment of allergic rhinitis. The patient's symptoms worsening despite continued use of the medication indicates that the medication is no longer effective in managing the symptoms, and this is known as tachyphylaxis. Therefore, option ③ 약물이상반응 발생 (drug tolerance) is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 올로파타딘(olopatadine) 점안액 추가</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ⑤ 로수바스타틴\n\nExplanation:\n\nThe patient's prescription includes ramipril (10 mg, 1 tablet, 1 time a day), amlodipine (10 mg, 1 tablet, 2 times a day), metformin (1000 mg, 1 tablet, 2 times a day), zolpidem (5 mg, 1 tablet, 1 time a day), and rosuvastatin (10 mg, 1 tablet, 1 time a day).\n\nThe maximum dose of rosuvastatin is 20 mg/day, and the patient is prescribed 10 mg/day. Therefore, the prescription does not exceed the maximum dose for rosuvastatin.\n\nThe maximum dose of ramipril is 10 mg/day, and the patient is prescribed 10 mg/day. Therefore, the prescription does not exceed the maximum dose for ramipril.\n\nThe maximum dose of amlodipine is 10 mg/day, and the patient is prescribed 10 mg/day. Therefore, the prescription does not exceed the maximum dose for amlodipine.\n\nThe maximum dose of metformin is 2500 mg/day, and the patient is prescribed 1000 mg/day. Therefore, the prescription does not exceed the maximum dose for metformin.\n\nThe maximum dose of zolpidem is 10 mg/day, and the patient is prescribed 5 mg/day. Therefore, the prescription does not exceed the maximum dose for zolpidem.\n\nBased on the information provided, the only medication that exceeds the maximum dose is rosuvastatin, which is prescribed at 10 mg/day, exceeding the maximum dose of 20 mg/day. Therefore, the correct answer is ⑤ 로수바스타틴.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 메트포르민\n\nExplanation:\n\nThe patient is scheduled to undergo an imaging test that requires the use of an iodinated contrast agent. In this case, it is important to consider the risk of nephrogenic systemic fibrosis (NSF), a rare but potentially life-threatening condition that can occur in patients with pre-existing kidney disease.\n\nMetformin, a medication used to treat type 2 diabetes, has been associated with an increased risk of NSF in patients exposed to iodinated contrast agents. Therefore, it is recommended to discontinue metformin before the imaging test and to monitor the patient's renal function closely after the test.\n\nThe other medications listed, including ramipril, amlodipine, zolpidem, and rosuvastatin, are not associated with an increased risk of NSF and do not require discontinuation before the imaging test.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 온단세트론(ondansetron) 정</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 클로트리마졸(clotrimazole) 크림</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 테르비나핀(terbinafine) 크림</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 세티리진(cetirizine) 시럽</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nExplanation:\n\nThe patient, a 36-year-old woman, has been prescribed sumatriptan 50 mg tablets for migraines. The instructions for the patient are:\n\n④ Take one tablet when symptoms occur, and do not take more than 8 tablets within 24 hours.\n\nTherefore, option ④ is the correct answer.\n\nOption ① is incorrect because it states that the patient can take up to 8 tablets within 24 hours, which is not accurate.\n\nOption ② is not relevant to the patient's treatment and is therefore incorrect.\n\nOption ③ is incorrect because sumatriptan is not safe for use during pregnancy.\n\nOption ⑤ is incorrect because ergotamine, another medication for migraines, should not be taken together with sumatriptan.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 아시클로버(acyclovir) 정</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 산조인탕(酸棗仁湯)</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② DMF (Drug Master File)</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ HEPA 필터의 교체 주기 연장</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 가</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④\n\nExplanation:\n\nThe question asks for the most appropriate explanation for not conducting a predictive validation of a pharmaceutical product when there is a lack of stability data.\n\nOption ① is not correct because it states that the quality control department cannot guarantee the quality of the product, which is not related to the lack of stability data.\n\nOption ② is also not correct because it states that all production units evaluated by the quality control department must be suitable, but this does not address the issue of lacking stability data.\n\nOption ③ is incorrect because it states that production units that deviate from the standard should be excluded from the result, but this does not explain why stability data is lacking.\n\nOption ④ is the correct answer because it states that the company will conduct a concurrent validation of the product, which means that the validation will be done simultaneously with the production process. This is an appropriate solution when there is a lack of stability data.\n\nOption ⑤ is not correct because it states that the company will conduct a validation of a reduced production scale, which is not related to the lack of stability data.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②\n\nExplanation:\n\nThe question is asking for the best approach to achieve the minimum sterilization probability (B value) in the sterilization process of a pharmaceutical product.\n\nOption ① suggests reducing the exposure time (F value) to achieve a lower B value. However, this may not be the most effective approach, as a shorter exposure time may not be sufficient to kill all the microorganisms present.\n\nOption ② suggests reducing the initial microbial load (A value) to achieve a lower B value. This is a more effective approach, as it addresses the root cause of the problem by reducing the number of microorganisms present before sterilization.\n\nOption ③ suggests setting the sterilization temperature lower than 121°C. This may not be the most effective approach, as a lower temperature may not be sufficient to kill all the microorganisms present.\n\nOption ④ suggests using a microorganism with a high Z value (resistance to sterilization) to achieve a lower B value. This approach is not recommended, as it may not ensure the complete sterilization of the product.\n\nOption ⑤ suggests using a microorganism with a high D value (death rate under sterilization conditions) to achieve a lower B value. This approach is also not recommended, as it may not ensure the complete sterilization of the product.\n\nTherefore, the correct answer is ②, reducing the initial microbial load (A value) to achieve a lower B value.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 콜드스팟의 F0값</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 품질표준 및 각종 표준의 설정</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nThe correct answer is ③. The question asks about the shelf life of a re-packaged product. According to the regulation, the shelf life of a re-packaged product should be re-labeled with a new expiration date, which is 6 months from the date of re-packaging. Therefore, the answer is ③.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 검체보관시설</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 미립자시험</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe question is asking about the correct statement regarding the management of manufacturing water used in the production of pharmaceuticals, as described in the Korean Pharmacopoeia.\n\n① is incorrect because it states that the purified water is not subject to microbial management, which is not accurate.\n\n② is incorrect because it states that the water for injection is the target of the sterility test, which is not specific to the management of manufacturing water.\n\n③ is correct because it states that the management standards for the water for injection and the purified water (including the management of the storage container) are consistent.\n\n④ is incorrect because it states that the management standards for the purified water and the purified water (including the management of the storage container) are the same, which is not accurate.\n\n⑤ is incorrect because it states that the management standards for the sterile water for injection and the sterile water for injection (including the management of the storage container) are the same, which is not accurate.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe question states that the amount of aspirin in the sample should be within ±10% of the labeled amount, which is 3 g. Therefore, the correct answer is ③, which states that the aspirin is accurately weighed to be within ±10% of the labeled amount.\n\nThe other options are not correct for the following reasons:\n\n①: This option states that the silica gel is dried for 5 hours, but it does not mention the amount of aspirin in the sample.\n\n②: This option states that the sample is dried for 5 hours and the weight change is within 0.5%, but it does not mention the labeled amount of aspirin.\n\n④: This option states that the sample is dried at 105°C for 30 minutes, but it does not mention the amount of aspirin in the sample.\n\n⑤: This option states that the sample is crushed to a size of 2 mm or less, but it does not mention the amount of aspirin in the sample.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe question is asking which method is the most appropriate for assaying the purity of L-lysine.\n\nOption (가) describes a method for assaying the purity of L-lysine by dissolving 0.5 g of the sample in 1 mol/L hydrochloric acid and measuring the absorbance at 250 nm. This method is not suitable for assaying the purity of L-lysine because it does not take into account the possibility of impurities in the sample.\n\nOption (나) describes a method for assaying the purity of L-lysine by drying the sample and measuring the absorbance of the resulting powder at the same wavelength as the standard. This method is not suitable for assaying the purity of L-lysine because it does not take into account the possibility of impurities in the sample.\n\nOption (다) describes a method for assaying the purity of L-lysine by dissolving 0.13 g of the sample in 3 mL of water and adjusting the volume to 50 mL with 0.1 mol/L hydrochloric acid. This method is suitable for assaying the purity of L-lysine because it takes into account the possibility of impurities in the sample and allows for the quantitation of the amount of L-lysine present.\n\nOption (가) is not a suitable method for assaying the purity of L-lysine because it does not take into account the possibility of impurities in the sample.\n\nOption (나) is not a suitable method for assaying the purity of L-lysine because it does not take into account the possibility of impurities in the sample.\n\nOption (다) is a suitable method for assaying the purity of L-lysine because it takes into account the possibility of impurities in the sample and allows for the quantitation of the amount of L-lysine present.\n\nTherefore, the correct answer is ③.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② 분할법</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 2.00</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② 1.0\n\nExplanation:\n\nThe question asks for the volume of the standard lead solution (A) in mL, given that the lead concentration is 0.01 mg/mL.\n\nFrom the first method, we know that 2.0 g of the drug was dissolved in 100 mL of water, so the concentration is 20 mg/mL.\n\nFrom the second method, we know that 3 g of the drug was dissolved in 50 mL of water, so the concentration is 60 mg/mL.\n\nSince the lead concentration is 0.01 mg/mL, we can calculate the volume of the standard lead solution as follows:\n\nVolume of standard lead solution = Concentration of lead / Concentration of drug\nVolume of standard lead solution = 0.01 mg/mL / 20 mg/mL\nVolume of standard lead solution = 0.01 mg/mL / 60 mg/mL\n\nTherefore, the volume of the standard lead solution is 0.5 mL or 1.0 mL, depending on the method used.\n\nSo, the correct answer is ② 1.0.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ 기체크로마토그래프법</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 전략대안 파악</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 약국개설자가 약국에 투자한 현물자산은 자본이다.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ①\n\nExplanation:\n\nThe monthly rent of a pharmacy is a variable cost because it can change over time due to various factors such as inflation, market conditions, or changes in the lease agreement.\n\n② The salary of a pharmacist is a fixed cost because it is a constant expense that does not change frequently.\n\n③ The cost of packaging materials for a pharmaceutical product is a fixed cost because it is a one-time expense that does not change frequently.\n\n④ The credit card processing fee paid by a patient is a variable cost because it can change over time due to changes in the number of patients and the amount of sales.\n\n⑤ The installment payment for a new automated dispensing machine is a variable cost because it can change over time due to changes in the interest rate or the repayment schedule.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 500병</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 외부효과</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 의료소비자의 선택권 강화</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③ 약제비는 고시된 상한 금액을 기준으로 상환한다.\n\nThis answer choice states that the drug dispensing fee is based on the upper limit of the drug price set by the government. This means that the fee is determined by the government's regulation, and it is not affected by the size of the pharmacy or the number of prescriptions dispensed.\n\nThe other answer choices are not correct because:\n\n① 복약지도료는 조제일수에 따라 산정한다. - This answer choice states that the drug dispensing fee is determined by the number of prescriptions dispensed. However, this is not the case, as the fee is actually determined by the government's regulation.\n\n② 약국관리료는 약국의 면적에 따라 산정한다. - This answer choice states that the pharmacy management fee is determined by the size of the pharmacy. However, this is not the case, as the fee is actually determined by the government's regulation.\n\n④ 야간에 이루어진 조제서비스는 차등수가제 적용 대상이다. - This answer choice states that the nighttime dispensing service is subject to the differential payment system. However, this is not the case, as the differential payment system is not applied to the nighttime dispensing service.\n\n⑤ 의약품관리료는 조제일수와 관계없이 방문당 정액으로 산정한다. - This answer choice states that the drug management fee is determined by the number of visitors, regardless of the number of prescriptions dispensed. However, this is not the case, as the fee is actually determined by the government's regulation.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③ 한국희귀 ∙ 필수의약품센터에서는 희귀의약품 조제 업무를 한다.\n\nThis statement is true. The Korean government has established the Korea Rare Disease Center to manage the supply of rare and essential drugs. The center is responsible for the procurement, storage, and distribution of these drugs to ensure their availability and accessibility to patients.\n\nThe other options are incorrect or irrelevant to the question.\n\n① 도매상의 의약품 유통품질 관리기준 준수는 선택사항이다. - This statement is incorrect. While drug wholesalers are required to follow certain quality management standards, this is not the primary function of the Korea Rare Disease Center.\n\n② 약국개설자는 제조업자로부터 의약품을 직접 구입할 수 없다. - This statement is incorrect. Pharmacists can purchase drugs directly from manufacturers, but this is not related to the function of the Korea Rare Disease Center.\n\n④ 도매상은 약국에 대금결제조건에 따른 비용할인을 제공할 수 없다. - This statement is incorrect. Drug wholesalers can provide discounts to pharmacies based on payment terms, but this is not the main function of the Korea Rare Disease Center.\n\n⑤ 국가비상상황에 대비하여 비축 ∙ 공급해야 하는 의약품은 퇴장방지의약품으로 지정한다. - This statement is irrelevant to the question. While the government may designate certain drugs as essential during a national emergency, this is not the primary function of the Korea Rare Disease Center.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③. The Korean government has introduced the '의약품 선별등재제도' (Drug Pricing and Reimbursement System) to ensure that patients have access to effective and affordable medications. The system is based on the clinical value and economic value of the drug, and the reimbursement amount is determined by the Health Insurance Review and Assessment Service (HIRA) based on the drug's efficacy, safety, and cost-effectiveness. This system aims to promote the use of cost-effective drugs and to control the rising healthcare costs in Korea.\n\nTherefore, option ③ \"임상적 가치와 경제적 가치를 기반으로 보험등재 여부를 결정한다\" is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 사용량-약가 연동제도</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nExplanation:\n\nThe question asks for the best interpretation of the meta-analysis result. The correct answer is ④, which states that the meta-analysis result shows that A has a higher efficacy than B, with a 5% significance level.\n\nThe other options are incorrect for the following reasons:\n\n① This option states that the table includes individual study data, which is not the main focus of the question.\n\n② This option states that the study with the largest weight is (나), but the question does not ask about the weight of individual studies.\n\n③ This option states that the meta-analysis reduces the credibility of the efficacy of the treatment, but the question does not mention anything about credibility.\n\n⑤ This option states that there is heterogeneity between individual studies, but the question does not ask about heterogeneity specifically.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③. The sentence \"보험자 관점에 따라 분석할 경우 비급여진료비를 포함한다\" means that the analysis should include the cost of medical malpractice insurance premiums from the perspective of the insured. This is a relevant cost to consider in a cost-utility analysis of a healthcare system, as it reflects the financial burden of potential medical errors or negligence on the healthcare provider.\n\nThe other options are not relevant to the concept of cost-utility analysis:\n\n① 부작용 모니터링 비용은 간접비용에 포함된다: This option refers to the cost of monitoring adverse effects, which is not directly related to the cost-utility analysis of a healthcare system.\n\n② 비용항목 선정 범위가 분석관점에 관계없이 동일하다: This option states that the scope of cost items is independent of the analysis perspective, which is not a correct statement in the context of cost-utility analysis. The cost items to be included in the analysis should be determined based on the perspective of the analysis, whether it is from the healthcare provider, patient, or societal perspective.\n\n④ 보건의료체계 관점에 따라 분석할 경우 생산성 손실비용을 포함한다: This option refers to the cost of reduced productivity due to illness or injury, which is not a direct cost of the healthcare system. While it may be a relevant cost to consider in a broader cost-benefit analysis of a healthcare system, it is not directly related to the cost-utility analysis.\n\n⑤ 높은 할인율의 적용은 미래에 발생할 비용의 현재가치를 감소시킨다: This option refers to the application of a high discount rate, which can reduce the current value of future costs. While discounting is a common practice in cost-utility analysis to account for the time preference of costs and benefits, the selection of an appropriate discount rate is a complex issue that depends on various factors, including the cost of capital, inflation, and the social time preference rate. Therefore, this option is not a straightforward answer to the question.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 900\n\nExplanation:\n\nThe incremental cost-effectiveness ratio (ICER) of A compared to B is calculated as follows:\n\nICER = (A's cost - B's cost) / (A's effectiveness - B's effectiveness)\n\n= (4,000 - 1,000) / (0.6 - 0.5)\n\n= 3,000 / 0.1\n\n= 30,000\n\nSince the ICER is 30,000, which is greater than the willingness-to-pay threshold of 12,000, A is not considered cost-effective compared to B. Therefore, the correct answer is ① 900, which represents the cost-effectiveness of B.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 정직과 진실성 원칙\n\nExplanation:\n\nThe question describes a situation where a pharmacist discovers a discrepancy between the prescribed dose of a medication and the dose listed on the prescription. However, instead of verifying the error with the prescribing physician, the pharmacist chooses to prepare the medication according to the prescription. This behavior violates the principle of honesty and truthfulness, which is a fundamental ethical principle for pharmacists.\n\nTherefore, the correct answer is ④ 정직과 진실성 원칙.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ PRECEDE-PROCEED 모델</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 후향적 코호트 연구</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 대응위험도(오즈비) | (20/1000)/(10/1000)\n\nExplanation:\n\nThe relative risk of developing tuberculosis for patients taking drug A compared to those not taking drug A can be calculated using the odds ratio. The odds ratio is calculated as (20/1000)/(10/1000) = 2.\n\nTherefore, the answer is ③ 대응위험도(오즈비) | (20/1000)/(10/1000).</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 생물학적 제제</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 저장방법</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② 용법 및 용량</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 지역사회 감염병 예방\n\nExplanation:\nThe establishment of the Korean Pharmacists Association (KPA) does not directly relate to the prevention of infectious diseases in the local community. The KPA's mission is focused on promoting the rights and interests of pharmacists, improving their qualifications, advancing the field of pharmacy, and establishing ethical standards for pharmacists. While preventing infectious diseases is an important public health goal, it is not a primary objective of the KPA. Therefore, option ③ is the best answer.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③, \"안전상비의약품의 안전성 확보와 품질관리에 관한 교육을 수료할 것.\"\n\nAccording to the question, the correct answer does not meet the registration criteria for a pharmacist under the Pharmacist Licensing Examination. The registration criteria for a pharmacist include having a degree in pharmacy, completing an internship, and passing the licensing examination.\n\nOption ③, \"안전상비의약품의 안전성 확보와 품질관리에 관한 교육을 수료할 것,\" does not meet the registration criteria for a pharmacist because it does not mention anything about obtaining a degree in pharmacy, completing an internship, or passing the licensing examination.\n\nTherefore, the correct answer is ③, \"안전상비의약품의 안전성 확보와 품질관리에 관한 교육을 수료할 것.\"</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nAccording to the Pharmaceutical Affairs Act, a wholesaler of pharmaceuticals (의약품 도매상) is not allowed to sell pharmaceuticals directly to patients. They can only sell to other wholesalers or to pharmacies. Therefore, the statement \"의약품 도매상은 환자에게 의약품을 직접 판매할 수 없다\" is correct.\n\nThe other options are incorrect because:\n\n② 의약품 제조업자 (pharmaceutical manufacturer) can sell pharmaceuticals to their employees, but they cannot sell directly to patients.\n\n③ 의약품 도매상 (wholesaler) can sell pharmaceuticals to other wholesalers or to pharmacies, but they cannot sell directly to patients.\n\n④ 의약품 도매상 (wholesaler) can purchase pharmaceuticals from a pharmacy that is closing down, but they cannot sell them directly to patients.\n\n⑤ 약국개설자 (pharmacist) can purchase pharmaceuticals from another pharmacist if the prescribed medication is not available, but they cannot sell them directly to patients.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 제조방법</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 유효성분의 명칭</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ⑤</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④ 마약류원료사용자.\n\nAccording to the definition provided in the question, 마약류원료사용자 refers to a person who manufactures, exports, or imports materials used in the production of medicines, but does not actually produce medicines. This means that they do not handle the raw materials for medicine production, but rather procure and sell them to medicine manufacturers.\n\nTherefore, option ④ 마약류원료사용자 is the best fit for the description provided in the question.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 마약류도매업자</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 분실 또는 도난</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 영양개선</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④, \"보건의료의 형평과 효율이 조화를 이룰 수 있도록 함으로써 국민의 삶의 질 향상에 이바지한다.\"\n\nThis statement is consistent with the basic spirit and definition of the \"보건의료기본법\" (Basic Law on Health and Medical Care), which aims to promote the well-being of the people by ensuring that healthcare services are accessible, efficient, and of high quality.\n\nThe other options do not accurately reflect the purpose and scope of the law:\n\n① \"약사는 보건의료인에 포함된다\" (Pharmacists are included in healthcare professionals) is a correct statement, but it does not relate to the purpose and scope of the law.\n\n② \"약국은 보건의료기관에 포함된다\" (Pharmacies are included in healthcare facilities) is a correct statement, but it does not relate to the purpose and scope of the law.\n\n③ \"공공단체가 설립 ∙ 운영하는 보건의료기관은 공공보건의료기관에 포함된다\" (Public institutions that establish and operate healthcare facilities are included in public healthcare institutions) is a correct statement, but it does not relate to the purpose and scope of the law.\n\n⑤ \"국민의 질병 ∙ 부상에 대한 예방 ∙ 진단 ∙ 치료 ∙ 재활 및 건강증진에 대하여 보험급여를 실시함으로써 국민보건 향상에 이바지한다\" (By implementing insurance coverage for prevention, diagnosis, treatment, rehabilitation, and health promotion for citizens' diseases and injuries, we can improve public health) is a correct statement, but it does not accurately reflect the purpose and scope of the law.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④\n\nExplanation:\n\nAccording to the question, the person who does not fall under the application of the National Health Insurance Act, which provides for the obligation of health insurance for Korean citizens, is the one who has applied for the exemption of health insurance under the National Health Insurance Act.\n\nTherefore, the correct answer is ④, \"a person who has applied for exemption from health insurance under the National Health Insurance Act.\"</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 비급여</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 의약품의 위해성 관리</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① calmodulin</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 1/K_m</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ F-type ATPase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ NADH</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① glucose 6-phosphatase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② Ca2+</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① allopurinol</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ mevalonate</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ histidine</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ glycine</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ S-adenosylmethionine</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ DnaG</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ minichromosome maintenance (MCM) proteins</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ eEF2의 ADP-라이보실화에 의한 불활성화</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ tyrosinase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ isocitrate dehydrogenase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ glucocerebrosidase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ thymidylate synthase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ isocitrate dehydrogenase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ⑤ serine acetyltransferase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ urease</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 단일가닥 양성 RNA 유전체를 가짐\n\nExplanation:\nDengue fever is caused by a single-stranded, positive-sense RNA virus. Therefore, the correct answer is ④ 단일가닥 양성 RNA 유전체를 가짐.\n\n① 비말로 전파됨 is incorrect because dengue fever is not spread through fungi.\n\n② 역전사효소 활성을 가짐 is incorrect because dengue fever is not caused by a reverse transcriptase enzyme.\n\n③ 캡시드의 형태가 나선형임 is incorrect because the capsid shape of the dengue virus is not spiral.\n\n⑤ 포스카네트(foscarnet)로 치료할 수 있음 is incorrect because foscarnet is not a treatment for dengue fever.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 라이노바이러스(rhinovirus)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 단순헤르페스바이러스(herpes simplex virus)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 레트로바이러스(retrovirus)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 클로람페니콜(chloramphenicol)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② DNA topoisomerase II</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 이트라코나졸(itraconazole)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ FoxP3</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① CD28</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① IFN-α</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 면역복합체를 과다 형성함\n\nExplanation:\n\nHyposensitization is a form of immunotherapy that involves the administration of small doses of an allergen to a patient over a period of time to reduce the body's sensitivity to that allergen. This process leads to the formation of immune complexes, which are clusters of antigens and antibodies that are normally removed by phagocytic cells. The formation of immune complexes is a characteristic feature of hyposensitization.\n\nTherefore, the correct answer is ③ 면역복합체를 과다 형성함, which means \"Excessive formation of immune complexes.\"</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 라파마이신(rapamycin)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ B형 간염 백신</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ IL-7</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Clostridium botulinum</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe symptoms described in the question, such as muscle weakness, respiratory difficulty, and decreased reflexes, are consistent with a condition known as botulism. Botulism is caused by the ingestion of food contaminated with botulinum toxin, which is produced by the bacteria Clostridium botulinum.\n\nThe mechanism of action of botulinum toxin is the inhibition of the release of acetylcholine, a neurotransmitter that plays a crucial role in muscle contraction and nerve transmission. Therefore, option ③, \"타깃 세포의 아세틸콜린 방출 억제\" (inhibition of acetylcholine release from target cells) is the correct answer.\n\nThe other options do not accurately describe the mechanism of action of botulinum toxin:\n\n① E-cadherin is a protein that plays a role in cell adhesion and is not involved in the mechanism of action of botulinum toxin.\n\n② cAMP (cyclic adenosine monophosphate) is a second messenger that plays a role in signal transduction pathways, but it is not involved in the mechanism of action of botulinum toxin.\n\n④ GABA (gamma-aminobutyric acid) and glycine are neurotransmitters that have inhibitory effects on neurons, but they are not involved in the mechanism of action of botulinum toxin.\n\n⑤ Protein translation is the process by which cells produce proteins from messenger RNA, but it is not involved in the mechanism of action of botulinum toxin.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 1\n\nExplanation:\n\nThe pKa of the drug is 3.0, which means that the drug is a weak acid. When the drug is administered orally, it will ionize partially in the stomach, which has a pH of 2.0.\n\nIn this case, the ratio of the ionized form (ionized drug) to the non-ionized form (unionized drug) can be calculated using the Henderson-Hasselbalch equation:\n\npH = pKa + log10([ionized drug]/[unionized drug])\n\nRearranging the equation to solve for [ionized drug]/[unionized drug], we get:\n\n[ionized drug]/[unionized drug] = 10^((pH - pKa))\n\nSubstituting the given values, we get:\n\n[ionized drug]/[unionized drug] = 10^((2.0 - 3.0)) = 0.1\n\nTherefore, the ratio of the ionized form to the non-ionized form is 0.1, which corresponds to option ③ 1.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ glycine conjugation</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 리바스티그민(rivastigmine) – 콜린에스테라아제(cholinesterase) 억제</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② 아테놀롤(atenolol)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 디아제팜(diazepam)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① GABA에 의한 K+ 유출의 증가</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 팔리페리돈(paliperidone) – 도파민 전구체</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ①\n\nExplanation:\n\n펙소페나딘(fexofenadine) is an antihistamine that has a strong sedative effect and is often used as a sleep aid. It is not suitable for drivers who need to stay alert and focused while driving, especially for long distances. Therefore, option ① is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 헤파린(heparin)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 암로디핀(amlodipine)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 스피로노락톤(spironolactone)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 페북소스타트(febuxostat) – 요산생성 억제</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 란소프라졸(lansoprazole)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 에제티미브(ezetimibe)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② 테르부탈린(terbutaline)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 리토나비르(ritonavir)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 세툭시맙(cetuximab)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ B＝펜톨라민(phentolamine), C＝아트로핀(atropine)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ A와 경쟁적으로 길항한다.\n\nExplanation:\n\nThe graph shows the effect of drugs A, B, and C on the contraction of rabbit blood vessels. Drug A (epinephrine) causes a significant increase in contraction, while drug B has a weaker effect. Drug C has a bell-shaped dose-response curve, indicating that it has a competitive antagonistic effect on the contraction caused by drug A. This means that drug C competes with drug A for the same receptor site, thereby reducing the effect of drug A.\n\nTherefore, the correct answer is ③ A와 경쟁적으로 길항한다, which means that drug C has a competitive antagonistic effect on drug A.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 영아사망률</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 95%\n\nExplanation:\nThe sensitivity of the test is 95%, which means that 95% of the actual positive cases (100) were correctly identified by the test (90).\n\nThe specificity of the test is 90.9%, which means that 90.9% of the actual negative cases (900) were correctly identified by the test (855).\n\nTherefore, the accuracy of the test is (95% + 90.9%) / 2 = 92.95%.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ NO</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 활성탄처리</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 50\n\nExplanation:\nThe biological index of water pollution (BIP) is a measure of the degree of pollution in water bodies based on the presence and abundance of certain aquatic organisms. In this case, the sample contains 200 nanoflagellates, 300 picoflagellates, 300 cryptophytes, and 200 zoogloea.\n\nAccording to the given information, the BIP value is 50, which falls under the \"moderate pollution\" category. This indicates that the water body is not severely polluted, but there is still a significant amount of pollutants present, which could potentially harm aquatic life and human health.\n\nTherefore, the correct answer is ④ 50.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 감각온도</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ①\n\nExplanation:\n\nThe question asks for the direct conjugation reaction participants that involve glutathione. The correct answer is ① glycine, glutathione, acetyl-CoA.\n\nGlycine and glutathione are involved in the conjugation reaction, where glutathione acts as a cofactor to facilitate the conjugation of drugs and other xenobiotics. Acetyl-CoA is also involved in the conjugation reaction as an acetyl group donor.\n\nThe other options do not directly participate in the conjugation reaction involving glutathione:\n\n② S-adenosylmethionine, benzoic acid, ornithine: S-adenosylmethionine is involved in methylation reactions, not conjugation. Benzoic acid and ornithine are not directly involved in glutathione conjugation.\n\n③ glucose 6-phosphate, hippuric acid, mercapturic acid: Glucose 6-phosphate and hippuric acid are not directly involved in glutathione conjugation. Mercapturic acid is a product of glutathione conjugation, but it is not a direct participant in the reaction.\n\n④ cholic acid, glutamine, UDP-α-D-glucuronic acid (UDP-GA): Cholic acid and glutamine are not directly involved in glutathione conjugation. UDP-GA is involved in the glucuronidation reaction, but it is not a direct participant in the conjugation reaction involving glutathione.\n\n⑤ ATP, bilirubin, 3’-phosphoadenosine-5’-phosphosulfate (PAPS): ATP and bilirubin are not directly involved in glutathione conjugation. PAPS is involved in the sulfation reaction, but it is not a direct participant in the conjugation reaction involving glutathione.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 사염화탄소의 대사 증가</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ iron</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤\n\nThe correct answer is ⑤, which corresponds to the description \"considers means to reduce the current risk level to below the acceptable level.\" This answer choice aligns with the concept of risk management, which involves identifying and implementing strategies to mitigate or manage risks.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 정단백질가(net protein utilization)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 호모시스틴뇨증(homocystinuria)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 아스코르빈산(ascorbic acid)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 티라민(tyramine)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 카보닐가</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Clostridium perfringens</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① aconitine</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 독미나리</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 시안화칼륨\n\nExplanation:\n\nThe symptoms described in the scenario, such as confusion, dizziness, and muscle weakness, are consistent with poisoning by a substance that affects the nervous system. The fact that the worker had been consuming coffee and instant noodles suggests that the poisoning may have been caused by a substance in one of these products.\n\nOf the options listed, 시안화칼륨 (cyanide) is a substance that can cause poisoning through ingestion, inhalation, or skin absorption. It can cause symptoms such as confusion, dizziness, and muscle weakness, and can also lead to respiratory failure and cardiac arrest if left untreated.\n\n벤젠 (benzene) is a known carcinogen, but it is not typically associated with the symptoms described in the scenario.\n\n메탄올 (methanol) is a toxic substance that can cause poisoning through ingestion or inhalation, but it is not typically associated with the symptoms described in the scenario.\n\n클로로포름 (chloroform) is a toxic substance that can cause poisoning through inhalation or ingestion, but it is not typically associated with the symptoms described in the scenario.\n\n에틸렌글리콜 (ethylene glycol) is a toxic substance that can cause poisoning through ingestion, but it is not typically associated with the symptoms described in the scenario.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 포메피졸(fomepizole) 투여와 혈액투석\n\nExplanation:\n\nThe patient is exhibiting symptoms of oxalate nephropathy, which is a type of kidney damage caused by the deposition of oxalate crystals in the kidneys. The diagnosis is supported by the presence of oxalate crystals in the urine and the patient's history of exposure to oxalate-containing substances.\n\nThe treatment of oxalate nephropathy involves the use of medications that can help dissolve the oxalate crystals and prevent further kidney damage. Fomepizole is a medication that is specifically used to treat oxalate nephropathy, and it has been shown to be effective in reducing the risk of kidney damage and improving renal function in patients with this condition.\n\nTherefore, option ③, fomepizole therapy and plasmapheresis, is the most appropriate answer for the treatment of this patient's condition. Plasmapheresis is a process that removes harmful substances from the blood, and it may be used in conjunction with fomepizole to help remove oxalate crystals from the patient's blood and prevent further kidney damage.\n\nOption ①, chelation therapy with succimer, is not appropriate for this patient's condition, as succimer is not effective in treating oxalate nephropathy.\n\nOption ②, amyl nitrite, is not appropriate for this patient's condition, as it is not a treatment for oxalate nephropathy.\n\nOption ④, supportive care without specific treatment, is not appropriate for this patient's condition, as it does not address the underlying cause of the patient's symptoms and may not prevent further kidney damage.\n\nOption ⑤, atropine and pralidoxime, is not appropriate for this patient's condition, as these medications are not effective in treating oxalate nephropathy.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ IL-12</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 굿파스처증후군(Goodpasture’s syndrome)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 47,XXY</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 폐 상피세포의 손상</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 그레이혈소판증후군(grey platelet syndrome)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 엽산 결핍</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 파종혈관내응고(disseminated intravascular coagulation)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 가와사키병(Kawasaki disease)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 죽상경화증(atherosclerosis)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 미란(erosion)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 위산 분비 증가</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 정맥성 전이</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① APC</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 프로게스테론 증가</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 말초말이집단백질22(PMP22) 이상</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② 멜라닌색소량에 비례하여 발생한다.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② 황반변성(macular degeneration)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ① 애디슨병(Addison’s disease)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 부신피질부전(adrenocortical insufficiency)</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 수소결합, 반데르발스힘</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 입자침강</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③, \"압력을 조절하여 선택적으로 화합물을 추출할 수 있다.\"\n\n이산화탄소 초임계유체(CO2-rich fluid) is a fluid that contains a high concentration of carbon dioxide. One of its characteristics is that it can selectively extract certain compounds under pressure. This means that by adjusting the pressure, it is possible to extract specific compounds from a mixture, which is not possible with traditional organic solvents. Therefore, option ③ is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ A와 B의 혼합물 액체상, 고체상 A</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 가수분해</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 글루코스의 생분해성</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ aRT/5</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ (a+4b)/5</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③, \"완충용량은 산과 그 짝염기의 농도합에 비례한다.\"\n\nIn a pH 5.0 buffer solution, the concentration of the acid and its conjugate base is related to the buffering capacity. The buffering capacity is the ability of the solution to resist changes in pH when an acid or a base is added. The concentration of the acid and its conjugate base determines the buffering capacity of the solution.\n\nTherefore, option ③ is the correct answer.\n\nOption ①, \"점도는 완충용량에 영향을 준다,\" is incorrect because viscosity does not affect the buffering capacity.\n\nOption ②, \"완충용량을 구하는 식은 디바이 – 허클식이다,\" is incorrect because the formula for calculating the buffering capacity is not related to the question.\n\nOption ④, \"최대 완충용량을 얻기 위해 pK a 7.0인 산을 선정한다,\" is incorrect because the pKa value of the acid does not directly affect the buffering capacity.\n\nOption ⑤, \"완충용량은 pH 변화량을 염기의 증가량으로 나눈 값으로 정의한다,\" is incorrect because the buffering capacity is not defined as the ratio of the pH change to the increase in the base concentration.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 0.57</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 25\n\nExplanation:\n\nThe partition coefficient (K) of drug A between oil and water at 25°C is 10. This means that drug A is equally distributed between the oil and water phases at this temperature.\n\nWhen 55 mg of drug A is dissolved in a mixture of 50 mL of water and 50 mL of chloroform, the concentration of drug A in the chloroform layer can be calculated using the partition coefficient.\n\nSince the partition coefficient is 10, the concentration of drug A in the chloroform layer is 10 times higher than the concentration in the water layer. Therefore, the concentration of drug A in the chloroform layer is 10 x 55 mg/50 mL = 25 mg/50 mL.\n\nSo, the amount of drug A present in the chloroform layer is 25 mg.\n\nTherefore, the correct answer is ③ 25.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 6</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 용출속도 감소</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 소용매성 콜로이드</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe question asks for the property that the surfactant should have when adding a linear alkylbenzene sulfonate surfactant to improve the (na) property of the formulation. The correct answer is ③, which states that the surfactant should increase the viscosity of the formulation when added.\n\nThe reason for this is that the (na) property is related to the viscosity of the formulation. When the viscosity is high, it means that the formulation is more viscous and has better resistance to shear stress. By adding a surfactant that increases the viscosity, the (na) property can be improved.\n\nThe other options do not relate to the improvement of the (na) property and are therefore incorrect. ① states that the surfactant should have a critical micelle concentration, which is not directly related to the viscosity of the formulation. ② states that the surfactant should have a certain ratio of hydrophilic to hydrophobic groups, but this does not necessarily affect the viscosity of the formulation. ④ states that the surfactant should increase the particle size of the formulation, but this could potentially decrease the viscosity of the formulation. ⑤ states that the surfactant should align in a specific direction, but this does not affect the viscosity of the formulation.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 1차 | 유사 0차\n\nExplanation:\n\nIn the given question, we are asked to compare the release rate of the drug from the designed sustained-release granules (A) and the release rate of the drug from the same granules after they have been crushed (B).\n\nFrom the given options, we can see that:\n\n① A is similar to 0-order release, and B is similar to 0-order release.\n\n② A is similar to 0-order release, and B is 1st-order release.\n\n③ A is 1st-order release, and B is similar to 0-order release.\n\n④ A is 1st-order release, and B is 1st-order release.\n\n⑤ A is 2nd-order release, and B is 2nd-order release.\n\nBased on the given information, we can see that the release rate of the drug from the designed sustained-release granules (A) is 1st-order release, and the release rate of the drug from the crushed granules (B) is similar to 0-order release. Therefore, the correct answer is ③ 1차 | 유사 0차.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Na+ 채널을 선택적으로 차단한다.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ benzyl cyanide</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ①</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ①</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ D</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 효능작용</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ DNA의 염기와 공유결합을 형성한다.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ σ(+) | π(-)</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ isoleucine</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① amide</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 0.1 mol/L H2CO3</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 0.04\n\nExplanation:\n\nThe question states that the volume of (NH4)2SO4 solution added is equal to the volume of 0.04 mol/L NH4OH solution. Therefore, the number of moles of (NH4)2SO4 added is equal to the number of moles of NH4OH.\n\nWe know that the number of moles of NH4OH is 0.04 mol/L x volume of NH4OH solution (which is equal to the volume of (NH4)2SO4 solution).\n\nSince (NH4)2SO4 has a molar mass of 116.14 g/mol, the number of moles of (NH4)2SO4 added is:\n\nNumber of moles of (NH4)2SO4 = 0.04 mol/L x volume of NH4OH solution / molar mass of (NH4)2SO4\n= 0.04 mol/L x volume of NH4OH solution / 116.14 g/mol\n\nWe want to find the concentration of (NH4)2SO4 in mol/L, so we can use the formula:\n\nConcentration = number of moles / volume of solution (in L)\n\nSubstituting the values we know:\n\nConcentration = 0.04 mol/L x volume of NH4OH solution / 116.14 g/mol\n= 0.04 mol/L x volume of NH4OH solution / (116.14 g/mol x 1 L/1000 mL)\n= 0.04 mol/L x volume of NH4OH solution / 1.1614 L/mol\n\nNow, we can see that the volume of NH4OH solution is equal to the volume of (NH4)2SO4 solution, so we can substitute the volume of (NH4)2SO4 solution for the volume of NH4OH solution:\n\nConcentration = 0.04 mol/L x volume of (NH4)2SO4 solution / 1.1614 L/mol\n= 0.04 mol/L x 1000 mL / 1.1614 L/mol\n= 0.04 mol/L x 1000 mL / (116.14 g/mol x 1 L/1000 mL)\n= 0.04 mol/L x 1000 mL / 1.1614 L/mol\n\nSimplifying and solving for the concentration, we get:\n\nConcentration = 0.04 mol/L x 1000 mL / 1.1614 L/mol\n= 0.04 mol/L x 1000 mL / (116.14 g/mol x 1 L/1000 mL)\n= 0.04 mol/L x 1000 mL / 1.1614 L/mol\n= 0.04 mol/L\n\nTherefore, the concentration of (NH4)2SO4 in mol/L is 0.04 mol/L, which corresponds to option ③.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 0.03</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 0.1\n\nExplanation:\n\nThe question is asking for the amount of silver nitrate (AgNO3) that will react with 0.1 mol/L NH4SCN solution (100 mL) using the Volhard method.\n\nThe reaction is:\n\nAgNO3 + NH4SCN → AgSCN + NH4NO3\n\nThe mole ratio of AgNO3 to NH4SCN is 1:1, so the amount of AgNO3 required to react with 0.1 mol/L NH4SCN solution (100 mL) is also 0.1 mol.\n\nTherefore, the correct answer is ③ 0.1.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 0.1\n\nExplanation:\n\nThe question asks for the amount of KI (in mmol) that corresponds to 0.05 mol/L KIO3 in 1.0 mL.\n\nWe know that 1 mol/L KIO3 contains 1 mole of KI, so 0.05 mol/L KIO3 contains 0.05 moles of KI.\n\nSince 1 mole of KI is equal to 1000 mmol, we can convert 0.05 moles of KI to mmol as follows:\n\n0.05 moles KI x 1000 mmol/mole KI = 50 mmol KI\n\nTherefore, the correct answer is ③ 0.1 mmol KI, which is the closest option to 50 mmol KI.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 32.1\n\nExplanation:\n\nThe question asks for the amount of piperazine citrate (in mg) that corresponds to 0.1 mol/L of piperazine citrate in 1 mL of 0.1 mol/L hydrochloric acid.\n\nFirst, we need to calculate the amount of piperazine citrate in 1 mL of 0.1 mol/L hydrochloric acid. We know that the molecular weight of piperazine citrate is 642 g/mol. Therefore, the amount of piperazine citrate in 1 mL of 0.1 mol/L hydrochloric acid can be calculated as follows:\n\nAmount of piperazine citrate = Concentration of piperazine citrate x Volume of hydrochloric acid\nAmount of piperazine citrate = 0.1 mol/L x 1 mL\nAmount of piperazine citrate = 0.1 mol\n\nSince the molecular weight of piperazine citrate is 642 g/mol, we can convert the amount of piperazine citrate from moles to grams as follows:\n\nAmount of piperazine citrate (in grams) = Amount of piperazine citrate (in moles) x Molecular weight of piperazine citrate\nAmount of piperazine citrate (in grams) = 0.1 mol x 642 g/mol\nAmount of piperazine citrate (in grams) = 64.2 g\n\nTherefore, the correct answer is ④ 32.1, which is the closest option to 64.2 g.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③. The molar absorptivity (εmax) of a sample is directly proportional to the concentration of the sample. This means that if the concentration of the sample increases, the molar absorptivity will also increase.\n\nThe other options are incorrect because:\n\n① The absorbance (A) is not equal to the inverse of the transmittance (T), so this option is incorrect.\n\n② The wavelength of maximum absorbance (λmax) is not directly proportional to the path length of the sample, so this option is incorrect.\n\n④ The molar absorptivity (εmax) for the π → π* transition is not necessarily greater than the molar absorptivity for the σ → σ* transition, so this option is incorrect.\n\n⑤ The wavelength of maximum absorbance (λmax) for the n → π* transition is not independent of the solvent used, so this option is incorrect.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 적외선분광광도법</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe given question states that the sample was measured using the KBr disc method, and the goal is to obtain the accurate frequency of the sample. The correct answer is ③, which states that the number of scans should be increased.\n\nIncreasing the number of scans will allow for a more accurate measurement of the sample's absorption spectrum, which will in turn provide a more accurate determination of the sample's frequency.\n\nThe other options are not correct because:\n\n① Replacing the light source with a new one will not necessarily improve the accuracy of the measurement.\n\n② Using NaCl instead of KBr will change the sample's absorption spectrum, which may not provide accurate results.\n\n④ Reducing the amount of sample used will also change the absorption spectrum, which may not provide accurate results.\n\n⑤ Crushing the sample will not improve the accuracy of the measurement, and may in fact introduce errors due to the changed particle size.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 친화크로마토그래피 – 분리 물질의 분자량 차이에 의한 선택성</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 고정상 입자의 크기</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④\n\nExplanation:\n\nThe question asks for the correct statement regarding the effect of the partition coefficient (k') on the analysis of a mixture using liquid chromatography.\n\nOption ① is incorrect because the partition coefficient is not affected by the distribution coefficient.\n\nOption ② is incorrect because the smaller the value of k', the shorter the retention time of the solute in the stationary phase.\n\nOption ③ is incorrect because changing the elution conditions does not affect the value of k'.\n\nOption ④ is correct because a higher value of k' (greater than 10) is desirable for efficient analysis.\n\nOption ⑤ is incorrect because it describes the relationship between the adjusted retention time (t') and the retention time (to) of a solute in a mixture, but it does not relate to the effect of k' on the analysis.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③, \"굴절률 검출기는 시료의 화학구조에 제한 없이 사용될 수 있다.\"\n\nThe question is asking about the advantage of using a refractive index detector in gas chromatography. The correct answer is that a refractive index detector can be used to detect samples without any restrictions on their chemical structure, unlike other detectors that may have limitations based on the sample's chemical properties.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 전기화학 검출기</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 0.04</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 평균편차</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 분자의 회전 운동\n\nExplanation:\nThe question is asking about the principle applied in the measurement of the ultraviolet-visible absorption spectrum of thiamine hydrochloride using a cuvette with a path length of 1 cm. The correct answer is ③ 분자의 회전 운동, which means the molecular rotation of thiamine hydrochloride.\n\nIn the measurement of ultraviolet-visible absorption spectra, the molecular rotation of the sample can affect the absorption of light. The absorption spectrum of a sample can change depending on the orientation of the molecules in the sample. In the case of thiamine hydrochloride, the molecules can rotate freely in solution, and the absorption spectrum can change depending on the orientation of the molecules.\n\nTherefore, the principle applied in the measurement of the ultraviolet-visible absorption spectrum of thiamine hydrochloride using a cuvette with a path length of 1 cm is the molecular rotation of thiamine hydrochloride.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ② 2.30\n\nExplanation:\n\nThe molar absorptivity (M^-1 ∙ cm^-1) of thiamine hydrochloride can be calculated using the following equation:\n\nMolar absorptivity = (absorbance / concentration) / (path length / 10)\n\nwhere absorbance is the peak absorbance (0.230) and concentration is the molar concentration (337 mg/100 mL = 3.37 mM).\n\nPath length is given as 1 cm, so we can plug in the values:\n\nMolar absorptivity = (0.230 / 3.37 mM) / (1 cm / 10)\n\nSimplifying and solving for M^-1 ∙ cm^-1, we get:\n\nMolar absorptivity = 2.30 M^-1 ∙ cm^-1\n\nTherefore, the correct answer is ② 2.30.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②\n\nExplanation:\n\nThe correct answer is ②, \"겉보기부피(Vbulk)를 압축부피(Vtapped)로 나눈 값이다.\"\n\nThe Hausner ratio is a measure of the ease of flow of a powder, and it is defined as the ratio of the bulk volume (Vbulk) to the tapped volume (Vtapped) of a powder. Therefore, option ② is the correct description of the Hausner ratio.\n\nOption ① is incorrect because the Hausner ratio and the angle of repose are not directly related. The angle of repose is a measure of the steepness of the slope of a powder bed, while the Hausner ratio is a measure of the ease of flow.\n\nOption ③ is incorrect because the Hausner ratio does not directly affect the flowability of a powder. While a higher Hausner ratio may indicate better flowability, it is not a direct relationship.\n\nOption ④ is incorrect because the Hausner ratio of 1.6 is not a universal standard for excellent flowability. Different powders may have different optimal Hausner ratios, and a ratio of 1.6 may not necessarily indicate excellent flowability for all powders.\n\nOption ⑤ is incorrect because the Hausner ratio does not directly affect the difference between the bulk and tapped volumes. While a higher Hausner ratio may result in a smaller difference between the bulk and tapped volumes, it is not a direct relationship.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ fluid-energy mill</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 계면중합법</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 소르비톨</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 셀라세페이트</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② polysorbate 80</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 유동파라핀</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ polyvinylpyrrolidone</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③, which states that the amount of stearic acid is increased. Stearic acid is a common lubricant used in the manufacture of tablets and capsules. It helps to reduce the friction between the powder particles and the machinery during the tableting process, resulting in a more efficient and uniform production of tablets. By increasing the amount of stearic acid, the flowability of the powder can be improved, leading to a higher output of tablets.\n\nThe other options are not correct for the following reasons:\n\n① Increasing the particle size of the drug would not necessarily improve the flowability of the powder.\n\n② Using ethylcellulose as a coating agent may improve the flowability of the powder, but it is not directly related to the production of tablets.\n\n④ Reducing the amount of sodium stannate would not have a significant impact on the flowability of the powder.\n\n⑤ Forming a solid dispersion of the drug using povidone would not necessarily improve the flowability of the powder.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④\n\nExplanation:\n\nThe question asks for a design of a pharmaceutical preparation that can increase the bioavailability of a drug that is specifically absorbed through the intestinal tract. The correct answer is ④, which describes a preparation that combines the drug with an ion-exchange resin and coats it with Eudragit L100. This design can enhance the bioavailability of the drug by protecting it from degradation in the stomach and promoting its absorption in the intestines.\n\nOption ① describes a preparation that uses a controlled-release technology to release the drug slowly in the intestines. While this design can provide sustained release of the drug, it may not necessarily increase its bioavailability.\n\nOption ② describes a preparation that includes a microcapsule containing the drug. While this design can protect the drug from degradation in the stomach, it may not necessarily enhance its absorption in the intestines.\n\nOption ③ describes a preparation that reduces the density of the drug to make it float in water. This design may not be effective in increasing the bioavailability of the drug, as it may not be absorbed efficiently in the intestines.\n\nOption ⑤ describes a preparation that includes the drug in a matrix and coats it with a shell. While this design can protect the drug from degradation in the stomach, it may not necessarily enhance its absorption in the intestines.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\nThe correct answer is ③, which corresponds to the following sequence:\n\n지지체 (base)\n약물저장고 (reservoir)\n점착층 (adhesive layer)\n조절막 (control layer)\n박리지 (protective layer)\n\nThis sequence represents the correct order of the layers in a transdermal patch, with the base layer (지지체) at the bottom, followed by the reservoir layer (약물저장고) containing the active ingredient, the adhesive layer (점착층) to secure the patch to the skin, the control layer (조절막) to regulate the release of the active ingredient, and finally the protective layer (박리지) to protect the patch from the external environment.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③. The description \"직장 하부로 흡수된 약물은 간문맥을 거치지 않고 전신순환계로 들어간다\" matches the characteristic of the small intestine, which is responsible for the absorption of nutrients and drugs into the bloodstream. The small intestine has a large surface area and a specialized structure that allows for efficient absorption, and the absorbed substances are then transported directly into the systemic circulation without passing through the liver.\n\nThe other options do not accurately describe the characteristic of the small intestine:\n\n① is incorrect because the small intestine does produce mucus, which helps to protect the epithelial lining and facilitate the absorption of nutrients.\n\n② is incorrect because while the small intestine does have a similar structure to the large intestine in terms of the presence of villi, the villi in the small intestine are much longer and more numerous, allowing for greater surface area for absorption.\n\n④ is incorrect because while the small intestine does have a high degree of cell-to-cell tight junctions, which helps to prevent the entry of toxins and large molecules into the bloodstream, the tight junctions are not necessarily less permeable than those in the large intestine.\n\n⑤ is incorrect because while the small intestine does have a thicker mucosa than the large intestine, this does not necessarily result in a lower absorption rate of drugs. In fact, the small intestine is responsible for the majority of drug absorption in the gastrointestinal tract.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 200\n\nExplanation:\n\nThe clearance of a drug can be calculated using the formula: Clearance = (Dose / AUC).\n\nIn this case, the dose of drug A is 1.2 L x 4 mg/mL = 4.8 mg.\n\nThe AUC is 24 mg ∙ h/mL.\n\nTherefore, the clearance of drug A can be calculated as: Clearance = (4.8 mg / 24 mg ∙ h/mL) = 0.2 mL/h.\n\nThe answer is ③ 200, as 0.2 mL/h is equivalent to 200 mL/h.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ②\n\nExplanation:\n\nThe correct answer is ②, \"낮은 용해도와 높은 막투과도를 가진다.\"\n\nThe BCS (Biopharmaceutics Classification System) is a system used to classify drugs based on their solubility and permeability properties. The first category, 제1군 (Class 1), includes drugs with low solubility and high permeability. These drugs are typically poorly soluble in water but are easily absorbed through the gastrointestinal tract.\n\nTherefore, the correct description of 제1군 is \"낮은 용해도와 높은 막투과도를 가진다,\" which means \"having low solubility and high permeability.\"</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 28\n\nExplanation:\n\nThe question asks for the loading dose (부하량) of theophylline that will reach a therapeutic concentration (Css) of 10 mg/L in a 70 kg patient. The patient's Vd is 0.5 L/kg, and CLt is 0.04 L/h/kg.\n\nUsing the linear 1-compartment model, the equation for Css is:\n\nCss = (Loading dose / Vd) \\* (1 - e^(-CLt/Vd))\n\nRearranging the equation to solve for the loading dose, we get:\n\nLoading dose = Vd \\* Css / (1 - e^(-CLt/Vd))\n\nPlugging in the values, we get:\n\nLoading dose = 0.5 L/kg \\* 10 mg/L / (1 - e^(-0.04 L/h/kg / 0.5 L/kg))\nLoading dose = 0.5 L/kg \\* 10 mg/L / (1 - e^(-0.08))\nLoading dose = 0.5 L/kg \\* 10 mg/L / (1 - 0.08)\nLoading dose = 0.5 L/kg \\* 10 mg/L / 0.02\nLoading dose = 25 mg/kg\n\nSince the patient weighs 70 kg, the total loading dose is:\n\nLoading dose = 25 mg/kg \\* 70 kg\nLoading dose = 1750 mg\n\nTherefore, the correct answer is ③ 28.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\n\nThe question asks about the changes in pharmacokinetics and clinical management of warfarin in a patient with a CYP2C9 gene variant (CYP2C9*2, *3, or *13).\n\n① is incorrect because warfarin's plasma concentration would decrease, not increase, in patients with CYP2C9*2 or *3 variants, due to increased metabolism.\n\n② is incorrect because the distribution volume of warfarin would not decrease in patients with CYP2C9*2 or *3 variants.\n\n③ is correct. Patients with CYP2C9*2 or *3 variants have a higher risk of bleeding due to reduced metabolism, which can lead to increased plasma concentrations of warfarin. Therefore, the dose of warfarin should be reduced, and the patient should be monitored closely for signs of bleeding.\n\n④ is incorrect because clearance of warfarin would not increase in patients with CYP2C9*2 or *3 variants.\n\n⑤ is incorrect because the shape of the warfarin plasma concentration-time curve would not change in patients with CYP2C9*2 or *3 variants.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 유동화, 겔화\n\nExplanation:\n\nThe purpose of adding Poloxamer 124 and Carbomer 940 in the formulation is to improve the solubility and stability of the drug, Adapalene, and to create a gel-like consistency for the topical cream.\n\nPoloxamer 124 is a nonionic surfactant that acts as a solubilizer and emulsifier, enabling the solubilization of hydrophobic drugs like Adapalene in water. It also helps to improve the drug's bioavailability and skin permeation.\n\nCarbomer 940 is a polymeric thickening agent that helps to create a gel-like consistency for the cream. It also acts as a stabilizer, preventing the separation of the drug from the vehicle over time.\n\nTherefore, the correct order of the functions of Poloxamer 124 and Carbomer 940 in the formulation is:\n\n1. Poloxamer 124: solubilization and emulsification of Adapalene\n2. Carbomer 940: thickening and stabilization of the cream.\n\nSo, the answer is ③ 유동화, 겔화 (solubilization, gelation).</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③. The formula for the cream contains a mixture of adapalene (0.3 g) and polyoxyethylene sorbitan monolaurate (0.2 g) as the active ingredients, along with other excipients such as purified water, carboxylic acid, sodium hydroxide, and propylene glycol. The mixture is then stirred and heated to a uniform consistency, indicating that the cream is a homogeneous system.\n\nTherefore, option ③, \"고분자가 액체에 균등하게 분포하여 단일상을 이룬다,\" is the correct answer.\n\nOption ①, \"전형적인 틱소트로피를 나타낸다,\" is incorrect because the formula does not contain any typical thickening agents such as carboxyvinyl polymer or hydroxyethyl cellulose.\n\nOption ②, \"고분자 계면활성제로 이루어진 크림제이다,\" is also incorrect because the formula does not contain any surfactants or emulsifiers that would suggest a cream-like consistency.\n\nOption ④, \"아주 작은 입자들의 응집체 덩어리로 이루어진 시스템이다,\" is incorrect because the formula does not contain any suspended particles or aggregates that would suggest a system consisting of small particles.\n\nOption ⑤, \"분자량이 다른 카보머를 사용하더라도 약물방출에는 영향을 주지 않는다,\" is incorrect because the formula contains a mixture of adapalene and polyoxyethylene sorbitan monolaurate, which could potentially affect the drug release profile.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① digitoxin</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ hesperidin</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① atropine</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ geraniin</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 산약</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 백지</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 사프란</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 당약</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Hyperici Herba</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ santonin</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 정향</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 오약(烏藥)</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 숙지황(熟地黃)</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 안중산(安中散)</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 용담사간탕(龍膽瀉肝湯)</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 삼황사심탕(三黃瀉心湯)</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 목향</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 칸데사르탄(candesartan)+펠로디핀(felodipine)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 비소프롤롤(bisoprolol)\n\nExplanation:\n\nThe patient has hypertension and chronic heart failure, and is currently taking ramipril and furosemide. The patient's blood pressure is 139/86 mmHg, which is still relatively high despite medication. The patient's heart rate is 78 beats per minute, which is normal. The patient's serum potassium level is 4.3 mEq/L, which is slightly low. The patient's SCr level is 1.0 mg/dL, which indicates that the patient's renal function is normal. The patient's BUN level is 18 mg/dL, which is slightly high. The patient's LVEF is 33%, which indicates that the patient has mild heart failure.\n\nGiven the patient's history of hypertension and chronic heart failure, it is important to add a medication that will help reduce the patient's cardiac risk. Bisoprolol, a beta-blocker, is an appropriate choice because it has been shown to reduce cardiac risk in patients with hypertension and heart failure. It works by reducing the heart rate and blood pressure, which can help reduce the workload on the heart and improve symptoms such as shortness of breath.\n\nDiltiazem, a calcium channel blocker, may also be considered as an alternative to bisoprolol. However, bisoprolol is a more appropriate choice because it has a more favorable effect on the heart rate and blood pressure, and it has been shown to have a more positive impact on cardiac outcomes in patients with hypertension and heart failure.\n\nValsartan, an angiotensin II receptor antagonist, may also be considered as an alternative to bisoprolol. However, valsartan is less effective in reducing blood pressure and heart rate compared to bisoprolol, and it may not have the same positive effects on cardiac outcomes.\n\nIvabradine, a funny channel blocker, is not appropriate for this patient because it is primarily used to treat angina pectoris and has not been shown to have a significant impact on cardiac outcomes in patients with hypertension and heart failure.\n\nHydrochlorothiazide, a diuretic, may also be considered as an alternative to bisoprolol. However, hydrochlorothiazide is primarily used to treat hypertension and edema, and it may not have the same positive effects on cardiac outcomes in patients with heart failure.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 사쿠비트릴/발사르탄(sacubitril/valsartan)\n\nExplanation:\n\nThe patient has chronic heart failure with a left ventricular ejection fraction (LVEF) of 32% and NYHA Class II. The goal of treatment is to reduce the risk of death and hospitalization due to heart failure.\n\nSacubitril/valsartan is a combination of an angiotensin receptor blocker (ARB) and a neprilysin inhibitor, which has been shown to reduce the risk of death and hospitalization in patients with chronic heart failure. It is a more appropriate choice compared to the other options, which include a cardiac glycoside (digoxin), a diuretic (furosemide), an aldosterone antagonist (spironolactone), and a combination of hydralazine and isosorbide dinitrate (which is not a commonly used combination for heart failure).\n\nTherefore, option ④ 사쿠비트릴/발사르탄(sacubitril/valsartan) is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 클로르탈리돈(chlorthalidone)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 라미프릴(ramipril)\n\nExplanation:\n\nThe patient has been diagnosed with hypertension and hyperlipidemia, and is currently taking medications such as hydrochlorothiazide, atorvastatin, metoprolol, aspirin, and prasugrel. The patient's blood pressure is still slightly high, at 138/88 mmHg, and their heart rate is 59 beats per minute.\n\nGiven the patient's medical history and current medications, the best additional medication to prescribe would be ramipril, which is an ACE inhibitor. ACE inhibitors are commonly used to treat hypertension and can also help to reduce proteinuria, which is a common complication of diabetes. Ramipril can also help to reduce the risk of cardiovascular events, such as heart attacks and strokes, in patients with hypertension and hyperlipidemia.\n\nThe other options, such as lacidipine, verapamil, indapamide, and nitroprusside, may also be effective in treating hypertension, but they may not be as appropriate for this patient's specific medical history and current medications. Lacidipine is a calcium channel blocker that may have negative interactions with metoprolol, which the patient is already taking. Verapamil is a calcium channel blocker that may have negative interactions with atorvastatin, which the patient is also taking. Indapamide is a diuretic that may not be effective in reducing blood pressure in patients with hypertension and hyperlipidemia. Nitroprusside is a vasodilator that may have negative interactions with other medications the patient is taking, such as metoprolol and aspirin.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ②\n\nExplanation:\n\nThe patient in question has been diagnosed with ST-segment elevation myocardial infarction (STEMI) and has received a stent implantation. The goal of treatment is to prevent further cardiovascular events, such as recurrent myocardial infarction or stroke.\n\nOption ②, aspirin 100mg/day + apixaban 5mg/day, is the most appropriate choice for this patient. Aspirin is an antiplatelet agent that works by inhibiting platelet aggregation, which can help prevent thrombus formation and subsequent cardiovascular events. Apixaban is an oral anticoagulant that works by inhibiting factor Xa, which is involved in the coagulation cascade. The combination of aspirin and apixaban has been shown to be effective in reducing the risk of recurrent cardiovascular events in patients with STEMI.\n\nOption ①, aspirin/dipyridamole 25/200mg/day, is not the best choice for this patient. While aspirin/dipyridamole is an effective antiplatelet regimen, it may not provide adequate anticoagulation therapy for a patient with STEMI who has received a stent implantation.\n\nOption ③, aspirin 100mg/day + ticagrelor 90mg/day, is not the best choice for this patient. Ticagrelor is a potent antiplatelet agent that may increase the risk of bleeding in patients with STEMI, especially when used in combination with aspirin.\n\nOption ④, aspirin 100mg/day + cilostazol 200mg/day, is not the best choice for this patient. Cilostazol is a phosphodiesterase inhibitor that may increase the risk of bleeding in patients with STEMI, especially when used in combination with aspirin.\n\nOption ⑤, aspirin 100mg/day + clopidogrel 300mg/day, is not the best choice for this patient. Clopidogrel is an antiplatelet agent that may increase the risk of bleeding in patients with STEMI, especially when used in combination with aspirin.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 메토프롤롤(metoprolol) 정\n\nExplanation:\n\nThe patient has a history of angina, hypertension, and erectile dysfunction. The patient's blood pressure is 132/84 mmHg, and the heart rate is 57 beats per minute. The patient is taking aspirin, carvedilol, losartan, rosuvastatin, and sildenafil as needed. The patient's recent symptoms of angina have increased, and the nitroglycerin patch dose has been increased.\n\nGiven the patient's history of hypertension and angina, it is appropriate to add a beta-blocker to the patient's regimen. Metoprolol is a beta-blocker that can be used to treat hypertension, angina, and migraines. It can also be used to reduce the risk of cardiovascular events in patients with a history of myocardial infarction.\n\nTherefore, option ③ 메토프롤롤(metoprolol) 정 is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 6시간 이상 12시간 미만\n\nExplanation:\n\nThe patient has been administered heparin for prevention of stroke, and the question is asking when to administer the second dose. The correct answer is ③ 6시간 이상 12시간 미만, which means between 6 and 12 hours after the first dose.\n\nThe rationale for this answer is that heparin has a relatively short half-life, around 2-4 hours, which means that its effectiveness wears off quickly. To maintain adequate anticoagulation, it is important to administer the second dose before the effect of the first dose wears off completely. Administering the second dose too early (within 3 hours) may not provide adequate protection against stroke, while waiting too long (beyond 12 hours) may increase the risk of bleeding complications. Therefore, the optimal time to administer the second dose is between 6 and 12 hours after the first dose.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 알테플라제(alteplase)\n\nExplanation:\n\nThe patient has been diagnosed with acute coronary syndrome (ACS) and has a history of hypertension and dyslipidemia. The appropriate medication for this patient would be an anti-thrombotic agent, specifically a thrombolytic agent such as alteplase. Alteplase is a recombinant tissue plasminogen activator that works by breaking down blood clots and restoring blood flow to the affected area. It is commonly used in the treatment of ACS, including myocardial infarction (heart attack) and pulmonary embolism.\n\nThe other options are not appropriate for this patient's condition:\n\n* Aspirin is an anti-platelet agent that is used to prevent blood clots, but it is not a thrombolytic agent and would not be effective in dissolving existing clots.\n* Apixaban is an oral anticoagulant that is used to prevent blood clots, but it is not a thrombolytic agent and would not be effective in dissolving existing clots.\n* Abciximab is a glycoprotein IIb/IIIa inhibitor that is used to prevent platelet aggregation and is often used in combination with aspirin and heparin in the treatment of ACS. However, it is not a thrombolytic agent and would not be effective in dissolving existing clots.\n* Enoxaparin is a low-molecular-weight heparin that is used to prevent blood clots, but it is not a thrombolytic agent and would not be effective in dissolving existing clots.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 와파린(warfarin)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 플레카이니드(flecainide) 경구제\n\nExplanation:\n\nThe patient has been diagnosed with stable angina and has a history of myocardial infarction. The patient's symptoms include chest tightness and shortness of breath, and the patient's vital signs show elevated blood pressure and heart rate. The patient is currently taking aspirin and pravastatin.\n\nGiven the patient's history of myocardial infarction and current symptoms, the most appropriate medication to add for rate control would be a calcium channel blocker, such as diltiazem or verapamil. These medications slow the entry of calcium into the cardiac muscle cells, which slows the heart rate and reduces the force of contraction, thereby reducing the myocardial oxygen demand.\n\nTherefore, the correct answer is ③ 플레카이니드(flecainide) 경구제.\n\nNote: The other options, ① 딜티아젬(diltiazem) 주사제, ② 아데노신(adenosine) 주사제, ④ 드로네다론(dronedarone) 경구제, and ⑤ 니트로글리세린(nitroglycerin) 주사제, may also be appropriate for rate control in certain situations, but based on the patient's history and current symptoms, 플레카이니드(flecainide) is the most appropriate choice.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ 아스피린을 다비가트란에텍실레이트(dabigatran etexilate)로 변경.\n\nExplanation:\n\nThe patient has been diagnosed with stable angina and has a history of myocardial infarction. The patient's current medications include aspirin and pravastatin. The addition of prasugrel (②) or dipyridamole (③) may be considered for the prevention of cardiac events, but they are not the most appropriate choices for this patient's current condition. Enoxaparin (④) is a low-molecular-weight heparin that is used for the prevention of deep vein thrombosis and pulmonary embolism, but it is not indicated for the prevention of cardiac events. Dabigatran etexilate (⑤) is a direct thrombin inhibitor that is used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and it may be a suitable alternative to aspirin for this patient.\n\nTherefore, the correct answer is ⑤ 아스피린을 다비가트란에텍실레이트(dabigatran etexilate)로 변경.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 로수바스타틴(rosuvastatin) 20 mg 1일 1회</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 티오트로퓸(tiotropium) 흡입제를 추가하여 매일 사용</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 저용량 플루티카손/살메테롤 흡입제를 중간용량 1일 2회로 변경</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 부데소니드 흡입제 1일 2회+살부타몰 흡입제 필요시</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe patient is already taking indacaterol, a long-acting beta-2 agonist, and salbutamol, a short-acting beta-2 agonist, as needed. However, the patient's symptoms are not controlled, indicating that the current treatment is not effective.\n\nAdding ipratropium, an anticholinergic, to the patient's regimen may help to improve lung function and symptoms, as it has a different mechanism of action than the beta-2 agonists. Ipratropium works by blocking the action of acetylcholine, a neurotransmitter that causes broncholar smooth muscle contraction, thereby relaxing the airways and improving lung function.\n\nThe other options, such as theophylline, fluticasone, umeclidinium, and methylprednisolone, may also be considered as additional therapies, but they are not as likely to provide the desired improvement in lung function and symptoms in this case, given the patient's current treatment regimen and medical history.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 아클리디늄(aclidinium) 흡입제</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 라모세트론(ramosetron)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 리팍시민(rifaximin)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② B형간염백신 투여</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 소포스부비르(sofosbuvir)+페그인터페론(peginterferon) 12주</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② 부데소니드(budesonide) 관장제\n\nExplanation:\n\nThe patient has been diagnosed with ulcerative colitis, which is a type of inflammatory bowel disease (IBD) that affects the colon and rectum. The symptoms described, including abdominal pain, bloody diarrhea, and mucus in the stool, are consistent with this diagnosis.\n\nBudesonide is a corticosteroid that is commonly used to treat ulcerative colitis. It works by reducing inflammation in the colon and rectum, which can help to relieve symptoms such as abdominal pain, diarrhea, and rectal bleeding. Budesonide is often prescribed as a first-line treatment for mild to moderate ulcerative colitis, as it is effective and has fewer side effects compared to other corticosteroids.\n\nMesalazine, which is another option, is an aminosalicylate that is also used to treat ulcerative colitis. However, it may not be as effective as budesonide in treating severe symptoms, and it may have a higher risk of side effects such as gastrointestinal disturbances and allergic reactions.\n\nAzathioprine is an immunosuppressant that is sometimes used to treat severe ulcerative colitis that has not responded to other treatments. However, it may take several months to a year or more to see the full effects of this medication, and it may have a higher risk of side effects such as nausea, vomiting, and an increased risk of infection.\n\nPrednisolone is a corticosteroid that is sometimes used to treat severe ulcerative colitis that has not responded to other treatments. However, it may have a higher risk of side effects compared to budesonide, such as weight gain, mood changes, and an increased risk of infection.\n\nTherefore, based on the patient's symptoms and diagnosis, the most appropriate treatment option would be budesonide.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④\n\nExplanation:\n\nThe patient has been diagnosed with Helicobacter pylori infection and has been taking esomeprazole (20 mg/day) for 2 weeks. The addition of amoxicillin (①) or levofloxacin (②) would not be appropriate as they are not effective against Helicobacter pylori. Azithromycin (③) and rifabutin (③) are not typically used for Helicobacter pylori eradication. Bismuth (⑤) is not effective against Helicobacter pylori.\n\nTherefore, the correct answer is ④, which is a combination of amoxicillin, azithromycin, and metronidazole, which is a common treatment regimen for Helicobacter pylori eradication.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 골밀도 감소</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 암로디핀\n\nExplanation:\nThe patient's lactic acid level is elevated, indicating lactic acidosis. This is a potential side effect of metformin, which is a biguanide medication used to treat type 2 diabetes. The patient's high blood pressure and abnormal liver function test results also suggest a possible adverse effect of metformin. Therefore, the drug that is most likely to be the cause of the patient's abnormal test results is metformin.\n\nAnswer: ④ 메트포르민</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 푸로세미드(furosemide)\n\nExplanation:\n\nThe patient has developed acute kidney injury (AKI) after a cardiac surgery, as evidenced by the decrease in urine output, dry mouth, and decreased skin turgor. The patient's FENa level is low (<1%), indicating that the kidneys are not able to concentrate the urine adequately. The patient's serum osmolality is high (>500 mOsm/kg), which suggests that the patient has excessive fluid accumulation in the body.\n\nIn this scenario, furosemide (③) would be the most appropriate medication to prevent further fluid accumulation and promote diuresis. Furosemide is a potent diuretic that works by inhibiting the reabsorption of sodium and chloride ions in the renal tubules, leading to increased urine production. By increasing urine output, furosemide can help to reduce the excess fluid accumulation in the body and improve the patient's fluid balance.\n\nThe other options are not as appropriate for this patient's condition:\n\n① Theophylline is a bronchodilator that is used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). It has no diuretic effect and would not help to improve the patient's fluid balance.\n\n② 0.9% NaCl solution is a normal saline solution that is used to replace fluids and electrolytes in patients who are dehydrated. However, in this patient's case, the high serum osmolality suggests that the patient has excessive fluid accumulation, and administering more fluids could exacerbate the problem.\n\n④ Dopamine is a vasopressor that is used to increase blood pressure in patients who are hypotensive. While dopamine may help to improve the patient's blood pressure, it does not have a diuretic effect and would not help to reduce the excess fluid accumulation in the body.\n\n⑤ Acetylcysteine is a medication that is used to treat acetaminophen overdose and to loosen mucus in patients with respiratory conditions. It has no diuretic effect and would not help to improve the patient's fluid balance.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② 칼시트리올(calcitriol) 투여\n\nExplanation:\n\nThe patient's laboratory results indicate that they have chronic kidney disease (CKD) with anemia, evidenced by a low hemoglobin level (9.5 g/dL) and a low hematocrit (29%). The patient's ferritin level is also high (540 ng/mL), indicating iron overload.\n\nThe most appropriate treatment for this patient's anemia would be calcitriol (option ②), which is a synthetic form of vitamin D. Calcitriol can help to increase the patient's red blood cell production and improve their anemia.\n\nThe other options are not appropriate for this patient's condition:\n\n* Option ①, maintaining current medication, is not a suitable option as the patient's anemia is not being effectively managed with their current treatment.\n* Option ③, aluminum hydroxide, is not appropriate for treating anemia in patients with CKD.\n* Option ④, sodium ferric gluconate, is a form of iron supplementation, but it is not appropriate for this patient as they have iron overload.\n* Option ⑤, methoxy polyethylene glycol-epoetin beta, is a form of erythropoietin, which is a hormone that stimulates red blood cell production. However, it is not appropriate for this patient as their anemia is not caused by a lack of erythropoietin.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 파리칼시톨(paricalcitol)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ④ 푸로세미드\n\nExplanation:\n\nThe patient's elevated serum potassium level (5.5 mEq/L) and decreased renal function (eGFR 32 mL/min/1.73 m^2) suggest that the patient may have developed hyperkalemia due to impaired renal potassium excretion. Among the medications the patient is taking, furosemide (④) is a potassium-sparing diuretic that can cause hyperkalemia by decreasing potassium excretion in the urine. Therefore, option ④ 푸로세미드 is the correct answer.\n\nThe other options do not have a direct effect on potassium levels:\n\n* ① 파록세틴 (paroxetine) is a selective serotonin reuptake inhibitor that does not affect potassium levels.\n* ② 모사프리드 (mosapride) is a prokinetic agent that does not affect potassium levels.\n* ③ 에날라프릴 (enalapril) is an ACE inhibitor that can cause hyperkalemia, but it is less likely to be the cause in this case given the patient's normal renal function and lack of other signs of kidney dysfunction.\n* ⑤ 로수바스타틴 (rosuvastatin) is a statin that does not affect potassium levels.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 탄산칼슘을 세벨라머로 변경\n\nRationale:\n\nThe patient has hypercalcemia (elevated calcium levels) due to the use of calcium carbonate. The calcium carbonate is not effectively lowering the patient's calcium levels, and the patient's kidney function is declining. In this case, it would be appropriate to switch the patient's calcium supplement from calcium carbonate to sevelamer, which is a phosphate-binding agent that can help lower calcium levels and improve kidney function.\n\nSevelamer is a better option than calcium polystyrene sulfonate (option ③) because it has been shown to be more effective in lowering calcium levels and improving kidney function in patients with hypercalcemia. Additionally, sevelamer has fewer side effects than calcium polystyrene sulfonate, which can cause gastrointestinal disturbances and electrolyte imbalances.\n\nTherefore, option ④, switching the patient's calcium supplement from calcium carbonate to sevelamer, is the best answer.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 인슐린 글라진(insulin glargine)\n\nExplanation:\n\nThe patient has been successfully managing their type 2 diabetes with metformin and linagliptin for 4 years, with a recent HbA1c level of 8.2%. The decision to add insulin therapy is appropriate, given the patient's history of stable blood sugar control and the recent increase in HbA1c.\n\nOf the options provided, insulin glargine (②) is the most appropriate choice for several reasons:\n\n1. Glargine is a long-acting insulin that provides a steady and sustained release of insulin over 24 hours, which aligns with the patient's current once-daily dosing regimen.\n2. Glargine has a flat and stable glucose-lowering profile, which reduces the risk of hypoglycemia compared to other insulin formulations.\n3. Glargine has been shown to improve glycemic control and reduce HbA1c levels in patients with type 2 diabetes, similar to the patient's current situation.\n4. Glargine is generally well-tolerated and has a low risk of allergic reactions or immune system responses.\n\nIn summary, insulin glargine is the most appropriate choice for this patient due to its long-acting profile, stable glucose-lowering effect, and established efficacy in improving glycemic control.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ 니트로글리세린\n\nExplanation:\nNitroglycerin is a vasodilator that can cause hypotension and decrease blood sugar levels. In this case, the patient's blood glucose level was measured at 63 mg/dL, which is lower than the normal range, and the patient did not experience any symptoms of hypoglycemia. Therefore, the most likely cause of the patient's hypoglycemia is the nitroglycerin that was added to their medication regimen.\n\nThe other options are less likely to cause hypoglycemia:\n\n* Aspirin can increase blood sugar levels and is not typically associated with hypoglycemia.\n* Atenolol is a beta-blocker that can decrease heart rate and blood pressure, but it is not known to cause hypoglycemia.\n* Ramipril is an ACE inhibitor that can decrease blood pressure and proteinuria, but it is not associated with hypoglycemia.\n* Rosuvastatin is a statin that can decrease cholesterol levels, but it is not known to cause hypoglycemia.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 인슐린 디터머(insulin detemir)\n\nExplanation:\n\nThe patient's symptoms of nausea, vomiting, and decreased consciousness, along with the laboratory results of hyperglycemia, suggest a diagnosis of diabetic ketoacidosis (DKA). DKA is a life-threatening metabolic complication that can occur in patients with type 1 diabetes, and it is important to treat it promptly and appropriately.\n\nInsulin detemir (③) is a long-acting insulin that is appropriate for the treatment of DKA, as it has a prolonged duration of action and can help to reduce the patient's blood glucose levels over a period of several hours. Regular insulin (②) may also be used, but it has a shorter duration of action and may need to be administered more frequently.\n\nLiraglutide (①) is a glucagon-like peptide-1 (GLP-1) receptor agonist that is used to treat type 2 diabetes, but it is not appropriate for the treatment of DKA. Sodium bicarbonate (④) may be used to treat metabolic acidosis, but it is not the most appropriate choice for the treatment of DKA. Calcium polystyrene sulfonate (⑤) is a cation-exchange resin that is used to treat hyperkalemia, but it is not relevant to the treatment of DKA.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 메트포르민(metformin)+엠파글리플로진(empagliflozin)\n\nExplanation:\n\nThe patient has been diagnosed with type 2 diabetes mellitus and is currently taking aspirin, lisinopril, carvedilol, spironolactone, and atorvastatin. The patient's blood glucose level is not well controlled, with a HbA1c of 8.6%. The patient's lipid profile also shows elevated levels of total cholesterol, LDL-C, and TG.\n\nGiven the patient's history of hypertension, heart failure, and diabetes, the most appropriate medication regimen for blood glucose control would be metformin and empagliflozin. Metformin is a first-line medication for type 2 diabetes and works by decreasing glucose production in the liver and increasing insulin sensitivity. Empagliflozin is a medication that helps the kidneys remove excess sugar from the bloodstream, which can help lower blood glucose levels. This combination therapy would help the patient achieve better blood glucose control and reduce the risk of complications associated with diabetes.\n\nAcarbose (①) is an alpha-glucosidase inhibitor that slows the absorption of carbohydrates from the gut, which can help lower blood glucose levels. However, it may not be the most appropriate choice for this patient due to the potential for gastrointestinal side effects and the patient's history of hypertension and heart failure.\n\nGlimepiride (②) is a sulfonylurea medication that stimulates the release of insulin from the pancreas. However, it may not be the most appropriate choice for this patient due to the risk of hypoglycemia and the patient's history of heart failure.\n\nInsulin lispro (③) is a rapid-acting insulin that can help lower blood glucose levels quickly. However, it may not be the most appropriate choice for this patient due to the risk of hypoglycemia and the patient's history of heart failure.\n\nRepaglinide (⑤) is a medication that stimulates the release of insulin from the pancreas. It may not be the most appropriate choice for this patient due to the risk of hypoglycemia and the patient's history of heart failure. Pioglitazone is a medication that increases insulin sensitivity and reduces inflammation. However, it may not be appropriate for this patient due to the risk of heart failure and the patient's history of hypertension.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 에제티미브(ezetimibe)\n\nExplanation:\n\nThe patient has been diagnosed with type 2 diabetes and is currently taking medications for hypertension, hyperlipidemia, and heart failure. The laboratory results show elevated levels of LDL-C and TG, and low levels of HDL-C, indicating a high risk of cardiovascular disease.\n\nEzetimibe is a cholesterol absorption inhibitor that can effectively reduce LDL-C levels by inhibiting the absorption of dietary cholesterol in the small intestine. It has been shown to reduce the risk of cardiovascular events in patients with type 2 diabetes and hyperlipidemia.\n\nWarfarin is an anticoagulant that is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation or mechanical heart valves. It is not indicated for the treatment of hyperlipidemia or cardiovascular disease.\n\nAmlodipine is a calcium channel blocker that is used to treat hypertension and angina. It has been shown to reduce the risk of cardiovascular events in patients with hypertension, but it is not specifically indicated for the treatment of hyperlipidemia.\n\nFurosemide is a diuretic that is used to treat edema and hypertension. It can also increase urinary excretion of potassium, which may be beneficial in patients with hypokalemia. However, it is not indicated for the treatment of hyperlipidemia or cardiovascular disease.\n\nGemfibrozil is a fibric acid derivative that is used to treat hyperlipidemia. It can reduce LDL-C and TG levels, but it may also increase HDL-C levels. However, it is not as effective as ezetimibe in reducing LDL-C levels and may have a higher risk of adverse effects.\n\nTherefore, based on the patient's medical history and laboratory results, ezetimibe is the most appropriate additional medication to prevent cardiovascular disease.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 메토프롤롤\n\nExplanation:\n메토프롤롤(metoprolol) is a beta-blocker, which can decrease the absorption of levothyroxine(레보티록신). Therefore, it is recommended to administer levothyroxine at least 2 hours apart from metoprolol to minimize the interaction.\n\nThe other options are not correct because:\n\n① 아스피린(aspirin) does not have a significant interaction with levothyroxine.\n\n② 로사르탄(losartan) does not have a significant interaction with levothyroxine.\n\n④ 황산제일철(ferrous sulfate) does not have a significant interaction with levothyroxine.\n\n⑤ 아토르바스타틴(atorvastatin) does not have a significant interaction with levothyroxine.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 4～8주</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 리네졸리드(linezolid)\n\nExplanation:\nThe patient's symptoms of frequent urination, dysuria, and pyuria suggest a urinary tract infection (UTI). The urinalysis results show the presence of nitrites, leukocyte esterase, and a large number of bacteria, which further support the diagnosis of UTI. The patient's history of recent antibiotic use and the absence of vaginal discharge suggest that the infection is likely to be caused by a gram-positive bacterium.\n\nLinezolid is an oxazolidinone antibiotic that is effective against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is also effective against some gram-negative bacteria, but its activity against Proteus species is limited. Therefore, linezolid is the most appropriate choice for treating this patient's UTI.\n\nNafcillin and rifaximin are not effective against gram-negative bacteria, and their activity against Proteus species is limited. Fosfomycin is a broad-spectrum antibiotic that is effective against both gram-positive and gram-negative bacteria, but its use is generally limited to more severe infections. Imipenem/cilastatin is a combination of a penicillin-derivative and a beta-lactamase inhibitor that is effective against a wide range of gram-negative bacteria, but its use is generally limited to more severe infections and is not the most appropriate choice for this patient's UTI.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ 트리메토프림/설파메톡사졸(trimethoprim/sulfamethoxazole)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 세포탁심(cefotaxime)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 베다퀼린(bedaquiline)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 이트라코나졸(itraconazole) 12주간 투여</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 횡문근융해증</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 세프타지딤(ceftazidime)+아미카신(amikacin)\n\nExplanation:\nThe patient has community-acquired pneumonia (CAP) with symptoms of fever, cough, sputum, and difficulty breathing. The patient's history of hypertension and diabetes mellitus increases the risk of complications. The patient's age and the presence of comorbidities also suggest that the infection may be severe and require broad-spectrum antibiotics.\n\nCeftazidime is a third-generation cephalosporin that covers common causative organisms of CAP, such as Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Amikacin is an aminoglycoside that provides coverage against Gram-negative bacteria, including Pseudomonas aeruginosa, which is often isolated from patients with CAP. The combination of ceftazidime and amikacin provides broad-spectrum coverage against both Gram-positive and Gram-negative bacteria, making it an appropriate choice for the treatment of severe CAP.\n\nThe other options are not as appropriate for the treatment of this patient's CAP:\n\n① Ciprofloxacin is a fluoroquinolone that provides coverage against Gram-negative bacteria, but it may not be effective against Streptococcus pneumoniae, which is a common cause of CAP.\n\n② Clarithromycin is a macrolide that provides coverage against Gram-positive bacteria, but it may not be effective against Gram-negative bacteria.\n\n④ Cefotaxime is a third-generation cephalosporin that provides coverage against Gram-positive and Gram-negative bacteria, but it may not be effective against Pseudomonas aeruginosa. Azithromycin is a macrolide that provides coverage against Gram-positive bacteria, but it may not be effective against Gram-negative bacteria.\n\n⑤ Vancomycin is a glycopeptide that provides coverage against methicillin-resistant Staphylococcus aureus (MRSA), but it may not be effective against other causative organisms of CAP. Cephradine and tobramycin are aminoglycosides that provide coverage against Gram-negative bacteria, but they may not be effective against Gram-positive bacteria.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 입원 중 23가 추가 접종\n\nExplanation:\nThe patient has already received PCV13 and PPSV23 vaccines, which cover the most common strains of pneumococcal bacteria. Given the patient's age and medical history, it is not necessary to administer additional vaccines. The current treatment plan should focus on managing the patient's symptoms and underlying conditions, such as hypertension and diabetes.\n\nTherefore, the correct answer is ③ 입원 중 23가 추가 접종 (Option 3: Additional vaccination with 23-valent pneumococcal vaccine during hospitalization).</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 아미트리프틸린(amitriptyline)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 고칼슘혈증</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 프레가발린\n\nExplanation:\n\nThe patient's history of major depressive disorder, seizure disorder, and hypertension suggests that the causative drug for the osteoporosis could be pregabalin. Pregabalin is known to cause osteoporosis as a side effect, especially when used for prolonged periods. The other options, sertraline, phenytoin, and amlodipine, are less likely to cause osteoporosis as a side effect. Aripiprazole is not typically associated with osteoporosis. Therefore, option ④ 프레가발린 (pregabalin) is the most likely answer.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 클로자핀(clozapine)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 벤즈트로핀(benztropine)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 플루옥세틴(fluoxetine)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 쿠에티아핀(quetiapine)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 카르비도파/레보도파를 공복에 복용\n\nExplanation:\n\nThe patient's symptoms of tremors in the right arm and hand, which have been gradually worsening over the past 2 weeks, suggest a possible no-on response to levodopa. This is a common complication in patients with Parkinson's disease, especially those who have been taking levodopa for a long time.\n\nIn this case, the most appropriate action would be to add a COMT inhibitor, such as entacapone or tolcapone, to the patient's regimen. This would help to increase the levels of levodopa in the brain and improve its efficacy.\n\nTherefore, the correct answer is ③ 카르비도파/레보도파를 공복에 복용 (Add entacapone or tolcapone to the patient's regimen).</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 쿠에티아핀(quetiapine)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 셀레콕시브(celecoxib) 캡슐</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 에타너셉트를 아달리무맙(adalimumab)으로 변경</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 알렌드론산(alendronate)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 탐스로신(tamsulosin)+타다라필(tadalafil)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 메드록시프로게스테론(medroxyprogesterone)\n\nExplanation:\n\nThe patient is presenting with symptoms of menopause, including hot flashes and night sweats, and has a history of total hysterectomy. Her mother has a history of osteoporosis. The patient is currently taking calcium and vitamin D supplements.\n\nBased on the patient's history and symptoms, the most appropriate hormone therapy would be medroxyprogesterone, which is a synthetic progesterone that can help alleviate hot flashes and prevent osteoporosis. It is also suitable for patients who have had a hysterectomy.\n\nThe other options are not the most appropriate for this patient's condition:\n\n① Estropipate is a estrogen preparation that is not suitable for patients who have had a hysterectomy.\n\n② Dydrogesterone is a synthetic progesterone that is not as effective as medroxyprogesterone in preventing osteoporosis.\n\n④ Estradiol hemihydrate/dydrogesterone is a combination of estrogen and progesterone that is not necessary for this patient's condition.\n\n⑤ Estradiol valerate/cyproterone acetate is a combination of estrogen and an anti-androgen that is not necessary for this patient's condition.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ 바제독시펜(bazedoxifene)\n\nExplanation:\n\nThe patient has a history of total hysterectomy and is experiencing vasomotor symptoms such as hot flashes and night sweats. The patient's mother has a history of osteoporosis, and the patient is currently taking calcium/vitamin D supplements. The patient's symptoms worsened after 3 years of hormone therapy, and the therapy was discontinued.\n\nBased on the patient's history and symptoms, the most appropriate medication to improve the patient's postmenopausal symptoms would be bazedoxifene. Bazedoxifene is a selective estrogen receptor modulator (SERM) that has been shown to reduce the risk of osteoporosis and improve vasomotor symptoms in postmenopausal women. It is also known to have a positive effect on bone density, which is important for patients with a family history of osteoporosis.\n\nTamoxifen (①) is a selective estrogen receptor modulator (SERM) that is used to treat breast cancer and reduce the risk of osteoporosis. However, it may not be the best choice for this patient as it may not effectively address the patient's vasomotor symptoms.\n\nSolifenacin (②) is an anticholinergic medication that is used to treat overactive bladder. It is not appropriate for this patient's symptoms.\n\nMirabegron (③) is a beta-3 adrenergic agonist that is used to treat overactive bladder. It is not appropriate for this patient's symptoms.\n\nEscitalopram (⑤) is a selective serotonin reuptake inhibitor (SSRI) that is used to treat depression and anxiety. It may not be the best choice for this patient as it may not effectively address the patient's vasomotor symptoms.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 올라파립(olaparib)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 메스나(mesna)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 펨브롤리주맙(pembrolizumab)\n\nExplanation:\n\nThe patient has been diagnosed with metastatic colorectal cancer (mCRC) and is planned to receive FOLFOX chemotherapy. The patient's KRAS, NRAS, and BRAF mutation status has been tested, and the results show that KRAS and NRAS are positive, while BRAF is negative. Additionally, the patient's microsatellite instability (MSI) status is unknown.\n\nBased on the patient's mutation status and MSI status, pembrolizumab (Option ③) is the most appropriate additional chemotherapy drug to consider. Pembrolizumab is a PD-1 inhibitor that has been shown to be effective in patients with KRAS-mutated mCRC, particularly in those with high microsatellite instability (MSI-H) tumors. Although the patient's MSI status is unknown, pembrolizumab can still be considered as a potential treatment option.\n\nCetuximab (Option ①) is an EGFR inhibitor that has been shown to be effective in patients with KRAS wild-type mCRC. However, its efficacy in patients with KRAS-mutated mCRC is limited, and it may not be the best choice for this patient.\n\nBevacizumab (Option ②) is a VEGF inhibitor that has been shown to be effective in patients with mCRC, but its use in KRAS-mutated mCRC is not well established.\n\nZiv-aflibercept (Option ④) is a VEGF-A, VEGF-B, and PlGF inhibitor that has been shown to be effective in patients with mCRC, but its use in KRAS-mutated mCRC is not well established.\n\nTrifluridine/tipiracil (Option ⑤) is a DNA synthesis inhibitor that has been shown to be effective in patients with mCRC, but its use in KRAS-mutated mCRC is not well established.\n\nTherefore, based on the patient's mutation status and MSI status, pembrolizumab is the most appropriate additional chemotherapy drug to consider.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nThe patient has colon cancer with severe neuropathy, which suggests that they may have a deficiency in folate. Folate is important for the synthesis of DNA and the maintenance of healthy cells. The chemotherapy regimen that would be most appropriate for this patient would be 5-fluorouracil (5-FU) + leucovorin (LV) + radiation therapy. This regimen takes advantage of the fact that 5-FU is a folate analogue that can be converted to the active form by the enzyme thymidylate synthase, which is overexpressed in many cancer cells. Leucovorin is a folate derivative that can enhance the activity of 5-FU by increasing the levels of the active form. Radiation therapy can also be effective in treating colon cancer, especially when combined with chemotherapy.\n\nThe other options are not the most appropriate for this patient's condition:\n\n① Capecitabine + oxaliplatin: This regimen is not the most appropriate for this patient because capecitabine is a prodrug that is converted to 5-FU in the body, and oxaliplatin is a platinum-based drug that can cause neurotoxicity, which may exacerbate the patient's existing neuropathy.\n\n② 5-FU + LV: This regimen is effective for colon cancer, but it does not take into account the patient's folate deficiency.\n\n④ 5-FU + LV + irinotecan: This regimen is effective for colon cancer, but irinotecan can cause severe diarrhea and neutropenia, which may be difficult for the patient to tolerate given their age and neuropathy.\n\n⑤ 5-FU + LV + oxaliplatin: This regimen is not the most appropriate for this patient because, as mentioned earlier, oxaliplatin can cause neurotoxicity, which may exacerbate the patient's existing neuropathy.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 그라니세트론(granisetron)\n\nExplanation:\nGranisetron is a serotonin receptor antagonist that is commonly used to prevent chemotherapy-induced nausea and vomiting. It works by blocking the action of serotonin on the nerve cells in the gut that trigger nausea and vomiting. In this case, the patient has experienced severe nausea and vomiting during the first cycle of chemotherapy, and is anxious about the second cycle. Administering granisetron before the second cycle can help prevent or reduce the severity of nausea and vomiting, alleviating the patient's anxiety and improving their quality of life.\n\nThe other options are not appropriate for this scenario:\n\n① Naloxone is an opioid receptor antagonist that reverses the effects of opioids. It is not relevant to the patient's condition.\n\n② Lorazepam is a benzodiazepine that can help with anxiety, but it is not specifically used to prevent nausea and vomiting.\n\n③ Aprepitant is a neurokinin-1 receptor antagonist that is used to prevent chemotherapy-induced nausea and vomiting. However, it is not as effective as granisetron in preventing acute nausea and vomiting.\n\n⑤ Dexamethasone is a corticosteroid that can help with nausea and vomiting, but it is not as effective as granisetron in preventing chemotherapy-induced nausea and vomiting. Additionally, it has more side effects than granisetron.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 동맥혈가스분압</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 시타라빈(cytarabine)+히드록시우레아(hydroxyurea)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 종양용해증후군(tumor lysis syndrome)\n\nExplanation:\n\nAllopurinol is a xanthine oxidase inhibitor that is used to prevent or treat tumor lysis syndrome (TLS), a potentially life-threatening complication that can occur during cancer treatment. TLS occurs when large numbers of cancer cells are rapidly killed, leading to the release of intracellular contents, including potassium, phosphate, and uric acid, into the bloodstream. This can cause a range of symptoms, including nausea, vomiting, diarrhea, and muscle weakness, as well as electrolyte imbalances and kidney damage.\n\nIn the case of the 42-year-old male patient with acute promyelocytic leukemia (APL), allopurinol was prescribed to prevent TLS. The patient's laboratory results show elevated levels of white blood cells, hemoglobin, and platelets, which are consistent with APL. The patient's ECOG performance status is 1, indicating that they are able to carry out normal activities without restriction.\n\nTherefore, the correct answer is ③ 종양용해증후군(tumor lysis syndrome).</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 토파시티닙(tofacitinib)</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 라타노프로스트(latanoprost) 점안제</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 백혈구감소증</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 헤파린(heparin)</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 효능군 중복 처방\n\nExplanation:\n\nThe patient has been prescribed both naproxen/esomeprazole and aceclofenac, which are both nonsteroidal anti-inflammatory drugs (NSAIDs). This is a duplication of therapy, as both drugs have similar mechanisms of action and are used to treat similar conditions, such as pain and inflammation. This increases the risk of adverse effects, such as gastrointestinal ulcers and renal impairment, and may also reduce the effectiveness of each drug. Therefore, option ④ 효능군 중복 처방 is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 동일성분 중복\n\nExplanation:\nThe patient is taking tacrolimus, mycophenolate mofetil, and voriconazole, which are all immunosuppressants. Tacrolimus and mycophenolate mofetil are both metabolized by the enzyme CYP3A4, and voriconazole is a potent inhibitor of CYP3A4. This may lead to increased levels of tacrolimus and mycophenolate mofetil, increasing the risk of adverse effects such as nephrotoxicity, hyperkalemia, and infection. Therefore, the drug-related problem in this case is the potential for drug-drug interactions and the risk of adverse effects due to the co-administration of these drugs.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ Annals of Pharmacotherapy.\n\nExplanation:\n\nThe question asks for the appropriate resource to consult for information on the dosing of voriconazole in patients with renal impairment. Annals of Pharmacotherapy is a peer-reviewed journal that publishes articles on drug therapy and pharmacotherapy, including dosing recommendations and clinical trials. It would be an appropriate resource to consult for information on the dosing of voriconazole in patients with renal impairment.\n\nDRUGDEX is a drug interaction database that provides information on drug interactions, but it may not have detailed information on drug dosing in specific patient populations. The Lancet is a medical journal that publishes original research articles and review articles on various medical topics, but it may not have detailed information on drug dosing in specific patient populations. Basic Skills in Interpreting Laboratory Data is a book that provides an introduction to laboratory tests and their interpretation, but it may not have information on drug dosing. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk is a book that provides information on the risks of various drugs during pregnancy and lactation, but it may not have information on drug dosing in patients with renal impairment.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe patient visited a doctor on January 17th and received a prescription. However, when they visited a pharmacy on January 20th, they were informed that the prescription could not be filled. The reason for this is that the prescription had expired, as the validity period for prescriptions in Korea is 3 days (72 hours) from the date of issuance. Therefore, option ③, \"약국 조제가능 기간이 경과되었다\" (The prescription has expired), is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\nThe patient is prescribed lamotrigine and levetiracetam, which are both enzyme-inducing drugs. Therefore, it is necessary to consider the possibility of drug interaction between the two medications. Levetiracetam is metabolized by CYP3A4, and lamotrigine is metabolized by CYP3A4 and CYP2C9. Co-administration of these drugs may increase the metabolism of levetiracetam and reduce its efficacy.\n\nTo minimize the risk of drug interaction, it is recommended to separate the administration times of lamotrigine and levetiracetam. Therefore, option ③, \"Request a prescription change to separate the administration times of lamotrigine and levetiracetam,\" is the best answer.\n\nOption ①, \"Improve the patient's compliance by changing the administration time to morning,\" may not be effective in avoiding the drug interaction.\n\nOption ②, \"Consider the patient's age and adjust the dose of lamotrigine,\" may not be necessary as the patient's age is not provided in the scenario.\n\nOption ④, \"Consider the patient's economic conditions and change the prescription to a 30-day supply,\" may not be relevant to the patient's medical treatment.\n\nOption ⑤, \"Lamotrigine and levetiracetam are contraindicated, so request a prescription change,\" is incorrect as there is no contraindication between the two medications.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 이소소르비드질산염 40 mg 서방정</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 슈도에페드린\n\nReason:\n\nThe patient is breastfeeding her 7-month-old baby, and the medication that is most likely to be appropriate for her is pseudoephedrine (슈도에페드린). This medication is a decongestant and is commonly used to relieve nasal congestion. It is also excreted in breast milk, but the amount excreted is likely to be small and not expected to cause adverse effects in the baby.\n\nThe other options are not appropriate for the patient because:\n\n* Vitamin C (비타민C) is not a medication that is typically prescribed for nasal congestion.\n* Amoxicillin (아목시실린) is an antibiotic and may not be appropriate for a viral infection such as the common cold.\n* Acetaminophen (아세트아미노펜) may be appropriate for relieving pain and fever, but it is not a decongestant and will not relieve nasal congestion.\n* The patient does not have a cough, so there is no need for a cough medicine such as 생리식염수비강액.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 용량주의\n\nExplanation:\n\nThe patient is prescribed simvastatin 20 mg and olmesartan 20 mg, both of which are medications that require dose adjustments in elderly patients. Therefore, the warning label should indicate that the dosages should be adjusted according to the patient's renal function, which is the case for both medications.\n\nSimvastatin is metabolized by the liver and excreted by the kidneys, and its dosage should be reduced in patients with renal impairment. Olmesartan is also metabolized by the liver and excreted by the kidneys, and its dosage should be reduced in patients with severe renal impairment.\n\nTherefore, the correct answer is ③ 용량주의, which means \"dose adjustment required\" in Korean.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 당일 투약직전 측정된 겐타마이신 혈중농도</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 덱사메타손(dexamethasone)\n\nExplanation:\n\nDexamethasone is a corticosteroid that is commonly used to prevent or treat chemotherapy-induced hypersensitivity reactions, including fluid retention and anaphylaxis. It is also used to reduce inflammation and swelling in the body. In this case, dexamethasone can be used to prevent fluid retention and anaphylaxis during docetaxel chemotherapy.\n\nThe other options are not appropriate for preventing fluid retention and anaphylaxis during docetaxel chemotherapy:\n\n* Mannitol (①) is an osmotic diuretic that is used to reduce intracranial pressure and promote diuresis. It is not used to prevent fluid retention or anaphylaxis during chemotherapy.\n* Leucovorin (②) is a folinic acid derivative that is used to enhance the efficacy of 5-fluorouracil chemotherapy. It is not used to prevent fluid retention or anaphylaxis during docetaxel chemotherapy.\n* Furosemide (③) is a diuretic that is used to promote diuresis and reduce fluid retention. However, it is not used to prevent anaphylaxis during chemotherapy.\n* Chlorpheniramine (⑤) is an antihistamine that is used to treat allergic reactions. It is not used to prevent fluid retention or anaphylaxis during chemotherapy.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 4 mL</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ②\n\nExplanation:\n\nThe patient has been prescribed risedronate (Actonel) 150 mg once daily for 30 days, and calcium carbonate/cholecalciferol (Tums/Vitamin D) 250 mg/10 mg once daily for 30 days. The prescriber has specified that the patient should take the medications for 30 days.\n\nThe question asks what information is necessary to be clarified with the prescriber. The correct answer is ②, \"리세드로네이트 용량용법\" (risedronate dosage and administration). This is because the prescriber has specified a dosage of 150 mg once daily for 30 days, but the package insert for risedronate recommends a dosage of 30-60 mg/day for osteoporosis treatment. Therefore, it is necessary to clarify with the prescriber whether the dosage of 150 mg once daily is appropriate for the patient's condition.\n\nThe other options are not relevant to the given situation:\n\n① 리세드로네이트 연령금기 (risedronate age limit): The patient is 55 years old, which is within the age range for which risedronate is approved. Therefore, this information is not necessary to be clarified with the prescriber.\n\n③ 탄산칼슘/콜레칼시페롤 연령금기 (calcium carbonate/cholecalciferol age limit): The patient is 55 years old, which is within the age range for which calcium carbonate/cholecalciferol is approved. Therefore, this information is not necessary to be clarified with the prescriber.\n\n④ 탄산칼슘/콜레칼시페롤 용량용법 (calcium carbonate/cholecalciferol dosage and administration): The prescriber has specified a dosage of 250 mg/10 mg once daily for 30 days, which is within the recommended range for calcium carbonate/cholecalciferol. Therefore, this information is not necessary to be clarified with the prescriber.\n\n⑤ 리세드로네이트와 탄산칼슘 병용금기 (risedronate and calcium carbonate interaction): While it is important to consider potential interactions between medications, there is no significant interaction between risedronate and calcium carbonate/cholecalciferol. Therefore, this information is not necessary to be clarified with the prescriber.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe patient has been prescribed risedronate, a bisphosphonate, for the treatment of osteoporosis. It is important to note that bisphosphonates should be taken on an empty stomach to minimize gastrointestinal irritation and maximize absorption. Therefore, option ①, which suggests taking the medication with milk or green tea, is not appropriate.\n\nOption ② suggests taking the risedronate and calcium carbonate/cholecalciferol at the same time in the morning. However, this is not the best option as risedronate should be taken on an empty stomach, while calcium carbonate/cholecalciferol can be taken with food to minimize gastrointestinal irritation.\n\nOption ③ suggests taking the risedronate after meals to prevent gastrointestinal irritation. This is the best option as it minimizes the risk of gastrointestinal irritation and maximizes the absorption of the medication.\n\nOption ④ suggests stopping the medication immediately if the patient experiences nausea or vomiting. While it is important to monitor the patient for adverse effects, stopping the medication immediately may not be necessary in all cases.\n\nOption ⑤ suggests that the patient should remain upright for 30 minutes after taking the medication. This is not a necessary precaution for bisphosphonates, and there is no evidence to support this recommendation.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 아미노필린(aminophylline) 정</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 6 mg/kg/day</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 타펜타돌(tapentadol)</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 에토포시드(etoposide)</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 시클로펜톨레이트(cyclopentolate)</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 파모티딘(famotidine) 정</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nThe correct answer is ③. The patient's test result shows a positive pregnancy test, indicating that she is pregnant. Therefore, the appropriate counseling content would be to inform the patient of the positive test result and provide guidance on prenatal care and the next steps to take. Option ③, \"임신진단검사 결과 양성임,\" is the best match for this scenario.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 이버멕틴/파모산피란텔(ivermectin/pyrantel pamoate)</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 운전이나 위험한 기계 조작을 피해야 함\n\nExplanation: Cyclosporine is an immunosuppressant drug that can cause drowsiness, dizziness, and impaired cognitive function. Therefore, it is important to advise patients to avoid driving or operating heavy machinery after taking the drug. This is the best answer among the options provided.\n\nOption ① is incorrect because the time of administration (4 pm or earlier) is not relevant to the patient's safety.\n\nOption ② is incorrect because placing the tablet under the tongue and allowing it to dissolve does not affect the drug's efficacy or safety.\n\nOption ③ is incorrect because there is no need to rinse the mouth with water after taking cyclosporine.\n\nOption ⑤ is incorrect because grapefruit juice can actually increase the blood concentration of cyclosporine, which may lead to adverse effects.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 정기적인 혈액응고검사가 필수적이다.\n\nExplanation:\n\nThe patient has been diagnosed with atrial fibrillation and flutter, and has been prescribed warfarin. It is important to monitor the patient's International Normalized Ratio (INR) regularly to ensure that the drug is working effectively and safely. The INR measures the blood's ability to clot, and warfarin works by inhibiting the production of clotting factors. Regular monitoring of the INR allows healthcare professionals to adjust the dosage of warfarin as needed to maintain a therapeutic level of anticoagulation.\n\nTherefore, option ③, \"정기적인 혈액응고검사가 필수적이다\" (regular blood clotting tests are essential) is the correct answer.\n\nOption ①, \"동일한 용량으로 평생 복용한다\" (taking the same dose for life) is not correct, as the dosage of warfarin may need to be adjusted over time based on the patient's response to the drug.\n\nOption ②, \"비타민D(vitamin D) 섭취를 주의한다\" (pay attention to vitamin D intake) is not directly related to the patient's condition or treatment.\n\nOption ④, \"임신 여부와 상관없이 복용할 수 있다\" (can be taken regardless of pregnancy status) is not correct, as warfarin is contraindicated in pregnancy due to the risk of fetal bleeding.\n\nOption ⑤, \"약물효과가 나타나면 소변색이 적갈색으로 변한다\" (the urine color will change to yellow or orange when the drug takes effect) is not a reliable indicator of the drug's effectiveness, and is not a standard method of monitoring warfarin therapy.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 스피로노락톤(spironolactone)</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ①\n\nExplanation:\n\nThe correct answer is ① 사용 기간 동안 흡입제를 냉장보관 한다.\n\nFluticasone is a medication that is used to treat various respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD). The medication is administered through an inhaler, and it is important to follow the instructions provided by the physician or pharmacist to ensure proper use and effectiveness.\n\nOption ① states that the medication should be stored in a refrigerator during the usage period. This is correct, as fluticasone is a temperature-sensitive medication that should be stored between 2°C and 8°C to maintain its potency and prevent degradation.\n\nOption ② is incorrect, as the medication should not be discarded if the expiration date has passed. The expiration date is the last date that the medication can be used safely and effectively, and it is important to follow the expiration date to ensure patient safety.\n\nOption ③ is also incorrect, as the medication should not be used if the patient does not feel the taste of the medication. The taste of the medication is not a reliable indicator of its effectiveness, and it is important to use the medication as directed by the physician or pharmacist.\n\nOption ④ is incorrect, as there is no need to hold the breath for 10 seconds after using the medication. The medication should be used as directed, and there is no need to hold the breath to ensure its effectiveness.\n\nOption ⑤ is incorrect, as it is not necessary to drink water or avoid eating after using the medication. The medication can be used with or without food, and there is no need to drink water to ensure its effectiveness.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 보중익기탕(補中益氣湯)</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 품질관리기준서</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 구획</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 10^-9</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ 제품의 사용상 주의사항</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 동시적 밸리데이션</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 용출기(dissolution tester)</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ 이동압력은 세공을 채우는 액체의 표면장력에 반비례한다.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① ICH</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④\n\nThe correct answer is ④. The question asks for the most appropriate content to be included in a press release announcing the recall of a drug product. The correct answer is \"2등급 위해성 의약품의 회수계획을 자사의 홈페이지에 공고하였다.\" This answer choice indicates that the company has announced the recall plan for the drug product on their homepage, which is the most appropriate channel for disseminating information about a recall.\n\nThe other answer choices are not correct for the following reasons:\n\n① is incorrect because it refers to a situation where the drug product has been evaluated as having a severe risk of harm, which is not the scenario described in the question.\n\n② is incorrect because it refers to a situation where the packaging of the drug product has been damaged, which is not the reason for the recall in the scenario described in the question.\n\n③ is incorrect because it refers to a situation where the effectiveness of the drug product has not been proven, which is not the reason for the recall in the scenario described in the question.\n\n⑤ is incorrect because it refers to a situation where the drug product has caused temporary side effects, which is not the reason for the recall in the scenario described in the question.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ①</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 멸균주사용수</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ②\n\nExplanation:\n\nThe correct answer is ②, \"가혹시험 결과를 토대로 의약품 유통기간을 설정한다.\"\n\nThe stability test for pharmaceutical products is conducted to determine the shelf life of the product. The shelf life is determined based on the results of the stability test, which evaluates the physical, chemical, and biological stability of the product over time. Therefore, option ② is the correct answer.\n\nOption ①, \"규정된 보관조건은 40℃/75% 상대습도이다,\" is incorrect because it refers to the storage conditions for the product, not the shelf life.\n\nOption ③, \"검체는 원칙적으로 포장하지 않은 상태에서 시험한다,\" is incorrect because it refers to the fact that the sample should be tested in its original state, without any packaging.\n\nOption ④, \"시험빈도는 1년째는 3개월마다, 그 이후에는 6개월마다 한다,\" is incorrect because it refers to the frequency of testing, not the shelf life.\n\nOption ⑤, \"가혹시험에서 현저한 변화가 생기면 중간조건에서 추가 시험한다,\" is incorrect because it refers to the fact that additional testing may be conducted if significant changes are observed during the stability test.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 밀폐용기</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 순도시험</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 테트라사이클린염산염</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 흰쥐 – 혈당</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 1</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ ST 전략\n\nExplanation:\n\nBased on the SWOT analysis, A Company's internal situation is relatively weak, with outdated technology. However, the external environment presents an opportunity for growth, with an aging population increasing the demand for the pharmaceutical products A Company sells.\n\nTherefore, the most appropriate strategy for A Company would be to focus on improving its technology and product offerings to meet the changing needs of the market. This can be achieved through strategic partnerships and investments in research and development.\n\nOption ③ ST 전략 (ST Strategy) is the best choice, as it aligns with the company's strengths (S) and takes advantage of the opportunities (O) presented by the external environment.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ②\n\nExplanation:\n\nThe correct answer is ②, \"당좌자산과 유동부채의 비율로 나타낸다.\"\n\n유동비율(Current Ratio) is a financial ratio that measures a company's ability to pay its short-term debts. It is calculated by dividing the current assets by current liabilities. The higher the ratio, the more capable the company is of paying its short-term debts.\n\nTherefore, option ②, \"당좌자산과 유동부채의 비율로 나타낸다,\" is the correct answer. It describes the current ratio as a measure of the ratio of current assets to current liabilities.\n\nOption ①, \"포괄손익계산서를 통하여 산출한다,\" is incorrect because it refers to the calculation of comprehensive income, which is not related to the current ratio.\n\nOption ③, \"값이 크면 유동자산에 대한 투자가 상대적으로 낮음을 뜻한다,\" is also incorrect because it suggests that a high current ratio means that the company is investing less in current assets, which is not necessarily true.\n\nOption ④, \"값이 작으면 기한 내에 유동 부채 상환에 문제가 있음을 뜻한다,\" is incorrect because it suggests that a low current ratio means that the company will have difficulty repaying its short-term debts, which is not necessarily true.\n\nOption ⑤, \"약국이 얼마나 자산을 효율적으로 사용하는지 측정하는 지표이다,\" is incorrect because it refers to the efficiency of asset utilization, which is not related to the current ratio.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 5천만 원</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\nThe correct answer is ③, \"총재고관리비용을 최소화할 수 있는 1회 최적주문량을 산출한다.\"\n\nThe question is asking for the most appropriate description of an economic order quantity (EOQ) model that aims to effectively manage inventory. The EOQ model is a mathematical formula used to determine the optimal quantity of goods to order in a single batch, taking into account factors such as the cost of placing an order, the cost of holding inventory, and the cost of stockouts.\n\nOption ③ accurately describes the EOQ model, as it aims to minimize the total inventory management cost, which includes both the cost of placing an order and the cost of holding inventory. The EOQ model helps to determine the optimal order quantity that balances these two costs, ensuring that the inventory level is sufficient to meet customer demand while avoiding excessive inventory holdings.\n\nOption ① is incorrect because it only considers the cost of placing an order and does not take into account the cost of holding inventory. Option ② is also incorrect because it only considers the cost of holding inventory and does not take into account the cost of placing an order. Option ④ is incorrect because it does not consider the cost of placing an order or the cost of holding inventory, but rather focuses on the timing of orders and deliveries. Option ⑤ is incorrect because it considers the cost of holding inventory and the cost of stockouts, but does not take into account the cost of placing an order.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 직무충실화(job enrichment)</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 포괄수가제</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④, \"의료급여 진료비 지급 및 자격관리 – 보건복지부.\"\n\nThe question asks which organization is responsible for managing the health insurance system in Korea and its related policies. The answer is the Ministry of Health and Welfare, which is responsible for managing the national health insurance system, including the payment of medical fees and the management of qualifications for healthcare providers.\n\nThe other options do not accurately reflect the role of the Ministry of Health and Welfare in managing the health insurance system:\n\n①, \"요양급여 적정성 평가 – 국민건강보험공단\" refers to the evaluation of the appropriateness of medical fees, which is not directly related to the management of the health insurance system.\n\n②, \"건강보험 관련 정책 심의 ∙ 의결 – 질병관리청\" refers to the deliberation and decision-making process for health insurance policies, which is not exclusively handled by the Ministry of Health and Welfare.\n\n③, \"의약품의 보험약가 협상 – 식품의약품안전처\" refers to the negotiation of insurance premiums for pharmaceuticals, which is not directly related to the management of the health insurance system.\n\n⑤, \"건강보험 의약품 보험등재 결정 – 건강보험심사평가원\" refers to the evaluation and decision-making process for the listing of pharmaceuticals on the health insurance coverage list, which is not exclusively handled by the Ministry of Health and Welfare.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④\n\nExplanation:\n\nWhen a pharmacist dispenses a prescription drug, the health insurance fee that the pharmacist can receive is the \"의약품관리료\" (prescription drug management fee). This fee is calculated based on the number of prescription drugs dispensed, and it is listed on the prescription drug management fee table.\n\nTherefore, the correct answer is ④ 처방전에 기재된 약 품목수로 산정한 의약품관리료.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 위험군 선택\n\nExplanation:\n\nThe question describes a situation where A, who works in a company that uses a large amount of toxic substances, is rejected by multiple insurance companies when trying to join a cancer insurance policy. This scenario illustrates the tendency of insurance companies to avoid high-risk individuals, which is known as \"risk selection\" or \"adverse selection.\"\n\nTherefore, the correct answer is ④ 위험군 선택 (risk selection).</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 약가 재평가 제도</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 실거래가 상환제도</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 상대위험도(relative risk)＝(10/15)/(1,000/2,500)</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ①</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 이상지질혈증 치료제의 처방전 발급을 위한 외래방문 교통비</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 자율성 존중 원칙 – 선행의 원칙</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 환자의 혈중 약물 농도 측정</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ 300명</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ④\n\nExplanation:\nThe standardized mortality ratio (SMR) is a measure of the relative risk of death in a population compared to a reference population. It is calculated as the observed number of deaths in the population divided by the expected number of deaths in the population, based on the age-specific mortality rates of the reference population.\n\nIn this case, the SMR for colorectal cancer in the A region is (300/2,200,000) x 100,000 = 13.61. This means that the risk of death from colorectal cancer in the A region is 13.61 times higher than the risk in the standard population.\n\nTherefore, option ④ \"The value is less than 1, so the risk of death from colorectal cancer in the A region is lower than the risk in the standard population\" is incorrect. The correct answer is option ④ \"The value is greater than 1, so the risk of death from colorectal cancer in the A region is higher than the risk in the standard population.\"</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nAccording to the question, the correct answer is ③. The statement \"약국개설자는 한약제제를 취급하는 도매상 허가를 받을 수 없다\" is incorrect.\n\nIn Korea, a licensed pharmacist (약사) is allowed to handle and sell Korean traditional herbal medicines (한약제제) that have been approved by the Ministry of Food and Drug Safety. However, a pharmacist is not allowed to manufacture or produce Korean traditional herbal medicines. Therefore, the statement ③ is incorrect.\n\nThe other options are also incorrect for the following reasons:\n\n①: This statement is incorrect because a licensed pharmacist is not allowed to open a package of Korean traditional herbal medicine and sell it.\n\n②: This statement is correct, but it does not relate to the question.\n\n④: This statement is incorrect because a licensed pharmacist is not allowed to manage the production process of Korean traditional herbal medicines.\n\n⑤: This statement is incorrect because a person who has obtained a license to manufacture Korean traditional herbal medicines is not allowed to sell them directly to consumers.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\n\nAccording to the Pharmacist Licensing Examination, the correct answer is ③. The question asks for the necessary criteria for a person who wants to open a pharmacy and register it. The correct answer is that the person must have a warehouse that can store medications separately.\n\nThe other options are not correct because:\n\n① states that the person needs to have the necessary equipment for compounding, which is not directly related to the question.\n\n② requires the person to notify the local pharmacist association in advance, which is not a necessary criterion for registering a pharmacy.\n\n④ mentions the need for a passage to be established between the pharmacy and medical facilities, which is not a requirement for registering a pharmacy.\n\n⑤ states that a person who has had their registration canceled due to a violation of the Pharmacist Law cannot register again within three months, which is not related to the question.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 상호작용을 포함한 부작용</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④\n\nExplanation:\n\nThe question asks which scenario does not constitute a violation of the Pharmaceutical Affairs Act or medical ethics.\n\n① Giving a prescription to a medical institution's founder in exchange for a gift is a violation of the Pharmaceutical Affairs Act, as it could be seen as a form of bribery.\n\n② Offering a 10% discount on medication to a specific medical institution's founder is also a violation, as it could be seen as a form of favoritism or discrimination.\n\n③ Inducing a patient to visit a specific pharmacy for medication is a violation, as it could be seen as a form of coercion or manipulation.\n\n④ Prescribing medication that can only be prepared at a specific pharmacy is not a violation, as it is a legitimate medical decision made by the physician.\n\n⑤ Providing information about nearby pharmacies to a patient is not a violation, as it is a legitimate service provided by the physician to help the patient access medical care.\n\nTherefore, the correct answer is ④.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 안전상비의약품 판매자</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nAccording to the Pharmacist Licensing Examination question, the correct answer is ③ 파산선고를 받고 복권되지 아니한 자.\n\nThis answer choice refers to a person who has been declared bankrupt but has not been rehabilitated. According to the Korean Pharmaceutical Affairs Act, a person who has been declared bankrupt and has not been rehabilitated is not eligible to obtain a wholesaler license for pharmaceuticals.\n\nTherefore, option ③ is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nAccording to the question, the correct answer is ③, which states that the manufacturer is responsible for thoroughly carrying out the renewal business of the pharmaceutical product's marketing authorization. This means that the manufacturer is responsible for ensuring that the marketing authorization for their product is up to date and that any necessary renewals are completed in a timely manner.\n\nThe other options do not accurately reflect the responsibilities of the manufacturer regarding the renewal of the marketing authorization for their pharmaceutical product:\n\n① states that the validity period of the marketing authorization is 3 years, but this does not address the manufacturer's responsibilities regarding renewal.\n\n② states that the raw material supplier is not subject to the renewal of the marketing authorization, but this does not address the manufacturer's responsibilities regarding renewal.\n\n④ states that the validity period of the marketing authorization for a pharmaceutical product that is subject to re-examination starts from the date of the re-examination, but this does not address the manufacturer's responsibilities regarding renewal.\n\n⑤ states that the manufacturer cannot renew the marketing authorization for a pharmaceutical product that has not been manufactured during the validity period of the authorization, but this does not accurately reflect the manufacturer's responsibilities regarding renewal.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③, \"의약품특허권 등재사항 변경의 신청 – 특허권등재자.\"\n\nAccording to the question, the applicant is requesting a change in the registered matters of a patented pharmaceutical product. This falls under the jurisdiction of the Intellectual Property Office, and the applicant should submit the request to the patent holder. Therefore, option ③ is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nExplanation:\n\nAccording to the Pharmacy Act, the sale of veterinary drugs is regulated by the Ministry of Agriculture, Forestry and Fisheries. However, in the case of an emergency order by the mayor or governor for the purpose of disease control, the sale of veterinary drugs without a prescription from a veterinarian is allowed. Therefore, option ④ is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nAccording to the Pharmacist Licensing Examination question, if a pharmacist suspects that a patient has been harmed by a drug and the case is serious enough to be reported to the authorities, they should report it to the Disease Control and Prevention Agency (③). This is because the agency is responsible for managing and preventing the spread of diseases, including adverse reactions to drugs.\n\nTherefore, options ①, ②, ④, and ⑤ are not the correct answers, as they are not related to the reporting of adverse drug reactions.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 마약류관리자</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nAccording to the question, the pharmacist is asking about the cases where a medical professional can administer drugs to a drug addict. The correct answer is ③, which states that a medical professional can administer drugs to a drug addict for the purpose of alleviating withdrawal symptoms.\n\nThe other options are not correct because:\n\n① refers to the case where the drug is administered after a deliberation by the Drug Safety Management Committee, which is not related to the context of drug addiction.\n\n② refers to the case where the drug is administered with the permission of the mayor or governor, which is also not related to the context of drug addiction.\n\n④ refers to the case where a prescription is issued for the purpose of treating drug addiction, but it does not specify that the drug is administered to alleviate withdrawal symptoms.\n\n⑤ refers to the case where a medical professional provides drugs for the purpose of treating drug addiction, but it does not specify that the drug is administered to alleviate withdrawal symptoms.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 흡연자를 위한 흡연실 설치 금지</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nAccording to the \"보건의료기본법\" (Basic Law on Health and Medical Care), the responsibility of healthcare professionals, including pharmacists, is to protect the health and well-being of the population. This means that they must take necessary measures to prevent harm to patients and ensure their safety.\n\nOption ③ states that healthcare professionals must make efforts to protect patients from various health hazards, including environmental factors, infectious diseases, and other health risks. This option best aligns with the responsibility of healthcare professionals as described in the law.\n\nTherefore, the correct answer is ③.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 재활\n\nExplanation:\n\nThe purpose of the National Health Insurance Act is to provide financial support for medical expenses to ensure the health and well-being of the population. Rehabilitation (재활) is not included in the benefits covered by the National Health Insurance Act, as it is not a direct medical expense.\n\nThe other options are all covered by the National Health Insurance Act:\n\n① Prevention (예방) refers to measures taken to prevent illnesses or health problems before they occur.\n\n② Transportation (이송) refers to the cost of transportation to and from medical facilities for treatment.\n\n④ Short-term care (단기보호) refers to temporary care provided for patients who require constant attention and care for a short period of time.\n\n⑤ Drug payment (약제의 지급) refers to the cost of medications prescribed by a doctor.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ①\n\nExplanation:\n\nAccording to the \"National Health Insurance Act,\" the calculation of health insurance benefits for medications is based on the actual cost of the medication. Therefore, the correct answer is ① 한약제에 대한 요양급여비용은 원칙적으로 구입금액을 기준으로 산정한다.\n\nThe other options are not correct because:\n\n② 치료재료에 대한 요양급여비용은 원칙적으로 상한금액을 기준으로 산정한다. - This statement is incorrect because the benefit for medical devices is calculated based on the actual cost, not the upper limit amount.\n\n③ 한약제 외의 약제의 구입금액이 상한금액을 초과하는 경우에도 구입금액 전부를 약국에 상환한다. - This statement is incorrect because the benefit for medications is not based on the full amount of the medication cost, but rather on the actual cost of the medication.\n\n④ 약국의 조제료에 대하여 대한약사회와 국민건강보험공단 이사장의 계약이 체결되면 그 계약은 국민건강보험공단과 각 약국 사이에 체결된 것으로 본다. - This statement is incorrect because the contract between the pharmacist association and the National Health Insurance Service is not directly related to the calculation of health insurance benefits for medications.\n\n⑤ 약사가 아닌 자가 「약사법」을 위반하여 약국을 개설한 사실을 수사기관의 수사 결과로 확인하더라도 그 약국이 청구한 요양급여비용의 지급을 보류할 수 없다. - This statement is incorrect because the payment of health insurance benefits for medications is not affected by whether the pharmacist has violated the Pharmacy Act or not.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nAccording to the \"지역보건법\" (Regional Public Health Act), the establishment and operation of health centers are determined by the Minister of Health and Welfare, based on the requirements of the \"의료법\" (Medical Act). Therefore, the correct answer is ③, which states that health centers must meet the requirements of the Medical Act.\n\nThe other options are incorrect for the following reasons:\n\n①: This option states that health centers should be established in each town, township, and neighborhood. While it is true that health centers should be established in a way that is easily accessible to residents, the specific number of health centers and their locations should be determined based on the population and healthcare needs of the area, rather than being fixed at one per town, township, or neighborhood.\n\n②: This option states that health centers cannot perform tasks related to drug management. While it is true that health centers are not responsible for drug management, they do provide prescription and dispensing services, as well as education and counseling on proper drug use.\n\n④: This option states that health centers must have a minimum number of pharmacists and other specialized personnel. While it is true that health centers must have a sufficient number of staff to provide quality healthcare services, the specific number of staff required varies depending on the size and needs of the health center, and is not fixed at a minimum of one pharmacist and one nurse.\n\n⑤: This option states that health centers are established by the Minister of Health and Welfare based on the \"농어촌 등 보건의료를 위한 특별조치법\" (Special Measures Act for Healthcare in Rural Areas, etc.). While it is true that the Minister of Health and Welfare has the authority to establish health centers in rural areas and other underserved communities, the establishment and operation of health centers are primarily governed by the \"지역보건법\" (Regional Public Health Act).</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 트로포닌 복합체의 형성</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 감소변화 | 없음\n\nExplanation:\n\nWhen a reversible inhibitor is added to a single enzyme-substrate reaction that follows Michaelis-Menten kinetics, the inhibitor binds to the enzyme-substrate complex, reducing the enzyme's activity. The inhibitor does not affect the activity of the enzyme when the substrate is not bound.\n\nThe addition of a reversible inhibitor will decrease the enzyme's Vmax, as the inhibitor reduces the enzyme's activity. However, the Km of the enzyme will not change, as the inhibitor does not affect the substrate's binding affinity to the enzyme.\n\nTherefore, the correct answer is ③ 감소변화 | 없음, indicating that the addition of the reversible inhibitor results in a decrease in Vmax, but no change in Km.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② glycosaminoglycan</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ coenzyme B12 – 아실기 전달 반응</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② 해당과정\n\nExplanation:\n\nThe three enzymes mentioned in the question are all involved in the pentose phosphate pathway, which is a metabolic pathway that generates NADPH and pentoses from glucose-6-phosphate. The pathway is also known as the \"hexose monophosphate shunt\" or \"HMP pathway.\"\n\nGlucose-6-phosphate dehydrogenase (G6PD) is the first enzyme in the pathway, which catalyzes the conversion of glucose-6-phosphate to 6-phosphogluconate.\n\n6-Phosphogluconate dehydrogenase (6PGD) is the second enzyme in the pathway, which catalyzes the conversion of 6-phosphogluconate to ribulose-5-phosphate.\n\nTransaldolase (TAL) is the third enzyme in the pathway, which catalyzes the conversion of ribulose-5-phosphate to xylulose-5-phosphate and ribose-5-phosphate.\n\nTherefore, the correct answer is ② 해당과정, which represents the pentose phosphate pathway.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② glycogen synthase kinase 3</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ phosphoenolpyruvate</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 고밀도지질단백질</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ lanosterol</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ ribonucleotide reductase</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ RNA 중합효소 III</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 유전자의 전사 촉진</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② pRb 단백질과의 결합</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 비효소적 당화(glycation)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 나이아신</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 면역결핍</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\n가족성고콜레스테롤혈증(familial hypercholesterolemia) is a genetic disorder that affects the regulation of cholesterol metabolism. The condition is caused by mutations in the genes that code for proteins involved in cholesterol transport and metabolism.\n\nOf the options given, ③ 스테롤 조절요소 결합 단백질(SREBP) 유전자 is the most likely answer. SREBP (sterol regulatory element-binding protein) is a transcription factor that regulates the expression of genes involved in cholesterol metabolism. Mutations in the SREBP gene can lead to the overexpression of genes involved in cholesterol synthesis and uptake, resulting in high levels of cholesterol in the blood.\n\nThe other options are not as closely related to the regulation of cholesterol metabolism:\n\n① 고밀도지질단백질 수용체 유전자 (option 1) refers to the gene for the low-density lipoprotein (LDL) receptor, which is responsible for removing excess cholesterol from the bloodstream and bringing it back to the liver for excretion. While mutations in this gene can also contribute to high cholesterol levels, it is not as directly related to the regulation of cholesterol metabolism as SREBP.\n\n② 저밀도지질단백질 수용체 유전자 (option 2) refers to the gene for the Apolipoprotein A-1 (ApoA-1) protein, which is the main protein component of high-density lipoprotein (HDL). While ApoA-1 plays a role in cholesterol transport and reverse cholesterol transport (the removal of cholesterol from peripheral tissues and transport back to the liver), it is not as directly related to the regulation of cholesterol metabolism as SREBP.\n\n④ SR-B1 수용체(scavenger receptor, class B type 1) 유전자 (option 4) refers to the gene for a receptor that is involved in the uptake of cholesterol from the bloodstream and its transport to the liver for excretion. While mutations in this gene can also contribute to high cholesterol levels, it is not as directly related to the regulation of cholesterol metabolism as SREBP.\n\n⑤ β-하이드록시-β-메틸글루타릴-CoA 환원효소(HMG-CoA reductase) 유전자 (option 5) refers to the gene for an enzyme that is involved in the synthesis of cholesterol from HMG-CoA. While mutations in this gene can also contribute to high cholesterol levels, it is not as directly related to the regulation of cholesterol metabolism as SREBP.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ EGFR의 티로신 인산화효소 활성이 증가하였다.\n\nExplanation:\nEGFR is a transmembrane receptor that plays a crucial role in cellular signaling pathways, including cell growth, differentiation, and survival. The activation of EGFR is known to be involved in various cancers, including non-small cell lung cancer (NSCLC). In this case, the patient's cancer cells have increased EGFR activity, which can be caused by several mechanisms, including increased expression of EGFR, mutations in the EGFR gene, or alterations in downstream signaling pathways.\n\nOption ③, \"EGFR의 티로신 인산화효소 활성이 증가하였다,\" is the correct answer because it suggests that the activation of EGFR's tyrosine kinase activity has increased, which can lead to the activation of downstream signaling pathways that promote cell growth and proliferation.\n\nOption ①, \"EGF의 세포막 통과가 촉진되었다,\" is incorrect because it suggests that the increase in EGFR activity is due to increased passage of EGF through the cell membrane, which is not the primary mechanism for EGFR activation.\n\nOption ②, \"EGFR과 β-어레스틴의 결합력이 증가하였다,\" is also incorrect because it suggests that the increase in EGFR activity is due to increased binding affinity between EGFR and β-arrestin, which is not the primary mechanism for EGFR activation.\n\nOption ④, \"EGF-EGFR 복합체의 세포내로의 유입이 증가하였다,\" is incorrect because it suggests that the increase in EGFR activity is due to increased internalization of EGF-EGFR complexes, which is not the primary mechanism for EGFR activation.\n\nOption ⑤, \"EGF-EGFR 복합체가 특정 DNA 서열에 결합하여 유전자 전사가 활성화되었다,\" is also incorrect because it suggests that the increase in EGFR activity is due to the binding of EGF-EGFR complexes to specific DNA sequences, leading to the activation of transcription, which is not the primary mechanism for EGFR activation.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ EGFR 활성을 저해하는 단일클론 항체를 투여한다.\n\nExplanation:\n\nThe correct answer is ③ EGFR 활성을 저해하는 단일클론 항체를 투여한다.\n\nThe patient's cancer cells have increased EGFR activity, which can be targeted with a monoclonal antibody that binds to and inhibits the activity of EGFR. This will slow down the growth and proliferation of the cancer cells.\n\nOption ①, ②, and ④ are not relevant to the patient's condition and would not be effective in treating the patient's cancer. Option ⑤ is not related to the patient's condition and would not be an appropriate treatment.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 리팜핀(rifampin)에 감수성이 있다.\n\nExplanation:\n\nThe question is asking about the characteristic of a bacterial cell membrane that has a hydrophobic region composed of glycerol and ether bonds. The correct answer is ③ 리팜핀(rifampin)에 감수성이 있다, as rifampin is a drug that is known to interact with the hydrophobic region of bacterial cell membranes and disrupt their structure and function.\n\n① 80S 리보솜을 가진다 is incorrect because the question is asking about the cell membrane, not the ribosome.\n\n② 세포벽 성분은 펩티도글리칸이다 is incorrect because peptidoglycan is a component of bacterial cell walls, not cell membranes.\n\n④ 카나마이신(kanamycin)에 감수성이 있다 is incorrect because kanamycin is an aminoglycoside antibiotic that targets bacterial ribosomes, not cell membranes.\n\n⑤ 단백질 합성 개시 아미노산은 메티오닌이다 is unrelated to the question and is therefore incorrect.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 마이콜산(mycolic acid)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 소포스부비르(sofosbuvir)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① hepatitis B virus</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 스쿠알렌 에폭시다아제(squalene epoxidase)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 전사과정에서 RNA 중합효소 억제</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 겐타마이신(gentamicin)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 타이제사이클린(tigecycline)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 텔리트로마이신(telithromycin)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 피닥소마이신(fidaxomicin)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 대식세포</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ CR3</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① HLA-DM</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 인터페론-γ(IFN-γ)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 혈청병(serum sickness)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 전환성장인자-β(TGF-β)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 리툭시맙(rituximab)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ Shigella dysenteriae</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ 시가독소(Shiga toxin) 생산</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 내성(tolerance)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 아미팜프리딘(amifampridine)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 총말초저항 증가\n\nExplanation:\n\nAdrenaline (아드레날린) and mirabegron (미라베그론) are both medications that act on the autonomic nervous system. They have a common mechanism of action, which is to increase the total peripheral resistance (TPR) by stimulating the alpha-1 adrenergic receptors. This leads to an increase in blood pressure. Therefore, the correct answer is ③ 총말초저항 증가 (increase in total peripheral resistance).</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 메토프롤롤(metoprolol)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 클로자핀(clozapine)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 올란자핀(olanzapine)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 셀레길린(selegiline)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 알비모판(alvimopan)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 시메티딘(cimetidine)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 인터루킨-1(IL-1) 작용 차단</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 데페록사민(deferoxamine)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 티클로피딘(ticlopidine)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② 심근수축력 억제</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 에날라프릴(enalapril) – 안지오텐신 전환효소(ACE) 억제</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 아로마타제(aromatase) 억제</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 메트포르민(metformin)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② DNA gyrase 억제</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 니볼루맙(nivolumab)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ 5-HT3 세로토닌 수용체</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 도부타민(dobutamine)\n\nExplanation: Dobutamine is a dopamine receptor agonist that is used to treat heart failure. It works by activating dopamine receptors in the heart, which helps to increase cardiac output and reduce systemic vascular resistance. This makes it a useful medication for treating acute heart failure, which is characterized by a sudden decrease in cardiac output and an increase in systemic vascular resistance.\n\nThe other options are not correct because they are not used to treat acute heart failure. Milrinone is a phosphodiesterase inhibitor that is used to treat heart failure by increasing cyclic AMP levels, which helps to relax the heart muscle and increase cardiac output. Nesiritide is a natriuretic peptide that is used to treat heart failure by increasing urine production and reducing systemic vascular resistance. Carvedilol is a beta-blocker that is used to treat heart failure by reducing the heart rate and systemic vascular resistance. Furosemide is a diuretic that is used to treat heart failure by increasing urine production and reducing systemic vascular resistance. While these medications may be used in the long-term management of heart failure, they are not typically used to treat acute heart failure.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 황반변성</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 시안화수소</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ NH2Cl, NHCl2</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 망간</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① troponin T</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 스트렙토조토신(streptozotocin)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① acrylamide</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 0.3\n\nExplanation:\nThe LOAEL (Lowest Observed Adverse Effect Level) is the lowest dose at which adverse effects have been observed in a study. In this case, the LOAEL is 0.3 mg/kg/day, which means that at this dose, adverse effects were observed in the study.\n\nThe question is asking for the reference dose (RfD) which is the dose at which the adverse effects were observed. Therefore, the correct answer is 0.3 mg/kg/day, which is the LOAEL.\n\nThe other options are not correct because they are not the LOAEL. Option ① 300 is much higher than the LOAEL, option ③ 3×10^-3 is lower than the LOAEL, option ④ 3×10^-4 is lower than the LOAEL, and option ⑤ 3×10^-5 is much lower than the LOAEL.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ②\n\nExplanation:\n\nThe given table shows the results of a bacterial reverse mutation assay, which is used to detect the mutagenic potential of a test substance. The assay involves exposing bacteria to the test substance and then selecting for mutants that have developed resistance to certain antibiotics. The results are interpreted based on the number of revertants (mutants) observed in each strain.\n\nIn this case, the test substance is a chemical substance, and the table shows the results for five different bacterial strains. The first column lists the strains, and the second column indicates whether the test substance was added (첨가) or not (무첨가). The third column shows the result of the assay, with 양성 indicating a positive result (mutants observed) and 음성 indicating a negative result (no mutants observed).\n\nBased on the results, we can see that the test substance induced mutations in three of the five strains tested (S. Typhimurium TA98, TA1535, and TA1537). This suggests that the test substance has mutagenic potential.\n\nTherefore, the correct answer is ② 소핵형성 여부가 음 ∙ 양성 판단의 기준이다. This means that the result of the assay is positive, indicating that the test substance has mutagenic potential.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 장기에 따른 대사효소 분포 차이</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ histamine</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 티아민</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 셀레늄</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 대사효소유도 감소\n\nExplanation:\nSt. John's wort (성요한풀) is an inducer of cytochrome P450 enzymes, which are responsible for the metabolism of many drugs, including simvastatin (심바스타틴). When St. John's wort is stopped, the activity of these enzymes decreases, leading to a decrease in the metabolism of simvastatin. As a result, the concentration of simvastatin in the body increases, which can cause muscle damage and myalgia. Therefore, option ④, \"대사효소유도 감소\" (decrease in drug metabolism) is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Salmonella Typhimurium</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ tetrodotoxin</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① α-amanitin</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 사카린나트륨</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 환자-대조군 연구\n\nExplanation:\n\nIn this study, the researcher is trying to investigate the relationship between smoking during pregnancy and the risk of low birth weight. The study population consists of 500 low birth weight infants and 500 normal birth weight infants born at a hospital between 2018 and 2020. The researcher is comparing the smoking habits of the mothers during pregnancy between the two groups to determine if there is a correlation between smoking and low birth weight.\n\nTherefore, the correct answer is ③ 환자-대조군 연구 (case-control study), as the study is comparing a group of patients (low birth weight infants) with a group of controls (normal birth weight infants) to identify a potential risk factor (smoking during pregnancy).</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ④\n\nExplanation:\n\nThe advantage of a cohort study, such as Study 1, compared to a case-control study, such as Study 2, is that it allows for the observation of the entire process from exposure to the risk factor (smoking) to the development of the disease (low birth weight or lung cancer). This is because a cohort study follows a group of people over time, allowing researchers to track the development of the disease and the exposure to the risk factor simultaneously.\n\nIn contrast, a case-control study, such as Study 2, only looks at the relationship between the risk factor (smoking) and the disease (lung cancer) at a single point in time. It does not allow for the observation of the entire process from exposure to disease development.\n\nTherefore, option ④, \"위험요인의 노출에서부터 질병 발생까지의 전 과정을 관찰할 수 있다\" (It allows for the observation of the entire process from exposure to the risk factor to the development of the disease), is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 세포막 파괴</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③, \"상처 수복 과정에서 형성된 일시적 육아조직\".\n\n결핵균 감염으로 인해 형성된 육아종은 상처 수복 과정에서 형성된 일시적 육아조직입니다. 이 과정에서 상처가 생겼을 때, 세포들이 분배되어 육아조직을 형성합니다. 이 육아조직은 일시적이며, 충분히 축적되면 사라집니다.\n\n①, ②, ④, ⑤ 옵션은 모두 잘못된 설명입니다.\n\n① 염증 부위에 발생한 양성종양은 염증 부위에 발생한 양성 세포의 집합체입니다. 이 양성종양은 결핵균 감염에 의해 형성되지 않습니다.\n\n② 낫모양 형태를 가진 세포들의 집합체는 결핵균 감염에 의해 형성되는 육아종과 관련이 없습니다.\n\n④ 중심부 괴사를 동반한 상피모양세포들의 집합체는 결핵균 감염에 의해 형성되는 육아종과 관련이 없습니다.\n\n⑤ 병소에 세포바깥바탕질이 과도하게 축적된 흉터종은 결핵균 감염에 의해 형성되는 육아종과 관련이 없습니다.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② 내피세포</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 종양억제유전자의 활성 유지</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 레닌(renin)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 철결핍빈혈</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 레이노현상(Raynaud phenomenon)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 뉴클레아제 활성 증가</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 화생</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ KRAS</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 지라기능저하증</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 색전증(embolism)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 5α-환원효소 작용 증가</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 사람유두종바이러스(HPV)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 자궁내막암</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ⑤ 푸린(purine) 염기 이화과정 결과물의 축적</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 파킨슨병</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 망막염</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 폐 모세혈관 울혈로 인한 체액의 폐포 내 축적</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 심근의 대사 요구 증가\n\nExplanation:\n\nThe Frank-Starling law of the heart states that the heart's output increases in response to an increase in preload (the volume of blood in the ventricles at the end of diastole). However, in the case of the patient described in the question, the heart's output is decreased due to the decrease in myocardial contractility. This means that the heart is unable to pump enough blood to meet the body's needs, leading to fatigue and shortness of breath, especially during physical activity.\n\nTherefore, the correct answer is ③ 심근의 대사 요구 증가 (increased oxygen demand of the myocardium). This is because the decreased myocardial contractility leads to a decrease in the heart's output, which in turn increases the oxygen demand of the myocardium. This can further exacerbate the fatigue and shortness of breath that the patient is experiencing.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 가성성</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 50기압, 90℃</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 33.3</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 탈탄산(decarboxylation) 반응</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe question states that the fluid's viscosity increases as the shear rate increases. This means that the fluid exhibits non-Newtonian behavior, specifically a shear thinning behavior. In shear thinning fluids, the viscosity decreases as the shear rate increases.\n\nOption ③ states that the relationship between shear stress and shear rate is proportional, which is consistent with the definition of a non-Newtonian fluid. Therefore, option ③ is the correct answer.\n\nOption ① is incorrect because it states that the fluid exhibits a yield stress, which is not mentioned in the question.\n\nOption ② is incorrect because it states that the volume of the fluid decreases, which is not mentioned in the question.\n\nOption ④ is incorrect because it refers to the behavior of a fluid in a Leogram, which is not relevant to the question.\n\nOption ⑤ is incorrect because it states that the increase in viscosity is due to the depletion of solvent around the particles, which is not mentioned in the question.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe question asks for the correct statement related to the colligative properties of a solution at 1 atm and 25°C.\n\n① is incorrect because the van 't Hoff factor (i) for a binary solution is not necessarily 2.\n\n② is incorrect because the isoelectric point (L_iso) of a weak electrolyte is not independent of the type of electrolyte.\n\n③ is correct. The osmolarity (OSM) of a solution is the product of the molar concentration (C) and the van 't Hoff factor (i) of the solute.\n\n④ is incorrect because the value of g (the activity coefficient) for a 0.1 mol/L solution of sodium chloride at 25°C is not necessarily 2.\n\n⑤ is incorrect because the van 't Hoff factor (i) for a 0.01 mol/L and 0.02 mol/L solution of acetic acid is not necessarily the same.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 이온강도</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 29.3R</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 1.5</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 결정을 가용성 무정형으로 바꾼다.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 위장관 점막에 대한 약물 확산도의 증가</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 20</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ②</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe question is asking about the relationship between the hydrophilic-lipophilic balance (HLB) of a surfactant and its properties.\n\nOption ① is incorrect because HLB decreases as the surfactant becomes more hydrophilic.\n\nOption ② is incorrect because HLB values of 1-3 are typically used for anionic surfactants, not nonionic surfactants.\n\nOption ③ is correct because HLB values of 15-18 are typically used for nonionic surfactants that are used in water-in-oil (w/o) emulsions.\n\nOption ④ is incorrect because the HLB of sorbitan monostearate is not necessarily greater than that of poloxamer 407, which is a nonionic surfactant.\n\nOption ⑤ is incorrect because the HLB of a nonionic surfactant increases as the mass fraction of polyoxyethylene increases, not as the mass fraction of polyoxypropylene increases.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②\n\nExplanation:\n\nThe settling velocity of a sphere in a fluid can be calculated using Stokes' law, which states that the settling velocity is proportional to the square of the particle's radius and inversely proportional to the fluid's viscosity. Therefore, the settling velocity of a particle is proportional to the square of its radius.\n\nSo, the correct answer is ② 입자 반경의 제곱에 비례한다.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe question states that the solubility of tretinoin in water is less than 0.1 mg/100 mL at 25°C, and its logP value is 6.3. This means that tretinoin is a hydrophobic compound, which means it has a low solubility in water.\n\nAdding ethanol to the water would increase the solubility of tretinoin, as ethanol is a hydrophobic solvent that can dissolve hydrophobic compounds like tretinoin. Therefore, option ③ \"물에 에탄올을 첨가하면 약물의 용해도는 감소한다\" is the correct answer.\n\nThe other options are incorrect because:\n\n① 산성 pH에서 물에 대한 용해도는 증가한다: This statement is incorrect because the pH of the solution does not affect the solubility of tretinoin.\n\n② 수용성 가용화제를 넣으면 logP 값은 증가한다: This statement is incorrect because the solubility of tretinoin in water is already low, and adding a solubilizer would not significantly increase its solubility.\n\n④ 온도를 40℃로 높이면 물에 대한 용해도는 증가한다: This statement is incorrect because increasing the temperature would actually decrease the solubility of tretinoin in water, not increase it.\n\n⑤ 계면활성제 라우릴황산나트륨을 첨가하면 약물의 용해도는 감소한다: This statement is incorrect because adding a surfactant like sodium lauryl sulfate would not significantly affect the solubility of tretinoin in water.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe Higuchi model is a mathematical model used to describe the release of drugs from a diffusion-controlled system, such as a gel matrix. The model assumes that the drug release is proportional to the surface area of the gel matrix and inversely proportional to the square root of time.\n\nAccording to the Higuchi model, the rate of drug release (dQ/dt) is given by:\n\ndQ/dt = -K \\* A \\* (t^(-1/2))\n\nwhere K is a constant, A is the surface area of the gel matrix, and t is time.\n\nTherefore, option ③ is the correct answer. The rate of drug release (dQ/dt) is proportional to time (t), but not to the square of time (t^2).</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ D</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ①</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ①</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ①</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ①</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 5-지방산화효소 저해</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ①</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 발사르탄(valsartan)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 디클로페낙(diclofenac)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 오메프라졸(omeprazole)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 미다졸람(midazolam)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ C</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 프로포폴(propofol)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 고리구조의 도입</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Na2HPO4와 Na3PO4</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ 티오시아나토(thiocyanato) 착이온</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 2.55×10^-3</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② K2Cr2O7</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 살리실산</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe question is asking for the concentration of dexamethasone in the sample. We can calculate this by using the formula:\n\nConcentration (%) = (Amount of dexamethasone / Total volume of solution) × 100\n\nIn this case, the amount of dexamethasone is 50.3 mg, and the total volume of solution is 100 mL. So, we can plug these values into the formula to get:\n\nConcentration (%) = (50.3 mg / 100 mL) × 100 = 503 mg/mL\n\nNow, we need to convert this concentration from mg/mL to % (w/v). We can do this by dividing the concentration in mg/mL by 1000:\n\nConcentration (%) = 503 mg/mL ÷ 1000 = 0.503%\n\nTherefore, the correct answer is ③ 0.418/845 × 1000 × 1/50.3 × 100 = 0.503%.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② +4.6°</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 0.8</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 겔투과크로마토그래프법</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③, \"다통로효과에 의한 확산(eddy diffusion)의 증가.\"\n\nWhen the mobile phase was replaced with a solution containing a non-volatile solvent, the separation efficiency increased. This is because the non-volatile solvent increased the eddy diffusion, which is the random movement of molecules in the mobile phase, thereby enhancing the separation process.\n\nEddy diffusion is a type of diffusion that occurs in the mobile phase of a liquid chromatography column. It is caused by the random movement of molecules in the mobile phase, which results in a continuous exchange of molecules between the mobile and stationary phases. This increases the interaction between the analytes and the stationary phase, leading to improved separation efficiency.\n\nTherefore, option ③, \"다통로효과에 의한 확산(eddy diffusion)의 증가\" is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 질량분석 검출기</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 기울기 용리(gradient elution)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④\n\nExplanation:\n\nThe question is asking for a method to separate two ionic strength drugs, A and B, using membrane electrophoresis. The correct answer is option ④, which states that the electric field strength should be increased to increase the electrophoresis speed.\n\nIn membrane electrophoresis, the separation of ions is based on their charge and size. The greater the electric field strength, the faster the ions will migrate through the membrane. By increasing the electric field strength, the separation of the two drugs can be improved, allowing for better resolution and separation of the peaks.\n\nOption ①, increasing the membrane length, may also improve the separation, but it is not the most direct or efficient method.\n\nOption ②, increasing the ionic strength of the mobile phase, may also improve the separation, but it may also increase the background conductivity, which could complicate the analysis.\n\nOption ③, making the pH of the mobile phase less than 2, may not be effective in separating the two drugs, as the pH may not have a significant effect on their ionic strength.\n\nOption ⑤, adding an ionic surfactant to the mobile phase, may also improve the separation, but it may not be the most effective method, as the surfactant may interact with the membrane and complicate the analysis.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 조절시험</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 1.0\n\nExplanation:\n\nThe relative standard deviation (RSD) of the mean absorbance of the drug substance A is calculated as follows:\n\nRSD = (standard deviation / mean) x 100\n\nIn this case, the mean absorbance is 0.40, and the standard deviation is 0.01. Therefore, the RSD is:\n\nRSD = (0.01 / 0.40) x 100 = 2.5%\n\nSo, the correct answer is ③ 1.0.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 100\n\nExplanation:\n\nThe question asks for the percentage of light absorption (E1%) of the drug substance A at a concentration of 10 mg/mL in methanol, which is the solvent used for the measurement.\n\nThe given information states that the mean absorbance (A) was 0.40, and the standard deviation (σ) was 0.01, which suggests that the data is normally distributed.\n\nUsing the formula for percentage of light absorption (E1%), we have:\n\nE1% = 100 \\* (A - A0) / (A0 \\* σ)\n\nwhere A0 is the absorbance of the blank (i.e., the solvent alone), which is not given in the question. However, we can assume that the blank absorbance is negligible, so A0 ≈ 0.\n\nSubstituting the given values, we get:\n\nE1% ≈ 100 \\* (0.40 - 0) / (0 \\* 0.01) = 100 \\* 40 = 4000\n\nTherefore, the percentage of light absorption (E1%) of the drug substance A at a concentration of 10 mg/mL in methanol is approximately 4000, which corresponds to option ③ 100.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 유동층과립법</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 카보머</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 유동엑스제</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 이산화탄소</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 단미연고</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 벤토나이트</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ polysorbate 80</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④, \"결정형 변경으로 화학구조가 변화되어 용해도가 달라진다.\"\n\nWhen designing a drug, the drug's crystal structure is an important factor to consider. The crystal structure can affect the drug's solubility, stability, and bioavailability. Therefore, changing the crystal structure of a drug can result in changes in its chemical properties, which can affect its efficacy and safety.\n\nOption ① is incorrect because the drug's crystal structure can affect its solubility and bioavailability.\n\nOption ② is incorrect because the rate of dissolution is not the only factor that determines the efficacy of a drug.\n\nOption ③ is incorrect because the use of an amorphous form of a drug is not always necessary or appropriate.\n\nOption ⑤ is incorrect because changing the crystal structure of a drug does not necessarily result in improved absorption in the gut.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 분배계수</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 약물산화 방지</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ B, B</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 200\n\nExplanation:\n\nThe question states that the drug A 10 mg was administered intravenously as a bolus, and the concentration of the drug in the blood at time t=0 (C0) was 20 μg/L.\n\nUsing the formula for the volume of distribution (Vd) of a drug, we can calculate:\n\nVd = C0 / (Kelimeler's constant x dose)\n\nwhere Kelimeler's constant is a constant value for the drug, and dose is the amount of drug administered.\n\nAssuming that the Kelimeler's constant for drug A is 1, and the dose is 10 mg, we can calculate:\n\nVd = 20 μg/L / (1 x 10 mg) = 200 L\n\nTherefore, the volume of distribution for drug A is 200 L.\n\nThe correct answer is ③ 200.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 100</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 투여용량 증가</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②\n\nExplanation:\nThe correct answer is ②, \"간세포로의 수송능력 저하로 혈중농도 증가\" (Reduced transport capacity of hepatocytes leads to increased blood concentration).\n\nThe question states that the 521T>C mutation in the SLCO1B1 gene, which encodes the OATP1B1 transporter, results in a high frequency of adverse reactions to simvastatin in patients. This suggests that the mutation affects the activity of the OATP1B1 transporter, leading to altered drug pharmacokinetics and increased blood concentrations of simvastatin.\n\nTherefore, option ②, \"간세포로의 수송능력 저하로 혈중농도 증가\" (Reduced transport capacity of hepatocytes leads to increased blood concentration), is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 위에서 녹지 않고 소장에서 용출\n\nExplanation:\nThe given formulation is a delayed-release formulation, which means that the drug is not released in the stomach but instead is released in the small intestine. This is achieved by using a coating that prevents the drug from being released in the stomach, but allows it to be released in the small intestine. Therefore, the main feature of this formulation is that the drug is not released in the stomach, but is released in the small intestine.\n\n③ 위에서 녹지 않고 소장에서 용출 is the correct answer.\n\n① 소량의 타액으로 신속 붕해 is incorrect because the formulation is not designed to release the drug quickly in the stomach.\n\n② 대장 미생물에 의한 약물방출 is incorrect because the formulation does not rely on the gut microbiome for drug release.\n\n④ 소장의 소화효소에 의한 약물방출 is incorrect because the formulation does not rely on enzymes in the small intestine for drug release.\n\n⑤ 위체류 연장을 통한 약물흡수 촉진 is incorrect because the formulation does not prolong the residence time of the drug in the stomach, but instead delays its release until the small intestine.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ① 캡핑(capping) – 유당일수화물\n\nExplanation:\n\nThe problem described in the question is related to the phenomenon of \"capping\" or \"piling\" of the powder mixture during the compression process. This occurs when the powder particles stick together and form a cohesive mass, which can cause difficulties in compressing the mixture into a uniform tablet.\n\nThe correct answer is ① 캡핑(capping) – 유당일수화물. The addition of a small amount of a binder such as lactose (유당일수화물) can help to improve the flowability of the powder mixture and prevent capping. Lactose is commonly used as a binder in pharmaceutical formulations, and it has been shown to improve the compressibility of powder mixtures.\n\nThe other options do not address the problem of capping and are therefore not appropriate. ② 피킹(picking) – 스테아륨산마그네슘 is not related to the problem of capping and is not a suitable solution. ③ 스플리팅(splitting) – 미결정셀룰로오스 is also not related to the problem of capping and is not a suitable solution. ④ 캡핑(capping) – 크로스카르멜로오스나트륨 is not a suitable solution because it does not address the root cause of the problem, which is the cohesive nature of the powder mixture. ⑤ 스티킹(sticking) – 크로스카르멜로오스나트륨 is also not a suitable solution because it does not address the root cause of the problem.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ quinidine</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ glucosinolate</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 뿌리</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Poria Sclerotium</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Platycodonis Radix</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Rehmanniae Radix Preparata</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Rhei Radix et Rhizoma</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 연교</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ ergotamine</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ isoquinoline alkaloid</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 진피(陳皮)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Prunella vulgaris var. lilacina</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 원기(元氣)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 소양병(少陽病)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 택사(澤瀉)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 삼황사심탕(三黃瀉心湯)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ amino acid-mevalonate 복합경로\n\nExplanation:\n\nThe question asks for the main biosynthetic pathway of the compounds identified in the case study. The compounds are:\n\n* Anethole (phenylpropanoid)\n* Scoparone (coumarin)\n* Sesamin (lignan)\n\nThe biosynthetic pathway of these compounds can be traced back to the amino acid-mevalonate pathway, which is also known as the shikimate pathway. This pathway involves the conversion of amino acids into mevalonate, which is then converted into isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). These intermediates are then used to synthesize a variety of compounds, including phenylpropanoids, coumarins, and lignans.\n\nTherefore, the correct answer is ③ amino acid-mevalonate 복합경로.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ gomisin A</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ⑤ 인터페론감마분비검사\n\nExplanation:\n\nDiltiazem is a calcium channel blocker that is commonly used to treat hypertension and angina. One of the potential side effects of diltiazem is an increase in interferon gamma (IFN-γ) levels, which can cause a variety of immune-related adverse events, such as lupus-like syndrome, autoimmune hepatitis, and agranulocytosis. Therefore, monitoring IFN-γ levels is important when prescribing diltiazem, especially in patients with a history of immune-related disorders.\n\nThe other options are not directly related to the potential side effects of diltiazem:\n\n① Heart rate: Diltiazem can slow down the heart rate, but this is not a direct effect of the drug on the immune system.\n\n② T4: Diltiazem does not affect thyroid function.\n\n③ Neutrophil count: Diltiazem can cause a decrease in neutrophil count, but this is not a direct effect of the drug on the immune system.\n\n④ Magnesium level: Diltiazem can cause a decrease in serum magnesium levels, but this is not a direct effect of the drug on the immune system.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 푸로세미드(furosemide)\n\nExplanation:\n\nThe patient has hypertension, diabetes, and kidney disease, and is currently taking medications that include metformin, saxagliptin, amlodipine, and allopurinol. The patient's potassium level is low, which may indicate that the patient is experiencing hypokalemia due to the diuretic effect of the furosemide. Therefore, the best option for adding a medication to control blood pressure would be a potassium-sparing diuretic such as furosemide.\n\nVerapamil (①) is a calcium channel blocker that may lower blood pressure, but it is not a potassium-sparing diuretic and may not address the hypokalemia. Clonidine (②) is an alpha-agonist that may lower blood pressure, but it is not a diuretic and may not address the patient's fluid retention. Candesartan (④) is an angiotensin II receptor antagonist that may lower blood pressure, but it is not a potassium-sparing diuretic and may not address the hypokalemia. Hydrochlorothiazide (⑤) is a thiazide diuretic that may lower blood pressure, but it may also further lower potassium levels and worsen hypokalemia.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 레바미피드\n\nExplanation:\n\nThe patient has been taking digoxin, a medication that can cause arrhythmias, and has been diagnosed with Helicobacter pylori infection and gastritis. The patient's recent medication history includes amoxicillin, pantoprazole, clarithromycin, and rebamipide. The patient's digoxin level has increased from 0.9 ng/mL to 1.7 ng/mL, indicating a potential interaction between digoxin and one of the recently administered medications.\n\nRebamipide, a medication used to treat gastritis, can increase the levels of digoxin by inhibiting its metabolism. Therefore, the most likely cause of the increased digoxin level in this patient is rebamipide.\n\nThe correct answer is ③ 레바미피드 (rebamipide).</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 이바브라딘(ivabradine)\n\nExplanation:\n\nThe patient has hypertension, hyperlipidemia, and heart failure with reduced ejection fraction (HFrEF). The patient's symptoms have worsened despite current treatment, indicating a need for additional therapy. Ivabradine, a selective sinus node modulator, can be added to the patient's regimen to reduce heart rate and improve symptoms of heart failure. It has been shown to reduce the risk of cardiovascular events and death in patients with HFrEF.\n\nThe other options are not the most appropriate choices for this patient's condition:\n\n① Lisinopril is an ACE inhibitor, which can reduce blood pressure and proteinuria, but it may not directly address the patient's heart failure symptoms.\n\n② Amlodipine is a calcium channel blocker, which can reduce blood pressure, but it may not have a direct effect on heart failure symptoms.\n\n④ Indapamide is a diuretic, which can reduce fluid overload in heart failure patients, but it may not address the patient's underlying hypertension and hyperlipidemia.\n\n⑤ Spironolactone is a potassium-sparing diuretic, which can reduce fluid overload and improve potassium levels, but it may not directly address the patient's heart failure symptoms.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 리바록사반(rivaroxaban)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 니카르디핀(nicardipine)\n\nExplanation: Nicardipine is a calcium channel blocker that can be used to lower blood pressure in hypertensive emergencies. In this case, the patient has acute pulmonary edema and hypertension, and nicardipine can help to reduce the blood pressure and alleviate the edema. The other options, valsartan, enalapril, carvedilol, and nitroprusside, may also be used to lower blood pressure, but they may not be as effective in this specific situation. Valsartan and enalapril are ACE inhibitors and angiotensin receptor blockers, respectively, which may take longer to take effect and may not be as potent as nicardipine in lowering blood pressure quickly. Carvedilol is a beta-blocker that may also take longer to take effect and may not be as effective in lowering blood pressure in this situation. Nitroprusside is a vasodilator that can lower blood pressure quickly, but it may cause hypotension and reflex tachycardia, which may not be desirable in this case. Therefore, nicardipine is the most appropriate choice.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 리바록사반(rivaroxaban)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 피타바스타틴\n\nExplanation:\n\nThe patient is taking aspirin, which is an antiplatelet drug that can increase the risk of bleeding. Pitavastatin, a HMG-CoA reductase inhibitor, can also increase the risk of bleeding when taken with aspirin. Therefore, the correct answer is ④ 피타바스타틴 (pitavastatin).</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 겜피브로질(gemfibrozil)\n\nExplanation:\nThe patient has familial hypercholesterolemia, which is a genetic disorder that causes high levels of low-density lipoprotein (LDL) cholesterol and low levels of high-density lipoprotein (HDL) cholesterol. The patient is already taking ezetimibe and atorvastatin, which are both lipid-lowering medications. However, the patient's LDL cholesterol level is still high, indicating that additional therapy is needed.\n\nGemfibrozil is a fibrate, which is a class of medications that lower triglyceride levels and increase HDL cholesterol levels. It is commonly used in combination with statins, such as atorvastatin, to treat patients with mixed dyslipidemia (elevated LDL cholesterol and triglycerides, low HDL cholesterol). Therefore, option ① 겜피브로질(gemfibrozil) is the most appropriate answer.\n\nOption ② 알리로쿠맙(alirocumab) is a PCSK9 inhibitor, which is a different class of medication that lowers LDL cholesterol levels by increasing the number of LDL receptors on liver cells. It is not appropriate for this patient's condition.\n\nOption ③ 로모소주맙(romosozumab) is an anti-sclerostin antibody, which is used to treat osteoporosis. It is not related to lipid management.\n\nOption ④ 콜레스티라민(cholestyramine) is a bile acid sequestrant, which lowers cholesterol levels by binding to bile acids in the gut and preventing their reabsorption into the bloodstream. It is not appropriate for this patient's condition.\n\nOption ⑤ 오메가3산에틸에스테르90(omega-3-acids ethyl esters 90) is a supplement that contains omega-3 fatty acids, which have been shown to have various health benefits, including reducing inflammation and improving lipid profiles. However, it is not a substitute for evidence-based medications like gemfibrozil or atorvastatin.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 아가트로반(argatroban)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 에녹사파린(enoxaparin)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 트리메타지딘(trimetazidine)\n\nExplanation:\nThe patient is experiencing angina and has been diagnosed with stable angina. The patient's medication list includes aspirin, lisinopril, carvedilol, and clopidogrel, which are all appropriate medications for stable angina. However, the patient's blood pressure is not well-controlled, and their LDL-C level is elevated. Trimetazidine, a nitrate-like medication, can be added to the patient's regimen to help improve their exercise tolerance and reduce their angina symptoms. It can also help to lower blood pressure and improve lipid profiles.\n\nTherefore, option ③ 트리메타지딘(trimetazidine) is the best answer.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 모르핀(morphine) 추가\n\nExplanation:\n\nThe patient is experiencing increased angina frequency, which suggests that the current medication regimen is not effectively managing their stable angina. The addition of morphine can help to reduce the frequency and severity of angina episodes. Morphine is a opioid receptor agonist that can produce vasodilation, which can help to decrease the workload on the heart and reduce the demand for oxygen. This can help to alleviate angina symptoms.\n\nThe other options are not the most appropriate for this patient's situation. Increasing the dose of lisinopril (Option ①) or carvedilol (Option ②) may help to reduce blood pressure and improve cardiac function, but they are not specifically indicated for the treatment of angina. Adding apixaban (Option ④) or nimodipine (Option ⑤) may be appropriate for patients with certain cardiovascular conditions, but they are not directly related to the management of stable angina.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ⑤ 프로프라놀롤(propranolol)\n\nExplanation:\n\nThe patient has been diagnosed with paroxysmal atrial fibrillation (PAF) and has been started on diltiazem, a calcium channel blocker, for rate control. However, the patient's symptoms persist, and the physician is considering adding another medication to convert the arrhythmia back to sinus rhythm.\n\nOf the options listed, 프로프라놀롤(propranolol) is the most appropriate choice. Propranolol is a beta-blocker that can be used to treat PAF and has a Class I indication for this condition. It can help to slow the heart rate and reduce the risk of recurrent arrhythmias.\n\n소타롤(sotalol) is a beta-blocker that is also used to treat PAF, but it has a Class II indication for this condition, which means that it is less effective than propranolol.\n\n디곡신(digoxin) is a cardiac glycoside that can be used to treat heart failure and atrial fibrillation, but it is not the most appropriate choice for this patient because it has a slower onset of action compared to propranolol and may not be effective in converting the arrhythmia back to sinus rhythm.\n\n아트로핀(atropine) is an anticholinergic medication that can be used to increase the heart rate and reduce the risk of bradycardia, but it is not the most appropriate choice for this patient because it does not have a direct effect on the arrhythmia.\n\n프로파페논(propafenone) is a Class III antiarrhythmic medication that can be used to treat PAF, but it has a slower onset of action compared to propranolol and may not be effective in converting the arrhythmia back to sinus rhythm.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 실로스타졸(cilostazol)\n\nExplanation:\n\nThe patient has been diagnosed with paroxysmal atrial fibrillation (PAF) and has been started on diltiazem for rate control. The patient also has a history of hypertension and dyslipidemia. The goal is to maintain sinus rhythm and prevent recurrence of atrial fibrillation.\n\nCilostazol is a phosphodiesterase inhibitor that has been shown to be effective in preventing recurrence of atrial fibrillation in patients with PAF. It has a class IIa recommendation in the 2019 ACC/AHA/HRS focused update on atrial fibrillation guidelines.\n\nAspirin, apixaban, dalteparin, and prasugrel are all anticoagulant agents that may be used in the prevention of stroke in patients with atrial fibrillation, but they are not specifically indicated for the prevention of recurrence of atrial fibrillation.\n\nTherefore, the best answer is ④ 실로스타졸(cilostazol).</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 플루티카손/살메테롤을 중단하고 레슬리주맙으로 변경.\n\nReason:\n\nThe patient has experienced two episodes of severe asthma exacerbations in the past year, despite using high-dose fluticasone/salmeterol and salbutamol as needed. This suggests that the patient's current treatment regimen is not effectively controlling their asthma symptoms.\n\nReslizumab is a monoclonal antibody that targets interleukin-5 (IL-5) and is used to treat severe asthma. It has been shown to reduce asthma exacerbations and improve lung function in patients with severe asthma. Omalizumab is another monoclonal antibody that targets immunoglobulin E (IgE) and is used to treat severe allergic asthma.\n\nIn this case, the patient's IgE level is elevated at 190 IU/mL, which suggests that they may have an allergic component to their asthma. However, the patient's history of severe asthma exacerbations despite using high-dose fluticasone/salmeterol and salbutamol suggests that their asthma may not be well-controlled by current treatment.\n\nTherefore, the best course of action would be to discontinue the patient's current treatment and switch to reslizumab, which has been shown to be effective in reducing asthma exacerbations and improving lung function in patients with severe asthma.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 저용량 부데소니드/포르모테롤(budesonide/formoterol) 흡입제 필요시 투여</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 이프라트로퓸(ipratropium) 비강분무제</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 유메클리디늄/빌란테롤 흡입제를 빌란테롤/플루티카손 흡입제로 변경.\n\nExplanation:\n\nThe patient's history of chronic obstructive pulmonary disease (COPD) and the recent exacerbation suggest that the current treatment with umeclidinium/vilanterol is not effective in managing the patient's symptoms. The patient's FEV1 is only 60% of the predicted value, indicating moderate to severe airflow obstruction. The COPD Assessment Test (CAT) score of 21 also suggests that the patient's symptoms are not well controlled.\n\nAdding theophylline (①) or fluticasone (②) may not be effective in managing the patient's symptoms, as they are not directly related to the patient's COPD symptoms. Azithromycin (③) may be effective in managing the patient's respiratory symptoms, but it is not clear whether the patient has a bacterial infection that would warrant the use of antibiotics.\n\nChanging the patient's medication to a different combination of bronchodilators, such as switching umeclidinium/vilanterol to vilanterol/fluticasone (④), may be a more appropriate option. This would provide a different combination of medications that may be more effective in managing the patient's symptoms.\n\nAlternatively, adding a different medication, such as theophylline (①) or azithromycin (③), to the patient's current regimen may also be considered. However, this would depend on the patient's individual needs and medical history, and would require careful monitoring and adjustment by a healthcare professional.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ⑤ QTc 간격 연장\n\nRoflumilast, a phosphodiesterase-4 inhibitor, is known to prolong the QTc interval, which can increase the risk of ventricular arrhythmias, such as torsades de pointes. This is a major adverse effect of the drug, especially in patients with a history of cardiovascular disease or risk factors for QT prolongation.\n\nTherefore, option ⑤ QTc 간격 연장 is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 란소프라졸(lansoprazole)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 레보설피리드(levosulpiride)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 푸로세미드(furosemide) 80 mg 1일 1회 추가\n\nExplanation:\nThe patient has developed edema, which is indicated by the recent weight gain of 3 kg in 1 week, and the urine output and proteinuria in the urinalysis. The patient is currently taking spironolactone, which is a potassium-sparing diuretic, but it seems that the diuretic effect is not enough to compensate for the excess fluid retention.\n\nAdding furosemide, a loop diuretic, will help increase urine production and reduce the fluid retention, which will help alleviate the edema. Amiloride and indapamide are also diuretics, but they may not be as effective in this case since the patient already has a potassium-sparing diuretic, spironolactone, and the main issue is fluid retention rather than potassium levels. Changing spironolactone to indapamide or furosemide may not be necessary, and the patient should continue taking spironolactone as prescribed.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 시프로플록사신(ciprofloxacin)\n\nExplanation:\n\nThe patient has a history of chronic bronchitis and has been taking norfloxacin for the past week, but the symptoms have worsened, and a diagnosis of acute exacerbation of chronic bronchitis (AECB) has been made. The patient's lab results show an elevated white blood cell count (WBC) and a high neutrophil count, which are indicative of a bacterial infection.\n\nCiprofloxacin is a fluoroquinolone antibiotic that is effective against a wide range of gram-negative and gram-positive bacteria, including the most common pathogens that cause AECB, such as Haemophilus influenzae and Streptococcus pneumoniae. It is also effective against Pseudomonas aeruginosa, which is often isolated from patients with chronic bronchitis.\n\nAmpicillin (①) is a penicillin-type antibiotic that is effective against gram-positive bacteria, but it has limited activity against gram-negative bacteria. Cefotaxime (②) is a cephalosporin antibiotic that is effective against a wide range of gram-positive and gram-negative bacteria, but it may not be the best choice for AECB, as it may not penetrate the lung tissue effectively. Vancomycin (③) is a glycopeptide antibiotic that is effective against methicillin-resistant Staphylococcus aureus (MRSA), but it has limited activity against other bacteria that cause AECB. Azithromycin (⑤) is a macrolide antibiotic that is effective against a wide range of gram-positive and gram-negative bacteria, but it may not be the best choice for AECB, as it may not have adequate coverage against Pseudomonas aeruginosa.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 엔테카비르(entecavir) 투여</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① 메살라진(mesalazine)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 골리무맙(golimumab)\n\nExplanation:\n\nThe patient has been diagnosed with Crohn's disease and has been treated with loperamide, but the symptoms persist. The doctor has decided to change the treatment to adalimumab, a biologic drug that targets TNF-alpha, a protein that promotes inflammation. However, the patient's condition has not improved after using adalimumab.\n\nIn this case, the best option for a single-agent therapy to maintain remission would be golimumab, another biologic drug that targets TNF-alpha. Golimumab has been shown to be effective in treating moderate to severe Crohn's disease and has a similar mechanism of action to adalimumab.\n\nMesalazine, a 5-aminosalicylic acid, is not appropriate for this patient as it is mainly used for mild to moderate Crohn's disease and has not been shown to be effective in treating severe Crohn's disease.\n\nAzathioprine, an immunosuppressant, may be effective in maintaining remission, but it has a slower onset of action compared to biologic drugs and may not be suitable for this patient who has already tried adalimumab.\n\nUstekinumab, an anti-IL-12/23 monoclonal antibody, is not appropriate for this patient as it is mainly used for treating psoriasis and psoriatic arthritis, not Crohn's disease.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 염화마그네슘(magnesium chloride)\n\nExplanation:\n\nThe patient has chronic kidney disease and metabolic acidosis, as evidenced by the elevated serum creatinine level and the abnormal arterial blood gas analysis. The patient's pH is 7.27, which is slightly acidotic, and the PaCO2 is 29 mmHg, which is lower than the reference range of 35-45 mmHg. The HCO3- level is also lower than the reference range, indicating metabolic acidosis.\n\nMagnesium chloride (③) is an appropriate medication to treat metabolic acidosis, as it can help to increase the serum HCO3- level and neutralize the excess hydrogen ions. It is also a safer option compared to other medications, such as sodium bicarbonate (⑤), which can cause fluid overload and worsen renal function in patients with chronic kidney disease.\n\nPotassium citrate (①) and calcium gluconate (②) are not appropriate medications for treating metabolic acidosis. Potassium citrate is a potassium-sparing diuretic that can increase the risk of hyperkalemia in patients with renal impairment, while calcium gluconate is primarily used to treat hypocalcemia and has no effect on metabolic acidosis. Magnesium lactate (④) is also not a suitable option, as it can cause gastrointestinal disturbances and has no significant advantage over magnesium chloride in treating metabolic acidosis.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 겐타마이신\n\nExplanation:\n\nThe question asks which medication among the given options can increase the risk of acute tubular necrosis when used in combination with amphotericin B. The correct answer is 겐타마이신 (gentamicin), which is a nephrotoxic antibiotic that can cause renal damage and acute kidney injury, especially when used in combination with other nephrotoxic drugs.\n\nThe other options are not associated with an increased risk of acute tubular necrosis when used with amphotericin B:\n\n* 졸피뎀 (zolpidem) is a sedative that is not known to cause nephrotoxicity.\n* 암로디핀 (amlodipine) is a calcium channel blocker that is not known to cause nephrotoxicity.\n* 메트로니다졸 (metronidazole) is an imidazole antibiotic that is not known to cause nephrotoxicity.\n* 아세트아미노펜 (acetaminophen) is a nonsteroidal anti-inflammatory drug (NSAID) that is not known to cause nephrotoxicity.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 만니톨(mannitol)\n\nExplanation:\n Mannitol is a sugar-like compound that is used to prevent renal damage caused by contrast media. It works by increasing the osmolality of the blood and reducing the risk of water movement into the renal tubules, which can cause damage to the kidneys. In patients with chronic kidney disease, mannitol can help to protect the kidneys from further damage caused by the contrast media.\n\nTherefore, option ③ 만니톨(mannitol) is the correct answer.\n\nOption ① 알부민(albumin) is not relevant to the question.\n\nOption ② 포도당(dextrose) is not relevant to the question.\n\nOption ④ 생리식염수(0.9% NaCl) is not relevant to the question.\n\nOption ⑤ 저용량 도파민(dopamine) is not relevant to the question.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 에포에틴 알파의 용량 감소</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 시나칼세트\n\nReason:\n\nThe patient's symptoms of muscle weakness, muscle cramps, and decreased serum calcium levels are consistent with hypocalcemia (low calcium levels). The patient's medication list includes cinacalcet (option ③), which is a calcium-lowering agent used to treat hyperparathyroidism. It is likely that the patient's hypocalcemia is caused by the cinacalcet, which is why it is the best answer.\n\nThe other options are not as likely to cause hypocalcemia:\n\n* Amlodipine (option ②) is a calcium channel blocker used to treat hypertension and angina, but it is not known to cause hypocalcemia.\n* Irbesartan (option ④) is an angiotensin II receptor antagonist used to treat hypertension, but it is not known to cause hypocalcemia.\n* Sevelamer (option ①) is a phosphate-binding agent used to treat hyperphosphatemia in patients with chronic kidney disease, but it is not known to cause hypocalcemia.\n* Calcium polystyrene sulfonate (option ⑤) is a calcium-binding agent used to treat hypercalcemia (high calcium levels), but it is not likely to cause hypocalcemia.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 에쿨리주맙(eculizumab)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 피오글리타존(pioglitazone)\n\nExplanation:\n\nThe patient has been diagnosed with type 2 diabetes and has been prescribed metformin, which is a first-line medication for this condition. However, the patient's HbA1c level is still high, indicating that the current treatment is not effectively controlling their blood sugar levels.\n\nPioglitazone is a thiazolidinedione medication that works by increasing insulin sensitivity and reducing insulin resistance. It is often used as a second-line medication for type 2 diabetes when metformin alone is not effective. Pioglitazone has been shown to improve glycemic control and reduce the risk of cardiovascular events in patients with type 2 diabetes.\n\nThe other options, Voglibose, Saxagliptin, Glimepiride, and Empagliflozin, may also be used to treat type 2 diabetes, but they have different mechanisms of action and may not be as effective in this case. Voglibose is an alpha-glucosidase inhibitor that slows the absorption of glucose from the gut, while Saxagliptin is a dipeptidyl peptidase-4 inhibitor that increases the amount of insulin produced by the body. Glimepiride is a sulfonylurea medication that stimulates the release of insulin from the pancreas. Empagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glucose reabsorption in the kidneys.\n\nTherefore, based on the patient's history and current medications, pioglitazone is the most appropriate additional medication to control their blood sugar levels.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 리라글루티드(liraglutide)\n\nExplanation:\n\nThe patient has type 2 diabetes and hypertension, and is currently taking metformin and amlodipine. The patient has a high BMI and is experiencing significant side effects from the medications, including weight gain and injection site reactions.\n\nLiraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that is used to treat type 2 diabetes. It has been shown to improve glycemic control, reduce body weight, and lower blood pressure. It is administered via injection, which may be more convenient for the patient than taking oral medications. Additionally, liraglutide has been shown to have a beneficial effect on cardiovascular risk factors, which is important for patients with hypertension.\n\nTherefore, liraglutide may be an appropriate addition to the patient's treatment regimen, taking into account the patient's medical history, current medications, and side effects.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 인슐린디터머(insulin detemir)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 피록시캄(piroxicam) 카타플라스마제\n\nExplanation:\n\nThe patient is experiencing symptoms of neuropathic pain, which can be treated with piroxicam, a nonsteroidal anti-inflammatory drug (NSAID). Piroxicam has been shown to be effective in reducing neuropathic pain in patients with diabetic neuropathy. The other options, olanzapine, duloxetine, ketoprofen, and metoclopramide, may also be used to treat neuropathic pain, but piroxicam is a more appropriate choice for this patient based on the given information.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ 로베글리타존(lobeglitazone)\n\nExplanation:\n\nThe patient has been diagnosed with type 2 diabetes, and the current medications include metformin, sulfonylurea, and thiazolidinedione. The addition of a glitazone, such as lobeglitazone, may provide additional glucose-lowering effects and improve insulin sensitivity. Lobeglitazone has been shown to decrease HbA1c levels and improve fasting plasma glucose levels in patients with type 2 diabetes.\n\nThe other options, acarbose, gemigliptin, liraglutide, and dapagliflozin, may also be effective in lowering blood glucose levels, but they have different mechanisms of action and may not be as appropriate for this patient's specific needs. Acarbose is an alpha-glucosidase inhibitor that delays carbohydrate absorption, while gemigliptin is a dipeptidyl peptidase-4 inhibitor that increases the amount of incretin hormones in the body. Liraglutide is a glucagon-like peptide-1 receptor agonist that helps to regulate blood sugar levels and reduce appetite. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor that helps to reduce glucose reabsorption in the kidneys.\n\nTherefore, the best answer is ④ 로베글리타존(lobeglitazone).</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 레보티록신(levothyroxine)\n\nExplanation:\n\nThe patient has been diagnosed with Graves' disease and has been taking methimazole, a thyroid antagonist, for treatment. However, the patient has stopped taking the medication for the past two weeks, which may have led to a worsening of symptoms. The patient's symptoms of tachycardia, fever, nausea, and confusion suggest a thyrotoxic crisis, which requires prompt treatment.\n\nLevothyroxine, a synthetic thyroid hormone, is the drug of choice to treat thyrotoxic crisis. It will help to reduce the symptoms of thyrotoxicosis by decreasing the levels of thyroid hormones in the body. The other options, methimazole, carbimazole, propranolol, and propylthiouracil, are not appropriate for treating thyrotoxic crisis. Methimazole and carbimazole are thyroid antagonists and may worsen the symptoms. Propranolol is a beta-blocker and may help to control symptoms such as tachycardia and tremors, but it will not address the underlying cause of the thyrotoxic crisis. Propylthiouracil is a thyroid suppressant and may also worsen the symptoms.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ 이부프로펜(ibuprofen)\n\nExplanation:\n\nThe patient has been diagnosed with thyroid storm, which is a life-threatening condition that requires prompt treatment. The patient has a history of Graves' disease and has been taking methimazole, which is an antithyroid medication. However, the patient has not taken the medication for the past two weeks, which may have contributed to the development of thyroid storm.\n\nIbuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is commonly used to treat pain and fever. In this case, it is the most appropriate medication to treat the patient's fever and pain, as it is effective and has a good safety profile.\n\nAspirin (①) and tramadol (②) are not the best choices for this patient, as they are not as effective in reducing fever and may have more side effects. Celecoxib (③) is a COX-2 inhibitor that is used to treat pain and inflammation, but it may not be as effective in reducing fever. Acetaminophen (⑤) is a common medication used to treat fever and pain, but it may not be as effective in reducing inflammation.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 고요산혈증\n\nRationale: Ciprofloxacin is a fluoroquinolone antibiotic that is known to increase the risk of hypokalemia (low potassium levels) and hyperglycemia (high blood sugar levels). In this patient, the concurrent use of prednisolone, a corticosteroid, may also contribute to the risk of hypokalemia. Calcipotriol, a vitamin D analog, may also increase the risk of hyperglycemia. Therefore, option ③ 고요산혈증 (hypokalemia) is the most appropriate answer.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 7일</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 수마트립탄(sumatriptan)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe patient has acute respiratory distress syndrome (ARDS) and sepsis, which requires broad-spectrum antibiotics that cover both gram-positive and gram-negative bacteria. The combination of cefepime (a cephalosporin) and vancomycin (a glycopeptide) would provide adequate coverage against most likely pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).\n\nMoxifloxacin, a fluoroquinolone, may not be effective against MRSA and may not provide adequate coverage for gram-positive bacteria. Ertapenem, a carbapenem, may be effective against gram-negative bacteria but may not provide adequate coverage against gram-positive bacteria. Piperacillin/tazobactam, a combination of a penicillin and a beta-lactamase inhibitor, may not provide adequate coverage against MRSA. Levofloxacin, a fluoroquinolone, may not be effective against MRSA and may not provide adequate coverage for gram-positive bacteria.\n\nTherefore, the best option is ③, which is the combination of cefepime and vancomycin.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 리네졸리드\n\nExplanation:\n\n리네졸리드(linezolid) is a synthetic antibiotic that belongs to the oxazolidinone class. It works by inhibiting the synthesis of the bacterial cell wall and is effective against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). However, it can cause QTc interval prolongation, which can lead to serious cardiac arrhythmias, as seen in the given case. Therefore, ③ 리네졸리드(linezolid) is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 플루코나졸을 미카펀진(micafungin)으로 변경\n\nExplanation:\nThe patient's symptoms have worsened despite fluconazole therapy, and the blood culture shows Candida krusei, which is resistant to fluconazole. Micafungin is a fungicidal agent that is effective against Candida species, including C. krusei. It is appropriate to switch the patient's medication to micafungin to improve efficacy and prevent further complications.\n\nTherefore, option ④ 플루코나졸을 미카펀진(micafungin)으로 변경 is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ 아목시실린과의 상호작용\n\nExplanation:\n\nThe patient has a history of Helicobacter pylori positive gastritis and is being treated with fluconazole. The reason for reducing the dose of fluconazole is to avoid a potential drug interaction with amoxicillin, which is also being prescribed to the patient. Amoxicillin may increase the serum concentration of fluconazole, leading to increased risk of adverse effects. Therefore, option ⑤ 아목시실린과의 상호작용 (interaction with amoxicillin) is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 메트로니다졸(metronidazole)\n\nReasoning:\n\nThe patient has symptoms of typhoid fever, which is caused by Salmonella Typhi. The fact that the patient has recently traveled abroad and has symptoms of fever, headache, and abdominal pain suggests that the infection is likely to be typhoid fever. The presence of Salmonella Typhi in the patient's stool further supports this diagnosis.\n\nMetronidazole is a nitroimidazole antibiotic that is effective against anaerobic bacteria, including Salmonella Typhi. It is the drug of choice for treating typhoid fever and has been shown to be effective in reducing the duration of fever and the severity of symptoms.\n\nThe other options are not as appropriate for treating typhoid fever. Colistin (①) is a polymyxin antibiotic that is effective against gram-negative bacteria, but it is not active against Salmonella Typhi. Meropenem (②) is a carbapenem antibiotic that is effective against a wide range of gram-negative bacteria, but it is not active against Salmonella Typhi. Vancomycin (③) is a glycopeptide antibiotic that is effective against gram-positive bacteria, but it is not active against Salmonella Typhi. Ciprofloxacin (⑤) is a fluoroquinolone antibiotic that is effective against a wide range of gram-negative bacteria, but it is not as effective against Salmonella Typhi as metronidazole.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 세프트리악손(ceftriaxone)＋반코마이신(vancomycin)\n\nExplanation:\nThe patient has been diagnosed with bacterial meningitis, which is a serious infection that requires prompt treatment. The appropriate treatment for this condition is a combination of antibiotics that cover both gram-positive and gram-negative bacteria.\n\nCeftriaxone is a third-generation cephalosporin that is effective against a wide range of gram-negative bacteria, including many strains of Streptococcus pneumoniae, which is a common cause of bacterial meningitis. Vancomycin is a glycopeptide antibiotic that is effective against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), which is a common cause of nosocomial infections.\n\nThe combination of ceftriaxone and vancomycin provides broad-spectrum coverage against both gram-positive and gram-negative bacteria, making it an appropriate choice for the treatment of bacterial meningitis.\n\nThe other options are not appropriate for the treatment of bacterial meningitis. Ampicillin and cefotaxime are both effective against gram-negative bacteria, but they have limited activity against gram-positive bacteria. Cefepime is a fourth-generation cephalosporin that is effective against a wide range of gram-negative bacteria, but it has limited activity against gram-positive bacteria. Ceftriaxone and vancomycin plus ampicillin or cefotaxime may provide adequate coverage against gram-negative bacteria, but they do not provide adequate coverage against gram-positive bacteria. Moxifloxacin is a fluoroquinolone antibiotic that is effective against gram-negative bacteria, but it has limited activity against gram-positive bacteria and is not typically used in the treatment of bacterial meningitis.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ 10일</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 에스시탈로프람\n\nExplanation:\nSumatriptan is a serotonin receptor agonist, and it can increase the risk of serotonin syndrome when taken with other drugs that affect serotonin levels. Escitalopram is a selective serotonin reuptake inhibitor (SSRI), which can increase serotonin levels in the body. Therefore, taking sumatriptan and escitalopram together can increase the risk of serotonin syndrome.\n\nThe other options do not have a significant interaction with sumatriptan:\n\n* Lisinopril is an ACE inhibitor and has no known interaction with sumatriptan.\n* Felodipine is a calcium channel blocker and has no known interaction with sumatriptan.\n* Dexibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) and has no known interaction with sumatriptan.\n* Omeprazole is a proton pump inhibitor and has no known interaction with sumatriptan.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 쿠에티아핀(quetiapine)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 프레가발린(pregabalin)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ VKORC1</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 동맥혈가스분압\n\nExplanation:\n\nThe patient's symptoms of fatigue, nausea, vomiting, weight gain, and irregular menstrual cycles suggest that the lithium carbonate medication may be causing hypothyroidism. The patient's lithium level of 1.6 mmol/L is also elevated, which supports this diagnosis.\n\nIn this case, it is important to check the patient's thyroid function tests, specifically the T4 and TSH levels, to confirm the diagnosis of hypothyroidism. Therefore, the answer is ③ 동맥혈가스분압 (thyroid function test).</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 졸피뎀(zolpidem)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 수면무호흡\n\nExplanation:\nMethylphenidate, a medication used to treat attention deficit hyperactivity disorder (ADHD), can cause sleep disorders, including sleep apnea. Sleep apnea is a condition where a person's breathing is interrupted during sleep, either due to a blockage in the airway or a lack of respiratory effort. In this case, the patient's age and the medication they are taking increase the risk of sleep apnea. Therefore, monitoring for sleep apnea is necessary to ensure the patient's safety and well-being.\n\nThe other options are not directly related to the patient's medication and condition:\n\n① Low blood sugar (hypoglycemia) is a potential side effect of some medications, but it is not typically associated with methylphenidate.\n\n② Decreased appetite is a common side effect of methylphenidate, but it is not a direct concern in this scenario.\n\n④ Hypothyroidism (an underactive thyroid gland) is not typically associated with methylphenidate.\n\n⑤ High blood pressure (hypertension) is not typically associated with methylphenidate. However, it is important to monitor blood pressure in patients taking any medication, especially in children and adolescents.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 경구제와 주사제를 2주 동안 병용한 후 주사제 단독 사용</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ 팔리페리돈(paliperidone)\n\nExplanation:\n\nThe patient has been diagnosed with treatment-resistant schizophrenia, which means that they have not responded to previous treatments with antipsychotic medications. In this case, the patient has been treated with risperidone and aripiprazole, but their symptoms have not improved. The patient's low adherence to aripiprazole treatment may be due to various factors, such as side effects, lack of efficacy, or patient non-compliance.\n\nGiven the patient's history of treatment resistance, it is appropriate to consider alternative antipsychotic medications that may be more effective for their condition. Paliperidone, a second-generation antipsychotic, has been shown to have efficacy in treating treatment-resistant schizophrenia. Therefore, option ④ 팔리페리돈(paliperidone) is the most appropriate answer.\n\nOption ① 클로자핀(clozapine) is not the most appropriate choice, as it is typically reserved for patients who have not responded to other antipsychotic medications and have significant side effects.\n\nOption ② 올란자핀(olanzapine) is not the most appropriate choice, as it has not been shown to have a significant advantage over other antipsychotic medications in treating treatment-resistant schizophrenia.\n\nOption ③ 할로페리돌(haloperidol) is not the most appropriate choice, as it is a first-generation antipsychotic that has been associated with significant side effects and has not been shown to have a significant advantage over second-generation antipsychotics in treating treatment-resistant schizophrenia.\n\nOption ⑤ 클로자핀＋할로페리돌 is not the most appropriate choice, as combining two antipsychotic medications may increase the risk of side effects and has not been shown to be more effective than using a single antipsychotic medication in treating treatment-resistant schizophrenia.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 트라마돌(tramadol)\n\nExplanation:\n\nThe patient has been diagnosed with osteoarthritis and has been taking acetaminophen at the maximum dose without significant pain relief. In this case, tramadol, a weak opioid, may be a suitable additional medication to consider. Tramadol has a ceiling effect, meaning that the pain-relieving effect plateaus at a certain dose and does not increase with further dose increases. This makes it a potentially safer option compared to other opioids. Additionally, tramadol has a lower risk of constipation compared to other opioids, which is a common side effect in patients with osteoarthritis.\n\nVitamin D (②) is not directly related to pain management and is not a suitable option for this patient's condition.\n\nDuloxetine (③) is a serotonin-norepinephrine reuptake inhibitor that is used to treat depression, anxiety, and some types of pain. However, it is not typically used to treat osteoarthritis pain.\n\nCelecoxib (④) is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat pain and inflammation associated with osteoarthritis. However, it may not be suitable for this patient due to the potential risk of gastrointestinal ulcers and bleeding, especially when combined with acetaminophen.\n\nDiclofenac (⑤) is another NSAID that is used to treat pain and inflammation associated with osteoarthritis. However, like celecoxib, it may not be suitable for this patient due to the potential risk of gastrointestinal ulcers and bleeding, especially when combined with acetaminophen.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 인터페론감마분비검사\n\nExplanation:\n\nInterferon gamma release assays (IGRA) are used to monitor the immune response to infections, such as tuberculosis. Hydroxychloroquine, the drug mentioned in the question, can cause an increased risk of tuberculosis, and therefore, monitoring the immune response to tuberculosis using an IGRA test is necessary.\n\nThe other options are not relevant to the scenario described in the question:\n\n① Angiography is a test that uses X-rays and contrast dye to visualize blood vessels and is not related to monitoring the immune response.\n\n② Liver function tests are used to assess liver damage or disease, but they are not directly related to monitoring the immune response.\n\n③ B-type natriuretic peptide (BNP) tests are used to diagnose and monitor heart failure, but they are not related to monitoring the immune response.\n\n⑤ Upper gastrointestinal endoscopy is a test that visualizes the inside of the upper digestive tract and is not related to monitoring the immune response.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 콜키신과 알로푸리놀\n\nExplanation:\nThe patient's symptoms of muscle pain and elevated creatine kinase suggest a possible interaction between colchicine and allopurinol, which can increase the risk of muscle damage. Colchicine is a drug that can cause muscle damage, and allopurinol can increase the risk of muscle damage by inhibiting the enzyme that breaks down colchicine. Therefore, option ③, 콜키신과 알로푸리놀, is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 벤라팍신(venlafaxine)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② 탐스로신(tamsulosin)\n\nExplanation:\n\nThe patient has been diagnosed with benign prostatic hyperplasia (BPH) and is experiencing symptoms such as difficulty starting to urinate, frequent urination, and urgency. Tamsulosin is an alpha-1 adrenergic receptor antagonist that is commonly used to treat BPH symptoms. It works by relaxing the smooth muscle in the prostate and bladder neck, making it easier to urinate.\n\nTadalafil, a phosphodiesterase type 5 inhibitor, is not appropriate for this patient's symptoms as it is primarily used to treat erectile dysfunction. Tolterodine, an anticholinergic agent, may be used to treat urinary incontinence, but it is not the most appropriate choice for this patient's symptoms. Oxybutynin, an anticholinergic agent, may be used to treat urinary incontinence, but it is not the most appropriate choice for this patient's symptoms. Dutasteride, a 5-alpha-reductase inhibitor, is not appropriate for this patient's symptoms as it is primarily used to treat an enlarged prostate.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ② 페소테로딘(fesoterodine)\n\nExplanation:\n\nThe patient is experiencing urinary retention and difficulty urinating, especially at night, which suggests a possible overactive bladder (OAB) symptom. Fesoterodine is a medication that is used to treat OAB symptoms, including urgency, frequency, and urgency urinary incontinence. It works by relaxing the bladder muscle and increasing the amount of urine that can be stored in the bladder.\n\nSildenafil (①) is a medication that is used to treat erectile dysfunction, and it is not appropriate for treating urinary retention. Finasteride (③) is a medication that is used to treat benign prostatic hyperplasia (BPH), but it may not be effective for treating OAB symptoms. Levofloxacin (④) is an antibiotic that is used to treat bacterial infections, and it is not appropriate for treating OAB symptoms. Desmopressin (⑤) is a medication that is used to treat central diabetes insipidus, and it is not appropriate for treating OAB symptoms.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 베네토클락스(venetoclax)＋아자시티딘(azacitidine)\n\nExplanation:\n\nThe patient has been diagnosed with acute myeloid leukemia (AML) and has achieved complete remission (CR) after receiving standard chemotherapy with cytarabine and idarubicin. The patient's ECOG performance status is currently 1.\n\nGiven the patient's age and ECOG status, and the fact that they have achieved CR after chemotherapy, the most appropriate treatment option would be to continue with maintenance therapy to prevent relapse.\n\nOption ③, venetoclax plus azacitidine, is a commonly used maintenance regimen for AML patients who have achieved CR. Venetoclax is a BCL-2 inhibitor that targets the BCL-2 protein, which is overexpressed in many AML cells. Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferases, leading to the reexpression of tumor suppressor genes and the inhibition of cell proliferation.\n\nThe other options are not the most appropriate for this patient's current situation:\n\nOption ①, high-dose cytarabine, may be considered for patients who have not achieved CR with standard chemotherapy, but it is not the most appropriate choice for this patient who has already achieved CR.\n\nOption ②, arsenic trioxide plus idarubicin, is a combination that has been used in the treatment of AML, but it is not a standard maintenance regimen.\n\nOption ④, mitoxantrone plus cladribine plus cytarabine, is a combination that has been used in the treatment of AML, but it is not a standard maintenance regimen and may be associated with more side effects.\n\nOption ⑤, cytarabine plus daunorubicin plus midostaurin, is a combination that has been used in the treatment of AML, but it is not a standard maintenance regimen and may be associated with more side effects.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 이매티닙 일시 중단\n\nExplanation:\n\nThe patient's significant decrease in white blood cell count and platelet count, along with the absence of Bcr-abl kinase domain mutation, suggests that the patient may be experiencing bone marrow suppression due to imatinib therapy. In this case, the most appropriate action would be to temporarily discontinue imatinib therapy (option ①) and monitor the patient's blood cell counts. If the counts recover, imatinib therapy can be reinstated at a lower dose or with dose adjustments.\n\nOption ②, dexamethasone, is a corticosteroid that can be used to treat imatinib-induced bone marrow suppression. However, it is not the most appropriate choice in this scenario as the patient's bone marrow suppression is likely due to imatinib therapy itself, rather than an inflammatory response.\n\nOption ③, hydroxyurea, is a medication that can be used to treat bone marrow suppression caused by myeloproliferative neoplasms. However, it is not appropriate in this scenario as the patient's bone marrow suppression is due to imatinib therapy, not a myeloproliferative neoplasm.\n\nOption ④, darbepoetin alfa, is a medication that can be used to stimulate the production of red blood cells. However, it is not appropriate in this scenario as the patient's anemia is likely due to bone marrow suppression caused by imatinib therapy, rather than a lack of red blood cell production.\n\nOption ⑤, switching imatinib to ponatinib, may be considered if the patient continues to experience bone marrow suppression despite dose adjustments. Ponatinib is a second-generation tyrosine kinase inhibitor that has been shown to have less myelotoxicity compared to imatinib. However, this option is not the most appropriate in this scenario as the patient's bone marrow suppression is likely due to imatinib therapy itself, rather than a lack of efficacy.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 요소호기검사\n\nExplanation:\n\nLetrozole is an aromatase inhibitor, which works by reducing the production of estrogen in the body. It is commonly used to treat hormone-sensitive breast cancer in postmenopausal women. One of the major adverse effects of letrozole is an increase in serum estrogen levels, which can lead to endometrial thickening and increased risk of endometrial cancer. Therefore, it is important to monitor the patient's endometrial status during letrozole therapy.\n\n option ④ 요소호기검사 (endometrial thickness test) is the most appropriate answer, as it can help assess the patient's endometrial status and detect any abnormal thickening of the endometrium that may indicate the development of endometrial cancer.\n\n option ① 청력검사 (hearing test) is not relevant to the patient's condition and treatment.\n\n option ② 골밀도검사 (bone density test) may be relevant for patients with breast cancer who are at risk of osteoporosis or bone metastases, but it is not directly related to the patient's current condition and treatment.\n\n option ③ 대변잠혈검사 (liver function test) may be relevant for patients with liver metastases or liver dysfunction, but it is not directly related to the patient's current condition and treatment.\n\n option ⑤ 투베르쿨린피부반응검사 (Tuberculin skin test) is not relevant to the patient's condition and treatment.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 오시머티닙(osimertinib)</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 1초간강제호기량</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 라파티닙(lapatinib)＋엑스메스탄(exemestane)\n\nExplanation:\n\nThe patient has been diagnosed with hormone receptor-negative (HR-) and human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Lapatinib is a tyrosine kinase inhibitor that targets HER2 and EGFR, which is overexpressed in HER2+ breast cancer. Exemestane is an aromatase inhibitor that reduces the production of estrogen, which can stimulate the growth of HR- breast cancer. The combination of lapatinib and exemestane has been shown to be effective in treating HER2+ breast cancer in postmenopausal women.\n\nTherefore, option ③ 라파티닙(lapatinib)＋엑스메스탄(exemestane) is the most appropriate answer.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 메토클로프라미드(metoclopramide)\n\nExplanation:\n\nMetoclopramide is a dopamine receptor antagonist that is commonly used to treat nausea and vomiting associated with chemotherapy. It works by blocking the action of dopamine on the vomiting center in the brain, thereby reducing the incidence of nausea and vomiting. In this case, the patient has experienced nausea and vomiting after receiving ondansetron, which suggests that the patient may have a dopamine-mediated response to chemotherapy. Therefore, metoclopramide may be an effective treatment option to alleviate the patient's symptoms.\n\nThe other options are not appropriate for this patient's condition:\n\n① Baclofen is a muscle relaxant that is not commonly used to treat nausea and vomiting.\n\n② Rebamipide is a gastric mucosal protectant that may help to protect the stomach lining from damage caused by chemotherapy, but it is not effective in treating nausea and vomiting.\n\n③ Misoprostol is a prostaglandin analog that is used to prevent gastric ulcers and reduce the risk of NSAID-induced gastrointestinal bleeding. It is not commonly used to treat nausea and vomiting.\n\n⑤ Dioctahedral smectite is a type of clay that is used as an antidiarrheal agent. It is not effective in treating nausea and vomiting.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 티몰롤(timolol) 점안제 1일 2회</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 시트르산칼슘(calcium citrate)</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 트라마돌(tramadol)</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 젖산 탈수소효소\n\nExplanation:\n\nAs a pharmacist, it is important to monitor the patient's renal function when prescribing metformin, especially in patients with pre-existing renal impairment. Metformin is known to increase the risk of lactic acidosis in patients with renal impairment, and this risk is further increased when metformin is prescribed in combination with other medications that may also affect renal function.\n\nTherefore, when reviewing the patient's medication chart, it is important to check for any signs of renal impairment, such as elevated serum creatinine levels or decreased estimated glomerular filtration rate (eGFR). Additionally, it is important to assess the patient's urinary output and proteinuria, as these can also be indicative of renal impairment.\n\nIn this case, the patient's age and pre-existing renal impairment suggest that monitoring of renal function is necessary. Therefore, the most appropriate answer is ④ 젖산 탈수소효소 (serum creatinine level).</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ①</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 건조분말흡입제(dry powder inhaler)</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 푸로세미드\n\nExplanation:\n\nThe patient is taking furosemide (⑤) 40 mg once daily, but the dosage interval is not specified. However, based on the information provided, it can be inferred that the patient is taking furosemide in the morning, as the other medications are also taken in the morning. Therefore, the dosage interval for furosemide should be adjusted to \"1일 1회, 아침\" to ensure consistent dosing.\n\nThe other options do not require adjustments to their dosage intervals:\n\n① Amlodipine (10 mg) is taken once daily in the morning.\n\n② Aspirin (100 mg) is taken once daily in the morning.\n\n③ Ibandronate (150 mg) is taken once a month, and the dosage interval is not specified. However, it is not necessary to adjust the dosage interval for this medication.\n\n④ Atorvastatin (10 mg) is taken once daily in the morning.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 알마게이트\n\nExplanation:\n\nWarfarin is a drug that works by inhibiting the vitamin K-dependent synthesis of clotting factors in the liver. When taken with other drugs that also interact with vitamin K, such as gabapentin, amiodarone, and spironolactone, it can increase the risk of bleeding. Almagate, which contains aluminum hydroxide, can also interact with warfarin by binding to it and reducing its absorption. Therefore, among the options listed, the drug that may require dose adjustment when taken with warfarin is almagate.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 카르바마제핀\n\nExplanation:\n\nThe patient should avoid taking protein-rich foods with the medication, so the best answer is ③ 카르바마제핀 (carbamazepine CR 200 mg). Carbamazepine is known to have a high risk of protein binding, which can lead to reduced efficacy and increased risk of adverse effects when taken with high-protein meals. Therefore, it is recommended to take carbamazepine at least 1 hour before or 2 hours after meals to minimize protein binding and optimize its efficacy.\n\nThe other options do not have significant protein binding effects and therefore do not require avoidance of protein-rich foods:\n\n① 클로자핀 (clozapine) has a low risk of protein binding.\n② 펠로디핀 (felodipine) has a low risk of protein binding.\n④ 아토르바스타틴 (atorvastatin) has a low risk of protein binding.\n⑤ 레보도파/카르비도파 (levodopa/carbidopa) CR has a low risk of protein binding.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 시타라빈(cytarabine)</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 암로디핀\n\nExplanation:\n\nThe patient is taking amlodipine, valsartan, simvastatin, aspirin, and omega-3-acids ethyl esters. The drug interaction service alerted the physician that clarithromycin, which the patient is prescribed, may have a severe interaction with amlodipine. Therefore, the correct answer is ③ 암로디핀 (amlodipine).</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ I: 클로피도그렐 투여\n\nExplanation:\n\nThe patient has a history of coronary artery disease and is currently taking amlodipine, valsartan, simvastatin, and aspirin. The addition of clopidogrel is being considered as a first-line preventive therapy for coronary artery disease. Therefore, the appropriate PICO (Population, Intervention, Comparison, Outcome) format for this scenario would be:\n\nP: Patients with coronary artery disease\nI: Clopidogrel therapy\nC: Comparison group (patients without clopidogrel therapy)\nO: Outcome (e.g. reduction in cardiovascular events)\n\nSo, the correct answer is ③ I: 클로피도그렐 투여.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 류코보린(leucovorin)</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 카르보플라틴의 반감기\n\nExplanation:\nThe patient's carboplatin dose is calculated based on their creatinine clearance, which is a measure of their kidney function. The creatinine clearance is used to determine the patient's glomerular filtration rate (GFR), which is then used to calculate the carboplatin dose. The GFR is calculated using the patient's serum creatinine concentration and their urine output. Therefore, the information needed to calculate the carboplatin dose is the patient's creatinine clearance, which is option ④.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 파클리탁셀(paclitaxel)</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ 혈중 알라닌아미노전달효소(ALT) 농도\n\nExplanation:\n\nAmiodarone is a medication that can cause liver damage, and ALT (alanine transaminase) is an enzyme that is often used as a marker of liver damage. Therefore, monitoring ALT levels is necessary to check for liver damage in a patient taking amiodarone.\n\nThe other options are not directly related to liver damage or are not specific enough to detect liver damage caused by amiodarone.\n\n① White blood cell count may be elevated in response to infection or inflammation, but it is not specific to liver damage.\n\n② Bilirubin is a marker of liver function, but it is not as sensitive as ALT for detecting early signs of liver damage.\n\n③ Total cholesterol levels may be affected by amiodarone, but it is not a specific marker of liver damage.\n\n④ Thyroid-stimulating hormone (TSH) levels may be affected by amiodarone, but it is not a specific marker of liver damage.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 90분에 걸쳐 천천히 주입</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 약물이상반응</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 톨터로딘(tolterodine) 정</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 세티리진(cetirizine)</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 로페라미드(loperamide)</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 로페라미드(loperamide)\n\nExplanation:\n\nLoperamide is an antidiarrheal medication that can help relieve diarrhea and abdominal pain. It works by slowing down the movement of the bowels and increasing the amount of water and electrolytes in the stool. This can help to firm up the stool and reduce the number of bowel movements.\n\nIn this case, the patient is experiencing diarrhea and abdominal pain, which are common symptoms of gastrointestinal problems. Loperamide is an appropriate treatment option for this patient because it can help to relieve these symptoms and improve the patient's quality of life.\n\nThe other options are not appropriate for this patient's symptoms. Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve pain and reduce inflammation. It is not effective in treating diarrhea or abdominal pain. Almagate is an antacid that is used to neutralize stomach acid and relieve heartburn and indigestion. It is not effective in treating diarrhea or abdominal pain. Flubendazole is an anthelmintic that is used to treat parasitic infections. It is not effective in treating diarrhea or abdominal pain. Guaifenesin is an expectorant that is used to thin and loosen mucus in the airways. It is not effective in treating diarrhea or abdominal pain.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 오림산(五淋散)</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 여성형유방이 나타날 수 있음\n\nExplanation:\n\nSpironolactone is a potassium-sparing diuretic that can cause breast tenderness and gynecomastia (the development of female-like breasts) in men. Therefore, option ① 여성형유방이 나타날 수 있음 (breast tenderness and gynecomastia may occur) is the correct answer.\n\nOption ② 이상반응 감소를 위하여 저녁에 투여함 (reducing the dose in the evening to minimize side effects) is incorrect because it does not address the specific side effect of breast tenderness and gynecomastia.\n\nOption ③ 전해질 불균형을 해소하기 위해 저염식이를 할 수 있음 (correcting electrolyte imbalances with diet) is incorrect because spironolactone does not cause electrolyte imbalances.\n\nOption ④ 투여 초기에 소변량 및 소변 횟수가 증가하면 즉시 중단함 (stopping the medication immediately if there is an increase in urine output and frequency during the initial stages of treatment) is incorrect because it does not relate to the side effect of breast tenderness and gynecomastia.\n\nOption ⑤ 체내 칼륨 소실이 심해지므로 칼륨을 많이 함유한 식품을 섭취함 (consuming foods rich in potassium to compensate for potassium loss) is incorrect because spironolactone is a potassium-sparing diuretic, meaning that it helps the body retain potassium, rather than losing it.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 1매가 48시간 지속형 제제이므로 2일 간격으로 붙임</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 7일</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② 펜타닐 설하정</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 효능 ∙ 효과, 용법 ∙ 용량 및 사용상의 주의사항</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 이온교환수지 통과</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nThe potential risk of cross-contamination in the production of pharmaceuticals can vary depending on the dosage form. In order of highest to lowest risk, the correct order is:\n\n1. Injectables (정맥투여제제) - Since injectables are directly administered into the bloodstream, any contamination can have a direct and immediate impact on the patient's health.\n2. Eye drops (점안제) - Eye drops are used to treat eye infections and other conditions, and any contamination can cause serious harm to the eye.\n3. Oral solutions (경구제제) - Oral solutions are used to treat a variety of conditions, and any contamination can cause gastrointestinal problems or other health issues.\n4. Topicals (경피제) - Topicals are applied directly to the skin, and any contamination can cause skin irritation or other localized reactions.\n\nTherefore, the correct order is: 정맥투여제제 > 점안제 > 경구제제 > 경피제.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 필터 세공의 평균크기</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 효력시험 자료</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② 정확성</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 액체크로마토그래프법</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 과립 혼합 후</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe question is asking about the conditions for measuring the optical density of glucosamine sulfate, a substance regulated by the Korean Pharmacopoeia. The correct answer is ③, which states that the measurement should be done using a spectrophotometer with a wavelength of 540 nm.\n\nThe other options are incorrect for the following reasons:\n\n① is incorrect because the question specifically states that the measurement should be done at 25°C, not at room temperature.\n\n② is incorrect because the question is asking about the conditions for measuring the optical density, not whether the substance is a standard sample.\n\n④ is incorrect because the question states that the substance should be dried at 100 mmHg, not under vacuum.\n\n⑤ is incorrect because the question states that the optical density should be measured at a wavelength of 540 nm, not +6° to +11°.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 강열잔분</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 글리세린</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 아스피린</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ 요인으로 인한 효과에 차이가 없게 블록을 만든다.\n\nExplanation:\n\nWhen designing an experiment, it is important to consider various factors that could affect the outcome. One way to ensure the objectivity of the experiment is to control for these factors by using a blocking design. A blocking design involves dividing the experimental units into groups, or blocks, based on certain characteristics, such as the source of the samples, the experimental conditions, or the time of day. By doing so, the experimenter can minimize the impact of these factors on the experimental outcome, ensuring that the results are not biased by any particular factor.\n\nOption ⑤, \"요인으로 인한 효과에 차이가 없게 블록을 만든다,\" is the correct answer because it describes the use of a blocking design to control for factors that could affect the experimental outcome.\n\nOption ①, \"시료의 채취량을 줄인다,\" is incorrect because it refers to reducing the sample size, which is not a method for controlling extraneous variables.\n\nOption ②, \"실험의 순서를 랜덤하게 한다,\" is incorrect because randomizing the order of the experiment does not necessarily control for extraneous variables.\n\nOption ③, \"인자간의 교호작용을 고려하지 않는다,\" is incorrect because it refers to ignoring the interaction between factors, which is not a method for controlling extraneous variables.\n\nOption ④, \"각 군당 자료의 수를 서로 다르게 한다,\" is incorrect because it refers to changing the number of samples in each group, which is not a method for controlling extraneous variables.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ④ 10^-4</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 111℃에서 80분간 멸균</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 유동부채는 2억 원이다.\n\nExplanation:\n\nThe question states that the pharmacist has 4 billion won in cash and has borrowed 2 billion won from the bank with a 5-year repayment term. The pharmacist used 5 billion won to purchase the pharmacy store, and the remaining 1 billion won was used to buy medicines.\n\nTherefore, the current assets of the pharmacy are:\n\n* Cash: 4 billion won\n* Inventory (medicines): 1 billion won\n\nThe current liabilities of the pharmacy are:\n\n* Bank loan: 2 billion won\n\nSo, the current ratio is:\n\nCurrent assets: 5 billion won\nCurrent liabilities: 2 billion won\n\nThe answer is ③ 유동부채는 2억 원이다.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 100병\n\nExplanation:\n\nThe average daily demand for the hospital's infusion solution is 7,300 / 365 = 20.17 bottles per day.\n\nThe lead time for procurement is 5 days, so the safety stock level should be enough to cover the demand during the lead time.\n\nThe safety stock level is 146 bottles, which is not enough to cover the demand during the lead time.\n\nTo prevent stockouts, the hospital should reorder the infusion solution when the inventory level falls below 100 bottles (③).\n\nTherefore, the answer is ③ 100병.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 2억 2천만 원</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 총액예산제</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ 보건의료공급자의 공급독점</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②\n\nExplanation:\n\nPharmacovigilance refers to the process of collecting, monitoring, and analyzing data on the safety of drugs in real-world settings. This includes collecting data on adverse events that occur during drug use, analyzing the data to identify potential safety issues, and taking appropriate action to minimize or mitigate those risks. Therefore, option ②, \"collecting and analyzing data on adverse events that occur during drug use,\" is the correct answer.\n\nOption ①, \"evaluating the competence of testing institutions,\" is not directly related to pharmacovigilance, as it refers to the evaluation of institutions that conduct tests on drugs rather than the monitoring of drug safety.\n\nOption ③, \"monitoring the use of drugs through the drug integration management system,\" is also not directly related to pharmacovigilance, as it refers to the monitoring of drug use patterns rather than the monitoring of drug safety.\n\nOption ④, \"ensuring that quality standards are met during the drug manufacturing process,\" is important for ensuring the safety and efficacy of drugs, but it is not directly related to pharmacovigilance, which focuses on monitoring drug safety in real-world settings.\n\nOption ⑤, \"conducting quality inspections on each production unit of vaccines,\" is related to ensuring the quality and safety of vaccines, but it is not directly related to pharmacovigilance, which focuses on monitoring drug safety in real-world settings rather than conducting quality inspections on individual production units.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤\n\nExplanation:\n\nThe correct answer is ⑤, \"a drug that has a low price but can replace high-priced drugs and is cost-effective in terms of its effectiveness.\"\n\nThe question is asking for a drug that can be designated as an \"essential drug\" in a hospital pharmacy. An essential drug is a drug that is considered necessary for addressing the priority health needs of a population, and is typically selected based on its efficacy, safety, and cost-effectiveness.\n\nOption ⑤ meets the criteria for an essential drug, as it is described as having a low price but still being effective in replacing high-priced drugs. This suggests that it is a cost-effective option that can provide similar benefits to more expensive drugs, making it a good choice for an essential drug.\n\nThe other options do not meet the criteria for an essential drug. Option ①, \"a high-priced drug,\" is not cost-effective and may not be accessible to all patients. Option ②, \"a drug that is supplied by the Korean Pharmaceutical Association,\" may not be widely available or accessible outside of Korea. Option ③, \"a drug with a high insurance claim amount and increasing usage,\" may not be cost-effective and may have safety concerns. Option ④, \"a drug that is essential for national security and should be stockpiled,\" is not relevant to the context of a hospital pharmacy.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 시간과 비용이 적게 든다.\n\nExplanation:\n\nIn a randomized controlled trial (RCT), participants are randomly assigned to either the treatment group or the control group. This design allows researchers to minimize confounding bias and ensure that the groups are comparable in terms of all relevant factors, including age, gender, and other demographic characteristics.\n\nOn the other hand, in an observational study, participants are not randomly assigned to groups, and researchers have no control over the assignment of participants to different groups. This can lead to confounding bias, as participants who choose to receive the treatment may differ from those who do not receive the treatment in terms of factors that can affect the outcome.\n\nTherefore, RCTs are generally considered to have a higher level of evidence than observational studies, as they are better able to establish causality between the intervention and the outcome.\n\nIn terms of the advantages of RCTs, option ①, \"시간과 비용이 적게 든다,\" is correct. RCTs are often more time-consuming and expensive than observational studies, as they require the recruitment of participants, the random assignment of participants to groups, and the collection of data on outcomes. However, the benefits of RCTs, including their ability to establish causality and minimize confounding bias, make them a valuable tool in medical research.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ②\n\nExplanation:\n\nThe correct answer is ②, \"간염치료제 A 비투여군\" (control group not receiving drug A).\n\nIn a patient-controlled study to investigate the association between the use of drug A and the risk of osteoporotic fractures, the control group should not receive drug A. This allows researchers to compare the outcomes between the group that receives drug A (the treatment group) and the group that does not receive drug A (the control group), thereby isolating the effect of drug A on the risk of osteoporotic fractures.\n\nOption ①, \"간염치료제 A 투여군\" (treatment group receiving drug A), is not the correct answer because it would not allow researchers to isolate the effect of drug A on the risk of osteoporotic fractures.\n\nOption ③, \"비교대상 치료제 투여군\" (comparison group receiving a different treatment), is also not the correct answer because it would not allow researchers to isolate the effect of drug A on the risk of osteoporotic fractures.\n\nOption ④, \"골다공증성 골절 발생군\" (group with osteoporotic fractures), is not the correct answer because it would not allow researchers to compare the outcomes between a group with osteoporotic fractures and a group without osteoporotic fractures.\n\nOption ⑤, \"골다공증성 골절 비발생군\" (group without osteoporotic fractures), is not the correct answer because it would not allow researchers to compare the outcomes between a group with osteoporotic fractures and a group without osteoporotic fractures.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤\n\nThe correct answer is ⑤. The meta-analysis result shows that the risk of emergency department visits after implementation of medication management services is lower compared to before implementation (OR = 0.85, 95% CI = 0.76, 0.95). This suggests that the implementation of medication management services may have a positive effect in reducing the risk of emergency department visits.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nIf the annual discount rate is reduced from 5% to 3%, the present value of the cost-effectiveness ratio will decrease, indicating that the intervention becomes more cost-effective. Therefore, the direction of change in the cost-effectiveness ratio will be towards a lower value, which is option ③.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 1,923\n\nExplanation:\n\nTo calculate the incremental cost-effectiveness ratio (ICER) of A compared to B, we need to calculate the difference in cost and effectiveness between the two drugs.\n\nThe difference in cost between A and B is 5,000 - 2,000 = 3,000.\n\nThe difference in effectiveness between A and B is 4 - 3.5 = 0.5 QALYs.\n\nTherefore, the ICER of A compared to B is 3,000 / 0.5 = 6,000.\n\nSo, the answer is ② 1,923.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nExplanation:\n\nThe ethical thing to do in this scenario would be to include in the informed consent document the possibility of compensation in case of harm or injury resulting from participation in the clinical trial, as well as the procedure for seeking compensation. This would ensure that participants are fully informed about the potential risks and benefits of the trial, and that they are able to make an informed decision about whether or not to participate.\n\nOption ① is not the best answer because it only mentions the promise to participate in the clinical trial, but does not address the issue of compensation for potential harm.\n\nOption ② is not relevant to the question.\n\nOption ③ is not ethical because it involves offering money to participants in exchange for their participation, which could be seen as coercive or exploitative.\n\nOption ⑤ is not the best answer because it does not address the issue of compensation for potential harm, and instead focuses on the potential impact on the participant's rights and interests.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 정의의 원칙 – 선행의 원칙\n\nExplanation:\n\nIn this scenario, the ethical principle that is most relevant is the principle of justice. The patient, A, is seeking treatment for their cancer, and the pharmacist has a duty to provide safe and effective treatment options. However, the patient's request for a specific treatment that has not been proven to be effective raises concerns about the principle of justice, as it may lead to unequal access to healthcare resources and potentially harm the patient.\n\nThe pharmacist must consider the principle of justice in their decision-making process, ensuring that they provide the patient with safe and effective treatment options that are backed by scientific evidence. This may involve discussing alternative treatment options with the patient and their healthcare provider, or referring the patient to a specialist who can provide further guidance.\n\nTherefore, option ③, 정의의 원칙 – 선행의 원칙, is the most appropriate answer.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 1.5\n\nExplanation:\n\nTo calculate the current ratio, we need to divide the current assets (유동자산) by the current liabilities (유동부채):\n\nCurrent Ratio = Current Assets / Current Liabilities\n= 80,000 / 20,000\n= 4\n\nSo, the current ratio is 4.\n\nTherefore, the answer is ③ 1.5.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 2.4회</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\nAccording to the Pharmacist Licensing Examination, a pharmacist is required to report their employment status and other relevant information to the licensing authority every year after obtaining their license. Failure to do so may result in disciplinary action, including license revocation. Therefore, option ③ is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④. According to the Pharmacist Licensing Examination, the question asks for the option that is not a duty of a pharmacist who opens a pharmacy. The correct answer is ④, which states that the pharmacist should designate a substitute pharmacist to manage the pharmacy if they are unable to manage it themselves. This is not a duty of a pharmacist who opens a pharmacy, as they are responsible for managing the pharmacy themselves.\n\nThe other options are all duties of a pharmacist who opens a pharmacy:\n\n① is a duty of a pharmacist who opens a pharmacy, as they are responsible for ensuring that their employees are properly trained and supervised.\n\n② is a duty of a pharmacist who opens a pharmacy, as they are responsible for displaying their pharmacist license in a conspicuous location within the pharmacy.\n\n③ is a duty of a pharmacist who opens a pharmacy, as they are responsible for reporting any changes in their business, including the transfer of ownership, to the relevant authorities within 7 days.\n\n⑤ is not a duty of a pharmacist who opens a pharmacy, as it refers to the practice of labeling prescription medications with the name and address of the pharmacy and the pharmacist responsible for dispensing the medication. While this may be a task that a pharmacist performs, it is not a duty specific to a pharmacist who opens a pharmacy.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nExplanation:\nAccording to the Pharmacist Licensing Examination, the document that a pharmacist must submit to prove that a patient's agent has the authority to request the patient's medical record is ④, a document that proves the patient's agent has legal authority to represent the patient.\n\nTherefore, the correct answer is ④, 요청인에게 법정대리권이 있음을 증명하는 서류 (A document that proves the patient's agent has legal authority to represent the patient).</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤\n\nExplanation:\n\nAccording to the Pharmacist Licensing Examination, the answer is ⑤, which refers to the case where a pharmacist can dispense or sell a drug without a prescription from a physician, in the event that the drug is designated by the Director of the Korea Disease Control and Prevention Agency as a preventive medication for a contagious disease that is likely to spread through a group, such as a pandemic.\n\nIn this scenario, the pharmacist is allowed to dispense the medication without a prescription, as it is considered a public health emergency and the medication is being used for preventive purposes. The other options do not fit the criteria for a situation where a pharmacist can dispense or sell a drug without a prescription.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④\n\nExplanation:\n\nAccording to the question, the correct answer is ④, \"일반의약품을 판매할 때에 필요하다고 판단되면 복약지도를 할 수 있다.\"\n\nThis statement is incorrect because 복약지도 (prescription) is only allowed for licensed pharmacists, and not for other healthcare professionals or individuals. Therefore, it is not appropriate to state that a non-pharmacist can prescribe medication, even if they believe it is necessary.\n\nThe other options are also incorrect for various reasons:\n\n① 한약제제는 개봉하여 판매할 수 있다: This statement is incorrect because 한약제제 (Korean traditional medicine) is not allowed to be opened and sold by non-licensed individuals.\n\n② 판매하는 의약품의 가격을 의약품의 용기나 포장에 적어야 한다: This statement is incorrect because the price of medication should be determined by the pharmacist based on various factors, such as the cost of the medication, the patient's needs, and the market price. It is not appropriate to state that the price should be determined by the packaging or labeling of the medication.\n\n③ 진단을 목적으로 한 건강상담을 통하여 일반의약품을 판매할 수 있다: This statement is incorrect because 건강상담 (health consultation) is not a valid reason to sell medication. Medication should only be sold based on a valid prescription from a licensed medical professional.\n\n⑤ 의사가 처방한 의약품이 없어 긴급하게 구하려는 다른 약국개설자에게 해당 의약품을 판매할 수 있다: This statement is incorrect because it is not appropriate to sell medication to another pharmacist who is not authorized to prescribe medication. Additionally, it is not appropriate to sell medication based on an emergency situation, as this could lead to unsafe or inappropriate use of medication.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 45일 | 6개월\n\nExplanation:\n\nAccording to the question, the person who submits the application for drug product approval should notify the patent holder of the application within 45 days from the date of application (③). The patent holder can then apply for an injunction to prohibit the sale of the drug product within 6 months from the date of notification (④). Therefore, the correct answer is ③ 45일 | 6개월.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤\n\nExplanation:\n\nThe correct answer is ⑤, \"원료 및 자재의 입고부터 완제품의 출고에 이르기까지 필요한 시험검사를 철저히 할 것\" because it is the responsibility of the manufacturing manager to ensure that all necessary tests and inspections are performed on the raw materials, packaging materials, and finished products to ensure their quality and safety. This is not mentioned in the other options.\n\nOption ①, \"제조관리기준서, 제품표준서 등에 따라 정확히 제조할 것\" refers to the responsibility of the manufacturing manager to follow the established standards and regulations for the manufacture of pharmaceutical products.\n\nOption ②, \"제조소의 시설을 위생적으로 관리하여 교차오염 등을 방지할 것\" refers to the responsibility of the manufacturing manager to ensure that the manufacturing facility is maintained in a clean and hygienic condition to prevent contamination.\n\nOption ③, \"의약품의 제조판매 품목허가 ∙ 품목신고의 갱신 업무를 철저히 할 것\" refers to the responsibility of the manufacturing manager to ensure that the necessary permits and notifications for the manufacture and sale of pharmaceutical products are obtained and maintained.\n\nOption ④, \"작업소에서 국민보건에 유해한 물질이 유출되거나 방출되지 아니하도록 할 것\" refers to the responsibility of the manufacturing manager to ensure that the manufacturing process does not release harmful substances into the environment.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\n\nAccording to the question, the pharmacist is asking about a veterinary drug that can be sold without a prescription from a veterinarian or a veterinary clinic manager. The correct answer is ③, which is the vaccine for preventing tetanus in cattle. Tetanus is a serious disease that can affect cattle and other animals, and vaccination is an important preventive measure. The vaccine is available for purchase without a prescription, and it is administered to cattle to protect them from tetanus infection.\n\nThe other options are not correct because they are not veterinary drugs that can be sold without a prescription. ① is a drug used to stimulate the production of milk in pigs, but it requires a prescription from a veterinarian. ② is a vaccine used to prevent rabies in dogs, but it also requires a prescription. ④ is a drug used to treat urinary tract infections in dogs and cats, but it requires a prescription. ⑤ is a drug used to treat bacterial infections in cats, but it also requires a prescription.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nAccording to the question, the correct answer is ③. 식품의약품안전처장 (Food and Drug Safety Directorate) has designated the adverse reactions that occur due to the use of medications for the treatment of diseases listed in the National Health Insurance Act as eligible for compensation. Therefore, if a patient experiences adverse reactions due to the use of medications for the treatment of a disease covered by the National Health Insurance Act, they are eligible for compensation.\n\nThe other options are incorrect for the following reasons:\n\n①: This option states that the person who wishes to receive compensation must apply for it directly to the National Health Insurance Corporation. However, this is not correct, as the application for compensation should be submitted to the Food and Drug Safety Directorate.\n\n②: This option states that if the adverse reaction is caused intentionally by the patient, they are not eligible for compensation. However, the question does not mention anything about the patient's intentions, so this option is not relevant.\n\n④: This option states that the compensation amount is determined based on the price of the medication and the severity of the adverse reaction. However, this is not correct, as the compensation amount is determined based on the severity of the adverse reaction, not the price of the medication.\n\n⑤: This option states that if the adverse reaction results in death, it is eligible for compensation if it is caused by a preventable disease under the Prevention and Control of Infectious Diseases Act. However, this is not correct, as the question does not mention anything about the cause of death, and the Prevention and Control of Infectious Diseases Act does not apply to adverse reactions caused by medications.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ①</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 프로포폴(propofol)</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nAccording to the \"마약류 관리에 관한 법률\" (Law on the Management of Narcotics), the mayor of a city or the head of a district can provide protection for a person who has been determined to be a drug addict. Therefore, option ③ is the correct answer.\n\nThe other options are not correct because:\n\n① The law does not specify a specific time limit for the protection period, so this option is not accurate.\n\n② The law does not mention anything about a two-month period for determining whether a person is a drug addict, so this option is also not accurate.\n\n④ While the law does give the authority to establish treatment institutions for drug addicts, it does not specify that the Food and Drug Safety Director has the authority to do so, so this option is not correct.\n\n⑤ While the law does establish a committee to deliberate on matters related to drug addiction diagnosis, it is not called the \"치료보호심사위원회\" (Treatment Protection Deliberation Committee), so this option is also not correct.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 마약류취급자를 위한 마약류 운반</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③. According to the \"National Health Promotion Act,\" warning labels must be printed on the front and back of tobacco product packaging to indicate the harmful effects of smoking. Therefore, option ③ is the correct answer.\n\nOption ① is incorrect because it states that the phone number for smoking cessation counseling should be printed on the packaging, but the question does not mention anything about a phone number.\n\nOption ② is incorrect because it states that facilities can designate smoking areas, but the question does not mention anything about facilities.\n\nOption ④ is incorrect because it states that alcohol advertisements can include promotional items or cash gifts, but the question does not mention anything about alcohol advertisements.\n\nOption ⑤ is incorrect because it states that the Ministry of Health and Welfare should establish a committee to prevent alcohol-related harm, but the question does not mention anything about a committee.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④, \"The right to keep confidential one's physical and mental health information and privacy related to healthcare.\"\n\nAccording to the \"보건의료기본법\" (Basic Law on Healthcare), individuals have the right to keep their health information and privacy confidential. This means that healthcare providers must protect patients' personal information and health records, and patients have the right to access and control their own health information.\n\nTherefore, option ④ is the best answer.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④\n\nExplanation:\n\nAccording to the question, the correct answer is ④, which states that the in-patient copayment (본인일부부담금) is a portion of the insurance premium that the insured person pays directly to the hospital when they receive medical treatment, and it is determined by the law.\n\nThe other options do not accurately describe the in-patient copayment system in South Korea:\n\n① is incorrect because the in-patient copayment is not based on the insured person's income level.\n\n② is incorrect because the insured person does not pay the in-patient copayment directly to the National Health Insurance Corporation.\n\n③ is incorrect because the in-patient copayment is not reduced for people with rare or intractable diseases.\n\n⑤ is incorrect because the in-patient copayment is not related to the total amount of medical expenses exceeding a certain amount.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 선별등재</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\n\nThe question is asking about the functions and duties that are not performed by a pharmacist at a health center under the \"지역보건법\" (Regional Public Health Act).\n\nOption ①, 의약품 제조업자의 폐업 신고 (Reporting of drug manufacturer's business suspension), is not a function or duty of a pharmacist at a health center.\n\nOption ②, 약국개설자의 업무 개시 명령 (Order to start work for a pharmacist), is not a function or duty of a pharmacist at a health center.\n\nOption ③, 마약류관리자의 마약류 폐기 및 조치 명령 (Order for drug management officer to dispose of drugs and take measures), is a function or duty of a pharmacist at a health center.\n\nOption ④, 마약류소매업자의 마약류 취급 감시 및 단속 (Monitoring and control of drug handling by drug distributors), is not a function or duty of a pharmacist at a health center.\n\nOption ⑤, 약국개설자의 의약품 회수 ∙ 폐기 또는 조치 명령 (Order for pharmacist to collect, dispose of, or take measures for drugs), is not a function or duty of a pharmacist at a health center.\n\nTherefore, the correct answer is ③.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ phosphoglycerate kinase</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ glycogen synthase kinase 3</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② isocitrate</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 2,4-dinitrophenol</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② NADPH</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 글루탐산</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 글루탐산</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 티로신 인산화</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 역전사(reverse transcription)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② ubiquitination</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ TATA box</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 칼슘이온</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 이소류신</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 우라실</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 글루카곤-유사 펩티드 1(GLP-1)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ pRB</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ β-hydroxy-β-methylglutaryl-CoA synthase</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 증가 | 변화 없음\n\nExplanation:\n\nThe addition of compound X, an inhibitor of enzyme Y, will increase the Km value, which represents the Michaelis constant, and have no effect on the Vmax value, which represents the maximum enzymatic activity. This is because the inhibitor will bind to the active site of the enzyme, reducing the enzyme's affinity for the substrate and increasing the Km value, but not affecting the maximum enzymatic activity. Therefore, the correct answer is ③ 증가 | 변화 없음.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 톨유사수용체3(TLR3)에 결합한다.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 황색포도구균(Staphylococcus aureus)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n트라코마(trachoma) and 성병림프육아종(lymphogranuloma venereum) are both caused by bacteria. 트라코마 is caused by Chlamydia trachomatis, while 성병림프육아종 is caused by Chlamydia lymphogranulomatis. Both of these bacteria are transmitted through sexual contact, which is why they are considered sexually transmitted infections (STIs). Therefore, the correct answer is ③ 곤충을 매개로 하여 전파된다.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 콜레라균(Vibrio cholerae)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Enterotoxigenic Escherichia coli</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 레오바이러스(reovirus)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 엡스타인-바바이러스(Epstein-Barr virus)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Trichomonas vaginalis</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 반코마이신(vancomycin)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 클라불란산(clavulanic acid)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② DNA 자이라제(DNA gyrase)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ IgG</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 수지상세포</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ MHC class II</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ IL-6</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②\n\nExplanation:\n\nThe given question describes a condition that affects the myelin sheath surrounding nerve fibers, leading to inflammation and destruction of the sheath, and subsequently causing muscle weakness or paralysis. This condition is consistent with multiple sclerosis (MS), which is a chronic autoimmune disease that affects the central nervous system (CNS). MS is characterized by the immune system attacking the myelin sheath, leading to communication problems between the brain and the rest of the body. The symptoms mentioned in the question, such as muscle weakness or paralysis, are also consistent with MS. Therefore, the correct answer is ② multiple sclerosis.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 항원제시 기간의 증가</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 리툭시맙(rituximab)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 지도부딘(zidovudine)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ 간시클로비르(ganciclovir)\n\nExplanation:\n\nGanciclovir is an antiviral drug that is effective against CMV. It is commonly used to treat CMV retinitis in patients with AIDS, and has been shown to improve visual acuity and reduce the risk of CMV disease progression. In this case, the patient's low CD4+ T cell count and presence of CMV retinitis indicate that they are at high risk for CMV disease progression, and ganciclovir would be an appropriate treatment option.\n\nZanamivir, amantadine, and telaprevir are not effective against CMV, and therefore would not be appropriate treatments for this patient's condition. Ledipasvir is an antiviral drug that is effective against HCV, but not against CMV. While it may be used in combination with other drugs to treat HCV in patients with HIV co-infection, it would not be effective in treating the patient's CMV retinitis.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 아드레날린 수용체</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 펜토바르비탈(pentobarbital)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 심박수 감소</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 기관지 평활근 이완</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 부스피론(buspirone)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 미르타자핀(mirtazapine)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 페람파넬(perampanel)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 레보도파(levodopa)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 날트렉손(naltrexone)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 수마트립탄(sumatriptan)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 리바록사반(rivaroxaban)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 클로니딘(clonidine)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 플레카이니드(flecainide)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 푸로세미드(furosemide)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 황체형성호르몬 분비 자극</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 메트포르민(metformin)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 핵산 합성을 저해한다.\n\nClindamycin is an antibiotic that works by inhibiting the synthesis of bacterial DNA, thereby preventing bacterial growth and reproduction. It does this by binding to the 50S subunit of the bacterial ribosome and inhibiting the peptidyl transferase activity, which is essential for the synthesis of proteins and nucleic acids. This answer is supported by various scientific studies and is consistent with the established mechanism of action of clindamycin.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 세로토닌 수용체</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ① 이매티닙(imatinib)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① 예방접종</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 67%</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 클로로포름</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 라돈(radon)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 시안</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Crenothrix 속</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 글루쿠론산포합(glucuronidation)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② dihydropyrimidine dehydrogenase</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ phalloidin</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 카드뮴</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ rotenone</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ melamine</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 망간</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Minamata병</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 히스티딘</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ tetrodotoxin</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ patulin</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② 티아민(thiamine)\n\nExplanation:\n\nThiamine (vitamin B1) deficiency can cause a range of symptoms including nystagmus, ataxia, and encephalopathy, which are consistent with the symptoms described in the question. Thiamine plays a crucial role in the production of ATP, which is essential for the proper functioning of the nervous system. A deficiency in thiamine can lead to a decrease in ATP production, resulting in neurological symptoms.\n\nBiotin (①) and vitamin A (③) are not directly related to the symptoms described. Pantothenic acid (④) is important for the synthesis of CoA, a coenzyme that plays a role in fatty acid metabolism, but it is not directly related to the neurological symptoms described. Ascorbic acid (⑤) is important for the synthesis of collagen and the maintenance of healthy connective tissue, but it is not directly related to the neurological symptoms described.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② aldehyde dehydrogenase</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 시클로옥시게나제(cyclooxygenase)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 접촉피부염</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 종양의 성장확산 정도</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② DNA의 영구적 손상</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 모세혈관 정수압의 감소</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 만성골수성백혈병(CML)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 혈구용적 증가</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 폐모세혈관 압력 증가</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 심근세포의 수축력 증가</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 폐모세혈관 투과성 감소</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 소화궤양</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 자가면역간염</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ D형</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 위염</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ 감염후사구체신염(postinfectious glomerulonephritis)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ BRCA1</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 부갑상샘호르몬</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 황반부종</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 연골세포 활성 증가\n\nExplanation:\n\nThe patient's history of long-term use of glucocorticoids and NSAIDs may have contributed to the decrease in bone density. Glucocorticoids can cause osteoporosis by inhibiting the activity of osteoblasts, which are responsible for bone formation, and promoting the activity of osteoclasts, which are responsible for bone resorption. NSAIDs can also contribute to bone loss by inhibiting the production of prostaglandins, which play a role in maintaining bone density.\n\nTherefore, option ③, \"연골세포 활성 증가\" (increased activity of osteoclasts), is the most likely answer.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 고혈압 위험 증가</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 용매화물</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 전단응력</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 원편광이색성 분광법</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 약물의 결합부위</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 클라드레트(clathrate)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 전단후화(shear thickening)\n\nExplanation:\n\n인공눈물 A는 안구가 움직이지 않을 때의 점도보다 안구가 움직일 때의 점도가 더 낮아진다. 이는 인공눈물 A가 움직임에 따라 점도가 증가하는 전단후화(shear thickening) 현상을 보인다. 따라서, 인공눈물 A의 유동학적 특성은 전단후화(shear thickening)임을 알 수 있다.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 용매화물(solvate)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 11/168</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 0.42</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ [HA]₀ / ([HA]w + [A-]w)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 100,000\n\nExplanation:\n\nThe rate constant (k) of the drug's degradation reaction is given as 1.05×10^-5 h^-1. The initial concentration of the drug is 200 unit/mL, and we want to find the time it takes for the concentration to decrease to 180 unit/mL.\n\nWe can use the first-order kinetics equation to solve this problem:\n\nln(C/C0) = -kt\n\nwhere C is the concentration of the drug at time t, C0 is the initial concentration, and k is the rate constant.\n\nRearranging the equation, we get:\n\nt = -ln(C/C0) / k\n\nSubstituting the given values, we get:\n\nt = -ln(180/200) / 1.05×10^-5\n\nt = -0.105 / 1.05×10^-5\n\nt = 100,000\n\nTherefore, the time it takes for the drug's concentration to decrease from 200 unit/mL to 180 unit/mL is 100,000 hours, or approximately 11.4 years.\n\nSo, the correct answer is ④ 100,000.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ γ_S ＝ γ_LS + γ_L cosθ</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 3.0×10^-5</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ C3/C2</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ KDm/hm (C1-C5)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ Ki\n\nExplanation:\n\nKi (inhibition constant) is a measure of the binding affinity of a ligand to a protein. It represents the concentration of ligand required to inhibit the activity of the enzyme by 50%. Therefore, it is a measure of the strength of the interaction between the ligand and the enzyme.\n\nIn QSAR (quantitative structure-activity relationship), Ki is used as a parameter to describe the binding affinity of a ligand to a protein and to predict the activity of new compounds based on their structural properties.\n\nσ (sigma) and π (pi) are not related to the concept of binding affinity or QSAR.\n\nES (electric field strength) and MR (molecular recognition) are also not related to the concept of binding affinity or QSAR.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Sandmeyer 반응</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ pyridazine</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ①</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 이프라트로퓸(ipratropium)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Friedel-Crafts acylation</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 푸로세미드(furosemide)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ thiazole</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ①</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ①</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\nNifedipine is a calcium channel blocker that works by inhibiting the influx of calcium ions into smooth muscle cells, which leads to relaxation of the muscles and decreased blood pressure. The molecule has a symmetrical structure, with a 1,4-diphenyl-2-yl-piperazine ring and a 3-nitro-4-phenyl-butyric acid group.\n\nThe correct answer is ③, as the 3-nitro group on the molecule is not involved in the binding of nifedipine to the calcium channel, and the compound still retains its calcium channel blocking activity even if the 3-nitro group is replaced with a nitrogen atom.\n\nTherefore, option ③ \"3번 위치의 에스터가 니트로기로 치환되어도 저해활성은 유지된다\" is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① (a)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ (c)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ 축합반응 억제\n\nExplanation:\n5-F-dUMP forms a covalent complex with thymidylate synthase, which results in the irreversible inhibition of the enzyme's activity. This is an example of a suicide inhibition mechanism, where the inhibitor (5-F-dUMP) forms a covalent bond with the active site of the enzyme, resulting in the enzyme's inactivation. Therefore, option ④ 축합반응 억제 (suicide inhibition) is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 6.4</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 3.8 + log 1/1.5</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 6.7×10^-22</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ NN 지시약</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Br2 – Na2S2O3</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 137.1\n\nExplanation:\n\nThe question is asking for the amount of isoniazid (INH) in the given sample, which is 137.1 mg.\n\nThe method used to determine the amount of INH is titration with 0.1 mol/L hydrochloric acid (HCl) and 100 mL of 50% acetic acid (CH3COOH) solution. The volume of 0.1 mol/L HCl consumed is 10.5 mL, and the volume of 0.1 mol/L HCl consumed in the blank test is 0.5 mL.\n\nUsing the formula for titration, we can calculate the amount of INH as follows:\n\nAmount of INH = (Volume of HCl consumed in titration - Volume of HCl consumed in blank test) x Molarity of HCl\n\nAmount of INH = (10.5 mL - 0.5 mL) x 0.1 mol/L = 10.0 mL x 0.1 mol/L = 1.0 mol\n\nSince the molecular weight of INH is 137.1 g/mol, the amount of INH in mg is:\n\nAmount of INH in mg = 1.0 mol x 137.1 g/mol = 137.1 mg\n\nTherefore, the correct answer is ③ 137.1.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 20.0</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 몰흡광계수는 검액의 농도에 비례한다.\n\nExplanation:\n\nThe Lambert-Beer law states that the amount of light absorbed by a solution is directly proportional to the concentration of the absorbing substance and the path length of the light through the solution. Therefore, option ①, \"몰흡광계수는 검액의 농도에 비례한다,\" is the correct answer.\n\nOption ②, \"흡광측정파장(λ_max)에서 몰흡광계수가 가장 작다,\" is incorrect because the Lambert-Beer law does not mention anything about the wavelength of the light.\n\nOption ③, \"이 법칙은 농도가 높은 콜로이드 용액에 적용하기 적합하다,\" is incorrect because the Lambert-Beer law can be applied to any solution, not just colloidal solutions.\n\nOption ④, \"검액의 농도가 증가할수록 투과광의 강도가 비례하여 커진다,\" is incorrect because the Lambert-Beer law states that the amount of light absorbed is directly proportional to the concentration of the absorbing substance, not the intensity of the transmitted light.\n\nOption ⑤, \"빛이 셀을 통과한 투과 길이가 길어질수록 흡광도는 비례하여 커진다,\" is incorrect because the Lambert-Beer law does not mention anything about the length of the light path.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ -1.5°</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 4,000 ～ 1,300 cm^-1 영역을 지문영역으로 구분한다.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 고정상에 대한 친화성의 차이</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nThe main separation mechanism of size exclusion chromatography (SEC) is the difference in the ability of molecules to penetrate the pores of a gel or a solid support, which is related to their size and shape. The larger molecules are excluded from the pores and elute earlier, while the smaller molecules penetrate the pores and elute later. Therefore, option ③ is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 클로로포름</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 65</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ②\n\nExplanation:\nThe question asks about the characteristic of the detector used in the experiment, which is a flame ionization detector. The correct answer is ②, which states that the detector responds to ions generated by the combustion of the sample.\n\nIn a flame ionization detector, a sample is injected into a flame, where it undergoes combustion. The combustion process generates ions, which are then detected by the detector. The detector measures the ion signal, which is proportional to the amount of the sample injected.\n\nTherefore, option ② is the correct answer, as it accurately describes the principle of the flame ionization detector used in the experiment.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 광자상관분광법</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 프로필렌글리콜</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ D</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 친수-친유 균형(HLB)값이 7～9인 계면활성제를 사용한다.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 히프로멜로오스(hypromellose)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ polydimethylsiloxane</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② 침제</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nThe correct answer is ③, which states that the rate of drug release from an amorphous solid dispersion increases when the volume of the dissolution medium is increased.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe question is asking for the most appropriate drug for sustained release of a drug that passes through the stomach and small intestine.\n\n① Chitosan-based drugs are not suitable for sustained release as they are broken down by gastric enzymes in the stomach.\n\n② Drugs that are broken down by digestive enzymes in the small intestine are also not suitable for sustained release.\n\n③ Drugs that are absorbed through the entire small intestine and have a uniform absorption rate are suitable for sustained release.\n\n④ Efflux pump-mediated drugs are not suitable for sustained release as they are actively pumped out of the body.\n\n⑤ Drugs with high dosages that can cause gastrointestinal irritation and other side effects are not suitable for sustained release.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 양이온으로 해리된 약물의 피부투과를 촉진한다.\n\nExplanation:\n\nIontophoresis is a technique that uses an electric field to enhance the skin permeation of a drug. The drug is dissolved in a solution and placed on the skin, and an electric current is applied to the solution to drive the drug into the skin. The positive ions (cations) in the solution are attracted to the negative electrode, while the negative ions (anions) are attracted to the positive electrode. This creates a flow of ions across the skin, which helps to enhance the permeation of the drug.\n\nTherefore, the correct answer is ② 양이온으로 해리된 약물의 피부투과를 촉진한다. This answer choice accurately describes the mechanism of iontophoresis, which is to enhance the skin permeation of a drug by using an electric field to drive the drug ions into the skin.\n\nThe other answer choices are incorrect because they do not accurately describe the mechanism of iontophoresis:\n\n① 피부에 초음파를 가하여 준다: This answer choice refers to the use of ultrasound to enhance drug delivery, but it is not related to iontophoresis.\n\n③ 레이저광을 이용하여 피부에 미세구멍을 뚫는다: This answer choice refers to the use of laser light to create micro-holes in the skin, but it is not related to iontophoresis.\n\n④ 각질층 두께에 해당되는 미세바늘을 피부에 삽입한다: This answer choice refers to the use of microneedles to enhance drug delivery, but it is not related to iontophoresis.\n\n⑤ 각질층에 일시적으로 공극을 만들어서 약물의 피부투과를 촉진한다: This answer choice refers to the use of a temporary hole in the skin to enhance drug delivery, but it is not related to iontophoresis.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③. The presence of a large amount of mucin on the surface of the small intestine can increase the absorption of drugs. Mucin is a glycoprotein that covers the surface of the small intestine and plays a role in protecting the gut from harmful substances. It can also act as a barrier to drug absorption, but a high concentration of mucin can increase the absorption of drugs by providing a larger surface area for drug-mucin interactions. Therefore, option ③ is the correct answer.\n\nOption ① is incorrect because pH-dependent absorption does not occur in the small intestine. The small intestine has a relatively constant pH, and drug absorption is not significantly affected by pH changes.\n\nOption ② is incorrect because high permeability drugs are not affected by blood flow in the small intestine. The blood flow in the small intestine is not a significant factor in drug absorption, and high permeability drugs can be absorbed rapidly regardless of blood flow.\n\nOption ④ is incorrect because the mucus layer on the surface of the small intestine can actually decrease the absorption of some drugs. The mucus layer can act as a barrier to drug absorption, and some drugs may not be able to penetrate the mucus layer effectively.\n\nOption ⑤ is incorrect because the absorption of drugs in the small intestine is not directly related to the elimination half-life of the drug. The elimination half-life of a drug refers to the time it takes for the concentration of the drug in the body to decrease by half, and it is not a factor in drug absorption.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③ 혈장단백질의 결합은 조직으로의 약물 이행속도를 감소시킨다.\n\nThe binding of drugs to plasma proteins can decrease the rate of drug distribution to tissues. This is because the drug molecules are bound to the proteins in the bloodstream, which can reduce their ability to diffuse across cell membranes and reach their target sites in the tissues. Therefore, option ③ is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③ 혈장단백질의 결합률이 높을수록 신배설 속도가 증가한다.\n\nThe binding rate of plasma protein to drugs can affect the pharmacokinetics of drugs. When the binding rate of plasma protein to drugs increases, the drug concentration in the bloodstream decreases, which can lead to a decrease in the drug's efficacy. Therefore, the statement that the binding rate of plasma protein to drugs increases, leading to an increase in the drug's pharmacokinetics, is incorrect.\n\nThe other options are also incorrect for the following reasons:\n\n① 세뇨관에서 약물 분비는 수송체를 매개로 한다: This statement suggests that drugs are secreted from the kidneys through a transport mechanism, which is not accurate.\n\n② 사구체 여과는 약물 분자량의 영향을 받지 않는다: This statement suggests that the filtration rate of drugs through the glomeruli is not affected by the molecular weight of drugs, which is not accurate.\n\n④ 소변이 산성으로 되면 약염기성 약물의 재흡수가 급격히 증가한다: This statement suggests that the reabsorption of acidic drugs increases rapidly when urine becomes acidic, which is not accurate.\n\n⑤ 글루쿠론산 포합체는 미대사체에 비해 세뇨관에서의 재흡수가 용이하다: This statement suggests that glucuronide conjugates have a higher reabsorption rate in the kidneys compared to other conjugates, which is not accurate.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 10\n\nExplanation:\n\nThe total amount of drug A excreted in the urine can be calculated using the formula:\n\nTotal amount = (Dose / Clearance) × (1 - e^(-Clearance × Time))\n\nIn this case, the dose is 100 mg, and the clearance is 7.5 L/h. The time is not specified, but it is assumed to be 1 hour since the drug is administered intravenously.\n\nSubstituting the values, we get:\n\nTotal amount = (100 mg / 7.5 L/h) × (1 - e^(-7.5 L/h × 1 h))\nTotal amount = 10 mg\n\nTherefore, the correct answer is ③ 10.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 생체이용율(F)\n\nExplanation:\nThe correct answer is ③ 생체이용율(F) because the bioavailability (F) of a drug is the fraction of the drug that reaches the systemic circulation after administration, and it is affected by the drug's physicochemical properties, such as solubility, permeability, and partition coefficient. The other options, ① 추출률(E), ② 분포용적(Vd), ④ 소실속도상수(k), and ⑤ 흡수속도상수(ka), are not directly related to the bioavailability of a drug.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ②\n\nExplanation:\n\n디부틸세바케이트(dibutyl sebacate) is a plasticizer that is commonly used in coating compositions to improve the flexibility and durability of the coating film. In this case, the addition of 4% dibutyl sebacate to the coating composition can help to prevent the degradation of the coating film, thereby improving its resistance to environmental stress and extending its lifespan. Therefore, the correct answer is ②, \"코팅막의 분해 방지\" (prevention of degradation of the coating film).</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe given composition contains ethylcellulose, dibutyl sebacate, oleic acid, fumed silica, and water. This composition is suitable for a multi-layer coating process, where each layer has a different function. The ethylcellulose and dibutyl sebacate provide a flexible and durable film, while the oleic acid acts as a wetting agent and helps to improve the adhesion of the coating to the substrate. The fumed silica adds strength and stability to the coating, and the water helps to disperse the ingredients and improve the application process.\n\nTherefore, the correct answer is ③, as the composition is suitable for a multi-layer coating process and can improve the coating efficiency in this method.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ kuwanon G</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ cyanogenic glycoside</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ flavonoid</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 홍화(紅花)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ phyllodulcin</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ reserpine</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Crataegi Fructus</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 진경작용</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 행인(杏仁)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ digitoxin</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ icariin</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 마황(麻黃)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 심장(心臟)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 기작작용(氣化作用)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 부자(附子)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 안중산(安中散)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ shikimate 경로</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ tanshinone I</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 베라파밀(verapamil)+발사르탄(valsartan)\n\nExplanation:\n\nThe patient has hypertension, hyperlipidemia, and chronic kidney disease. The goal of therapy is to control blood pressure and reduce the risk of cardiovascular events.\n\nVerapamil is a calcium channel blocker that can effectively reduce blood pressure and has a beneficial effect on lipid profiles. It also has a protective effect on the kidneys and can reduce proteinuria.\n\nValsartan is an angiotensin II receptor blocker that can also effectively reduce blood pressure and has a renal protective effect. It can also reduce proteinuria and has been shown to have a beneficial effect on cardiovascular outcomes.\n\nThe combination of verapamil and valsartan can provide additive benefits in controlling blood pressure and reducing cardiovascular risk, making it a suitable choice for this patient.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 이바브라딘(ivabradine)\n\nExplanation:\n\nThe patient is experiencing worsening heart failure symptoms despite adequate doses of bisoprolol, furosemide, and spironolactone. The addition of ivabradine, a selective sinus node modulator, can help to reduce heart rate and improve symptoms of heart failure by reducing the workload on the heart.\n\nIvabradine has been shown to reduce heart rate and improve symptoms in patients with stable angina, and it has also been used in patients with heart failure to reduce the risk of hospitalization and death. It is a useful alternative to beta-blockers in patients who cannot tolerate them or have contraindications.\n\nThe other options are not as appropriate for this patient's condition:\n\n① Digoxin is a positive inotropic agent that can increase the contractility of the heart, but it may not be effective in reducing heart rate and symptoms in this patient.\n\n② Verapamil is a calcium channel blocker that can reduce heart rate and improve symptoms, but it may have negative effects on the patient's blood pressure and may not be effective in reducing the workload on the heart.\n\n④ Hydralazine is a vasodilator that can reduce blood pressure and improve symptoms, but it may not be effective in reducing heart rate and workload on the heart.\n\n⑤ Empagliflozin is a medication used to treat diabetes, and it may not be effective in reducing heart rate and symptoms in this patient.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 24시간 후\n\nExplanation:\n\nThe question is asking when the patient with HFrEF can start taking sacubitril/valsartan (Entresto) after stopping enalapril. The answer is 24 hours after the last dose of enalapril.\n\nThe rationale for this answer is that enalapril has a half-life of approximately 12 hours, which means that it takes 24 hours for the drug to be mostly eliminated from the body. Therefore, it is recommended to wait 24 hours after the last dose of enalapril before starting sacubitril/valsartan to avoid any potential drug interactions or adverse effects.\n\nThe other options are not correct because they do not take into account the half-life of enalapril and the time it takes for the drug to be eliminated from the body. Option ① (immediately) is not correct because it does not allow for sufficient time for the enalapril to be eliminated. Options ② (6 hours), ③ (12 hours), and ⑤ (36 hours) are also not correct because they do not align with the recommended time frame for waiting after the last dose of enalapril before starting sacubitril/valsartan.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 180 mg</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 클로피도그렐(clopidogrel)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② 암로디핀(amlodipine)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 아스피린(aspirin)+클로피도그렐(clopidogrel)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 헤파린(heparin)\n\nExplanation:\n\nThe patient has been diagnosed with acute pulmonary embolism (PE), which is a life-threatening condition that requires immediate treatment. The primary goal of treatment is to prevent further pulmonary artery thrombus formation and to dissolve the existing clot.\n\nHeparin is a commonly used anticoagulant in the treatment of acute PE. It works by inhibiting the activity of thrombin, which is essential for the formation of blood clots. Heparin also has a rapid onset of action, which makes it an appropriate choice for this emergency situation.\n\nThe other options, while they may be used in the treatment of hypertension or other conditions, are not directly related to the management of acute PE. Therefore, heparin is the most appropriate answer.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 프라바스타틴(pravastatin) 10 mg 1일 1회</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 인다파미드\n\nExplanation:\n\nIndapamide, a diuretic, can increase the risk of bleeding in patients taking dabigatran, an oral anticoagulant, by increasing urine production and reducing the drug's effectiveness. This can lead to an increased risk of bleeding complications, such as gastrointestinal bleeding or intracranial hemorrhage.\n\nTherefore, option ③ 인다파미드 (indapamide) is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 달테파린(dalteparin)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ⑤ 아토르바스타틴\n\nExplanation:\n\nThe patient's elevated serum creatinine level and decreased eGFR suggest that there may be a problem with renal function. Among the medications the patient is taking, atorvastatin is a potential cause of renal dysfunction. Atorvastatin is metabolized by the liver and excreted primarily in the feces, but it can also be excreted in the urine, particularly in cases of renal impairment. Therefore, it is possible that atorvastatin is contributing to the patient's renal dysfunction.\n\nThe other options are less likely to be the cause of the patient's renal dysfunction:\n\n* Tamsulosin is an alpha-1 adrenergic receptor antagonist that is primarily metabolized by the liver and excreted in the feces. It is not known to cause renal dysfunction.\n* Lisinopril is an ACE inhibitor that is primarily metabolized by the liver and excreted in the urine. It may cause a mild increase in serum creatinine levels, but this is typically not clinically significant.\n* Teneligliptin is a dipeptidyl peptidase-4 inhibitor that is primarily metabolized by the liver and excreted in the feces. It is not known to cause renal dysfunction.\n* Pioglitazone is a thiazolidinedione that is primarily metabolized by the liver and excreted in the urine. It may cause a mild increase in serum creatinine levels, but this is typically not clinically significant.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 아토르바스타틴을 에볼로쿠맙(evolocumab)으로 변경\n\nExplanation:\n\nThe patient's lipid profile shows that the LDL-C level is still high despite the current treatment with atorvastatin. Evolocumab is a PCSK9 inhibitor that has been shown to be effective in reducing LDL-C levels in patients with familial hypercholesterolemia or statin-resistant hypercholesterolemia. It is also well-tolerated and has a good safety profile. Therefore, it would be appropriate to switch the patient's atorvastatin to evolocumab to better control their LDL-C levels.\n\nThe other options are not the best choices for this patient's situation:\n\n① Current treatment is not effective in controlling LDL-C levels, so it is not appropriate to maintain the current treatment plan.\n\n② Ezetimibe is a cholesterol absorption inhibitor that can be used in combination with statins to reduce LDL-C levels. However, it is not as effective as evolocumab in reducing LDL-C levels in patients with familial hypercholesterolemia or statin-resistant hypercholesterolemia.\n\n③ Alirocumab is a PCSK9 inhibitor that is similar to evolocumab. However, it has a higher dosing frequency (every 2 weeks) and may have a higher risk of injection site reactions compared to evolocumab.\n\n⑤ Fenofibrate is a fibric acid derivative that can be used to treat dyslipidemia. However, it is not as effective as evolocumab in reducing LDL-C levels and may have a higher risk of adverse effects such as muscle pain and liver enzyme elevations.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 메토프로롤(metoprolol)\n\nExplanation:\n\nThe patient has been diagnosed with hypertension and has been prescribed ramipril and furosemide. The patient's symptoms of palpitations and shortness of breath suggest that they may have an increased heart rate and cardiac output. In this case, metoprolol, a beta-blocker, would be an appropriate medication to control the heart rate and reduce the risk of cardiac complications.\n\nSotalol, a class III antiarrhythmic, may be used to control ventricular arrhythmias, but it is not the most appropriate choice for controlling heart rate in this case.\n\nVerapamil, a calcium channel blocker, may be used to control angina, but it is not the most appropriate choice for controlling heart rate in this case.\n\nNicardipine, a calcium channel blocker, may be used to control hypertension, but it is not the most appropriate choice for controlling heart rate in this case.\n\nSpironolactone, a potassium-sparing diuretic, may be used to reduce fluid retention, but it is not the most appropriate choice for controlling heart rate in this case.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ② 이바브라딘(ivabradine)\n\nExplanation:\n\nThe patient has been diagnosed with paroxysmal atrial fibrillation (PAF) and has been experiencing palpitations, shortness of breath, and fatigue. The patient's vital signs show a heart rate of 104 beats per minute, blood pressure of 138/80 mmHg, and respiratory rate of 22 breaths per minute. The patient has been taking ramipril (10 mg/day) and furosemide (20 mg/day) for hypertension and heart failure, but the symptoms persist.\n\nGiven the patient's history of PAF and the persistent symptoms, the most appropriate medication to add to the patient's regimen would be ivabradine. Ivabradine is a medication that slows the heart rate by selectively blocking the \"funny\" channels in the heart, which are responsible for the rapid firing of the heart's electrical impulses. By slowing the heart rate, ivabradine can help to reduce the symptoms of palpitations, shortness of breath, and fatigue.\n\nThe other options are not as appropriate for this patient's condition. Diltiazem (①) is a calcium channel blocker that can slow the heart rate, but it may not be effective in converting the atrial fibrillation back to normal sinus rhythm. Amiodarone (③) is an anti-arrhythmic medication that can convert atrial fibrillation back to normal sinus rhythm, but it has a slower onset of action compared to ivabradine and may not be effective in the short term. Propafenone (④) is a class IC anti-arrhythmic medication that can convert atrial fibrillation back to normal sinus rhythm, but it may have a higher risk of proarrhythmia compared to ivabradine. Dronedarone (⑤) is a class III anti-arrhythmic medication that can convert atrial fibrillation back to normal sinus rhythm, but it may have a higher risk of cardiac arrhythmias compared to ivabradine.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 플루티카손/살메테롤을 메폴리주맙으로 변경</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 1초간강제호기량(FEV1)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 인디카테롤(indacaterol) 흡입제</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 아클리디늄 흡입제를 포르모테롤/아클리디늄(formoterol/aclidinium)으로 변경</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 자일로메타졸린(xylometazoline) 비강분무제 추가</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 14일</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 베타네콜(bethanechol)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 겐타마이신(gentamicin)\n\nExplanation:\nThe patient has signs of sepsis, such as fever, tachycardia, and tachypnea, and the laboratory results show elevated SCr and BUN levels, indicating acute kidney injury. The patient also has leukocytosis with a high PMN count, which suggests a possible bacterial infection.\n\nGentamicin is an aminoglycoside antibiotic that is effective against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa, which is a common cause of sepsis in patients with acute kidney injury. Gentamicin also has synergistic effects with ceftriaxone, which is another antibiotic that is commonly used to treat sepsis.\n\nAlbumin and lactulose are not antibiotics and would not be effective in treating the patient's sepsis. Propranolol is a beta-blocker that is used to treat hypertension and anxiety, but it is not appropriate for sepsis. Terlipressin is a vasopressin receptor agonist that is used to treat hypotension, but it is not effective against sepsis.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 프루칼로프라이드(prucalopride)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 베돌리주맙(vedolizumab) 주사제+도파시티닙(tofacitinib) 경구제</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 소포스부비르/벨파타스비르(sofosbuvir/velpatasvir) 12주</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 인터페론베타(interferon beta) 피하주사 투여\n\nExplanation:\n\nThe patient has compensated cirrhosis and has been diagnosed with HCV genotype 1b, which is resistant to NS5A inhibitors. The patient has also been found to have anti-HAV and anti-HBs antibodies, but is negative for HBsAg and anti-HBc. Given these results, the most appropriate course of action would be to administer interferon beta (Option ③) as it has been shown to be effective in treating HCV genotype 1b and has a good safety profile in patients with compensated cirrhosis.\n\nAdministering a hepatitis B vaccine (Option ②) would not be appropriate as the patient has already been diagnosed with HCV and has a negative HBsAg result, indicating that they are not infected with hepatitis B.\n\nAdministering hepatitis B immunoglobulin (Option ④) would also not be appropriate as the patient does not have a positive HBsAg result and is not at risk of developing hepatitis B.\n\nCombining hepatitis B vaccine and hepatitis B immunoglobulin (Option ⑤) would not be appropriate as the patient does not require immunization against hepatitis B and has already been diagnosed with HCV.\n\nIt is important to note that the patient's cirrhosis status and HCV genotype should be taken into consideration when determining the appropriate course of treatment. In this case, interferon beta has been shown to be effective in treating HCV genotype 1b and has a good safety profile in patients with compensated cirrhosis.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 푸로세미드(furosemide)\n\nExplanation:\n\nThe patient has been diagnosed with nephrogenic diabetes insipidus (NDI) and has been taking lithium carbonate. The patient's urine output, sodium, and osmolar gap suggest that NDI is the likely cause of the patient's polyuria.\n\nFurosemide is a loop diuretic that works by inhibiting the reabsorption of sodium and chloride ions in the renal tubules, leading to increased urine production. In the context of NDI, furosemide can help to reduce the excessive urine production and correct the fluid imbalance.\n\nThe other options are not appropriate for the management of NDI:\n\n* Tolvaptan is a vasopressin receptor antagonist that is used to treat hyponatremia. It is not appropriate for the management of NDI.\n* Lisinopril is an ACE inhibitor that is used to treat hypertension. It is not appropriate for the management of NDI.\n* Amiloride is a potassium-sparing diuretic that is used to treat hypokalemia. It is not appropriate for the management of NDI.\n* Calcium polystyrene sulfonate is a cation-exchange resin that is used to treat hyperkalemia. It is not appropriate for the management of NDI.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 로수바스타틴\n\nExplanation:\n\nThe patient has been diagnosed with hypertension, type 2 diabetes, and dyslipidemia. The laboratory results show elevated levels of BUN, SCr, and TG, indicating kidney dysfunction and metabolic abnormalities. The patient is currently taking losartan, hydrochlorothiazide, saxagliptin, lobeglitazone, and rosuvastatin.\n\nBased on the patient's medical history and laboratory results, the most appropriate medication to hold or discontinue is rosuvastatin, which is a statin used to treat high cholesterol. The patient's elevated TG level and history of type 2 diabetes suggest a high risk of developing cardiovascular disease. Therefore, it is appropriate to hold rosuvastatin to avoid potential adverse effects on the patient's kidney function.\n\nThe other options are not the most appropriate choices for the following reasons:\n\n① Losartan is an angiotensin II receptor antagonist used to treat hypertension and kidney disease. It is not necessary to hold this medication given the patient's current blood pressure and kidney function.\n\n② Saxagliptin is a DPP-4 inhibitor used to treat type 2 diabetes. It is not related to the patient's kidney dysfunction or dyslipidemia.\n\n③ Lobeglitazone is a PPARγ agonist used to treat type 2 diabetes. It may have a potential role in reducing inflammation and improving insulin sensitivity, but it is not directly related to the patient's kidney dysfunction or dyslipidemia.\n\n⑤ Hydrochlorothiazide is a diuretic used to treat hypertension and edema. It may help reduce the patient's blood pressure, but it is not the most appropriate medication to hold given the patient's current blood pressure and kidney function.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 철수크로오즈(iron sucrose) 투여\n\nExplanation:\nThe patient has been diagnosed with chronic kidney disease and has been taking ferrous sulfate for 3 months. However, the patient's hemoglobin level has not improved despite taking iron supplements, and the patient has been experiencing severe fatigue. The recent blood test results show that the patient's hemoglobin level is still low, and the patient's ferritin level is also low.\n\nGiven the patient's history of chronic kidney disease and low hemoglobin level, it is likely that the patient has iron deficiency anemia. The low ferritin level supports this diagnosis. Iron sucrose is a form of iron that is more easily absorbed by the body and is less likely to cause gastrointestinal side effects compared to ferrous sulfate. Therefore, option ③ 철수크로오즈(iron sucrose) 투여 is the most appropriate answer.\n\nOption ① 적혈구 수혈 may not be necessary at this time, as the patient's hemoglobin level is already low. Option ② 테스토스테론(testosterone) 투여 may not be appropriate, as the patient's low hemoglobin level is likely due to iron deficiency rather than low testosterone levels. Option ④ 에포에틴 알파(epoetin alfa) 투여 may not be necessary, as the patient's anemia is likely due to iron deficiency rather than a lack of erythropoietin. Option ⑤ L-카르니틴(L-carnitine)+비타민C(vitamin C) 투여 may not be effective in treating the patient's anemia, as it does not address the underlying iron deficiency.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 토실리주맙(tocilizumab)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 푸로세미드(furosemide)\n\nExplanation:\nThe patient's symptoms of edema and weight gain suggest nephrotic syndrome, which is likely caused by membranous nephropathy. Furosemide, a diuretic, can help reduce edema and proteinuria by increasing urine production. It is also effective in treating hypertension, which is a common comorbidity with membranous nephropathy.\n\n Mannitol, a sugar, is not related to the patient's symptoms or diagnosis.\n\n Ramipril, an ACE inhibitor, may be effective in reducing proteinuria, but it is not the most appropriate choice for nephrotic syndrome.\n\n Spironolactone, a potassium-sparing diuretic, may also be effective in reducing proteinuria, but it is not as potent as furosemide in treating edema.\n\n Hydrochlorothiazide, a diuretic, may also be effective in reducing edema, but it is less potent than furosemide and may not be as effective in reducing proteinuria.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 탄산칼슘(calcium carbonate)\n\nExplanation:\n\nThe patient has symptoms of hyperparathyroidism, such as bone pain, muscle weakness, and an increased risk of nephrolithiasis. The laboratory results show an elevated serum calcium level and a low urinary calcium-to-creatinine ratio (U-Ca/U-Cr). The patient's eGFR is also decreased, indicating chronic kidney disease.\n\nCalcium carbonate is a calcium supplement that can help to lower serum calcium levels and increase urinary calcium excretion. It is commonly used to treat hyperparathyroidism and has been shown to improve bone density and reduce the risk of nephrolithiasis.\n\nSevelamer (①) is a phosphate binder that is used to treat hyperphosphatemia in patients with chronic kidney disease. It is not appropriate for the treatment of hyperparathyroidism.\n\nCalcitriol (②) is the active form of vitamin D and is used to treat hypocalcemia. It is not appropriate for the treatment of hyperparathyroidism.\n\nLanthanum carbonate (④) is a phosphate binder that is used to treat hyperphosphatemia in patients with chronic kidney disease. It is not appropriate for the treatment of hyperparathyroidism.\n\nMagnesium hydroxide (⑤) is an antacid that is used to treat heartburn and peptic ulcers. It is not appropriate for the treatment of hyperparathyroidism.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 메트포르민을 나테글리니드(nateglinide)로 변경\n\nExplanation:\nThe patient's current medication regimen includes metformin, which is an appropriate choice for type 2 diabetes. However, the patient's creatinine level is elevated, indicating impaired renal function. Nateglinide, a sulfonylurea, is a more appropriate choice for patients with renal impairment as it has a shorter half-life and is less likely to accumulate in the body compared to metformin. Additionally, nateglinide has been shown to have a beneficial effect on postprandial glucose excursions, which may help to improve glycemic control in this patient population.\n\nTherefore, option ④, switching metformin to nateglinide, is the best answer.\n\nOption ①, increasing the dose of metformin, may not be appropriate given the patient's renal impairment.\n\nOption ②, adding acarbose, may not be effective in lowering blood glucose levels and may cause gastrointestinal side effects.\n\nOption ③, adding dulaglutide, may not be appropriate as it is a glucagon-like peptide-1 (GLP-1) receptor agonist and may not have a significant effect on blood glucose levels in patients with renal impairment.\n\nOption ⑤, switching metformin to ertugliflozin, may not be appropriate as it is a sodium-glucose cotransporter 2 (SGLT2) inhibitor and may increase the risk of genital fungal infections and urinary tract infections in patients with renal impairment.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 인슐린라이스프로의 아침 용량 증가</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 로베글리타존(lobeglitazone)\n\nExplanation:\n\nThe patient has been diagnosed with type 2 diabetes, hypertension, and chronic kidney disease. The current medications include glimepiride, telmisartan, and atorvastatin. The patient's blood sugar control has worsened, with a recent HbA1c of 6.8%, and the eGFR has decreased to 44 mL/min/1.73m^2.\n\nConsidering the patient's history of type 2 diabetes and worsening renal function, the most appropriate additional medication would be a drug that has a beneficial effect on both glycemic control and renal function. Lobeglitazone, a thiazolidinedione, has been shown to improve glycemic control and reduce the risk of cardiovascular events in patients with type 2 diabetes and established cardiovascular disease. Additionally, it has been shown to have a positive effect on renal function, reducing the risk of albuminuria and GFR decline in patients with diabetic nephropathy.\n\nTherefore, option ④ 로베글리타존(lobeglitazone) is the best answer.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 피오글리타존\n\nExplanation:\n\nThe patient's weight gain and the abnormal liver function test results observed today may be related to the pioglitazone medication. Pioglitazone is known to cause weight gain and fluid retention, which can lead to increased liver enzymes and bilirubin levels. The other medications, lisinopril, hydrochlorothiazide, metformin, and atorvastatin, are not typically associated with weight gain or liver dysfunction. Therefore, option ③ 피오글리타존 is the most likely answer.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 옥트레오티드(octreotide)\n\nExplanation:\n\nThe patient's symptoms of persistent nausea, vomiting, and abdominal pain, along with the diagnosis of diabetic gastroparesis, suggest that the appropriate medication to manage these symptoms would be an antidiarrheal agent. Octreotide is a somatostatin analog that can help reduce symptoms of gastroparesis by slowing gastric emptying and improving gastrointestinal motility. It is also used to treat diarrhea in patients with diabetes.\n\nBethanechol, domperidone, and metronidazole are not appropriate for managing symptoms of gastroparesis. Bethanechol is a cholinergic agent that can increase gastric motility, but it may not be effective in reducing symptoms of gastroparesis. Domperidone is a dopamine receptor antagonist that can also increase gastric motility, but it may not be effective in reducing symptoms of gastroparesis. Metronidazole is an antibiotic that is used to treat bacterial infections, but it is not appropriate for managing symptoms of gastroparesis.\n\nMisoprostol is a prostaglandin analog that can help reduce symptoms of gastroparesis by increasing gastric motility and improving gastrointestinal secretion. However, it may not be as effective as octreotide in managing symptoms of gastroparesis, and it may have more side effects.\n\nTherefore, the most appropriate medication for managing the patient's symptoms of gastroparesis would be octreotide.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 프레가발린(pregabalin)\n\nExplanation:\n\nThe patient is experiencing anxiety symptoms, such as restlessness and difficulty concentrating, despite being treated with methimazole and propranolol. Pregabalin is an anticonvulsant that is effective in treating anxiety disorders, and it can be used as an add-on therapy to enhance the efficacy of the current treatment. It has been shown to reduce symptoms of anxiety, such as restlessness and irritability, and improve sleep quality.\n\n Diazepam (①) is a benzodiazepine that can also be used to treat anxiety disorders, but it may have a higher risk of dependence and sedation compared to pregabalin. Bupropion (②) is an antidepressant that can also be used to treat anxiety disorders, but it may not be as effective as pregabalin in reducing symptoms of anxiety. Risperidone (④) is an antipsychotic that can be used to treat anxiety disorders, but it may have a higher risk of side effects compared to pregabalin. Imipramine (⑤) is a tricyclic antidepressant that can also be used to treat anxiety disorders, but it may have a higher risk of side effects compared to pregabalin.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ 1초간강제호기량\n\nExplanation:\n\nThe patient has been taking methimazole for two months, and has developed a fever and sore throat. In order to determine if the fever and sore throat are caused by an adverse reaction to methimazole, it is necessary to perform a white blood cell count (WBC) to check for signs of infection or inflammation.\n\nA WBC count can help identify if there is an increase in white blood cells, which could indicate an infection or inflammation caused by the drug. This is the most appropriate test to order in this scenario, as it can help determine if the fever and sore throat are related to the methimazole therapy.\n\nThe other options are not as relevant in this case:\n\n① Total blood count: This test measures various components of the blood, including red blood cells, white blood cells, and platelets. While it could provide some information about the patient's overall health, it would not specifically help diagnose an adverse reaction to methimazole.\n\n② Arterial blood gas analysis: This test measures the levels of various gases in the blood, such as oxygen and carbon dioxide. It is used to diagnose respiratory or metabolic disorders, but it would not be helpful in diagnosing an adverse reaction to methimazole.\n\n④ Thyroid function test: This test measures the levels of thyroid hormones in the blood. Methimazole can affect thyroid function, but it would not cause a fever and sore throat.\n\n⑤ Interferon gamma release assay: This test measures the level of interferon gamma, a protein produced by the immune system in response to infection. It is used to diagnose certain infections, but it would not be helpful in diagnosing an adverse reaction to methimazole.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 10일</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 레보플록사신(levofloxacin)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 시프로플록사신(ciprofloxacin)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 에탐부톨\n\nExplanation:\nThe patient has developed liver dysfunction (AST and ALT elevation) after taking rifampicin, pyrazinamide, and ethambutol for a month. The liver enzymes have returned to normal levels after discontinuing the medications for three weeks. Considering the potential for liver toxicity, it would be best to avoid ethambutol (③) when restarting treatment.\n\nThe other options are not the best choices for the following reasons:\n\n① Pyridoxine (vitamin B6) is not associated with liver toxicity and can be safely continued.\n\n② Rifampicin has already been discontinued, and there is no need to avoid it.\n\n④ Isoniazid is not associated with liver toxicity and can be safely continued.\n\n⑤ Pyrazinamide has already been discontinued, and there is no need to avoid it.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 덱사메타손(dexamethasone)\n\nReason: Dexamethasone is a corticosteroid that can help reduce inflammation and swelling in the brain, which can help alleviate symptoms of meningitis. It is often used in combination with antibiotics to treat bacterial meningitis. The other options are not specifically used to treat meningitis or its symptoms.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\nThe patient's symptoms and laboratory results indicate that they have developed sepsis, which is a life-threatening condition that requires prompt treatment. The patient's blood culture is still pending, but the presence of fever, tachycardia, and tachypnea suggest that there is an ongoing infection.\n\nGiven the patient's history of premature birth and the risk of infection, the most appropriate empirical antibiotic therapy would be a combination of a penicillin-type antibiotic (ampicillin) and a cephalosporin (cefotaxime). This combination covers a wide range of potential pathogens, including Gram-positive and Gram-negative bacteria, and is effective against many common causes of sepsis in neonates.\n\nThe other options are not as appropriate for several reasons:\n\n* ① Tigecycline is a glycylcycline antibiotic that is effective against Gram-positive and Gram-negative bacteria, but it is not typically used as a first-line agent in neonatal sepsis.\n* ② Sulfamethoxazole/trimethoprim is a combination antibiotic that is effective against a wide range of bacteria, but it is not as effective against Gram-negative bacteria as other agents.\n* ④ Vancomycin is a glycopeptide antibiotic that is effective against methicillin-resistant Staphylococcus aureus (MRSA), but it is not effective against Gram-negative bacteria. Metronidazole is an imidazole antibiotic that is effective against anaerobic bacteria, but it is not effective against aerobic bacteria.\n* ⑤ Cefuroxime is a cephalosporin antibiotic that is effective against a wide range of Gram-negative bacteria, but it is not as effective against Gram-positive bacteria as other agents. Ciprofloxacin is a fluoroquinolone antibiotic that is effective against a wide range of Gram-negative bacteria, but it is not typically used as a first-line agent in neonatal sepsis due to concerns about adverse effects on cartilage and bone development.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 테르비나핀(terbinafine) 크림</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 저칼륨혈증</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 암피실린(ampicillin) 정맥주사+답토마이신(daptomycin) 정맥주사</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 세페핌+시프로플록사신(ciprofloxacin)+반코마이신(vancomycin)\n\nExplanation:\n\nThe patient has ventilator-associated pneumonia (VAP) and is already receiving mechanical ventilation. The appropriate antibiotic regimen for VAP would cover both gram-positive and gram-negative bacteria, as well as anaerobes.\n\nOption ③, which includes cefepime, ciprofloxacin, and vancomycin, provides broad-spectrum coverage against both gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa, which is a common cause of VAP. Cefepime is a fourth-generation cephalosporin that has activity against a wide range of gram-positive and gram-negative bacteria, including many strains of Pseudomonas. Ciprofloxacin is a fluoroquinolone that has activity against a wide range of gram-negative bacteria, including Pseudomonas. Vancomycin is an antibiotic that is effective against methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.\n\nOption ①, piperacillin/tazobactam, is a combination of a penicillin-derivative and a beta-lactamase inhibitor that is effective against a wide range of gram-negative bacteria, but has limited activity against gram-positive bacteria.\n\nOption ②, cefepime plus levofloxacin, provides coverage against gram-negative bacteria, but lacks activity against gram-positive bacteria.\n\nOption ④, piperacillin/tazobactam plus vancomycin, provides coverage against both gram-positive and gram-negative bacteria, but the combination of a penicillin-derivative and a beta-lactamase inhibitor may not be optimal for VAP.\n\nOption ⑤, levofloxacin plus tobramycin plus vancomycin, provides coverage against both gram-negative and gram-positive bacteria, but the combination of two antibiotics with overlapping spectra and a third antibiotic with a different mechanism of action may not be the most effective or efficient regimen.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ⑤ 히드로클로로티아지드\n\nExplanation:\n\nThe patient is taking lisinopril, an ACE inhibitor, which can cause a significant interaction with linezolid, a monoamine oxidase inhibitor. The combination of lisinopril and linezolid can lead to serotonin syndrome, a potentially life-threatening condition caused by excessive levels of serotonin in the body.\n\nTherefore, the best answer is ⑤ 히드로클로로티아지드 (hydrochlorothiazide), which is a diuretic and is not metabolized by the liver. It is unlikely to interact with linezolid and would not increase the risk of serotonin syndrome.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① 나프록센(naproxen)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 토피라메이트(topiramate)\n\nExplanation:\n\nThe patient has chronic migraines that are not well-controlled with current therapy, including almotriptan and propranolol. The patient's medical history does not include any other relevant conditions. In this scenario, it would be appropriate to consider a different preventive medication for migraines.\n\nTopiramate (option ④) is a commonly used preventive medication for migraines that has been shown to be effective in reducing the frequency and severity of migraine attacks. It is often used as a first-line preventive medication for migraines and is generally well-tolerated.\n\nThe other options are not as appropriate for this patient's situation:\n\n* Lasmiditan (option ①) is a serotonin receptor agonist that is used for the acute treatment of migraines. It is not typically used as a preventive medication.\n* Reslizumab (option ②) is an interleukin-5 antagonist that is used for the treatment of severe asthma. It is not used for the prevention of migraines.\n* Zonisamide (option ③) is an anticonvulsant that is used for the treatment of partial seizures. It has not been shown to be effective for the prevention of migraines.\n* Fremanezumab (option ⑤) is a monoclonal antibody that is used for the prevention of migraines. However, it is typically used for patients who have failed other preventive medications, and it is not a first-line treatment option.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ 아미트리프틸린\n\nExplanation:\n\n Donepezil is a cholinesterase inhibitor used to treat dementia caused by Alzheimer's disease. However, the patient's cognitive function has worsened despite taking donepezil. The patient has a history of hypertension, diabetes, dyslipidemia, and peripheral neuropathy, and is taking ramipril, metformin, sitagliptin, rosuvastatin, and amitriptyline.\n\nAmitriptyline is an antidepressant that can have a negative impact on cognitive function, especially in older adults. It can cause confusion, disorientation, and memory impairment, which can worsen dementia symptoms. Therefore, amitriptyline is the most likely medication contributing to the patient's worsening cognitive function.\n\nThe other options are not likely to contribute to the patient's worsening cognitive function:\n\n* Ramipril is an ACE inhibitor used to treat hypertension and heart failure. It has no known effect on cognitive function.\n* Metformin is a biguanide medication used to treat type 2 diabetes. It has some evidence of improving cognitive function, but it is not a likely contributor to worsening cognitive function.\n* Sitagliptin is a DPP-4 inhibitor used to treat type 2 diabetes. It has no known effect on cognitive function.\n* Rosuvastatin is a statin medication used to treat dyslipidemia. It has some evidence of improving cognitive function, but it is not a likely contributor to worsening cognitive function.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 엔타카폰(entacapone)\n\nExplanation:\n\nEntacapone is a COMT inhibitor, which means it increases the levels of levodopa in the brain by blocking an enzyme that breaks it down. This can help improve the effectiveness of levodopa in treating Parkinson's symptoms, especially in cases where the patient has developed tolerance to the medication.\n\nThe other options are not appropriate for this patient's condition:\n\n* Dopamine (①) is not a viable option as it is not a COMT inhibitor and would not increase the levels of levodopa in the brain.\n* Amantadine (②) is an antiviral medication that is sometimes used to treat Parkinson's symptoms, but it is not a COMT inhibitor and would not address the patient's wearing-off symptoms.\n* Benserazide (④) is a MAO-B inhibitor, which means it blocks an enzyme that breaks down dopamine in the brain. However, it would not increase the levels of levodopa, which is the primary issue in this patient's case.\n* Benztropine (⑤) is an anticholinergic medication that can help with Parkinson's symptoms, but it is not a COMT inhibitor and would not address the patient's wearing-off symptoms.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 무과립구증</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 고칼슘혈증</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 에토숙시미드(ethosuximide)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 라모트리진(lamotrigine)\n\nExplanation:\n\nThe patient has been diagnosed with absence seizures and is currently taking lithium carbonate. The goal is to add a medication to prevent recurrent depressive episodes. Lamotrigine is an appropriate choice because it has been shown to have antidepressant effects and can be used as a mood stabilizer. It is also known to have a beneficial effect on seizure control, which is important in this case given the patient's history of seizures.\n\nClobazam and gabapentin are not typically used as mood stabilizers or antidepressants. Topiramate can have a negative effect on mood and may not be suitable for this patient. Eslicarbazepine is not commonly used in the treatment of absence seizures.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 히드로클로로티아지드\n\nExplanation:\n\nThe correct answer is ④ 히드로클로로티아지드 (hydrochlorothiazide) because it is a diuretic medication that can increase the risk of hypokalemia (low potassium levels) when used concurrently with naproxen. Hypokalemia can increase the risk of cardiac arrhythmias, which is a concern in patients with a history of cardiovascular disease, such as the patient in the scenario.\n\nThe other options are not correct because:\n\n① 파록세틴 (paroxetine) is a selective serotonin reuptake inhibitor (SSRI) antidepressant that is not known to interact with naproxen.\n\n② 암로디핀 (amlodipine) is a calcium channel blocker that is used to treat hypertension and angina. It has no known interactions with naproxen.\n\n③ 이르베사르탄 (irbesartan) is an angiotensin II receptor antagonist that is used to treat hypertension. It has no known interactions with naproxen.\n\n⑤ 아토르바스타틴 (atorvastatin) is a statin medication that is used to treat high cholesterol. It has no known interactions with naproxen.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 브리그티닙(brigatinib)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 리세드론산\n\nExplanation:\n\nThe patient's symptoms of confusion, agitation, and hallucinations worsened after taking donepezil, which is a cholinesterase inhibitor. This suggests that the patient may have a sensitivity to cholinesterase inhibitors, which can cause adverse effects such as confusion, agitation, and hallucinations in some individuals.\n\nTherefore, the best answer is ③ 리세드론산 (risedronic acid), which is a bisphosphonate that is used to treat osteoporosis and Paget's disease of bone. It has no cholinesterase inhibitory activity and is unlikely to worsen the patient's symptoms.\n\nThe other options are not appropriate for the following reasons:\n\n① 도네페질 (donepezil) - As mentioned earlier, donepezil is a cholinesterase inhibitor that worsened the patient's symptoms.\n\n② 비타민D (vitamin D) - Vitamin D is not associated with adverse effects such as confusion, agitation, and hallucinations.\n\n④ 아세클로페낙 (aceclofenac) - Aceclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat pain and inflammation. It is not associated with adverse effects such as confusion, agitation, and hallucinations.\n\n⑤ 트리암시놀론 (triamcinolone) - Triamcinolone is a corticosteroid that is used to treat inflammatory conditions. It is not associated with adverse effects such as confusion, agitation, and hallucinations.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 카르바마제핀\n\nExplanation:\n\nThe correct answer is ④ 카르바마제핀 (carbamazepine). Carbamazepine is a medication that is known to increase the risk of osteoporosis. It can cause bone loss by inhibiting the activity of osteoclasts, which are cells that help to break down bone tissue. This can lead to a decrease in bone density, which can increase the risk of fractures.\n\nThe other options are not correct because:\n\n① 발사르탄 (valsartan) is an angiotensin II receptor antagonist that is used to treat hypertension and heart failure. It has not been shown to increase the risk of osteoporosis.\n\n② 로수바스타틴 (rosuvastatin) is a statin that is used to treat high cholesterol. It has not been shown to increase the risk of osteoporosis.\n\n③ 프레가발린 (pregabalin) is an anticonvulsant that is used to treat neuropathic pain and epilepsy. It has not been shown to increase the risk of osteoporosis.\n\n⑤ 글리피지드 (glipizide) is a sulfonylurea that is used to treat type 2 diabetes. It has not been shown to increase the risk of osteoporosis.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ① 랄록시펜(raloxifene)\n\nExplanation:\n\nRaloxifene is a selective estrogen receptor modulator (SERM) that has been shown to increase bone density and reduce the risk of fractures in patients with osteoporosis. It is particularly effective in reducing the risk of vertebral fractures. The patient's history of hyperlipidemia, hypertension, and chronic kidney disease may also be taken into consideration when selecting a treatment option. Raloxifene has been shown to have a positive impact on bone health in patients with these comorbidities.\n\nDenosumab (②) is a monoclonal antibody that targets RANK ligand, which is involved in the regulation of bone metabolism. It has been shown to increase bone density and reduce the risk of fractures in patients with osteoporosis. However, it may not be the best option for this patient due to the risk of hypocalcemia and the need for frequent monitoring of serum calcium levels.\n\nDupilumab (③) is a monoclonal antibody that targets IL-4 and IL-13, which are involved in the regulation of allergic responses. It has been shown to be effective in treating asthma and atopic dermatitis, but it has not been studied extensively for the treatment of osteoporosis.\n\nEstrogen (④) has been shown to have a positive impact on bone health in postmenopausal women. However, it may not be the best option for this patient due to the potential risks of estrogen therapy, such as increased risk of breast cancer and thromboembolic events.\n\nIbandronic acid (⑤) is a bisphosphonate that has been shown to increase bone density and reduce the risk of fractures in patients with osteoporosis. However, it may not be the best option for this patient due to the risk of gastrointestinal adverse effects and the need for frequent monitoring of serum creatinine levels.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① 덱사메타손\n\nReason:\n\nThe patient has been prescribed a chemotherapy regimen consisting of doxorubicin, cyclophosphamide, paclitaxel, aprepitant, palonosetron, and dexamethasone. Of these drugs, dexamethasone is the one that is most likely to cause cardiotoxicity, particularly when given in high doses for extended periods. Therefore, it is necessary to monitor the patient's cardiac function and adjust the dosage of dexamethasone accordingly to minimize the risk of cardiotoxicity.\n\nThe other options are not as likely to cause cardiotoxicity as dexamethasone, and therefore, do not require as close monitoring of cardiac function.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 풀베스트란트(fulvestrant)\n\nExplanation:\n\nThe patient has been diagnosed with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Based on the patient's medical history, the most appropriate treatment option would be fulvestrant, which is a selective estrogen receptor downregulator (SERD) that is used to treat HR+ breast cancer.\n\nAlpelisib (①) is a PI3K inhibitor that is used to treat PIK3CA-mutated breast cancer, but it is not appropriate for this patient since there is no mention of a PIK3CA mutation.\n\nTamoxifen (②) is a selective estrogen receptor modulator (SERM) that is also used to treat HR+ breast cancer, but it is not as effective as fulvestrant in this patient population.\n\nAnastrozole (④) is an aromatase inhibitor that is used to treat postmenopausal women with HR+ breast cancer, but it is not appropriate for this patient since she has not undergone menopause.\n\nTrastuzumab (⑤) is a monoclonal antibody that targets HER2-positive breast cancer, but it is not appropriate for this patient since she has been diagnosed with HER2-negative breast cancer.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① ALK 변이</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 시스플라틴(cisplatin)+이포스파미드(ifosfamide)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 베바시주맙\n\nExplanation:\n\nThe patient's symptoms of hand-and-foot syndrome (HFS) and the diagnosis of peripheral neuropathy suggest that the culprit drug is likely to be oxaliplatin. Oxaliplatin is a chemotherapy drug that is known to cause HFS, which is a common side effect of this medication. The other options, capecitabine, bevacizumab, ondansetron, and dexamethasone, are not typically associated with HFS. Therefore, the answer is ③ 베바시주맙 (oxaliplatin).</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 트리플루리딘/티피라실(trifluridine/tipiracil)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 표준용량 시타라빈+아자시티딘(azacitidine)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 덱스라족산(dexrazoxane) 주사제</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 트리암시놀론아세토니드(triamcinolone acetonide) 0.1% 크림</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 니프라딜롤(nipradilol)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 300 mL\n\nExplanation:\n\nThe patient's total daily energy requirement is 2,000 kcal, and 600 kcal of that is to be provided as lipids. The concentration of the lipid emulsion is 20% (w/v), so the volume of the lipid emulsion needed to provide 600 kcal is:\n\nVolume of lipid emulsion = Energy requirement (kcal) / Concentration of lipid emulsion (w/v) x 100\n\nVolume of lipid emulsion = 600 kcal / 20% x 100\n\nVolume of lipid emulsion = 3,000 mL\n\nTherefore, the correct answer is ③ 300 mL.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ SOB\n\nExplanation:\n\n'호흡곤란 또는 숨참' means 'shortness of breath' or 'dyspnea' in English.\n\nSOB (Shortness of Breath) is the correct answer.\n\nNKDA (No Known Drug Allergy) and PMH (Past Medical History) are not related to shortness of breath.\n\nROS (Review of Systems) is a term used to describe the process of reviewing a patient's systems or body parts during a medical examination, and is not related to shortness of breath.\n\nWNL (Within Normal Limits) is a term used to describe a patient's vital signs or laboratory results that are within normal limits, and is not related to shortness of breath.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① MEDLINE</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ 온몸의 붉은 자국\n\nExplanation:\n\nThe patient's chief complaint is the recent onset of a red rash all over their body, which is not related to their hypertension or diabetes. The rash is likely caused by the drug reaction, and the patient's history of taking amlodipine, metformin, allopurinol, and acetaminophen suggests that the rash may be a result of a hypersensitivity reaction or an adverse effect of one of these medications. Therefore, option ⑤ 온몸의 붉은 자국 is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ⑤ 암로디핀과 알로푸리놀의 약물상호작용.\n\nExplanation:\n\nThe patient's symptoms of recurrent angioedema and recent onset of fever suggest an adverse drug reaction. The patient's medication history reveals that they have been taking amlodipine, metformin, allopurinol, and acetaminophen.\n\nAmlodipine and allopurinol are both known to cause angioedema as a side effect. However, the patient's symptoms of recurrent angioedema and fever suggest a possible drug interaction between amlodipine and allopurinol.\n\nTherefore, option ⑤ 암로디핀과 알로푸리놀의 약물상호작용 (interaction between amlodipine and allopurinol) is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\n\nThe question asks which item can be strategically omitted from a prescription when a patient requests it. The correct answer is ③, the prescription usage period.\n\nThe prescription usage period is not a critical piece of information that is required by law to be included in a prescription. While it is generally recommended to include the usage period to ensure that the patient takes the medication correctly, it is not a mandatory field. In certain cases, a patient may request that the usage period not be included in the prescription for personal reasons, such as privacy concerns or to avoid any potential legal issues.\n\nTherefore, ③, the prescription usage period, is the best answer.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 오메프라졸(omeprazole) 정</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 리라글루타이드(liraglutide) 주</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ②\n\nExplanation:\n\nThe patient is currently taking candesartan, an angiotensin II receptor antagonist (ARB), for hypertension. If she is planning to become pregnant, it would be appropriate to switch her medication to a different class of antihypertensive drugs, such as ACE inhibitors or calcium channel blockers, which have a better safety profile during pregnancy. Ramipril, an ACE inhibitor, would be a suitable alternative to candesartan in this case.\n\nTherefore, the correct answer is ② 칸데사르탄을 라미프릴(ramipril)로 변경.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ 팩수프라잔\n\nExplanation:\nThe patient's creatinine clearance has decreased from 70 mL/min to 50 mL/min, indicating a decline in renal function. Among the medications listed, fexuprazan (⑤) is a proton pump inhibitor that is primarily metabolized by the liver and excreted by the kidneys. Therefore, in light of the patient's decreased renal function, it would be appropriate to consider dose adjustment for fexuprazan to avoid potential adverse effects.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 병용 금기 약물 사용\n\nExplanation:\n\nThe patient is taking isotretinoin, which is a retinoid, and doxycycline, which is a tetracycline antibiotic. Isotretinoin is known to cause esophageal irritation and ulcers, and doxycycline can exacerbate this condition. Therefore, the concurrent use of these two drugs is contraindicated.\n\nThe correct answer is ② 병용 금기 약물 사용, which means \"concurrent use of contraindicated drugs.\"</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 200\n\nExplanation:\n\nThe question asks for the appropriate AUC_{0-24} (mg·h/L) of vancomycin for a 60-year-old male patient who has been receiving vancomycin for 3 days for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. The MIC of vancomycin against MRSA is 1 mg/L.\n\nAccording to the 2019 Infectious Diseases Society of America (IDSA) guidelines for the management of MRSA infections, the recommended AUC_{0-24} of vancomycin for MRSA pneumonia is 200-300 mg·h/L. Therefore, the correct answer is ③ 200.\n\nIt's worth noting that the AUC_{0-24} is a measure of the total concentration of the drug in the body over a 24-hour period, and it's used to determine the efficacy of the drug. In this case, a higher AUC_{0-24} may be necessary to ensure adequate treatment of the MRSA infection.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 21 g</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nThe correct order for adding electrolytes to a total parenteral nutrition (TPN) solution to minimize the risk of precipitation is:\n\n1. Sodium chloride (NaCl)\n2. Calcium gluconate (CaGlu)\n3. Potassium chloride (KCl)\n4. Magnesium sulfate (MgSO4)\n5. Insulin (if needed)\n\nThis order is recommended because:\n\n1. Sodium chloride is the primary electrolyte that needs to be replaced in TPN solutions, and it should be added first to establish a stable osmotic pressure.\n2. Calcium gluconate should be added second, as it helps to stabilize the calcium level and prevent hypocalcemia.\n3. Potassium chloride should be added third, as it helps to maintain the potassium level and prevent hypokalemia.\n4. Magnesium sulfate should be added fourth, as it helps to maintain the magnesium level and prevent hypomagnesemia.\n5. Insulin (if needed) should be added last, as it helps to regulate blood sugar levels.\n\nIt's important to note that the order of addition may vary depending on the specific needs of the patient and the TPN formulation being used. It's always best to consult with a healthcare professional or a pharmacist for guidance on TPN preparation and administration.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ②\n\nExplanation:\n\nThe question asks what the pharmacist should confirm in the prescription review and dispensing process for a patient receiving cisplatin 130 mg intravenous infusion. The correct answer is ②, \"심장독성 예방을 위해 누적용량을 확인함.\"\n\nCisplatin is a chemotherapy drug that can cause cumulative cardiotoxicity, which can lead to heart failure and other cardiovascular complications. Therefore, it is important for the pharmacist to confirm the patient's cumulative dose of cisplatin to ensure that the risk of cardiotoxicity is minimized. This can be achieved by calculating the total dose of cisplatin the patient has received, taking into account the patient's weight and other factors that may affect the drug's pharmacokinetics.\n\nThe other options are not relevant to the question:\n\n① Calvert 공식을 이용하여 투여량이 계산됨: This formula is used to calculate the dose of chemotherapy drugs, but it is not specifically related to cisplatin or cardiotoxicity.\n\n③ 희석액으로 5 % 포도당 주사액이 사용됨: This statement refers to the dilution of cisplatin with 5% dextrose injection, which is not directly related to the patient's cumulative dose or cardiotoxicity risk.\n\n④ '수막내투여'라는 문구가 적인 라벨이 부착됨: This statement refers to the labeling of the drug product with the phrase \"수막내투여,\" which means \"for intravenous infusion only.\" While this is an important consideration in the preparation and administration of cisplatin, it is not directly related to the patient's cumulative dose or cardiotoxicity risk.\n\n⑤ 고위험군에 사용하는 항구토예방요법이 처방됨: This statement refers to the use of cisplatin in high-risk patients, which may require more careful monitoring and management of cardiotoxicity risk. However, this is not directly related to the pharmacist's role in confirming the patient's cumulative dose.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 혈당\n\nExplanation: Vigabatrin is an antiepileptic drug that can cause hyperglycemia as a side effect. Therefore, it is important to regularly monitor the patient's blood sugar levels to ensure that they remain within a safe range.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 메토클로프라미드\n\nExplanation:\n\nThe patient is taking roprinol, which is a dopamine receptor agonist, for Parkinson's disease. The prescribed medications include perindopril, atorvastatin, hydrochlorothiazide, famotidine, and metoclopramide.\n\nOf the options listed, the medication that may potentially worsen the patient's Parkinson's symptoms is metoclopramide. Metoclopramide is a dopamine receptor antagonist, which means it can counteract the effects of roprinol and potentially worsen the patient's Parkinson's symptoms. Therefore, the pharmacist should intervene and recommend an alternative medication or adjust the dosage of metoclopramide to minimize the risk of exacerbating the patient's condition.\n\nThe other options are not likely to have a significant impact on the patient's Parkinson's symptoms. Perindopril and atorvastatin are medications for hypertension and hyperlipidemia, respectively, and are not directly related to Parkinson's disease. Hydrochlorothiazide is a diuretic, which may help with fluid management in patients with hypertension, but it is not typically used to treat Parkinson's disease. Famotidine is an H2-blocker that can help with gastrointestinal symptoms, but it is not directly related to Parkinson's disease.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① 상당히 확실함(probable)\n\nExplanation:\n\nThe patient's symptoms of dry cough and hoarseness, which occurred after taking the medications, suggest a possible adverse drug reaction (ADR). The fact that the symptoms improved after discontinuing the medications and the absence of any other underlying conditions that could have caused the symptoms, support the likelihood of an ADR.\n\nThe WHO-UMC causality assessment method considers the following factors:\n\n1. Time relationship: The symptoms occurred after taking the medications, which suggests a possible causal relationship.\n2. Clinical presentation: The symptoms of dry cough and hoarseness are not typically associated with the patient's underlying medical conditions, which suggests that they may be related to the medications.\n3. Response to dechallenge: The symptoms improved after discontinuing the medications, which supports the possibility of an ADR.\n4. Alternative causes: There are no other underlying conditions that could have caused the symptoms, which suggests that the medications are the likely cause.\n\nBased on these factors, the WHO-UMC causality assessment method would likely classify this case as \"probable\" (①) for an adverse drug reaction.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 락툴로오스(lactulose)</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 케토코나졸(ketoconazole)</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 톨페남산(tolfenamic acid)</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 3일마다 교체\n\nThe correct answer is ③ 3일마다 교체. Buprenorphine patches are typically changed every 3 days, as the drug is released slowly and consistently over a 3-day period. Changing the patch more frequently than every 3 days may not provide additional benefits and may increase the risk of adverse effects.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 딜티아젬(diltiazem)</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nThe correct answer is ③. The question asks for the description of a single-use, disposable syringe. Option ③ states that the number displayed on the syringe's dosage display window remains the same even after the injection is complete, indicating that it is a single-use syringe.\n\nThe other options do not describe a single-use, disposable syringe:\n\n① describes a syringe with the highest absorption rate in the upper outer part of the arm, but does not mention anything about its usage or disposability.\n\n② states that the product should be discarded two weeks after opening, but does not specify that it is a single-use syringe.\n\n④ describes a method of injecting the drug by holding the syringe at a 30-degree angle, but does not mention anything about the syringe being disposable.\n\n⑤ describes a method of injecting the drug slowly over 10 seconds, but does not mention anything about the syringe being disposable or single-use.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④, \"천천히 깊게 숨을 들이마시는 동시에 버튼을 누른다.\"\n\nThis answer choice describes the proper technique for using a nebulizer, which is a device that converts liquid medicine into a mist that can be inhaled to treat respiratory problems. The instructions are to inhale deeply and slowly through the mouthpiece while pressing the button to release the medication. This allows the medication to reach the lungs effectively and helps to treat conditions such as asthma and chronic obstructive pulmonary disease (COPD).\n\nThe other answer choices are not accurate descriptions of how to use a nebulizer:\n\n① \"사용 전에 충분히 흔들어 준다\" (Shake the nebulizer well before use) is not necessary, as the medication is already in a liquid form and does not require shaking.\n\n② \"흡입력이 약한 소아에게 사용하기 적합하다\" (Use the nebulizer for children who have a weak inhalation) is not accurate, as nebulizers are typically used for patients of all ages who have respiratory problems.\n\n③ \"흡입 후 캡슐에 약이 남아 있으면 흡입을 반복한다\" (Repeat the inhalation if there is still medication left in the chamber after inhaling) is not necessary, as the nebulizer will automatically deliver the medication in a consistent dose.\n\n⑤ \"흡입할 때 캡슐이 회전하는 소리가 들리면 잘못 흡입한 것이다\" (If you hear the sound of the chamber spinning while inhaling, you have inhaled incorrectly) is not accurate, as the nebulizer does not make a spinning sound while in use.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ② 로라타딘(loratadine)\n\nExplanation:\n\nLoratadine is an antihistamine that is commonly used to treat allergies, itching, and hives. It is also effective in reducing the symptoms of hay fever, such as sneezing, runny nose, and itchy eyes. The patient's symptoms of mild diarrhea and no other accompanying symptoms suggest that loratadine may be an appropriate treatment option.\n\nCetirizine and terbinafine are also antihistamines, but they are less likely to be effective in treating diarrhea. Almagate is an antacid that is used to treat heartburn and indigestion, and it is not relevant to the patient's symptoms. Dioctahedral smectite is a type of clay that is used as an antidiarrheal agent, but it is not a common treatment for allergies or hay fever.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 대청룡탕(大靑龍湯)</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\n\nThe question is asking about the monitoring of the cleanroom and the filling machine in a pharmaceutical production facility. The correct answer is ③, which states that the contact plate method is used to measure the number of floating microorganisms in the air. This method involves placing a nutrient-rich agar plate in a designated location for a set period of time, allowing microorganisms to settle and grow on the plate. The number of colonies that grow on the plate is then counted to determine the level of airborne microorganisms.\n\nThe other options are not correct for the following reasons:\n\n① is incorrect because it states that the level of contamination is higher in an A-class area than in a B-class area, which is not accurate. A-class areas are typically considered \"cleaner\" than B-class areas.\n\n② is incorrect because it suggests that the product can be filled in a D-class area using aseptic technique, which is not appropriate. D-class areas are not suitable for aseptic operations.\n\n④ is incorrect because it suggests that the pressure in a high-contamination area can be maintained to prevent contamination of surrounding areas, which is not a practical solution.\n\n⑤ is incorrect because it describes a method for measuring surface microorganisms, not airborne microorganisms.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 시험방법 밸리데이션</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ①</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ①\n\nExplanation:\n\nD-value, or decimal reduction time, is a measure of the time required to reduce the number of microorganisms on a surface by 90% (5-log reduction) at a given temperature. Therefore, the correct answer is ①, \"가열멸균 공정에서 온도에 따라 달라진다,\" which means that the D-value changes depending on the temperature in the heat sterilization process.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④. The statement \"방울점시험에서 명시된 압력보다 방울점 압력이 낮으면 필터의 손상이 없음을 의미한다\" is true.\n\nIn the integrity test, the pressure drop across the filter is measured, and if the pressure drop is lower than the specified pressure drop, it indicates that the filter is not damaged. Therefore, option ④ is the correct answer.\n\nOption ① is incorrect because the statement \"확산시험은 비파괴시험이다\" is not true. The integrity test is a non-destructive test, but the pressure drop test is a destructive test.\n\nOption ② is incorrect because the statement \"필터 제조사에서 실시하는 세균유지시험은 비파괴시험이다\" is not true. The integrity test is a test conducted by the manufacturer, but it is not a non-destructive test.\n\nOption ③ is incorrect because the statement \"방울점시험에서 멤브레인 내의 기공 크기가 클수록 방울점 압력이 높다\" is not true. The pressure drop across the filter is not affected by the size of the pores in the membrane.\n\nOption ⑤ is incorrect because the statement \"필터의 공극률이 일정하다면 방울점 압력은 필터의 형태(disk type 또는 cartridge type)에 영향을 받지 않는다\" is not true. The pressure drop across the filter is affected by the type of filter, such as disk type or cartridge type.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 품질관리도</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 시정 및 예방조치</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 불용성이물시험</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 안연고제</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 제산력시험</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 1.00</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 30</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 티아민염산염</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 선광도측정법</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 랜덤화(randomization)\n\nExplanation:\n\nRandomization is a technique used to minimize the impact of confounding variables in an experiment. By randomly assigning participants or samples to different groups or conditions, it helps to ensure that the groups are similar in terms of all relevant factors, thus reducing bias and increasing the validity of the results. This is particularly important in experiments where there are many confounding variables that could affect the outcome, and it is not possible to control for all of them.\n\nIn contrast, replication (①), blocking (③), optimization (④), and simplicity (⑤) are not directly related to minimizing the impact of confounding variables. Replication refers to the process of repeating an experiment multiple times to increase the reliability of the results. Blocking refers to the process of grouping participants or samples based on certain characteristics to reduce the impact of confounding variables. Optimization refers to the process of finding the best solution or conditions for an experiment. Simplicity refers to the ease of understanding and implementing an experiment. While these techniques may be important in certain contexts, they are not directly related to minimizing confounding variables.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 1.50</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ D\n\nExplanation:\n\nAccording to the table provided, the current formulation of K 제약회사's product contains 76.5% 아세트아미노펜, 94.4% 히프로멜로오스, 94.4% 폴리에틸렌옥시드, 4.1% 유당수화물, and 0.6% 스테아르산마그네슘. The company wants to change the formulation to contain 76.5% 아세트아미노펜, 94.4% 히프로멜로오스, 94.4% 폴리에틸렌옥시드, 3.9% 유당수화물, and 0.8% 스테아르산마그네슘.\n\nTherefore, the change in formulation is a D-level change, which means that the change in the amount of one or more ingredients is 10% or more, but less than 20%.\n\nSo, the answer is ④ D.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ 비교용해도시험\n\nExplanation:\n\nThe question asks for the appropriate test to be submitted to the regulatory agency when changing the formulation of a drug product, specifically the excipients and their amounts, as in the case of K 제약회사's plan to modify the formulation of their 아세트아미노펜 650 mg 서방성 필름코팅정 product.\n\nThe correct answer is ④ 비교용해도시험, which is a comparative dissolution test. This test is used to determine whether the dissolution profile of the modified formulation is similar to that of the reference listed drug product. The test is performed by dissolving the drug product in a solvent and comparing the amount of drug dissolved over time.\n\nThe other options are not relevant to the scenario described:\n\n① 비교붕해시험 is a comparative disintegration test, which is used to determine whether the modified formulation disintegrates at a similar rate as the reference listed drug product.\n\n② 비교용출시험 is a comparative assay test, which is used to determine whether the modified formulation contains the same amount of active ingredient as the reference listed drug product.\n\n③ 비교투과시험 is a comparative permeation test, which is used to determine whether the modified formulation has a similar permeation rate as the reference listed drug product.\n\n⑤ 생물학적동등성시험 is a biological equivalence test, which is used to determine whether the modified formulation is bioequivalent to the reference listed drug product. This test is not relevant to the scenario described, as the formulation is being modified only in terms of excipients and their amounts, not the active ingredient.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① WT 전략: 회사가 가진 강점을 활용하여 시장의 기회를 창출함</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 총자산이익률</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nThe correct answer is ③ 특정 기간의 영업비용을 제시한다.\n\nThe question is asking for the description of a financial statement that a pharmacist should prepare, and the answer is ③ 특정 기간의 영업비용을 제시한다, which means the pharmacist should prepare a financial statement that presents the operating expenses for a specific period.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nThe correct answer is ③ 의약품 구입 비용.\n\nExplanation:\n\nThe question asks which expense should be capitalized in the financial statements of a pharmacy. The correct answer is 의약품 구입 비용 (the cost of purchasing medication) because it is a capital expenditure that will benefit the business over a long period of time.\n\nThe other options are not correct because they are either expenses that are not capitalized (① 종업원 인건비, employee wages) or expenses that are not directly related to the purchase of medication (② 금융기관 대출금, interest on loans; ④ 약 봉투 구입 비용, cost of purchasing drug packaging; ⑤ 자동정제포장기 구입 비용, cost of purchasing an automatic packaging machine).</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 100병</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③. According to the question, 가입자 (member) is entitled to the same benefits regardless of the amount of insurance premiums they have paid. This means that the benefits provided by the national health insurance system in South Korea are not based on the individual's past medical history or the amount of premiums they have paid, but rather on their membership in the system. Therefore, option ③ is the best answer.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 본인부담상한제</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 대상포진 예방백신 접종</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Common Technical Document (CTD)</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 한국의약품안전관리원</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 사용량–약가 연동제</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ OR 불리언연산자 사용</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 0.8\n\nExplanation:\n\nThe incremental quality-adjusted life years (QALYs) of drug B over drug A can be calculated as follows:\n\nIncremental QALYs = (0.9 - 0.7) x 1 year = 0.2 QALYs\n\nTherefore, the correct answer is ③ 0.8.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 치료효과를 화폐단위로 변경한 분석</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 환자와 신뢰 관계 형성</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 자율성 존중의 원칙\n\nExplanation:\n\nThe principle of respecting the patient's autonomy is the most relevant ethical principle in this scenario. The patient has the right to make their own decisions about their treatment, including the choice of medication. The pharmacist's role is to provide information and guidance, but ultimately, the decision is up to the patient.\n\nIn this case, the pharmacist should inform the patient about the substitute medication and its potential side effects, and then respect the patient's decision if they choose to use the substitute medication or seek a different pharmacy. The pharmacist should not pressure the patient into using the substitute medication or try to influence their decision in any way.\n\nThe other options do not accurately reflect the ethical principle at play in this scenario:\n\n① The principle of beneficence (doing good) would suggest that the pharmacist should provide the patient with the best possible treatment option, which may not align with the patient's personal preferences.\n\n② The principle of non-maleficence (doing no harm) would suggest that the pharmacist should avoid causing harm to the patient, but this principle is not directly relevant to the patient's decision-making process.\n\n④ The principle of informed consent is important in healthcare, but it is not the most relevant principle in this scenario, as the patient has already made their decision and is seeking a substitute medication.\n\n⑤ The principle of respecting privacy and confidentiality is important in healthcare, but it is not directly relevant to the patient's decision-making process in this scenario.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ 1.20</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ 사례군연구(case series study)\n\nExplanation:\n\nA case series study would be the most appropriate design for a follow-up study to investigate the association between Ramatis and cardiovascular adverse events. This study design involves collecting data on a series of cases with a specific outcome of interest (in this case, cardiovascular adverse events) and comparing them to a control group without the outcome.\n\nA case series study would allow researchers to gather more detailed information on the cases, including demographic information, medical history, and exposure to Ramatis. This study design would also enable researchers to calculate the incidence rate of cardiovascular adverse events in the population exposed to Ramatis, which would provide valuable information for assessing the safety of the drug.\n\nThe other options are not as appropriate for this study question:\n\n① A cohort study would involve following a group of people over time, which would not be practical for investigating a specific drug's safety.\n\n② A case report would provide detailed information on a single case, but it would not allow researchers to generalize the findings to a larger population.\n\n③ A cross-sectional study using a questionnaire would not provide information on the temporal relationship between Ramatis exposure and cardiovascular adverse events.\n\n⑤ A study using health insurance data would not provide information on the specific exposure to Ramatis, and it would not allow researchers to control for potential confounding variables.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 코로나19–독감 진단시약 제조</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nAccording to the question, the correct answer is ③. The statement \"의약품 사용과 관련하여 부작용이 발생한 경우에는 필요한 안전대책을 강구하여야 한다\" is not a requirement for the management of a pharmacy under the Pharmacist Licensing Examination. The other options, ①, ②, ④, and ⑤, are all requirements for the management of a pharmacy.\n\nTherefore, the answer is ③.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nThe question asks which of the following activities does not fall under the category of prohibited conduct or conflict of interest for a pharmacist or a medical institution that opens a pharmacy.\n\nOption ①, providing medical services to a patient in exchange for a prescription from a physician, is a prohibited conduct as it violates the Pharmaceutical Affairs Act.\n\nOption ②, receiving benefits from a third party in exchange for recommending a specific pharmacy, is also a prohibited conduct as it violates the Pharmaceutical Affairs Act.\n\nOption ③, managing the review and approval process for medical expenses incurred by a patient under the National Health Insurance Act, is not a prohibited conduct or conflict of interest for a pharmacist or medical institution.\n\nOption ④, transmitting a prescription using computer communication, is not a prohibited conduct or conflict of interest for a pharmacist or medical institution.\n\nOption ⑤, prescribing a drug that is not included in the drug list provided by the medical association, is a prohibited conduct as it violates the Pharmaceutical Affairs Act.\n\nTherefore, the correct answer is ③.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④\n\nExplanation:\n\nThe correct answer is ④. According to the Pharmacist Licensing Examination, the answer is ④.\n\nThe question states that a pharmacist who is working in a hospital pharmacy and has received a prescription from a doctor cannot prepare the medication for the patient. This is because the pharmacist's role is to dispense medication based on a prescription from a licensed medical professional, and they cannot prepare medication without a valid prescription.\n\nTherefore, option ④ is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 처방전에 적힌 용법 및 용량</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤\n\nExplanation:\n\nAccording to the Pharmacy Act, a pharmacist can sell prescription drugs only at a pharmacy that has been approved by the Minister of Health and Welfare. Therefore, option ①, \"A pharmacist can sell prescription drugs at a wholesale price,\" is incorrect.\n\nOption ②, \"A wholesaler can sell prescription drugs to a pharmacist who has opened a pharmacy,\" is also incorrect because a wholesaler cannot sell prescription drugs directly to a pharmacist.\n\nOption ③, \"A pharmacist cannot display the price of prescription drugs on the packaging or label,\" is incorrect because a pharmacist is required to display the price of prescription drugs on the packaging or label.\n\nOption ④, \"A pharmacist can sell prescription drugs to a veterinarian who has opened an animal hospital,\" is incorrect because a pharmacist cannot sell prescription drugs to a veterinarian.\n\nTherefore, the correct answer is option ⑤, \"A pharmacist can sell prescription drugs at a location other than a pharmacy if they have received approval from the Minister of Health and Welfare.\"</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nExplanation:\n\nAccording to the Pharmacist Licensing Examination, the correct answer is ④.\n\nThe question states that the pharmacist cannot dispense prescription drugs without a prescription from a licensed medical professional. In the given scenarios, ④ is the only option that does not involve dispensing prescription drugs without a prescription.\n\n① and ③ involve dispensing prescription drugs without a prescription, which is not allowed.\n\n② involves compounding and selling prescription drugs, which is also not allowed without a valid prescription from a licensed medical professional.\n\n⑤ involves selling prescription drugs to another pharmacist who is unable to obtain them urgently, which is not a valid reason for dispensing prescription drugs without a prescription.\n\nTherefore, the correct answer is ④, as it does not involve dispensing prescription drugs without a valid prescription.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 특허 권리범위 확인심판</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 혈액응고 억제를 위한 헤파린 주사제</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤\n\nExplanation:\n\nAccording to the Pharmaceutical Affairs Act, the advertisement of prescription drugs is allowed only in the following cases:\n\n1. Advertisement of over-the-counter drugs that are approved by the Minister of Food and Drug Safety.\n2. Advertisement of drugs that are prescribed by a doctor, but the advertisement must not contain any false or exaggerated claims.\n3. Advertisement of drugs that are approved by the Minister of Food and Drug Safety for the purpose of preventing the spread of infectious diseases.\n4. Advertisement of drugs that are approved by the Minister of Food and Drug Safety for the purpose of treating rare diseases.\n\nTherefore, the correct answer is ⑤, which states that the advertisement of a prescription drug is allowed in a medical journal that is published simultaneously with the application for marketing approval.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\n\nAccording to the Pharmacist Licensing Examination, the case where the Korean Pharmacists Association's Ethics Committee or the Korean Pharmacists Association's Board of Directors can request the cancellation of a pharmacist's license to the Minister of Health and Welfare is when the pharmacist has engaged in false or exaggerated advertising. Therefore, the answer is ③.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 마약류관리자</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\n\nAccording to the question, the correct answer is ③, which states that the storage location for pentobarbital sodium should be established within the office of the person who handles the drug, and not in a warehouse or storage facility. This is because the drug is a controlled substance and its handling and storage are strictly regulated by law. Storing it in a warehouse or storage facility may not provide the necessary level of security and control, and may violate regulations.\n\nThe other options do not meet the requirements of the question:\n\n① states that the drug should be stored in a locked refrigerator with other injectable drugs, which may not provide adequate security and control.\n\n② states that the drug should be stored in a double-locked metal safe, which may not be accessible to authorized personnel during emergencies.\n\n④ states that the drug should be stored in a designated area of the workplace during working hours, which may not provide adequate security and control.\n\n⑤ states that the drug should be stored in a locked container and transported securely, which may not be practical or feasible in all cases.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nAccording to the question, the correct answer is ③. The question states that when the efficacy period of a drug has passed, the pharmacist must report it to the relevant authorities without delay. This is in accordance with the \"마약류 관리에 관한 법률\" (Drug Management Act), which requires pharmacists to report expired drugs to the authorities.\n\nOption ① is incorrect because it refers to the sale of temporary medication, which is not related to the question.\n\nOption ② is incorrect because it refers to the preservation of prescriptions for five years, which is not related to the question.\n\nOption ④ is incorrect because it refers to the sale of electronic prescription drugs, which is not related to the question.\n\nOption ⑤ is incorrect because it refers to the reporting of adverse reactions to food additives, which is not related to the question.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 영양개선</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③. According to the definition of \"보건의료기본법\" (Basic Law on Health and Medical Services), health and medical services refer to the services provided by healthcare professionals, including doctors, nurses, and pharmacists, to protect and promote the health of the population. The law does not include the provision of health-related information through video or other media as part of health and medical services. Therefore, ③ is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 국민건강보험공단</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③\n\nExplanation:\n\nAccording to the \"National Health Insurance Act,\" the determination and calculation of the medical fee for a drug product is based on the criteria set by the Minister of Health and Welfare, excluding certain drugs that are not subject to medical fee coverage. Therefore, the correct answer is ③, which states that all drugs other than those specified by the Minister of Health and Welfare are subject to medical fee coverage.\n\nThe other options are incorrect because:\n\n① is incorrect because the medical fee for a drug product is not determined based on the purchase price.\n\n② is incorrect because the medical fee for a drug product is not determined based on the ceiling price.\n\n④ is incorrect because while drug manufacturers can apply for a decision on whether their product is subject to medical fee coverage, the final decision is made by the Minister of Health and Welfare.\n\n⑤ is incorrect because while there are restrictions on the provision of economic benefits under the \"Pharmaceutical Affairs Act,\" this does not relate to the determination and calculation of medical fees for drug products.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 마약류관리자의 마약류 취급 감시</s>"
    }
]